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Tumour necrosis factor alpha (TNFa), a mediator of inflammatory
responses and pathologies of a wide variety of diseases, has been
extensively studied in humans and mice. However, little has previously
been known about this cytokine in the sheep, a species of value not
only to the agricultural industry, but also as a laboratory animal.
In this work, the cDNA encoding ovine TNFa has been amplified,
cloned, sequenced and used to express recombinant ovine TNFa
(rovTNFa). The latter has been partially purified, characterised and
used to raise both poly- and mono- clonal antibodies.
The sequence of ovine TNFa shows a high degree of homology to those
of other species. Certain regions, which are known to be structurally
or functionally important to the mRNA and/or protein, are particularly
well conserved. Consequently, rovTNFa displays several biological
activities previously noted for TNF'sa of other species, including
cytotoxicity, enhancement of thymocyte and fibroblast proliferation
and cartilage-degrading and anti-viral activities. However, whilst
rovTNFa is active in assays on ovine cells at concentrations
comparable to those observed in similar assays for other species, it
is 1000 fold less active than recombinant human TNFa (rhTNFa) in cyto¬
toxicity assays on TNF-sensitive murine (L929) cells, whose general
lack of species specificity allows their use in detecting TNF'sa from
many sources.
A monoclonal antibody raised to rovTNFa detects a glycoprotein of
appropriate size for mature ovine TNFa in the supernatants of
stimulated ovine cell cultures. As in other species both ovine TNFa
mRNA and protein are rapidly inducible. Such supernatants repeatedly
have no activity in cytotoxicity assays (sensitive to 30pg rhTNFa/ml)
on L929 cells, in spite of many containing >lng ovine TNFa/ml. At
least one of these supernatants displays biological activity
attributable to TNFa (through its neutralisation by a polyclonal
antiserum raised to rovTNFa) in an assay on ovine cells. By comparing
the amino acid sequences of TNF'sa from many species and using
knowledge gained from structure/function studies on human TNFa,
possible explanations for the apparent species specificity of ovine
TNFa are proposed.
Finally, preliminary investigations have been performed to examine
the role that TNFa plays in Maedi-Visna (MV) disease, a chronic lenti-
virally-induced ovine disease. RovTNFa can differentially regulate MV
viral expression in different cell types in vitro, whilst the native
protein is produced in MV-infected cultures of adherent ovine lung
cells. Ovine TNFa may therefore play a complex role in MV disease,
both by contributing to its pathogenesis and influencing the viral
life-cycle.
 
CHAPTER 1:- TUMOUR NECROSIS FACTOR ALPHA AND ITS POTENTIAL ROLES IN
OVINE DISEASE: AN INTRODUCTION.
1.1. TNFa: historical aspects:-
In the second half of the 19th century, several workers observed
the spontaneous regression of some human tumours following episodes of
bacterial infection and attempted to exploit this phenomenon by
deliberately infecting selected cancer patients (Busch, 1866;
Fehleisen, 1882; Coley, 1893). Though partial responses were sometimes
obtained, such therapy was not surprisingly marred by undesirable
reactions. Coley (1906) later found that some bacterial extracts could
also be effective and although the use of 'Coley's toxins' was still
associated with iatrogenic toxicity, it became one of the few-
recognised medical treatments for neoplasia in the early 1900's.
In attempts to isolate the active fraction(s) from Gram-negative
bacteria, Shear et al. (1943) succeeded in purifying the component now
known as endotoxin, or lipopolysaccharide (LPS). Unfortunately
however, whilst LPS could induce haemorrhagic necrosis of transplanted
tumours in mice, a 'shock-inducing' toxic activity co-purified with
this fraction (Shear, 1944).
In 1962, O'Malley et al. demonstrated that the anti-tumour effect
of heat-stable LPS was indirect, since it induced a heat-labile
agent(s) in the sera of treated mice, which had tumour-necrotising
activity when transferred to other tumour-bearing mice. The existence
of an endogenous mediator was confirmed by Carswell et al. (1975), who
extended the observation of tumour necrosis activity in vivo to a
direct, in vitro cytotoxicity of such sera for cells of the
transformed, murine, L cell line. This provided a simpler assay for
the component they dubbed 'Tumour Necrosis Factor' (TNF).
TNF was subsequently purified (Aggarwal et al., 1985b) and cDNA's
encoding TNF in several species were cloned and sequenced (see chapter
2), whereupon it became apparent (Pennica et al., 1984) that TNF
shared significant homology with another cytotoxic factor, lymphotoxin
(LT), a product of mitogen-stimulated T-lymphocytes (Gray et al.,
1984). Though antigenically distinct, it was shown that TNF and LT
bind to the same cell surface receptors (Aggarwal et al. , 1985a),
generally evoking similar responses. This led to the renaming of TNF
and LT as TNFa and TNF/?, respectively.
Sequencing also demonstrated that TNFa was identical to 'cachectin'
(Beutler et al., 1985a). Cachectin had been studied for several years
by Cerami et al. as a result of investigations into the cachexia
suffered by trypanosome-infected cattle and rabbits. These rabbits
developed an hypertryglyceridaemia, linked to a deficiency of the
enzyme lipoprotein lipase (LPL) (Rouzer & Cerami, 1980). Similar
derangement of lipid metabolism could be induced by LPS-treatment of
endotoxin -sensitive, but not -resistant, strains of mice (Kawakami &
Cerami, 1981) and the presence of an endogenous mediator, which they
later named cachectin because of its likely role in the metabolic
disturbances of cachexia, was confirmed by inter-strain transfer of
serum.
The identity of TNF and cachectin defined TNFa as a pleiotropic
molecule and fuelled searches for other actions. Michalek et al.
(1980) had previously demonstrated that in addition to its tumour-
necrotising action, the toxic effects of LPS were also indirect. It
was soon found that TNFa could induce a shock-like state itself
(Tracey et al.,1986) and furthermore, prior, passive immunisation with
antibodies to TNFa could confer protection against LPS-induced
lethality (Beutler et al.,1985c). Thus TNFa was identified not only as
an essential mediator of LPS toxicity but also as 'much more than a
tumour necrosis factor,' as will be further illustrated below.
1.2. TNFa: cell sources and inducers
In their early work, Carswell et al. (1975) found that mice
required priming with an agent such as BCG before LPS treatment
induced sufficient TNFa for detection. Since BCG was known to induce
hyperplasia of the lymphoreticular system, cells of monocyte/
macrophage lineage were considered possible sources of LPS-induced
TNFa. Such suspicions were subsequently confirmed by several workers
using isolated cell populations (Mannel et al., 1980; Matthews, 1978,
1981a,b; Zacharchuk et al., 1983), whilst Kawakami and Cerami (1981)
had likewise found that macrophages were a major source of cachectin.
TNFa does not exist in stored form in these cells, nor is it secreted
by resting monocyte/macrophages (Beutler et al. , 1986a). However,
their potential for producing large amounts of TNFa de novo on
activation was demonstrated by Beutler et al. (1985b), who estimated
that TNFa comprised as much as 2% of the total secreted product of
LPS-stimulated RAW 264.7 cells (a macrophage cell line).
Whilst macrophages from all tissues studied can produce TNFa
(Decker et al., 1987), the potential to induce TNFa varies between
different forms of LPS and shows some correlation with the
pathogenicity of their source (Loppnow et al.. 1990). LPS derived from
non-pathogenic bacteria, or incomplete forms of LPS, may even block
the induction of TNFa by other forms (Mannel & Falk, 1989).
Many other agents have also been tested for their ability to induce
TNFa, occasionally with conflicting results. Amounts of TNFa produced
in response to these alternative stimuli are often much lower than
those induced by endotoxin. Hence, because of its potency and
widespread presence in vitro, possible contributions by contaminating
LPS should always be considered in such studies.
Several other types of bacteria or their products have now been
shown to be capable of inducing TNFa from monocyte/macrophages. These
include some products of Gram-positive bacteria, for example
polysaccharide f from Streptococcus mutans and toxic shock syndrome
toxin 1 from Staphylococcus aureus (Benabdelmoumene et al., 1991; Fast
et al., 1988; Jupin et al., 1988), as well as organisms with a
predominantly intracellular lifestyle, such as Listeria monocytogenes
(Havell, 1987), Mycobacterium tuberculosis (Rook et al., 1987) and
Mycoplasmae (Sugama et al., 1990). With regard to the latter group,
it has also been noted that phagocytosis of undigested particles, such
as zymosan, can lead to sustained TNFa release (Stein & Gordon, 1991).
Since cachectin was originally discovered following research into
trypanosomiasis, it is not surprising that other protozoa, such as
Plasmodium, or their soluble antigens, have proven to be TNFa inducers
(Bate et al., 1988). Macrophages also produce TNFa on encountering
assorted viruses, including Encephalomyocarditis virus, Vesicular
Stomatitis virus, Adenovirus 2, Herpes simplex virus and even viral
features such as double-stranded RNA (Wong & Goeddel, 1986). TNFa
production in response to infection with Human Immunodeficiency virus
(HIV) has also been documented (Merrill et al., 1989), though this has
been the subject of some debate (see 1.8.5). Aderka et al. (1986)
found that Sendai virus can be as potent a stimulus as LPS, whilst
Influenza A virus not only stimulates TNFa production but also
markedly potentiates its induction by LPS (Nain et al.. 1990). In
summary, TNFa can be induced by a wide range of aetiological agents.
Numerous endogenous inducers of TNFa have also been described.
These include specific pathological products, such as urate crystals
(diGiovine et al., 1991), components of tumour cells (Janicke &
Mannel, 1990) and advanced glycosylation end-products, found in ageing
tissues (Vlassara et al., 1988), as well as products of the immune
system, such as IgG immune complexes (Warren et al.. 1991) and C5a,
formed during activation of complement (Okusawa et al., 1988). The
second group also includes several cytokines:- GM-CSF (Chantry et al..
1990); IL-2 (Economou et al., 1989a); IL-1 and TNFa itself (Philip &
Epstein, 1986).
TNFa was once believed to be exclusively produced by monocyte/
macrophages. However, more sensitive detection methods have now
identified its production in many other cell types and though such
cells generally produce much smaller amounts of TNFa in cell-for-cell
comparisons with macrophages, they can represent an important source
of TNFa on account of their overall tissue mass.
Most known subsets of lymphocytes can make TNFa in addition to
TNFi3. First reports of TNFa production by lymphocytes involved Natural
Killer (NK) cells, from which it can be induced by NK -sensitive but
not -resistant cell targets (Degliantoni et al.. 1985; Peters et al..
1986) and yeast cells (Djeu et al.. 1988). Both CD4+ and CD8+ subsets
of T-lymphocytes secrete TNFa in response to mitogens, but not LPS
(Cuturi et al., 1987) and Van Kooten et al. (1991) have further
suggested that memory and naive sub-divisions of CD4+ cells have
similar capacities for TNFa production. Lymphokine-activated killer
(LAK) cells secrete TNFa in response to IL-2 (Espevik et al.. 1988),
whilst immature T-cells, in the form of thymocytes (Ranges et al.,
1988), and B-cells (Sung et al., 1988b) also produce TNFa when induced
to proliferate. Furthermore, TNFa transcripts have been observed in
the latter following infection with Sendai virus (Goldfeld & Maniatis,
1989).
Neutrophils make and release TNFa in response to LPS (Dubravec et
al., 1990) and yeast (Djeu et al., 1990), whilst mast cells appear to
be unique amongst TNFa-producers in storing pre-formed TNFa, which is
released, along with other mediators, on degranulation (Steffen et
al., 1989; Gordon & Galli, 1990).
Other potential TNFa sources include astrocytes exposed to LPS or
some neurotropic viruses (Robbins et al.. 1987; Lieberman et al.,
1989) and LPS-stimulated renal mesangial cells (Baud et al.. 1989) and
keratinocytes. The latter also produce TNFa in response to UV-light
(Kock et al., 1990) and possibly irritants (Piguet et al.. 1991). In
the normal, pregnant uterus, TNFa mRNA and protein have been found in
several non-macrophage cell types, including epithelial and decidual
cells, as well as placental trophoblasts (Yelavarthi et al.. 1991).
Smooth muscle cells secrete TNFa in response to a 'non-physiological'
combined stimulus of LPS with a brief exposure to protein synthesis
inhibitors (Warner & Libby, 1989) and the secretory Paneth cells of
normal intestine can contain TNFa transcripts (Keshav et al., 1990).
'Inappropriate' expression of TNFa has also been documented from a
variety of tumour cells. Assorted EBV-transformed B-cell lines
(Williamson et al., 1983), many B-cell chronic lymphocytic leukaemias
(Cordingley et al., 1988) and several human epithelioid cell lines
(Spriggs et al., 1988) may secrete TNFa constitutively, whilst
selection of TNF-resistant murine fibrosarcoma cells led to the
identification of a subset of these cells producing low levels of TNFa
themselves (Rubin et al., 1986).
Finally, it has recently emerged that poorly-understood neural or
neuro-endocrine pathways to TNFa production also exist. Intracerebro-
ventricular injection of LPS induces a marked peripheral accumulation
of TNFa that cannot be accounted for either by export of TNFa or
leakage of LPS from the central nervous system (Ghezzi, 1992).
1.3. Induction of TNFa; gene, transcript and protein structure:-
1.3.1. Gene structure:-
Shortly after the cDNA's for human and murine TNFa were cloned (see
chapter 2) the corresponding genes were also cloned and sequenced
(Nedwin et al., 1985a; Semon et al., 1987), revealing that in each of
these species the TNFa gene is closely linked to that of TNFJ3, being
some 1100 bases 3' of the latter. This locus mapped to chromosomes 6
and 17 in the human and mouse respectively (Nedwin et al.,1985a;
Nedospasov et al. , 1986), the same chromosomal location as the MHC in
each. Later work confirmed that the TNF locus actually resides within
the MHC (Spies et al., 1986; Miiller et al., 1987), though the reasons
for this association are unclear.
Each TNF gene is approximately 3kb long and interrupted by three
introns with the fourth exon coding for the majority of the secreted
protein in each case, suggesting that the two genes arose from a
duplication event. Significant homology between the TNFa and B genes
only occurs in the fourth exon, though the whole TNF locus shows
considerable homology between the two species.
1.3.2. Gene induction:-
The early identification, potency and importance of the LPS-
stimulated macrophage as a TNFa producer have made it the most
extensively analysed model of TNFa production. These studies
demonstrate that TNFa production is controlled at several levels.
Whilst some workers conclude that the TNFa gene is transcriptionally
inactive in resting, human monocytes in vitro (Sariban et al., 1988),
others have found a low level of constitutive transcription in murine
peritoneal macrophages, both in vitro and in vivo (Jongeneel et al.,
1989; Collart et al., 1990). All agree, however, that following
appropriate stimulation the rate of TNFa gene transcription increases.
The regulatory region of this gene contains several sites which
appear to be important in transcriptional control, including four with
homology to recognition motifs for the NF-kappaB family of
transcription factors (Sen & Baltimore, 1986) and a single MHC class
II-like 'Y box' (Dorn et al.. 1987). Following stimulation of
macrophages with LPS, the nuclear concentration of NF-kappaB-like
proteins rises (Collart et al., 1990), presumably following
dissociation of these factors from I-kappaB in the cytoplasm (Baeuerle
& Baltimore, 1988), and several DNA-protein complexes form in the TNFa
promoter, formations which can be specifically blocked by oligo¬
nucleotides with the afforementioned sequences (Collart et al., 1990;
Shakhov et al., 1990). Furthermore, the inclusion of two or more of
the NF-kappaB motifs confers LPS-inducibility on an heterologous
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promoter, and deletion analyses, using promoter/reporter gene
constructs, suggest that a region containing the Y box is essential
for LPS-inducibility of the TNFa promoter (Shakhov et al., 1990).
Pathways linking LPS-exposure to alterations in the binding of
transcription factors to the TNFa promoter are incompletely
understood. However, some features are apparent:- 1) LPS induction of
TNFa appears to be mediated via interaction with a cellular receptor,
CD14 (Wright et_al., 1990); 2) known second messengers may be
involved: inhibitors of protein kinase C can block LPS induction of
TNFa (Kovacs et al., 1988), whilst raised levels of cAMP and cGMP are
associated with decreased and increased TNFa production, respectively
(Renz et al., 1988; Endres et al., 1991); 3) differential responses to
cyclic nucleotides in these studies and the results of others, which
demonstrate that cells rendered refractory to LPS with respect to TNFa
production can still secrete IL—1, IL-6 and IL-8 (Takasuka et al.,
1991; Fantuzzi et al., 1992), suggest that the LPS-induced pathway
leading to TNFa production differs from those leading to the
production of other LPS-inducible monokines; and 4) there is clearly
more than one pathway to TNFa induction, since zymosan can induce TNFa
from LPS-refractory cells (Takasuka et al.. 1991).
Involvement of NF-kappaB proteins in TNFa transcriptional control
helps to explain its inducibility by some other stimuli, particularly
other cytokines (see 1.2, 1.6). However, the extent to which different
pathways to TNFa induction may converge is not clear. Although
activators of protein kinase C such as phorbol-esters can increase the
nuclear concentration of an NF-kappaB-like protein (Griffin et al.,
1989) and induce TNFa gene transcription, an area of the TNFa promoter
which does not contain any NF-kappaB binding sites is sufficient for
full phorbol ester-responsiveness (Economou et al.. 1989b), suggesting
the existence of an NF-kappaB-independent pathway to induction.
Regions with homology to other known transcription factor binding
motifs (such as an AP-1 site and a cAMP-responsive element) do exist
in the TNFa promoter, which can also bind another transcription
factor, NF-IL-6 (Hensel et al., 1989), though the importance of these
findings is unclear. Nedospasov et al. (1992) have also identified
another protein-binding site in the 3' untranslated region (UTR) of
the TNFa gene, which may play a role in TNFa inducibility.
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How the expression of the TNFa gene is restricted to certain cells
is also poorly understood. Clearly, differential distribution of
molecules like CD14 or NF-kappaB proteins could contribute to tissue-
specific expression. However, Kruys et al. (1992) have demonstrated
that components in the TNFa gene 3' UTR effectively cancel out a
potentially constitutive activity of the gene promoter in some cell
types, but not others.
1.3.3. TNFa transcripts:-
Following LPS stimulation of monocyte/macrophages, spliced TNFa
transcripts of 1.6-1.7 kb accumulate then rapidly disappear. For
example, TNFa mRNA reaches maximum levels within one hour, then
becomes undetectable, by Northern blotting, within four hours of
stimulating murine macrophages in vivo (Remick et al. . 1989).
The short-lived nature of TNFa mRNA may be associated with the
presence of a UA-rich sequence in the 3' UTR. This sequence, which is
well conserved across species, contains an overlapping and repeated
octomeric element (UUAUUUAU), also found in the mRNA of many other
inflammatory cytokines (Caput et al.. 1986), which confers instability
on transcripts bearing it (Shaw & Kamen, 1986), probably mediated by a
selective ribonuclease (Beutler et al.. 1988).
Consideration of the quantity of TNFa secreted by the LPS-
stimulated macrophage, which is difficult to account for purely by
increases in mRNA levels, helped lead to suggestions of additional,
post-transcriptional control of TNFa production (Beutler et al.,
1986a). Han et al. (1990) subsequently showed that the same region
responsible for transcript instability also bestows (with contri¬
butions from surrounding sequences) the property of translational
inducibility by LPS. Though the additional LPS-stimulated pathway
which leads to this induction is poorly understood, the presence of a
similar sequence (derived from interferon [IFN] 13 mRNA) can inhibit
translation in animal, but not plant, systems (Kruys et al., 1987),
suggesting the presence of a translational block, which can be
overcome by an appropriate stimulus.
1.3.4. TNFa protein structure
The open reading frame (ORF) of an human TNFa transcript comprises
233 codons, predicting a full-length protein of 26kDa (Pennica et al.,
1984), whilst secreted human TNFa is only c,17kDa. Amino-terminal
sequence analysis of the purified, mature protein reveals that it
derives from the carboxy-terminal 157 amino acids (aa) of the pre-
protein (Aggarwal et al.. 1985b).
At 76 aa the 'discarded' propeptide is significantly longer than
typical signal peptides of many secreted proteins and is better
conserved across species than the secreted protein (86% compared to
79% in a human-mouse comparison), suggesting that it has an important
role. Kriegler et al. (1988) found that, in addition to the secreted
form, human TNFa also exists in stimulated macrophages as an integral,
transmembrane 26kDa protein with an extracellular carboxy-terminus.
Thus, one function of the leader is to anchor the full-length molecule
to the membrane. These authors also demonstrated that, although
inactive in free solution, recombinant 26kDa TNFa can function when
membrane-bound, a finding which extends to native cell-surface TNFa
(Decker et al., 1987). This form of TNFa also exists in activated T-
cells (Kinkhabwala et al., 1990).
Scuderi (1989) proposed that 17kDa, mature, human TNFa is finally
secreted via cleavage of the 26kDa precursor at the cell-surface by a
serine protease, though whether all secreted TNFa is produced in this
way is unclear. In humans and mice the presence of alternative, minor
cleavage sites may contribute to some heterogeneity in the size of the
secreted protein (Perez et al., 1990; Cseh & Beutler, 1989) and in the
latter species additional post-translational modification takes place
in the form of glycosylation (Green et al.. 1976), though the role of
the carbohydrate group is unclear. Factors governing how, and to what
extent, cleavage occurs are still largely unknown. However, the
existence of post-translational control of TNFa secretion must be
suspected, since conditions allowing the accumulation of TNFa pre-
protein have been described (Zuckerman et al., 1989).
Early characterisations suggested that TNFa exists in higher
molecular weight forms than the 17kDa or 26kDa monomeric entities
(Matthews, 1981a; Aggarwal et al., 1985b). Whilst each 17kDa molecule
has two cysteine residues, these form an intrachain disulphide bridge
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(Davis et al. , 1987). However, larger structures can be explained by
non-covalent association of 17kDa subunits (Davis et al.. 1987). Smith
and Baglioni (1987) proposed that most of the activity of TNFa is
associated with a homo-trimeric form, though others have postulated
that significant activity can be associated with dimers of TNFa
(Petersen et al. , 1989). Crystallographic studies confirm TNFa's
trimeric nature (Eck et al., 1988) and suggest that three 17kDa
monomers, each folded into an elongated, antiparallel, /1-pleated
sandwich, with a 'jelly-roll' topology and some structural homology to
a viral coat protein, come together to form a compact, bell-shaped
structure (Eck & Sprang, 1989; Jones et al., 1989). The significance
of such homology is currently unclear, as is the point at which newly-
synthesised TNFa trimerises, though self-assembly in solution is
possible (Davis et al.. 1987).
1.4. Actions of TNFa in vitro:-
Since its early recognition as a pleiotropic molecule, the
catalogue of actions attributable to TNFa has steadily grown. This
list includes the following, partially-overlapping, groups of
activities:- pro-inflammatory; tissue-remodelling; metabolic; cyto¬
toxic; endocrine; and direct influences on the life-cycles of assorted
pathogens.
1.4.1. Pro-inflammatory actions:-
Many of the pro-inflammatory activities attributable to TNFa can be
perceived as being likely to lead to the accumulation of activated
leukocytes at an appropriate site. They involve TNFa acting on cells
of the immune system, as well as the vascular endothelium.
In addition to being a prime source of TNFa, cells of monocyte/
macrophage lineage are also targets for its action. TNFa is
chemotactic for these cells (Wang et al., 1987, 1990), can promote the
maturation of promonocytic cell lines (Griffin et al., 1989; Peetre et
al., 1986) and increase the survival time of monocytes in serum-free
conditions (Mangan et al., 1991). Macrophages cultured in the presence
of TNFa also acquire increased abilities to destroy some pathogens
(Bermudez & Young, 1988), mediated, at least in part, via the
induction of reactive nitrogen intermediates (Liew et al., 1990a).
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TNFa's potential as a pro-inflammatory agent is also heightened by its
ability to stimulate these cells and/or fibroblasts and endothelial
cells, to produce other inflammatory mediators such as IL-1 (Dinarello
et al., 1986), IL-6 (Kohase et al., 1986), IL-8 (Matsushima et al.,
1988), GM-CSF (Munker et al..1986). M-CSF (Oster et al.. 1987),
platelet activating factor (PAF)(Cammussi et al., 1987), monocyte
chemotactic factor (Dixit et al.. 1990), platelet-derived growth
factor (Hajjar et al.. 1987), PGE2 (Dinarello et al.. 1986) and itself
(Philip & Epstein 1986).
Other leukocytes are similarly affected following exposure to TNFa.
It can cause neutrophils to rapidly adhere to endothelial cells
(Gamble et al., 1985) and is also a chemotactic factor for these cells
(Wang et al.. 1987). Subsequent migration away from a source of TNFa
may then be inhibited (Fast et al., 1988). TNFa also primes or,
provided they have migrated from suspension to be supported by a
suitable matrix, actually stimulates neutrophils' functional responses
(Nathan, 1987). Thus, TNFa-treatment enhances their binding to certain
bacteria (Steadman et al., 1991), increases their phagocytic ability
(Klebanoff et al., 1986; Van Strijp et al., 1991), promotes a
respiratory burst, H2O2 production and degranulation (Nathan, 1987)
and induces them to secrete other mediators such as PAF (Camussi et
al. , 1987). Eosinophils are likewise functionally activated by TNFa to
show enhanced antiparasitic activity (Silberstein & David, 1986).
TNFa not only helps to activate lymphocytes but it also enhances
their proliferation. Many surface markers associated with lymphocyte
activation, such as TNF receptors (TNF-R's), MHC class II proteins and
the Ly6A/E protein, are upregulated on T-cells, an NK cell line and
LAK precursors by treatment with TNFa, as are IL-2-R's (Scheurich et
al., 1987; Hackett et al.. 1988; Lee J. et al., 1987; Chouaib et al..
1988; Malek et al., 1989), helping to explain several synergistic
actions between TNFa and IL-2. TNFa enhances IL-2-induced secretion of
immunoglobulin by B-cells (Kehrl et_al., 1987) and, in combination
with IL-2, induces T-cells to secrete IFN gamma (Scheurich et al.,
1987). T-cells, thymocytes and B-cells all show enhanced proliferation
to mitogens, or IL-2, in the presence of TNFa (Hackett et al.. 1988;
Ranges et al., 1988; Kerhl et al., 1987; Jelinek & Lipsky, 1987;
Zucali et al., 1987), whilst Ranges et al. (1989) identified a T-cell
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line for which TNFa can actually replace IL-2 as a proliferative
signal. It also appears to play a role in the development of cytotoxic
lymphocytes (Ranges et al. . 1987) and augments the IL-2-induced
generation of LAK cells (Espevik et al.. 1988; Chouaib et al., 1988).
In addition to acting on peripheral blood elements, TNFa influences
erythroid progenitors, since it inhibits colony formation by
granulocyte/ macrophage-, erythroid- and multipotential- progenitor
cells (Broxmeyer et al., 1986; Peetre et al., 1986).
The vascular endothelial cell responds to TNFa with morphological,
secretory (see above) and cell surface changes, many of which favour
the development of an inflammatory response. Following TNFa treatment,
endothelial cells increase their metabolic rate, enlarge and change
shape, forming intercellular gaps and thus increasing the permeability
of a monolayer to macromolecules and other solutes (Stolpen et al.,
1986; Cavender et al., 1989; Brett et al., 1989). At the same time,
they display increased adhesiveness for leukocytes (Gamble et al.,
1985; Cavender et al., 1987) (and even some bacteria [Cheung et al.,
1991]), largely due to the upregulation of adhesion molecules, such as
ICAM-1, ELAM-1 and VCAM-1 (Pober et al., 1986b; Bevilacqua et al.,
1987; Osborn et al., 1989a). Ikuta et al. (1991) observed that such
increases may lead to the binding of NK cells and a subset of memory,
helper T-cells in preference to other lymphocytes. MHC class I
molecules also become more abundant on these (Pober et al., 1986b) and
other (Collins et al., 1986) cells.
TNFa also acts on endothelial cells to favour coagulation
(Bevilacqua et al., 1986). Enhanced procoagulant-, and reduced
anticoagulant-, activities have been associated with increased tissue
factor expression and a decrease in endothelial cell-dependent protein
C activation, respectively (Nawroth & Stern, 1986). Reduced production
of thrombomodulin (Lentz et al., 1991), as well as its internalisation
and degradation (Moore et al., 1989), increased levels of plasminogen
activator inhibitors (Mawatari et al.. 1991) and the sequestration of
plasminogen activator away from the circulation (Van Hinsbergh et al.,
1990) all contribute to the latter effect.
TNFa can also increase the expression of MHC class II molecules
induced on these cells (Lezcynski, 1990), as well as some monocytic
cell lines (Arenzana-Seisdedos et al., 1988), by IFN gamma. However,
these effects may depend on the chronology of events and the state of
cellular differentiation. Leeuwenberg et al. (1988) found that TNFa
added with, or before, IFN gamma actually opposed its effects on
endothelial cells, whilst Watanabe and Jacob (1991) observed
antagonism on a selection of mature but not immature cells.
1.4.2. Tissue-remodelling actions:-
Several actions of TNFa are involved in processes of tissue
remodelling. Fibroblasts respond to TNFa with enhanced proliferation
in the presence of serum (Sugarman et al., 1985; Vilcek et al., 1986),
perhaps mediated by an upregulation of EGF-R's (Palombella et al.,
1987). This is accompanied by a prolonged increase in collagenase
production (Dayer et al., 1985) and a concurrent decrease in collagen
synthesis (Solis-Herruzo et al., 1988). Under the influence of TNFa,
bone and cartilage resorption are also stimulated, whilst new bone
formation and the synthesis of glycosaminoglycans are suppressed
(Bertolini et al., 1986; Saklatvala, 1986; Ikebe et al.,1988). TNFa
also enhances the proliferation of astrocytes (Selmaj et al. , 1990)
and a role for TNFa in angiogenesis may be predicted by the
observation that it induces endothelial cells to form capillary-tube¬
like structures when grown on collagen cells (Leibovich et al., 1987).
1.4.3. Metabolic actions:-
Early suggestions by Cerami et al. (see 1.1) that TNFa has
important effects on body metabolism have since been confirmed by
several studies on fat, muscle and liver cells. It downregulates the
transcription of several, normally-active genes in adipocytes, as well
as preventing the morphological differentiation of these cells.
Specific enzymic activities reduced include LPL, fatty acid
synthetase, acetyl CoA carboxylase and glycerolphosphate dehydrogenase
(Pekala et al., 1983; Torti et al., 1985). TNFa also inhibits the
differentiation of myocytes (Miller et al., 1988) and stimulates
glycogenolysis in these cells (Lee M. et al.. 1987).
Hepatoma cells produce some complement proteins and al-chymotrypsin
in response to TNFa, whilst decreasing their synthesis of albumin and
transferrin (Perlmutter et al., 1986), suggesting a possible role for
TNFa in acute phase protein synthesis.
1.4.4. Cytotoxic actions;-
Whilst TNFa generally does not kill normal cells, responses can be
changed when cells become transformed or parasitised. Following
Carswell et al.' s original observation (1975) that TNFa was toxic to
cells derived from a murine fibrosarcoma, subsequent surveys showed
that 30-50% of transformed cell lines are susceptible to the cytotoxic
or sometimes cytostatic action of TNFa (Williamson et al., 1983;
Sugarman et al., 1985). Wong and Goeddel (1986) found that TNFa can
also kill some cells infected with certain viruses, whilst others have
since shown that simply expressing some viral proteins (such as
Adenovirus E1A or SV40 large T) can convert a cell to TNFa sensitivity
(Chen M-J. et al., 1987; Duersken-Hughes et al., 1989; Ames et al.,
1990). TNF's a &. 13 appear to be major mediators of the antiviral
activity of NK cells by such actions (Paya et al., 1988). Other
intracellular pathogens, such as Mycobacteria, and their antigens, can
also render cells more sensitive to TNFa cytotoxicity (Filley & Rook,
1991).
Some exceptions to the above generalisations can be found. High
doses of TNFa can kill normal endothelial cells (Robaye et al., 1991),
though this effect may depend on cellular sub-type, as Meyrick et al.
(1991) found that TNFa could kill cells derived from the aorta, but
not the pulmonary microvasculature, of the same animal. TNFa is also
toxic to normal oligodendrocytes and can damage the myelin they
produce (Robbins et al., 1987; Selmaj & Raine, 1988). Furthermore, it
can combine with IFN gamma to kill pancreatic islet cells in culture
(Pukel et al., 1988). However, the evolutionary reasons for such
apparently undesirable activities are unclear. Also in contrast to its
general actions, TNFa may actually be a growth factor for a few
transformed cells, notably those derived from some B-cell chronic
lymphocytic leukaemias (Cordingley et al., 1988; Digel et al., 1989).
1.4.5. Endocrine actions:-
TNFa forms one link between the body's immune and endocrine
systems. It induces the release of ACTH, growth hormone and
thyrotropin from pituitary cells (Milenkovic et al., 1989), yet
inhibits ACTH-, FSH- and HCG- induced steroidogenesis in adrenal,
ovarian and testicular cells respectively (Jaattela et al., 1990;
Adashi et al.. 1989; Warren et al., 1989). In contrast, the direct
effects of TNFa on steroidogenesis in these cells is stimulatory
(Darling et al.. 1989; Roby & Terranova, 1988; Warren et al., 1989).
Whilst some of these actions presumably help to mobilise body
resources during illness, others may be involved in reproductive
biology, growth (see 1.8.7) or have feedback implications (see 1.7).
1.4.6 Direct influences on life-cycles:-
TNFa can also affect the life-cycles of assorted pathogens in
several, sometimes-surprising ways. In addition to killing some
virally-infected cells, TNFa also exerts an antiviral action via the
induction of 2'-5' oligoadenylate synthetase (Mestan et al. , 1988;
Wong & Goeddel, 1986). How much of this activity is actually mediated
via the induction of interferons, with which TNFa synergises, has been
a subject of dispute (Mestan et al., 1986; Kohase et al.. 1986; Van
Damme et al., 1987; Reis et al., 1988). However, TNFa only appears to
be able to inhibit some viruses in some cell types. Schijns et al.
(1991) found that of brain cells infected with Aujeszky's virus, TNFa
only exerted antiviral activity in astrocytes. Furthermore, TNFa can
actually enhance the proliferation of HIV in some cells (see 1.8.5).
The ability of TNFa to kill cells infected with other pathogens, or
to activate macrophages to kill, has been mentioned. In addition, TNFa
can simply inhibit the intracellular replication of some pathogens (de
Titto et al., 1986) and may kill malarial parasites more directly
(Taverne et al., 1984).
Finally, some nematodes may actually exploit TNFa to their
advantage, in spite of its ability to enhance parasiticidal activity.
Adult Schistosoma mansoni worms respond directly to TNFa by a 15-fold
increase in egg-laying, a response the parasite may have developed to
leave eggs in the protective environment of a TNF-induced granuloma
(Amiri et al.. 1992).
1.5. Actions of TNFa in vivo:-
Given the myriad of activities displayed by TNFa, the net effect of
its administration to normal animals in vivo is highly dependent on
the dose, route and duration of treatment. Due to the induction of
other mediators, it may also, on occasion, be opposite to that
expected from the results of in vitro studies.
Tracey et al. (1986) first demonstrated that the intravenous (IV)
infusion of rats with high doses of TNFa reproduces most of the
clinical signs of septic shock, including hypotension, metabolic
acidosis, early hyperglycaemia later converting to hypoglycaemia,
hyperkalaemia, bloody diarrhoea and ultimately death from respiratory
arrest. Post-mortem examination of these animals revealed
inflammation, haemorrhage and necrosis in many organs.
Changes seen following sub-lethal doses of IV TNFa are less severe
but include some intravascular coagulation (Van der Poll et al.,
1990), panleukopaenia then subsequent neutrophilia (Van der Poll et
al., 1992a) and increases in energy expenditure, CO2 production, blood
Cortisol and triglyceride levels, and muscle catabolism, though blood
amino acid levels may actually fall (Starnes et al., 1988; Flores et
al., 1989), perhaps due in part to enhanced uptake by the liver
(Warren et al.. 1987). Dinarello et al. (1986) also found that low
doses of TNFa induce a single peak of fever, probably mediated via the
direct induction of PGE2 from hypothalamic cells. Higher doses,
however, induce a biphasic response, with a second peak attributable
to TNFa-induced IL-1. The importance of secondary agents in mediating
TNFa actions in vivo is further illustrated by observations that
antagonists to PAF (Sun & Hsueh, 1988), IL-1 (Everaerdt et al.. 1992)
or IL-6 (Starnes et al., 1990) can each confer significant protection
against TNFa-induced toxicity.
In contrast to their findings following the IV administration of
high doses of TNFa, Tracey et al. (1988) found that repeated intra¬
peritoneal (IP) injections of lower doses led to a different syndrome
involving anaemia and weight loss, with reductions in both body
protein and fat. Tissue inflammation with leukocytosis was also noted
at the site of injections. Cachexia was similarly observed following
the inoculation of nude mice with neoplastic cells constitutively
expressing TNFa, but not with control cells (Oliff et al.. 1987).
However, there is more than one pathway to TNFa-induced weight-loss.
Whilst classical cachexia results when these cells are implanted
intramuscularly, their inoculation intracerebrally induces profound
anorexia (Tracey et al., 1990). Chronic infusion of TNFa can also
cause some hepatic necrosis (Gaskill, 1988).
The effects of continuous, dysregulated overproduction of TNFa have
been further studied using transgenic mice which constitutively
express human TNFa (Keffer et al., 1991). Whilst these mice fail to
put on weight normally, they also develop a chronic, inflammatory
polyarthritis, a finding in keeping with a proposed role for TNFa in
rheumatoid arthritis (see 1.8.6).
Acute, local administration of TNFa leads to inflammation, whether
in the skin (Sharpe et al., 1987) or brain (Ramilo et al., 1990). This
can involve oedema and an early neutrophil accumulation, particularly
in the presence of a vasodilator such as PGE2 (Rampart et al., 1989).
A slower mononuclear accumulation may follow (Munro et al.. 1989),
whilst dendritic cells migrate to the local draining lymph node
(Cumberbatch & Kimber, 1992).
Sustained infusion of TNFa in a local, skin model again leads to an
early accumulation of neutrophils but after a few days the nature of
the reaction changes, with epidermal thickening, fibroblastosis,
increased collagen deposition and new capillary formation being
evident (Piguet et al., 1990), underlining TNFa's potential role in
tissue remodelling.
1.6. Cellular mechanisms of TNFa actions
Early work indicated that TNFa interacts with high-affinity cell
surface receptors (Aggarwal et al., 1985a). cDNA's encoding two
distinct human TNF-R's, types I and II (TNF-RI and TNF-RII) have now
been cloned, sequenced and expressed (Nophar et al., 1990; Schall et
ad., 1990; Loetscher et al., 1990; Smith C. et al. , 1990) as have
their murine homologs (Barrett et al.. 1991; Lewis et al., 1991).
(Different authors have also called these receptors p55, p60, type B
or confusingly type II receptor, and p75, p80, type A or confusingly
type I receptor, respectively.)
TNF-R's have been found on most mammalian cells, except for red
blood cells and platelets (Munker et al., 1987), in keeping with
TNFa's widespread activities. Cells of epithelial origin seem to
predominantly express TNF-RI, whilst myeloid cells may express both
types (Hohmann et al., 1989, 1990a; Brockhaus et al.. 1990). Whether
further TNF-R's exist remains to be seen. Using a combination of high-
affinity antibodies to TNF-RI and TNF-RII it is possible to totally
block the binding of TNFa to some cell types but not others (Dr.B.
Aggarwal, personal communication). Whilst this might point to the
existence of other receptors, TNFa can bind to lipid membranes
directly under some conditions, notably those of low pH (Yoshimura &
Sone, 1987).
Sequence analyses suggest that each receptor is organised into
extracellular, transmembrane and intracellular domains. The extra¬
cellular domains of TNF-RI and -RII share some homology in amino acid
sequence, (including the conservation of several cysteine residues)
with each other (28% for the human molecules) and several other
proteins, including putative cytokine receptors, such as NGF-R, 0x40,
Bp50, CD27, and Fas antigen (Smith C. et al., 1990; Itoh et al. , 1991;
Camerini et al., 1991). Expression studies have also revealed that
whilst murine TNFa displays high affinity binding to both murine
receptors, its affinity for TNF-RII is slightly greater than that for
TNF-RI and, though murine TNF-RI shows similar affinity for human and
murine TNFa, the murine TNF-RII has little affinity for the human
cytokine (Lewis et al., 1991). This can perhaps be explained by the
fact that the extracellular domain of TNF-RII shows less conservation
across the two species than that of TNF-RI.
Following binding, TNFa-receptor complexes are internalised and the
cytokine is degraded (Tsujimoto et al., 1985; Mosselmans et al.,
1988). Whilst one report using microinjection techniques documents an
ability of TNFa to perform some functions intracellularly (Smith M. et
al., 1990), fixed, cell-surface TNFa can induce cytotoxicity (Decker
et al., 1987) and one can elicit many functions associated with TNFa
by using whole antibodies (but not monovalent Fab fragments, against
TNF-RI at least) to each of the two receptors (Engelmann et al.,
1990a; Espevik et al.. 1990; Tartaglia et al., 1991), suggesting that
cross-linking of receptors is sufficient to convey the correct
cellular signals for several functions. Studies with soluble receptors
also suggest that an individual TNFa trimer may bind up to 3 molecules
of only one type of receptor (Scheurich et_al., 1992), a prerequisite
condition for achieving high cross-linking efficiency.
By using agonistic, receptor-specific antibodies one can define
certain TNFa actions as being mediated via TNF-RI or TNF-RII
(Tartaglia et al.. 1991). Functions such as cytotoxicity and the
induction of the enzyme manganous superoxide dismutase (MnSOD, see
below) can be elicited, in susceptible cells expressing both types of
receptor, by antibodies to TNF-RI but not TNF-RII, whilst enhancement
of thymocyte proliferation and induction of proliferation of CT-6
cells, previously shown to be species-specific effects (Ranges et al. ,
1988, 1989), may be elicited by antibodies to TNF-RII but not TNF-RI.
Thus, appropriate stimulation of either receptor activates a different
set of pathways.
Understanding the mechanisms by which TNFa binding to its receptors
is converted into its many actions is complicated by several factors.
These include:- 1) it appears to activate many, possibly inter¬
dependent, pathways simultaneously (not surprisingly in view of its
pleiotropic nature); 2) TNFa may have different, even opposite,
effects in different cell types: differential receptor distribution
may contribute to such disparity, particularly since TNF-RI and TNF-
RII expression can be independently regulated (Hohmann et al.,
1990a), but alternative effector mechanisms could also be involved in
different cells; 3) though two sets of pathways exist (see above),
there seems to be some interaction between them, or between TNF-RI and
TNF-RII, since one can reduce the cytotoxicity of TNFa for certain
cells by blocking its binding to TNF-RII (Shalaby et al.. 1990);
4) more than one pathway may lead to the same end result (e.g. cell
death, see below); and 5) the intracellular domains of TNF-RI and TNF-
RII share little or no homology with each other, or those of other
known receptors, giving few clues as to signalling methods, though
studies with deletion mutants do show that the intracellular domain of
human TNF-RI is essential (Tartaglia & Goeddel, 1992).
It has been found that G-proteins, known couplers of receptors to
intracellular enzyme systems, can be activated by TNFa (Imamura et
al., 1988) and blocking studies suggest that these may be involved in
some, but not all, of TNFa's actions on endothelial cells (Brett et
al., 1989). Furthermore, in some cell types TNFa activates phospho-
lipase A2 (PLA2) (Neale et al.. 1988; Hollenbach et al., 1992) (an
enzyme which can be influenced by G-proteins [Jelsema & Axelrod,
1987]), with the release of arachidonic acid. TNFa also increases the
intracellular levels of cAMP in fibroblasts (Zhang et al., 1988),
though whether this is the result of increased activity of G-protein-
associated adenylate cyclase is unclear. A phosphatidylcholine-
specific phospholipase C and a phospholipase D may also be activated
by TNFa, leading to the formation of another second messenger,
diacylglycerol (DAG) (Schiitze et al., 1991; Billah et al., 1989;
Bauldry et al.. 1991).
It is apparent that within minutes of binding to many cell types
TNFa induces the phosphorylation of several cytoplasmic and nuclear
proteins (Zhang et al. . 1988; Schiitze et al. , 1989; Shiroo &
Matsushima, 1990; Guy et al., 1992), including an mRNA cap-binding
protein (Marino et al., 1989), though the method(s) remains a matter
of debate. Different studies have documented increased activities, in
response to TNFa, of protein kinases C (Brenner et al.. 1989) and A
(Zhang et al., 1988) and the tyrosine kinase located within the EGF-R
(Donato et al.. 1989), whilst Shiroo and Matsushima (1990) proposed
that a novel kinase was responsible for TNFa-induced phosphorylation
of two proteins in PBM's. More recently, however, Guy et al. (1992)
found that of 116 fibroblast cell proteins whose phosphorylation
status was altered by TNFa, 95% were similarly affected by okadaic
acid, a phosphatase inhibitor, in contrast to far less faithful
mimicry shown by assorted protein kinase agonists.
One end result of TNFa action is clearly the altered expression of
numerous proteins. Whilst an effect on mRNA cap-binding (see above),
and hence transcript translation, may be one method of protein
regulation, TNFa also induces the expression of several 'primary
response genes' (Dixit et al., 1990). Genes known to be induced by
TNFa include those of transcription factors such as c-fos and c-.iun
(AP-1) (Lin & Vilcek, 1987; Brenner et al., 1989; Dixit et al., 1989),
which may then mediate the induction of 'secondary genes'. A growing
list of other transcription factors either induced or initially
activated by TNFa, has been compiled. These include:- NF-kappaB
(Griffin et al. , 1989) (helping to account for the ability of TNFa to
induce itself); NF-GMa (Shannon et al., 1990); and IRF-1 (Fujita et
al., 1989). TNFa may also decrease the DNA-binding activity of others
such as C/EBP (Ron et al., 1990). Whilst pathways linking TNFa
exposure to altered nucleic acid-protein bindings are incompletely
understood, it does appear that the enhanced binding of NF-kappaB is
dependent on DAG-mediated activation of a sphingomyelinase, to produce
another second messenger, ceramide (Schiitze et al. . 1992).
How TNFa induces the killing of some cell types and not others has
also been a matter of interest. Matthews et al. (1987) found that the
cytotoxicity of TNFa was markedly reduced under anaerobic conditions,
implicating oxidative damage as a cause of death. Oxygen radicals can
originate from metabolism of arachidonic acid, amongst other sources,
and inhibitors of PLA2 or arachidonate metabolism may inhibit TNFa-
induced cytotoxicity (Matthews et al., 1987; Neale et al.. 1988).
Agarwal et al. (1988), however, found that TNFa induces ADP-
ribosylation (also known to be a potential route to cytotoxicity
[Skidmore et al.. 1979]) in susceptible cells and that inhibitors of
this process were protective. It seems probable, therefore, that more
than one pathway may be involved in TNFa-mediated cytotoxicity, as one
might expect from the observation that TNFa can cause both apoptotic
and necrotic forms of cell death (Laster et al., 1988).
Early receptor studies (Kull et al., 1985) failed to implicate the
absolute presence or absence of TNFa binding as a means of determining
TNFa-susceptibility or -resistance. The facts that an inhibitor of
transcription such as actinomycin D can render cells more susceptible
to TNFa (Ostrove & Gifford, 1979) and that TNFa can induce tolerance
to subsequent, combined treatment (Hahn et al., 1985) have been taken
to suggest that TNFa may also induce protective factors. At least
three such proteins have been found:- MnSOD (Wong & Goeddel, 1988), a
scavenger of free radicals, plasminogen activator inhibitor type-2
(Kumar & Baglioni, 1991) and A20 (Opipari et al., 1992), a novel
protein whose function is less well understood. Wong and Goeddel
(1988) also suggested that, since some TNFa-resistant cells were found
to express MnSOD constitutively, susceptibility to TNFa may depend on
the levels of this enzyme. Hollenbach et al. (1992), however, found
that TNFa could not activate PLA2 in some TNFa-resistant cell lines
unless actinomycin D was present, when these cells became susceptible.
Thus, not surprisingly, there may be more than one way of achieving
TNFa resistance.
1.7. Controlling TNFa activity:-
To derive benefit from TNFa, whilst avoiding its harmful effects,
its activity must clearly be tightly regulated, yet capable of
adjustment to suit changing needs. Several factors affecting the
production and availability of, as well as cellular responsiveness to,
TNFa have been identified, though the extent to which each operates in
individual situations is poorly understood.
Since TNFa is not produced without appropriate stimulation, the
successful removal of a pathogen by the inflammatory reactions it
provokes and the short-lived nature of TNFa transcripts (see 1.3.3)
would appear to be two methods by which TNFa production may be
limited, though the potential for spatial amplification of TNFa
production, mediated by LPS/TNFa-induced cytokines, such as IL-1, TNFa
and GM-CSF, clearly exists. Though precise details of the
downregulation of TNFa transcript production and translation are
poorly understood, many mediators are known to reduce or prevent TNFa
production, including:- PGE2 (Renz et al.. 1988); corticosteroids
(Beutler et al., 1986a); TGF/1 (Espevik et al., 1987; Chantry et al.,
1989); IL-4 (te Velde et al., 1990); IL-6 (Aderka et al., 1989); and
IL-10 (de Waal et al.. 1991). Since several of these agents can be
induced by LPS and/or TNFa (see 1.4, 1.5), they may constitute the
effectors of feedback mechanisms by which TNFa production can be
switched off and/or limited. In the case of failure to clear some
offending pathogens, production may also be restricted by the
development of tolerance to the inducing stimulus, as occurs with LPS
(Takasuka et al., 1991). The potential to boost TNFa production under
certain circumstances also exists. Exposure to IFN gamma (Beutler et
al., 1986b), or the stimulation of a-adrenergic receptors (Spengler et
al., 1990), markedly increase the expression of LPS-induced TNFa. IFN
gamma can also enhance the induction of TNFa by other cytokines (Hart
et al., 1988; Nedwin et al., 1985b) and overcome the post-
transcriptional blockade of TNFa production imposed by corticosteroids
(Luedke & Cerami, 1990).
TNFa's availability can be affected by its distribution, clearance
from the body and the presence of specific inhibitors. Putative
controls over the release of mature TNFa from its cell-surface form
(see 1.3.4) may serve to regulate the proportions of TNFa available to
act locally or more distantly. Furthermore, TNFa can bind reversibly
to heparin (Lantz et al., 1991) and it is possible, therefore, that
sub-saturating amounts of tissue-derived TNFa may be retained close to
the site of production, by heparan sulphate in connective tissue.
Similarly, TNFa secreted into certain body compartments such as the
sub-arachnoid space or pulmonary alveoli may be 'trapped' by
structural barriers (Waage et al., 1989; Nelson et al., 1989). Any
TNFa reaching, or produced within, the circulation, may still have a
limited distribution, since it can bind to a-2-macroglobulin
(Wollenberg et al., 1991) and thus perhaps be targeted to certain
tissues via receptors for this carrier.
Intravenously administered TNFa is rapidly cleared from the
circulation with a half-life of only 6-7 minutes (Beutler et al.,
1985d). Much of its removal can be accounted for by binding to TNF-R's
(and its subsequent internalisation and degradation) within well-
vascularised tissues. However, TNFa can also bind to the renal protein
uromodulin (Hession et al., 1987), hence allowing some additional
clearance via the kidney.
Two other TNFa-binding proteins, sharing immunological identity
with TNF-RI and TNF-RII, and able to inhibit the cytotoxicity of TNFa
by competing with cell receptors for its binding, have been found in
urine, purified and partially sequenced (Seckinger et al., 1988, 1989,
1990; Engelmann et al., 1989, 1990b). Sequence analysis suggests that
they derive from cleavage of the extracellular domains of the two
receptors (indeed sequence derived from one of these proteins was used
to help clone the cDNA for human TNF-RI [Nophar et al., 1990]).
Furthermore, there is a large circulating pool of these proteins in
the plasma of normal individuals (Aderka et al.. 1991), a pool which
increases following exposure to LPS or TNFa (Van der Poll et al.,
1992b). They are thus likely to be an important physiological method
of inactivating circulating TNFa. Curiously, they may also actually
help enhance TNFa activity in situations where TNFa enjoys a longer
half-life (such as body compartments, see above) by stabilising its
trimeric structure (Aderka et al., 1992). An 'activity-prolonging'
function has also been proposed (Bendtzen et al., 1990) for the high
levels of non-neutralising auto-antibodies to TNFa seen in the plasma
of some individuals (Fomsgaard et al., 1989), though their
significance is poorly understood.
Responsiveness to TNFa may be adjusted intracellularly (e.g. by the
induction of protective proteins and hence tolerance [see 1.6]) or at
the level of receptor expression. On activation, the initially low
numbers of TNF-R's on most resting lymphocyte subsets rises (Kerhl et
al., 1987; Munker et al., 1987; Scheurich et al., 1987; Owen-Schaub et
al., 1989), largely via an increase in TNF-RII (Erikstein et al..
1991; Ware et al.. 1991), though NK and LAK cells may also increase
levels of TNF-RI (Naume et al., 1991; Dett et al.. 1991). In contrast,
stimulation of activated T-cells via the TCR leads to an early
downregulation of TNF-R's, before TNFa is produced itself (Ware et
al., 1991), thus limiting a possible autocrine stimulatory loop.
Exposure of macrophages, but not endothelial cells, to LPS leads to a
rapid, and total, internalisation of their TNF-R's (Ding et al.,
1989), again preventing the action of TNFa on its source cell.
Furthermore, neutrophils shed their receptors on exposure to formyl-
Met-Leu-Phe peptide, C5a and GM-CSF (Porteu & Nathan, 1990). Since
these might be found, or induced, in the vicinity of bacteria, one may
envisage that having been successfully summoned to an appropriate
site, neutrophils can help inhibit further TNFa activity by raising
the local (and possibly systemic) concentration of soluble receptors.
Not surprisingly, many of TNFa's actions may be modified by the
presence of other mediators. TNFa is more toxic to normal cells and
tissues in the presence of some bacterial toxins, including LPS
(Rothstein & Schreiber, 1988; Louise & Obrig, 1991), though how much
of this synergy actually involves endogenous mediators is unclear. IFN
gamma is also known to enhance many of TNFa's actions (and vice versa
- see 1.4). These include:- its cytotoxicity to many cell lines
(Williamson et al., 1983; Sugarman et al.. 1985); the activation of
neutrophils (Shalaby et al., 1985; Djeu et al., 1986), endothelial
cells (Doukas & Pober, 1990) and keratinocytes (Barker et al., 1990);
and the suppression of haematopoiesis (Broxmeyer et al., 1986).
Furthermore, some activities, such as the activation of macrophages to
kill certain cells and parasites (Esparza et al. , 1987; Liew et al.,
1990a) and the induction of class II molecules on pancreatic islet
cells (Pujol-Borrell et al., 1987), may only be seen when both of
these cytokines are present. Part of this synergy may be explained by
the potential of I FN gamma to upregulate TNF-R's on some cells
(Aggarwal et al., 1985a), an ability sometimes exhibited by other
IFN's (Billard et al., 1990). However, other pathways are also
involved as Johnson and Pober (1990) found that IFN gamma could not
upregulate TNF-R's on the same endothelial cells where it synergised
with TNFa in the induction of class I MHC molecules.
Additive or synergistic effects may also be seen with IL-1 (e.g.
Seelentag et al., 1987; Ranges et al., 1988), a cytokine with which
TNFa shares many pro-inflammatory and other activities (Pober et al.,
1986a,b; Le & Vilcek, 1987). This overlapping pattern of activity
includes phosphorylation of many of the same proteins (Guy et al.,
1991) and induction of the same transcription factors (Osborn et al.,
1989b) and proteins (Beresini et al., 1988). Why should there be such
redundancy of function between these frequently co-induced molecules?
Observations that Epstein-Barr virus can inhibit TNFa gene
transcription (Gosselin et al., 1991) and that, by its homology to the
TNF-R's, the T2 protein of Shope fibroma virus is actually a form of
soluble TNF-R (Smith et al., 1991) suggest one possibility. Since
pathogens can apparently acquire the ability to subvert one cytokine's
activities, then having others with overlapping abilities could be an
evolutionary advantage.
TNF/3 is another such mediator. Like TNFa, TNF/3 molecules form homo-
trimers with a similar 3D structure (Eck et al., 1992) and a
comparable ability to TNFa to bind to TNF-RI (Schall et al., 1990).
Thus, in sub-saturating amounts, the two often display additive
activities. There are significant differences between them, however.
Though TNF/3 can also bind to TNF-RII, it shows slightly less affinity
for this molecule and its soluble form than does its 'twin' (Smith C.
et al.. 1990; Engelmann et al., 1990b). Somewhat surprisingly, it also
shows considerably less affinity than TNFa for the soluble form of
TNF-RI (Pennica et al.. 1992). It is produced by a more limited cell
range (activated lymphocytes) and in these cells TNFa and TNF/3
induction is independently regulated (Cuturi et al., 1987; Sung et
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al., 1988a). When coinduced, TNF/? is also produced more slowly than
TNFa (Nedwin et al., 1985b). Furthermore, TNFJ3 is markedly less potent
than TNFa in many activities, such as inducing endothelial cells to
secrete IL-1 (Locksley et al. . 1987) and to adhere to neutrophils
(Desch et al., 1990). Broudy et al. (1987) also found that, in
contrast to TNFa, TNFi3 was totally unable to induce haematopoietic
growth factors from endothelial cells at any concentration tested,
whilst Oster et al. (1987) even found that TNF/I could block a similar
action of TNFa on monocytes. This would suggest either that TNF/1 is
incapable of adequately cross-linking one of the TNF-R's or that not
all of TNFa's actions are signalled simply by cross-linking TNF-R's
(see also chapter 3). Whether the existence of a second TNF may also
be due to previous outmanoeuvreing of a pathogen's subversive
activities and/or perhaps to a need to respond slightly differently in
different circumstances remains to be seen.
Finally, the activity of TNFa may be affected by the presence of
antagonistic agents. These include other LPS-inducible monokines such
as TGF/I, which may be described as generally immunosuppressive (Kehrl
et al., 1986; Ristow, 1986; Rook et al.. 1986) and which also induces
directly opposing effects to TNFa on collagen and proteoglycan
synthesis (Ignotz & Massague, 1986; Chen J. et al., 1987) and
curiously, IL-1, since it may actually inhibit some aspects of
endothelial cell activation caused by TNFa (Cavender & Edelbaum, 1988;
Leszcynski, 1990). Furthermore, IL-1 can cause a temporary reduction
in TNF-R numbers on some cells, as well as inducing longer-lasting
tolerance to TNFa cytotoxicity (Holtmann & Wallach, 1987).
Consequently, quantitative, temporal and spatial differences in the
production and distribution of many other cytokines are also of
importance in ultimately determining TNFa activity, adding to the
complexity of its control.
1.8. TNFq in disease and development;-
Prominent roles have been proposed for TNFa in many diseases, often
following demonstrations of its altered production and/or ability to
modify the disease outcome, or to reproduce some of its features.
However, since the induction of TNFa does not necessarily mean that
the same range of activities associated with giving a similar quantity
of TNFa will follow (see 1.7), studies measuring alterations to
disease progression when endogenous TNFa activity is blocked are
invaluable in confirming its net effect. On the basis of such
findings, modification of TNFa activity has been suggested as a
possible therapeutic approach for some illnesses. Such treatments
merit caution, however. Whilst controlled TNFa production can
contribute to the elimination of a pathogen, acute overproduction in
the face of an overwhelming infection, or more chronic dysregulations
of its activity, which may occur, for example, during persistance of
some stimuli, can clearly be deleterious. Consequently, an underlying
theme in many diseases is that TNFa can be simultaneously associated
with both beneficial and harmful actions. Furthermore, TNFa is but one
of a network of mediators and cannot be considered in isolation.
1.8.1. Acute bacterial infection:-
The finding that antagonising TNFa activity could protect mice from
the lethal effects of LPS (see 1.1) has since been extended to an
ability of anti-TNFa antibodies to protect baboons from an
experimentally-induced lethal bacteraemia (Tracey et_al., 1987). Such
treatments were only effective if given prior to, or within a very
short space of time after, the lethal infusion, a finding consistent
with TNFa inducing a cascade of other mediators (see 1.4, 1.5).
Elevated levels of TNFa have been detected in the sera of patients
suffering from septic shock and show some correlation with the outcome
(Calandra et al., 1990). TNFa can also be found in the sera and other
body fluids of patients with localised infections such as pneumonitis
and meningitis, though these levels do not always correlate with
clinical severity (Waage et al., 1989; Moller et al., 1991; Millar et
al., 1989; Nohynek et al., 1991). This fits with findings that in more
slowly-progressive models of septic disease TNFa may exert a pre¬
dominantly protective effect. For example, anti-TNFa antibodies
capable of protecting against the lethal effects of IV LPS could not
protect against lethality in one model of peritonitis (Bagby et al.,
1991) and even increased mortality in another (Echtenacher et al.,
1990). Predominantly protective roles for TNFa have also been proposed
in Listeriosis, where anti-TNFa treatment can convert a mild infection
into a lethal one (Havell, 1987), and in Salmonellosis where similar
treatment also exacerbates the infection (Mastroeni et al., 1991; Tite
et al.. 1991), partly by abolishing TNFa-induced enhancement of
immunity. An IP injection of TNFa may even enhance survival when given
prior to an inoculation of Salmonella (Nakano et al., 1990).
1.8.2. Protozoal infection;-
TNFa has not only been incriminated in the cachexia of
trypanosomiasis (see 1.1) but raised serum levels of TNFa have been
observed in other parasitic diseases such as Leishmaniasis and Malaria
(Scuderi et al., 1986). Higher TNFa concentrations can be associated
with several manifestations of severe malaria (Shaffer et al., 1991)
and antibodies to TNFa can be protective against one such syndrome,
cerebral malaria, in a murine model (Grau et al., 1987), though these
mice still eventually die from other manifestations of the disease. In
this context, TNFa is likely to be simultaneously playing a protective
role since it may be involved in killing malarial parasites (Taverne
et al., 1984), especially in combination with IFN gamma and other
serum factors (Naotunne et al., 1991). A predominantly protective role
has been proposed for TNFa in Leishmaniasis, where anti-TNFa
treatments worsen the condition and injections of TNFa lead to
clinical improvement (Titus et al., 1989; Liew et al., 1990b). A major
involvement of IFN gamma is also likely here since the two synergise
in mediating the killing of these organisms (Liew et al., 1990a) and
the latter primes monocytes for TNFa production in response to
Leishmania donovani (Reiner et al., 1990).
1.8.3. Granuloma formation
Prominent roles for TNFa have also been found in more chronic
granulomatous and fibrotic types of disease. Elevated levels of
probably locally-produced TNFa have been found in the pleural fluid of
patients with tuberculous pleurisy (Barnes et al., 1990) and in the
serum of patients with other Mycobacterial diseases such as leprosy
(Sarno et al. , 1991), in keeping with findings that Mycobacteria can
directly induce TNFa production (see 1,2). Macrophages from
tuberculosis (TB) patients also seem to be primed to secrete more TNFa
in response to LPS (Ogawa et al., 1991). Whilst it is possible that
chronic overproduction of TNFa contributes to the cachexia seen in TB,
it may play a predominantly beneficial role in this disease. Not only
can TNFa kill some infected cells and help macrophages to kill
Mycobacteria (see 1.4) but anti-TNFa treatment prevents or disperses
granuloma formation in BCG-infected mice, allowing fatal dissemination
of the organism (Kindler et al., 1989). TNFa also appears to be
responsible for the formation of other granulomata. A single injection
of TNFa bestows on SCID-mice a previously absent ability to form
granulomata in response to Schistosoma mansoni eggs (Amiri et al.,
1992). A major part for TNFa in some fibrotic diseases also seems
likely, since anti-TNFa treatment inhibits the pulmonary fibrosis seen
after an injection of bleomycin (Piguet et al., 1989).
1.8.4. Cancer
Elevated serum levels of TNFa may be present in many people with
active neoplasia (Balkwill et al., 1987) and although raised
concentrations of soluble TNF-R's are also found in a high percentage
(Aderka et al., 1991), a role for TNFa in the cachexia suffered by
these patients is suggested by demonstrations that anti-TNFa treatment
can attenuate weight loss in some cancer models (Sherry et al♦, 1989;
Yoneda et al., 1991). Whilst the source of this TNFa may occasionally
be the tumour cells themselves (see 1.2), tumour-infiltrating
macrophages and lymphocytes produce TNFa (Beissert et al., 1989; Barth
et al., 1991), presumably in response to components of the transformed
cells (see 1.2). Although TNFa can be directly toxic to many
transformed cells, experiments using some TNFa- producing (and hence
-resistant) tumour cells have shown that their growth may actually be
prevented by TNFa-mediated recruitment of lymphocytes (Asher et al..
1991). The spontaneous regression of some tumours following acute
administration of TNFa also appears not to be mediated via direct
cytotoxicity. TNFa destroys the center of an SA1 sarcoma in mice via a
haemorrhagic reaction and whilst the peripheral rim of tumour tissue
survives in some mice, in others this too may regress following TNFa
treatment, but only in the presence of T-cells (Havell et al., 1988).
Similarly, Palladino et al. (1987) demonstrated that TNFa can induce
the haemorrhagic necrosis of a MethA sarcoma when grown in a vascular,
subcutaneous site but not intraperitoneally. The action of LPS on
these tumours also involves central haemorrhagic necrosis (Algire et
al., 1947), though anti-TNFa antibodies inhibit this reaction by only
50%, suggesting that other mediators are also involved (North &
Havell, 1988). Why should TNFa act selectively on the vascular bed of
tumours? The answer may partly involve 'Vascular Permeability Factor',
a tumour-derived protein which can synergise with TNFa in the
induction of procoagulant activity on local endothelial cells (Clauss
et al. , 1990).
1,8.5. Lentiviral disease:-
Elevated levels of circulating TNFa, correlating to some extent
with disease progression, are also seen in both adults and children
with AIDS (Lahdevirta et al., 1988; Rautonen et al., 1991).
Consequently, chronic overproduction of TNFa could mediate some of the
cachexia and other pathologies, such as inflammatory cell
infiltration, lymphoproliferation and demyelination, seen in this
disease. A possible role for TNFa in the generation of AIDS-associated
Kaposi's sarcomata has also been postulated following demonstration of
its accumulation at these sites (Oxholm et al.. 1989).
The mechanism of TNFa production in AIDS patients has been a matter
of debate. Whilst infection with agents known to be common secondary
pathogens in AIDS, such as cytomegalovirus, can be associated with a
prolonged increase in TNFa levels (Tilg et_al., 1991), some workers
have observed spontaneous secretion of TNFa by monocytes or
macrophages either derived from AIDS patients (with or without
secondary infections) or infected with HIV in vitro (Wright et al.,
1988; Roux-Lombard et al., 1989; D'Addario et al., 1990; Krishnan et
al., 1990; Vyakarnam et al., 1990; Israel-Biet et al., 1991; Mabondzo
et al., 1991). Merrill et al. (1989) found that the act of gpl20, the
envelope glycoprotein of HIV, binding to its cellular receptor CD4,
was capable of inducing TNFa and this has been confirmed by Clouse et
al. (1991). TNFa is also secreted during the fusion of SIV-infected
macrophages with CD4+ lymphocytes, which may involve similar binding
(McEntee et al., 1992). HIV or gpl20 can even induce TNFa from rat
brain cells (Merrill et al., 1992). However, it is possible that other
mechanisms might also be involved in the induction of TNFa by HIV (see
chapter 5, part i). Others have documented an increased ability of
cells from AIDS patients, or infected cell-lines, to respond to LPS,
Sendai virus or other stimuli (in the case of T-cells) by TNFa
production, both in terms of their sensitivity and levels produced
(Hober et al., 1989; Roux-Lombard et al., 1989; D'Addario et al.,
1990; Vyakarnam et al., 1991). This enhancement may involve an
increased stability of TNFa transcripts (Voth et al., 1990) and/or
priming of macrophages by the high levels of a form of IFNa seen in
many AIDS patients (Lau & Livesey, 1989). Enhanced sensitivity to TNFa
may also be induced by this interferon via an upregulation of TNF-R's
(Lau et al., 1991). Interestingly, B-cells from AIDS patients may
spontaneously secrete TNFa, a secretion which is enhanced in the
presence of gpl20 (Rieckmann et al.. 1991). Synthetic peptides derived
from both gpl20 and the transmembrane viral protein gp41 have also
been seen to enhance the secretion of TNFa by normal PBM's in response
to LPS (Tyring et al., 1991).
Observations of increased TNFa production in the presence of HIV
have not been universal, however. Many workers have failed to observe
either constitutive secretion of TNFa by chronically-infected cell
lines, or the release of TNFa by monocytes/ macrophages on infection
with HIV or SIV, nor any alteration in their response to LPS (Molina
et al., 1989, 1990a,b; Kornbluth et al., 1990; Munis et al., 1990;
Horvath et al., 1991; Peters et al■. 1991) (though Molina et al.
[1989] did find that a monocytic cell line could respond with enhanced
TNFa production in response to LPS at the time of acute infection).
Others have even documented defective TNFa production by PBM's from
AIDS patients (Ammann et al., 1987; Cox et al.. 1990) and a loss of
the ability of macrophages from simian AIDS cases to respond to LPS on
culture (Horvath et al., 1991), though the reasons for such
contrasting findings are presently unclear.
Clouse et al. (1989) observed that the supernatants of LPS-
stimulated macrophages could enhance the replication of HIV in a
chronically-infected T-cell clone and that much of this phenomenon was
mediated by TNFa. This effect has been confirmed in some T-cells
(Folks et al. , 1989), primary monocytes (Michihiko et al., 1989;
Mellors et al.. 1991) and glial cells (Tornatore et al.. 1991), and
extends to enhancement of SIV replication in macrophages (Walsh et
al., 1991), though not all models of HIV infection show this response
(Folks et al., 1987; Ito et al., 1989; Hazan et al.. 1990; Lacoste et
al.. 1990). Novak et al. (1990) found that TNFa even caused resistant
cells from some donors to become permissive for HIV infection and
Kobayashi et al. (1990a) demonstrated that spontaneous secretion of
both TNF's by HTLV-l-infected T-cell lines helps to mediate their high
susceptibility to infection. Much of this enhancing effect is
attributable to TNFa inducing the binding of NF-kappaB proteins to the
long terminal repeat (LTR) of the HIV DNA provirus and increasing
transcription from it (Duh et al.. 1989; Israel et al., 1989; Osborn
et al., 1989b). TNFa can also synergise with IL-6 in enhancing HIV
replication (Poli et al., 1990a).
Induction of TNFa by HIV and vice versa suggests the possibility of
an autocrine stimulatory loop and indeed antibodies to TNFa can
suppress the constitutive production of HIV in a chronically-infected
promonocytic line (Poli et al., 1990b; Locardi et al., 1990).
Interestingly, the cell surface form of TNFa may be responsible for
much of this constitutive induction (Tadmori et al.. 1991). However,
it is difficult to reconcile such a positive feedback process in vitro
with a disease which is slowly progressive in vivo, without the
existence of negative feedback processes. Not surprisingly, TNFa also
appears to play a part in more than one such process. Matsuyama et al.
(1989a) observed that in addition to being able to enhance the
transcription of HIV in chronically-infected T-cell lines, TNFa could
also kill these cells, whilst Wong et al. (1988) found that TNFa, in
combination with IFN gamma, could also decrease the susceptibility of
some T- and B- cell lines to HIV infection. The latter authors have
subsequently found that some infected cells may be rendered
susceptible to the cytotoxic action of TNFa via an inability to
produce MnSOD in response to TNFa (Wong et al., 1991). TNFa may also
inhibit the stimulatory effect that HIV can exert on B-cell function
(Delfraissy et al., 1991).
1.8.6. Immunologically-mediated disease:-
TNFa appears to be an important mediator of many 'immunological'
diseases. Not only is it induced at the site of delayed type
hypersensitivity (and irritant) reactions, but anti-TNFa antibodies
can also prevent their development (Piguet et al., 1991). Similarly
anti-TNFa treatment alleviates much of the pathology associated with
immune-complex deposition in the lung (Warren et al. , 1991) and an
antibody which neutralises both TNF's can be protective in one model
of experimental allergic encephalomyelitis (EAE) (Ruddle et al.,
1990). Interestingly, astrocytes from strains of rats which are
susceptible to this disease can be primed for TNFa production by IFN
gamma, whilst those from resistant strains cannot (Chung et al. ,
1991). Both TNF's have also been found at active sites of multiple
sclerosis (MS), which shares many morphological features with EAE
(Hofman et al., 1989; Selmaj et al., 1991). T-cell clones derived from
the CSF of MS patients have been found to secrete high levels of this
cytokine (Benvenuto et al.. 1991).
TNFa also seems to be involved in autoimmune disease. Not only can
it be found in the synovial fluid of most rheumatoid arthritis joints
(Hopkins & Meager, 1988) but anti-TNFa antibodies can attenuate
pathology in the DBA/1 collagen type II-induced model of autoimmune
arthritis (Feldmann et al., 1992). Conversely, therapy with TNFa can
delay the onset of glomerulo-nephritis seen in murine autoimmune lupus
nephritis (Jacob & McDevitt, 1988) (though others have found that it
can aggravate the problem [Brennan et al.. 1989]). Furthermore,
susceptible mice have a reduced ability to secrete TNFa and this
correlates with an RFLP in the TNFa gene (Jacob & McDevitt, 1988).
TNFa activity may also be prominent in transplant-related problems.
It is induced during cardiac transplant rejection (Arbustini et al.,
1991) and increased serum levels of TNFa are seen both during
rejection of kidney transplants (Maury & Teppo, 1987) and prior to
complications of bone-marrow transplants (Holler et al., 1990), in
keeping with demonstrations of the induction of high levels of TNFa
during a mixed lymphocyte response (Shalaby et al.. 1988). This
induced TNFa seems to be involved in causing some of the
manifestations of graft-versus-host disease, as anti-TNFa antibodies
can prevent the skin and gut lesions seen in the latter (Piguet et
al. , 1987).
1.8.7. Development:-
Finally, TNFa appears to play a role in normal development. Some
TNFa is found in the normal pregnant uterus (see 1.2). It is also
expressed constitutively in the thymus (Giroir et al.. 1992) and
blocking its activity in the foetus or neonate leads to a marked
suppression in early growth (de Kossodo et al., 1992).
1.9. The potential role of TNFa in ovine disease:-
A standard text of sheep medicine (Blood et al., 1979) reveals
several ovine diseases where one could speculate that TNFa might play
a prominent role, either because of their clinical signs and/or their
similarity to diseases of other species where TNFa is known to be
important.
Sheep, particularly neonatal lambs, are susceptible to septicaemias
caused by a wide range of both gram -negative and -positive organisms.
Such problems include colibacillosis, listeriosis, salmonellosis,
leptospirosis, anthrax, erysipelas and, occasionally, pasteurellosis,
as well as streptococcal and staphylococcal ('tick pyaemia')
septicaemias. Though several of these can also cause more slowly
progressive and/or localised septic disease, each can feature acute
mortality with many symptoms that are highly reminiscent of excessive
TNFa activity, such as fever, widespread haemorrhages and/or oedema,
organ necrosis, respiratory distress and diarrhoea or dysentery.
Similar signs may also be seen:- in enterotoxigenic forms of
colibacillosis and salmonellosis, where endotoxin may be absorbed from
the gastro-intestinal tract; following acute infections of the mammary
gland with Pasteurellae or Staphylococci; and in some viral diseases,
such as 'blue tongue' and 'sheep pox'. It is also conceivable that
TNFa activity could contribute to the haemorrhages, oedema and
mortality seen in the many different forms of clostridial disease to
which this species is prone.
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A number of severe protozoal diseases also afflict the sheep. As in
other species, toxoplasmosis can induce an encephalitis or pneumonia,
though it is more commonly associated with abortion and neonatal
death, whilst babesiosis involves parasitaemia, fever, intravascular
clotting and haemorrhages. An involvement of TNFa in modulating the
life-cycles of, or mediating the pathologies caused by, either of
these organisms would seem to be a possibility.
Judging from their respective pathologies, TNFa could also play
significant parts in 'louping 111', an acute, febrile, viral
encephalomyelitis, which involves perivascular accumulations of
inflammatory cells in the meninges and CNS, and 'border disease',
another virally-induced disease featuring defective myelination of the
CNS of new born lambs.
Sheep are also prone to many chronic diseases involving cachexia
and where TNFa may therefore be important. Like other species they can
succumb to TB, as well as Johne's disease, a debilitating, enteric
illness caused by another mycobacterium. Actinobacillosis is a not
uncommon ovine disease, involving fibrosis and a pyo-granulomatous
response, which could be mediated, at least in part, by TNFa, whilst
maedi-visna disease, a lentivirally-induced illness, involving multi-
organ inflammatory cell infiltration, lymphoproliferation and
cachexia, has several features in common with AIDS (see chapter 5,
part i). Scrapie is another slowly-progressive disease involving
emaciation and neuronal degeneration. Finally, whilst neoplasia is not
particularly common in the sheep, some flocks may have a high
incidence of adenocarcinoma of the small intestine and the
debilitating illness 'jaagsiekte' or 'driving sickness' results from a
retrovirally-induced tumour of the lung.
1.10. TNFa in ungulates
The sheep is an animal of undoubted agricultural importance.
Consequently, the understanding and prevention of ovine disease is of
tremendous economic concern world-wide. In 1989, however, when the
work described in the following chapters commenced, apart from a
documented ability of human TNFa to mimic many endotoxin-like effects
in live sheep (Horvath et al., 1988), very little was known about TNFa
in this species. Such studies have since been confirmed and extended
by others (Johnson et al. , 1989; Wheeler et al.. 1990; Redl et__al.,
1990) and more recently, Winstanley (1992) demonstrated that
recombinant human TNFa (rhTNFa) can bind to ovine leukocytes.
A little more was known about TNFa in other ungulates. The cDNA
encoding bovine TNFa had been cloned and sequenced, though only the
deduced amino acid sequence had been presented (Goeddel et al.. 1986).
Recombinant bovine TNFa (rboTNFa) had also been expressed and a few
papers were beginning to document that it had similar activities to
TNFs'a from other species, such as the induction of cachexia when
repeatedly administered to cattle (Ohmann et al., 1989b) and an
antiviral activity (Campos et al., 1987) mediated via an ability to
induce 2'-5' oligo-adenylate synthetase in some cells (Campos et al.,
1988) but not others (Ohmann & Babiuk, 1988; Ohmann et al., 1989a).
RboTNFa has also found to be effective in inducing lymphocyte
localisation in sheep skin (Kalaaji et al., 1990). More recently,
Chiang et al. (1991) demonstrated that it could enhance some functions
of bovine neutrophils. It has also now been shown that, as in other
species, the TNF locus is linked to the MHC locus in goats (Cameron et
al., 1990).
A few studies have been dedicated to the detection of ungulate
TNF'sa. Kenison et al. (1988) developed a radioimmunoassay (RIA) for
bovine TNFa, though, since this is based on a polyclonal antiserum, it
may be subject to interference by TNFa-binding proteins (see chapter
4). Using this assay, Peel et al. (1990) could detect circulating
bovine TNFa following the administration of LPS to calves, but not in
calves with Salmonellosis. Adams and Czuprynski (1990) demonstrated
that TNFa could be induced from bovine macrophages by LPS and detected
using TNF-sensitive murine cells. They also found that the molecular
weight of bovine TNFa was consistent with a multimeric form. Similar
findings have also been made in horses (Seethanathan et al., 1990;
Mackay et al., 1991a), where TNF-like activity can be detected in
serum after giving LPS (Morris et al., 1990; Mackay et al., 1991b) and
in some cases of neonatal septicaemia (Morris & Moore, 1991). As in
other species, dexamethasone appears to inhibit TNF production in the
horse (Morris et al., 1991). Baarsch et al. (1991) have also been able
to detect porcine TNFa using cytotoxicity assays and the cDNA encoding
TNFa in this species has now been sequenced (Pauli et al., 1989; Drews
et al., 1990).
1.11. Aims of the project:-
Whilst some studies have now documented that other ovine cytokines
such as IL-1, IL-2 and IFN gamma show significant homology in
structure and/or function to their human and murine counterparts
(Fiskerstrand & Sargan, 1990; Fiskerstrand et al., 1992, Andrews et
al., 1991; Seow et al., 1990; Mclnnes et al., 1990), some features of
the ovine immune system show marked differences to other species. For
example, there seems to exist a large population of functionally-
important pulmonary intravascular macrophages in sheep, whereas these
are not found in humans (Warner et al., 1986). Consequently one cannot
assume that aspects of the immune system, including TNFa biology, will
necessarily be the same in the two species. The importance of this
point was made all the more clear when preliminary experiments,
described in chapter 4, failed to detect cytotoxic activity in the
supernatants of LPS-stimulated ovine macrophages using murine cell
lines known to be sensitive to TNF's from many species.
In the absence of any knowledge about ovine TNFa, it was essential
to establish some basic information about this molecule (including
proof of its existence) before being able to investigate its role in
specific diseases. The following chapters therefore describe how the
cDNA encoding ovine TNFa was cloned and sequenced (chapter 2), before
recombinant ovine TNFa (rovTNFa) was expressed and characterised
(chapter 3). Chapter 4 discusses how antibodies raised to the
recombinant protein were used in the immunological detection of ovine
TNFa and presents reasons for the apparent failure of TNF-sensitive
murine cells to respond to ovine TNFa. Finally, these reagents were
then applied in a preliminary study of the r3le of ovine TNFa in one
particular problem, maedi-visna disease (as described in chapter 5,
part i).
CHAPTER 2:- CLONING AND SEQUENCING THE cDNA ENCODING OVINE TNFa.
2.1.Introduction
A preliminary objective in studying ovine TNFa was to clone and
sequence the cDNA encoding it, in order to:- 1) demonstrate the
presence in sheep of a mRNA species which might encode a protein
homologous to TNF'sa from other species; 2) derive predictive
information on the structures of such an ovine TNFa and some of the
elements which might (by analogy to other species) be involved in
regulating its synthesis; and 3) obtain DNA probes suitable for use in
studies of the induction of ovine TNFa mRNA.
Prior to commencing this work, the sequences of cDNA's encoding
TNFa in humans (Pennica et al.. 1984; Marmenout et al., 1985; Wang et
al., 1985), mice (Pennica et al., 1985; Fransen et al., 1985) and
rabbits (Ito et al.. 1986) had been published. The strategies used in
these studies were broadly similar. Initially, TNFa cDNA clones were
identified by screening cDNA libraries with degenerate oligo¬
nucleotide probes, which had been constructed based on knowledge of
partial amino acid sequences of purified TNFa. Expression of the
cloned cDNA's, to produce proteins with appropriate characteristics,
was used to confirm that these were indeed TNFa encoding cDNA's.
Clones thus derived from one species were then used to probe libraries
from another species and a sufficient degree of homology of TNFa
sequences between species enabled this approach to succeed.
Against this background, one possible method for cloning ovine TNFa
cDNA would have been to screen a suitable, ovine, cDNA library with a
DNA probe from one of these species. Indeed this was an approach
adopted by other workers (see discussion [2.3]), who, it later
transpired, were concurrently working towards the same objective.
In comparison with the laborious techniques involved in screening
libraries, cloning techniques based on the use of the polymerase chain
reaction (PCR) (Mullis & Faloona, 1987), to generate large amounts of
DNA of specific, primer-directed sequence, offer a potentially quicker
route to cloning a gene from one species, when the equivalent genes in
other species have already been sequenced. These techniques require
identification of regions of the gene where sequence is extremely well
conserved across species, enabling the construction of 'inwardly-
facing' primer pairs, which should be capable of annealing to the cDNA
for the equivalent gene in most species. These primer pairs may then
be used to direct the amplification of an internal fragment of the
cDNA for that gene of the species under study (Ohara et al., 1989).
This approach has been used successfully in cloning a number of genes,
including those of other ovine cytokines, such as IL-1B (Fiskerstrand
& Sargan, 1990), IL-2 (Seow et al., 1990) and IFN gamma (Mclnnes et
al., 1990).
There are shortcomings to this approach, however, when trying to
obtain an accurate and complete gene sequence. One problem is caused
by the relatively poor fidelity of sequence reproduction by Tag
polymerase, the thermostable enzyme preferred for PCR, when compared
to other DNA polymerases (Saiki et al., 1988). This can be overcome by
obtaining a consensus sequence from several PCR-derived clones, or by
directly sequencing the PCR product. A second problem is that of
obtaining complete sequences, including the 5' and 3' regions flanking
the internal fragment amplified by the initial 'direct' PCR. At least
two approaches to this problem have been described. One, 'anchored'
PCR, involves ligating an oligonucleotide, of known sequence, to a
terminus and performing a PCR on this template using one outwardly-
facing primer specific for the cDNA and one oligonucleotide-specific
primer (Ohara et al., 1989). This obviously requires a PCR and
cloning/sequencing procedure for each end of the transcript. A second
approach, 'inverse' PCR, in which the molecule concerned is
circularised and used as the template in a PCR using a pair of
specific, outwardly-facing primers (Ochman et al., 1988; Triglia et
al. , 1988), offers the potential to amplify both 5' and 3' ends with a
single PCR.
The strategy I chose to follow, therefore, was to generate,
sequence and clone an internal fragment of ovine TNFa cDNA via direct
PCR, using primers complementary to regions which are highly conserved
between human, mouse and rabbit TNFa cDNAs. This was to be followed by
an inverse PCR, using primers specific to the ovine sequence, to
amplify the 5' and 3' termini, prior to their cloning and sequencing.
The ability to obtain large numbers of alveolar macrophages by lung
lavage and the known inducibility of TNFa mRNA in cells of monocyte/
macrophage lineage by LPS (Beutler et al.. 1986a) suggested a source
of mRNA from which to prepare a suitable cDNA template.
The cloning vectors used in this work were the multifunctional
'phagemids pTZ18R and pTZ19R (Mead et al.. 1986). Whilst these were
primarily selected because of their ready availability, other features
of these vectors which contributed to their suitability for this work
include:- 1) an ampicillin resistance gene, allowing identification of
transformed bacteria (from an ampicillin-sensitive host strain) on
ampicillin-containing solid media; 2) a multiple cloning site,
conferring, on appropriately digested vectors, the ability to accept
inserts with a wide range of termini; 3) flanking the multiple cloning
site, a lac Z gene, whose disruption by the presence of inserted DNA
allows the identification of recombinants by colony colour when a
suitable lac Z substrate and chromogen are included in media; 4) an F1
origin of replication, allowing synthesis of large amounts of single-
stranded DNA, suitable for sequencing, when transformed bacteria of
appropriate phenotype are superinfected by the helper 'phage M13K07;
5) high transformation efficiency due to their small size (<3kb); and
lastly 6) the orientation of the multiple cloning site with respect to
the F1 origin of replication is reversed between the 2 vectors,
allowing single-stranded DNA to be produced from both strands of an
insert when it is excised from one 'phagemid, by a pair of restriction
endonucleases which leave different termini, and inserted into the
other vector (prepared by digestion with the same enzymes). This
latter feature facilitates the sequencing of larger inserts. 'Reverse'
sequencing primer, which anneals to a region of 'phage DNA adjacent to
the multiple cloning site and directs DNA polymerisation across it, is




2.2.1.Preparation of first strand ovine cDNA:-
Lavaging the lungs of a freshly-slaughtered, healthy, Scottish
Blackface ewe yielded a total of 108 cells. Selection of the adherent
fraction 24 hours after they were plated out (at 5 x 105/ml in 2 x
225cm2 tissue culture flasks) left a population comprising
approximately 90% macrophages, as assessed by morphology under the
light microscope. An estimated 250pg of total RNA was collected and
purified from these cells 2 hours after they were then stimulated with
lOOng/ml of LPS.
Several distinct bands, including putative 28S and 18S RNA bands,
were clearly visible when an aliquot of this preparation was assessed
by agarose gel electrophoresis (fig.2.la), suggesting that there had
been no wholesale deterioration of the RNA during preparation.
An estimated 300ng of cDNA was then produced when 12pg of this RNA
was used as the template in a 'first strand only' cDNA synthesis
reaction. Analysis of the labelled fraction of this reaction indicated
that a wide range of sizes of cDNA had been formed (fig.2.lb).
2.2.2.Initial PCR's:-
Primers A and B (fig.2.2) were selected, following a comparison of
published TNFa cDNA sequences, for use in direct PCR. A single base
difference exists between the species' sequences within the regions
from which each of these primers were derived, hence inositol, or a
choice of nucleotides, was used in the corresponding primer positions
to allow for possible mismatches. Use of these primers in a PCR on
suitable human cDNA should amplify a 590bp fragment of DNA.
Initial PCR's, performed at annealing temperatures of 48°C or 45°C
using primers A and B at 0.1 or lpM each, on 5 or 25ng of cDNA
template, failed to produce any DNA (as assessed by UV trans¬
illumination of ethidium bromide-containing gels, following
electrophoresis of an aliquot of reaction mixes) with the exception of
possible primer-dimers (fig.2.1c).
Figure 2.1:-
Figure 2.1:- photographs oftransitlaminated, RNA (2.1a) 3 DNA (2.1c,d) gels, an
autoradiograph of a DNA gel (2.1b) 3 a Southern blot ofthe gel shown in 2. Id
(with corresponding lane no.s), following hybridisation to an human TNFa cDNA
probe (2.1e). DNA gels were 1.2% agarose. The positions ofputative 28S 3 18S RNA
bands or molecular size markers (in kb) are indicated. Samples submitted to
electrophoresis comprised:- a 1 Ojug aliquot ofthe RNA preparation usedfor 1st
strand cDNA synthesis (2.1a), 5pi ofa labelled, 1st strand cDNA synthesis reaction
(2.1b) 3 10% aliquots ofPCR's performed at annealing temperatures of45"C (2.1c)
or 40"C (2. Id). Primers A & B (fig.2.2) were used in these PCR's at IpM (2.1c, lanes
2 &4; 2. Id, lanes 1 3 2), 0.1pM (2.1c. lanes 13 3; 2.Id, lanes 33 4) or 0.01pM
(2. Id. lanes 5 3 6) on templates of25ng (2. lc, lanes 13 2; 2. Id, lanes 2,3 3 6) or
5ng (2. lc. lanes 3 3 4: 2. Id, lanes 1,4 3 5) of 1st strand cDNA.
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Figure 2.2:-
Primer 5' Sequence il Position
A CTC AGC CTC TTC TCI TTC CTG 249-269
B CCA AAG TAG ACC TGC CCR GAC TC 838-816
C CAC CAC GCT CTT CTG CC 284-300
D GGT CAC CCT TCT CCA ICT GG 771-752
E GCA GAG AGG ATG TTG ACC 674-657
F ATC AAG AGC CCT TGC CAC AGG 676-696
G AAG ccc TGG TAC GAA CCC 721-738
H ACC AGA GGC CTG TTG AAG G 380-362
I AAC ACA TCT GAG CCA AGG C 1430-1412
J AGT CAT GCC TGT AAC CGC 1600-1617
Figures 2.2a & b:- schematic diagrams (not to scale) of TNFa cDNA molecules,
derived from the human & sheep (after circularisation), respectively. The annealing
positions of primers used in the work described in this chapter are indicated, in
addition to thefirst (A TG) & last (TGA) codons of the coding region & the
polyadenylated tail (AAA). The bold segment ofthe ovine molecule represents the
portion amplified & clonedfollowing direct PGR.
Figure 2.2c:- the actual sequences of individual primers. I represents an inositol
residue & R . a 50.50 mix ofA & G residues. Position no.s from which these
sequences derive are according to Pennica et al. (1984) forprimers A-D, orfig.2.8
for all other primers. Descending position no.s indicate antisense primers.
Analyses of subsequent PCR's, where similar primer and template
concentrations were used, revealed that a range of sizes of DNAs were
produced, however, when the annealing temperature was lowered to 40°C
(fig. 2.Id).
Southern blotting, followed by hybridisation to an human TNFa cDNA
probe with washing to only a low final stringency (lxSSC at 50°C),
then revealed the presence of a band of DNA (c.600bp), which
hybridised more strongly than the rest of the smear (fig.2.1e),
suggesting that some desired amplification had taken place, even
though it had been insufficiently specific.
2.2.3.Subsequent nested PCR:-
Primers C and D (fig.2.2) were then selected, by the same criteria
used in the selection of primers A and B, for use in a 'nested' PCR to
specifically amplify a fragment within the c.600bp band. Using these
primers in a PCR on a human cDNA template should amplify a DNA
fragment of 488bp.
Their use, over a range of concentrations, in PCR's performed at an
annealing temperature of 48°C using lpl of a previous reaction
(fig.2.Id, lane 4) as template, led to the amplification of a c.500bp
fragment (fig. 2.3a), which hybridised to the same human probe when
used at the above stringency (fig.2.3b).
2.2.4.Cloning and sequencing of the c.500bp PCR product
When the remainder of these reaction mixes were pooled, an
estimated lpg of the c.500bp product was available, after appropriate
preparation (terminal phosphorylation, end filling and preparative
electrophoresis), for 'blunt-ended' ligation into pTZ19R. 4 similar,
repeat PCR's (conditions of fig. 2.3a, lane 1) generated an estimated
2pg of c.500bp product, after preparation, for use in direct
sequencing (and, later, as a probe). Gene cleaning (Bio 101), which
was used for final purification in each case (after preparative
electrophoresis and band excision), led to satisfactory recovery of
the c.500bp product (fig.2.3c,d).
Direct sequencing of this product using primer C yielded some short
stretches of readable sequence which showed homology with sequence
contained in human TNFa cDNA, whilst analysis of a direct sequencing
Figure 2.3:-
Figure 2.3:- photographs oftransilhiminated, 1.2% agarose DNA gels (2.3a,c,d & e)
& a Southern blot ofthe gel shown in 2.3a (with corresponding lane no. s), following
hybridisation to an human TNFacDNA probe (2.3b). The positions ofmolecular size
markers (in kb) are shown for each. Samples submitted to electrophoresis comprised:-
10% aliquots ofPCR's (2.3a. lanes 1-4), the products offour repeat PCR's
(conditions as forfig.2.3a, lanes 1 or 4), after pooling, terminal phosphorylation,
end-filling, purification & division between 3 lanes (2.3c), 5% ofthefinal yield after
the c.SOObp product was excisedfrom the gel in 2.3c & purified by gene clean (2.3d)
& miniplasmid preparations (following digestion with Hindlll, then EcoRI) from a
p TZ1)R-transformed E.coli colony or povTNFl (2.3e, lanes 1 & 2, respectively).
PCR's used primers C <& D (fig.2.2) at 0.1. 1, 0.01 or 0.1 pM (2.3a, lanes 1-4,
respectively) on a template of 1pi ofa previous PCR (seefig. 2. Id, lane 4).
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reaction using primer D produced a long stretch (c.300b) of readable
sequence, which, when converted into sense form, also showed a high
degree of homology to a region of human TNFa cDNA contained between
the sequences of primers C and D.
Knowledge of this ovine sequence then allowed the selection of
primers E and F (fig.2.2), primarily for subsequent use in an inverse
PGR. However, the use of primer E in a 'nested' direct sequencing
reaction extended the known ovine sequence by a further c.lOOb and
confirmed, in the region where there was overlap, the sequence
obtained using primer D. (The regions for which sequence was derived
from any of the sequencing reactions described above or below are
shown schematically in fig.2.7.)
A single recombinant clone, designated povTNFl, was obtained
following transformation of bacteria with the products of a ligation
reaction involving 50ng of c.500bp product and 50ng of Smal-digested
pTZ19R. Earlier reactions, involving 25, 50 or lOOng of PCR product,
and simultaneous reactions, involving 25 or lOOng of PCR product,
failed to produce any recombinant colonies when their products were
used for transformation. In each case large numbers (>1000) of
colonies were obtained in control transformations involving undigested
plasmid and no colonies were seen on plates coated with untransformed
bacteria. More colonies were obtained on control plates derived from
reactions involving ligase and digested vector than on those derived
from reactions with digested vector but no ligase (60 vs 20 and 83 vs
12). Numbers of non-recombinant colonies growing on plates derived
from reactions with PCR product were similar to those on plates
derived from control reactions with vector and ligase but no added
When plasmids were recovered from povTNFl and digested with Hindi 11
then EcoRI (Hindlll and EcoRI sites flank the Smal site of pTZ18R and
19R) a c.500bp fragment was excised (fig.2.3e). A preparation of
single-stranded (ss) DNA from this clone produced an estimated lOpg of
DNA. The analyses of sequencing reactions involving this ssDNA and
initially reverse sequencing primer, then, once the orientation of the
insert had been established, primers C then F, showed that the DNA
which had been ligated into pTZ19R was 491bp long and contained the
sequence of primers C and D at either end. The intervening region was
DNA.
highly homologous to that region of human TNFa cDNA between the
sequences from which primers C and D were derived and, where it
overlapped, was in perfect agreement with the sequence obtained by
direct sequencing of the c.500bp product.
2.2.5.Northern blot analysis of the induction of ovine TNFa mBNA:-
Lavaging the lungs of a healthy Scottish Blackface ewe yielded 1.4
x 108 cells. This population, which was immediately divided between 7
x 75cm2 tissue culture flasks containing 25mls of medium with or
without lOOng/ml LPS, produced approximately 30pg of RNA per flask
when the total RNA was collected and purified at assorted time points
thereafter.
Fig.2.4 shows the result when an estimated lOpg of RNA from each
time point were submitted to electrophoresis then Northern blotting
and the blot washed, after hybridisation to an ovine TNFa cDNA probe
(povTNFl insert, excised from a large-scale plasmid preparation and
purified by electrophoresis and gene-cleaning, then radio-labelled),
to a final stringency of 0.3xSSC at 52°C.
The probe appeared to hybridise to a single species of RNA. This
RNA had a slightly slower mobility through the gel than 18S RNA and
was inducible, reaching a maximum density between 90 and 180 minutes
after plating out in the presence of LPS. However, it was also noted
that a similar density was achieved in the absence of added LPS.
A previous Northern blotting experiment, which was performed, using
cells from another sheep, with a slight change in protocol (the
addition of LPS was delayed for 24 hours, by which time the adherent
fraction had been selected, and RNA collected thereafter), failed to
demonstrate any hybridisation to RNA, even though lOpg of the RNA
preparation used for first strand cDNA synthesis were loaded on the
same gel and prolonged exposure times were used for autoradiography.
2.2.6.Synthesis of double-stranded cDNA for use in inverse PCR:-
The Northern blotting experiments described above suggested that
the RNA preparation previously used for production of first strand
cDNA may not have been particularly rich in TNFa transcripts. Double-
Figure 2.4:-
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Figure 2.4:- a Northern blot (2.4a) following hybridisation to an ovine TNFa cDNA
probe (povTNFI insert) & the transilluminated gel (with corresponding lane no.s)
from which the blot was taken (2.4b). The positions ofputative 2AS & IAS RNA are
indicated.. Samples submitted to electrophoresis comprised RNA collectedfrom ovine
lung-cells 0, 0.75, 1.5. 2.25. 3 or 24 hours (lanes I. 2. 3, 4 & 7. 5. 6, respectively)
after plating out in the presence (lanes 1-6), or absence (lane 7) of lOOng LPS/ ml.
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stranded (ds) cDNA was therefore synthesised using a template of RNA
demonstrated to be relatively rich in ovine TNFa mRNA (RNA collected
2.25 hours after plating out with LPS [see fig.2.4 lane 4]).
When 12pg of this RNA preparation were used in the synthesis of ds
cDNA, 240ng of first strand cDNA were synthesised and an estimated 88%
of this was converted into ds cDNA. Analysis of an aliquot of labelled
second strand synthesis reaction, by electrophoresis and auto¬
radiography, suggested that a wide range of sizes of ds cDNA had been
formed. A pellet of 'circularised' cDNA, ready for use as the template
in an inverse PCR, was obtained after purification of a ligation
reaction involving lOOng of ds cDNA in dilute solution.
2.2.7,Initial inverse PCR:-
The positions of the sequences from which primers E and F were
derived were such that it was anticipated that the use of these
primers in an inverse PCR on an appropriate template would amplify a
DNA fragment almost as long as the full length of ovine TNFa cDNA,
hence having considerable overlap with the region already cloned.
Whilst the exact length of ovine TNFa cDNA was unknown, the lengths of
human, murine and rabbit TNFa cDNA's are all between 1600 and 1700
bp's. The results of Northern blotting, however, suggested that the
ovine sequence could be slightly longer (see discussion [2.3]).
An inverse PCR performed on 25ng of this 'circularised' template
using primers E and F and an annealing temperature of 45°C led to the
formation of a major product of only c.lOOObp, as well as minor
products of larger and smaller size (fig.2.5a). This major product
appeared to remain hybridised to the central region probe (povTNFl
insert) after washing to a high stringency (0.3xSSC, 65°C)(fig.2.5b).
2,2.8.Investigation of the c.lOOObp product:-
Consideration of the ways in which a smaller than anticipated
product could have arisen led to several different theories. These
included the following:- 1) during first strand cDNA synthesis, DNA
polymerisation may have terminated prior to reaching the 5' terminus,
or the oligo dT primer might have annealed to an A-rich region other
than the 3' terminus, leading in either case to the production of a
'shortened' cDNA; or 2) during template preparation, insufficient
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Figure 2.5:- photographs of transilluminated. 1.2% agarose gels (2.5a. c, e & g) &
Southern blots ofthe gels shown in 2.5a. c & e (with corresponding lane no.s),
following hybridisation to an ovine TNFa cDNA probe (povTNFI insert) (2.5b, d &f
respectively). The positions ofmolecular size markers (in kb) are shown for each.
Samples submitted to electrophoresis comprised 10% aliquots ofPCR's (2.5a, c & e)
& miniplasmid preparations , following digestion with Hindlll then EcoRl. taken
from a pTZ19R-transformed E.coli colony, povTNF2 & povTNF3 (2.5g, lanes 1-3.
respectively). Primers (fig.2.2) used in PCR's were:- E & F (2.5a: 2.5c, lane 1); E
only (2.5c, lane 2; 2.5e, lane 2); F only (2.5c, lane 3): E & G (2.5e, lane 1); or G
only (2.5e. lane 3). PGR templates comprised circularised cDNA (2.5a) or 1 pi of the
product shown in 2.5a (2.5c, lanes 1-3: 2.5e, lanes 1-3).
dilution of the cDNA might have occurred for the ligation reaction to
result in circularisation. This latter possibility could have resulted
in the head-to-head, or tail-to-tail, ligation of some abundant
molecules and the subsequent amplification of an internal portion by
either primer alone.
To test the second hypothesis, PCR's were performed using primers E
and F, or either primer alone, at an annealing temperature of 45°C
with lpl of the original inverse PCR product as template. A band
c.lOOObp was produced using primer F alone, initially suggesting that
some form of tail-to-tail ligation might have occurred (fig.2.5c).
However, Southern blotting analysis, using the probe and stringencies
described above, subsequently demonstrated that although a component
of the c.lOOObp product generated in the presence of both primers
hybridised to the ovine TNFa probe, the c.lOOObp band generated by
primer F alone did not (fig.2.5d).
2.2■9■Semi-nested inverse PCR:-
Whilst some amplification of ovine TNFa cDNA had clearly occurred
during the original inverse PCR, the above results suggested that
there was likely to be considerable contamination caused by non¬
specific amplification of other molecules by primer F. Primer G
(fig.2.2) was therefore selected in order to anneal to a site just 3'
to the complementary region of primer F in a 'semi-nested' PCR.
Whilst no significant product was formed when either primer alone
was used, a PCR, performed on lpl of the original PCR product using
primers E and G with an annealing temperature of 44°C, again produced
a major product c.lOOObp (fig.2.5e), which clearly hybridised to the
central region clone (p.ovTNFl insert, final washing stringency as
above) (fig.2.5f).
2.2.10.Cloning and analysis of the c.lOOObp product of semi-nested
PCR: -
Preparative electrophoresis of the remainder of this and 3
identical PCR's, with recovery of the c.lOOObp band by excision and
gene cleaning, yielded 1.5pg of DNA for direct sequencing. However,
attempts to directly sequence this product using primers E or G failed
to produce any substantial lengths of readable sequence.
3 further identical PCR's produced 750ng of this product in LGT
agar, after preparation, for use in ligation. No colonies with
recombinant plasmids resulted from initial ligation reactions
involving 25, 50 or lOOng of PCR product. Control plates gave similar
results to previous cloning experiments. Following subsequent
identical ligation reactions and transformations, however,
approximately 100 recombinant colonies were derived from each
reaction. Use of an ovine TNFa cDNA probe (c.500bp product of direct
PCR) in colony hybridisations identified only 2 which were positive
for the presence of homologous sequence, when washed to a final
stringency of 0.2xSSC at 60°C. A band of appropriate size could be
excised from a miniplasmid preparation of each of these two colonies,
which were designated povTNF2 and povTNF3 (fig.2.5g).
llpg of ssDNA were obtained for sequencing when preparations were
made from each colony. The analyses of initial sequencing reactions
using reverse sequencing primer produced c.350b of readable sequence
from each and revealed that their plasmids contained similar DNA
fragments inserted in the same orientation. The sequences of these
inserts began with that of primer G and continued with sequence
totally homologous to the short region of povTNFl insert 3' to that
from which primer G was derived, before continuing with sequence
showing a high degree of homology to the equivalent region of the
human molecule. Further sequencing reactions using primer G as a
sequencing primer extended knowledge of the inserts' sequences by a
further c.80b and confirmed the sequence already obtained in the
region of overlap.
50ng of EcoRI, HindiII-excised insert was obtained in LGT from a
miniplasmid preparation of each colony and ligated to 50ng of EcoRI,
Hindlll-cut pTZ18R. >200 recombinant colonies resulted, most of which
hybridised to an ovine TNFa cDNA probe (c.500bp product of direct PCR,
using stringencies as before). After preparing plasmids from 8
representative colonies derived from each original clone, EcoRI and
Hindlll digestion released a c.lOOObp insert from all of them.
lOpg of ssDNA were then obtained from 4 of these clones:- povTNF4
and povTNF5 (derived from ligation of the insert of povTNF2) and
povTNF6 and povTNF7 (derived from ligation of the insert of povTNF3).
Subsequent sequencing reactions using reverse sequencing primer
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produced c.350b of readable sequence. When converted to sense form,
these sequences comprised the sequence of primer E, then 23 or 76 bp
(for povTNF4,5 and povTNF6,7 respectively) of sequence showing total
homology with the c.500bp product of direct PGR 5' to the region from
which primer E was derived, a short poly-A tract (11 or 5 bases) and
finally, sequence with homology to the extreme 3' end of the human
molecule. Knowledge of this sequence was confirmed, where there was
overlap, and extended (by c.80b) using primer E as a sequencing primer
in further reactions.
Primer I (fig.2.2) was then selected to assist in sequencing the
remainder of these inserts and its use in subsequent sequencing
reactions produced a further c.400b of sequence. The distal end of
this new sequence contained several bases of totally homologous
overlap (when converted to sense form) with the sequences of povTNF2
and povTNF3 derived using primer G. Thus, these clones contained the
entire sequence of ovine TNFa cDNA 3' to the complementary region for
primer G, though they clearly lacked several hundred bases of 5'
sequence.
These sequencing reactions also showed that the sequences of
povTNF4 and povTNF5 were identical, as were the sequences of povTNF6
and povTNF7. However, a handful of minor differences did exist between
the sequences of povTNF2 and povTNF3 and between povTNF4,5 and
povTNF6,7 (see discussion [2.3]).
2.2.11.Attempts to amplify the 5' terminus of the molecule:-
The above sequences demonstrated that the c.lOOObp major product of
semi-nested inverse PCR derived from amplification of incomplete cDNA
molecules. The use of two new ds cDNA preparations as the template,
after circularisation, in inverse PCR's with primers E and G (using
the same annealing temperatures as before) failed to produce a larger
major product (fig.2.6a) even though the RNA preparation was submitted
to a further round of phenol/chloroform purification and longer
incubation times (2.5 hours) were used for first strand synthesis.
As well as the major product, it was evident that there were larger
molecules in both the original and semi-nested inverse PCR's which
hybridised to the ovine TNFa probe, including a concentration of
molecules c.2000bp (fig. 2. 5b,d,f). Preparative electrophoresis in LGT
agarose of lOpl of the original inverse PCR allowed separation of this
c.2000bp band (fig.2.6b) and its subsequent excision. However, when
this DNA was used as the template in subsequent PCR's with primers E
and G (lpl LGT agarose/reaction, annealing temperature 44°C) the major
product was once again c.lOOObp (fig.2.6c), suggesting that the
c.2000bp band was a concatemer of the c.lOOObp band, produced as a
result of Tag polymerase working in a 'rolling circle' fashion on the
original circular template (see discussion [2.3]).
To ascertain whether amplification of more complete cDNA molecules
had occurred during the initial inverse PCR, a test PCR was performed,
using an annealing temperature of 44°C, on lpl of the original inverse
PCR product with primers E and C (since the c.lOOObp band was clearly
derived from amplification of cDNA molecules lacking the 5' terminus,
including the region to which primer C should anneal). A product of
appropriate size (c.387bp) was generated (fig. 2.6d), indicating that
more complete molecules were present.
A further primer, primer H (fig.2.2) was therefore selected to
anneal close to the 5' extremity of the known sequence and used in a
fully-nested PCR on lpl of the original inverse PCR product, with
primer G, at an annealing temperature of 45°C. The use of these
primers in PCR on a complete, circularised cDNA template should
amplify a fragment lacking 340bp of the central region. Consequently
such a product would share only a limited stretch of sequence with
povTNFl but several hundred bp of sequence with povTNF2-7.
The major product of this PCR was once again c.lOOObp. However, a
c,1300bp product was also prominent (fig.2.6e). Both bands appeared to
hybridise to an ovine TNFa probe (povTNF2 insert, final purification
by electroelution) when washed to a final stringency of 0.3xSSC at
65°C (fig.2.6f).
2.2.12.Analysis and cloning of the c.1300 bp product:-
Since it was a more appropriate size, subsequent analysis
concentrated on the c.l300bp product. 2 and 1.5 pg of this product
were obtained, after preparation, for direct sequencing and cloning
respectively, from the remains of this and 6 identical PCR's. (Final































transilluminated, 1.2% agarose gels
(2.6a. c, d. e) & a 1% LGT-agarose
gel (2.6b), following electrophoresis
of10% aliquots ofPCR's, & a
Southern blot of the gel shown in 2.6e,
following hybridisation to an ovine
TNFa cDNA probe (povTNF2 insert)
(2.6f). The positions ofmolecular size
markers (in kb) are shown for each.
Primers (fig. 2.2) used in PCR's were
E & G (2.6a, lanes 1 & 2; 2.6c), C &
E (2.6d) or G & H (2.6e) on templates
of25ng circularised fresh' cDNA
(2.6a, lanes I & 2), 1pi oforiginal,
inverse PGR product (seefig.2.5a)
(2.6d,e) or 1pi ofmolten LGT-agarose
containing the c.2000 bp product seen
in fig.2.6b, following its excision from
this gel (2.6c). The sample shown in
fig.2.6b is original, inverse PCR
product, i.e. as in fig. 2.5a, but was
submitted to slower, preparative
electrophoresis, startingfrom a wider
well.
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Analysis of a direct sequencing reaction using primer H produced
c.300b of readable sequence, which (when converted into sense form)
showed homology with the 5' region of human TNFa cDNA and, in the
short region where there was overlap, total homology with the insert
of povTNFl.
10, 8 and 12 recombinant colonies resulted from transformations
with the products of ligation reactions involving 25, 50 or 100 ng of
PCR product respectively. However, only 1 of these showed positive
hybridisation to an ovine TNFa probe (c.lOOObp product of semi-nested
inverse PCR) when washed to a final stringency of 0.2xSSC at 60°C.
Although no insert could be freed from plasmids prepared from this
clone, which was designated povTNF8, ssDNA was prepared from it and
submitted to sequencing reactions, initially with reverse sequencing
primer. The readable sequence generated by this reaction corresponded
to that of primer G and some 340b with >99% identity to the sequences
of povTNF2 and povTNF3 immediately 3' to the annealing site of primer
G.
Since the insert of povTNF8 could not be freed and inserted into
pTZ18R, primer J (fig.2.2) was selected in order to sequence its other
end. Sequencing reactions using this primer produced c.400b of
readable sequence. These comprised the terminal (3') few bases of the
ovine TNFa cDNA sequence (according to povTNF4-7), including a short
(lib) poly-A tract, then a stretch with homology to the extreme 5'
terminus of the human sequence extending to the region from which
primer H was derived, and finally, the multiple cloning site of
pTZ19R, where it could be seen that a mutation (likely to be
responsible for the inability to free the insert) had occurred. After
the first 10 bases of the ' TNFa 5' ' stretch this sequence reached
the extent of the sequence derived by direct sequencing of the
c.l300bp PCR product and in the subsequent region of overlap showed
total homology with it.
2.2.13.Final sequence:-
The complete sequence of ovine TNFa cDNA is presented in fig.2.8.
This represents a composite, consensus sequence of all the overlapping





F G (TGA) J
H E D 1
Set}, reaction Primer used
a 440 <— 738 D
b 33? 630 E
c 30? 634 RP
d 32? 723 C
e 7P- 758 F
f 730 1060 RP
8 763 1142 G
h 739 -106? RP
i 763 1146 G
i 634^-656 1341^ AAA RP
k 634^639 1258^ AAA E ,
1 998^- 1390 I
m 581 < 656 1405£ AAA RP
n 581 < 638 1320 ^ AAA E
0 990^- 1390 I
p 11 ^ 342 H
q 739 -1081 RP
r 1 -361 1643—AAA J
Figiire 2.7:- shown at the top of thefigure is a linear representation ofthe complete
ovine TNFa cDNA molecule, indicating:- the approximate, annealing positions ofsense-
& antisense- primers (labelled as in fig. 2.2), above & below the line, respectively; the
translation initiation (AUG) & termination (TGA) codons; <& thepolyadenylated tail
(AAA). Below this are indicated the relative positions ofsequences derivedfrom
individual sequencing reactions (with sequence no.s referring to those offig. 2.8;
sequences ofPCR primers were excludedfrom results), using the primers indicated
(RP= reverse sequencingprimer). Templates used in individual reactions were:- c.500bp
product ofdirect PCR (a,b); ss.DNA from povTNFl (c,d,e); ss.DNA from povTNF2
(f,g); ss.DNA from povTNF3 (h,i); ss.DNA from povTNF4 & 5 (j,k,l; identical results
were obtainedfrom each plasmid); ss.DNA frompovTNF6 & 7 (m,n,o; identical results
were obtainedfrom each plasmid); c,1300bp product offully-nested inverse PCR (p); &
ss.DNA from povTNF8 (q,r). Leftwardfacing arrows indicate that sequences, as read,
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. * . . . C/ 1100
TGAGGCCTGGACAATGGGCCACCAACCATCACCAAGGACTGGAACTGGAACTTCCAGAACTCCTCGGGTCCACAAGTTTGGGTTCC
CGGATGCAACCTGGGACACCCAGAATGCAAGGGCCAGGGTTCTTACCGGAATACTTCGCAACGTTCCTTGAGAAGATCTCACCTAG







. . .rrl-115.°°A.i.lj.rri-i-r;. AAAAA ' CATCAAGTTGTCTAAATG
C/ . . . . . 1600
ATGCTGATTTGGTGACTGATTTGTCGCTACATCACTGAACCTCCGCTCCCCAGGGGAGTCATGCCTGTAACCGCCCTACTGGTCAG
. CCG< . 1669
TGGCGAGAAATAAAGTGTCCTGAGAAAAGAAAAAAAAAAA
Figure 2.8:- the complete sequence ofovine TNFa cDNA & (below the start ofeach
codon) the deduced amino acid sequence of the corresponding protein. A potential
glycosylation site (NIS) & thepolyadenylation signal (AATAAA) are underlined, as
are two AT-exclusive regions in the 3'UTR. An asterisk underlies the translation
termination codon. The presumed start of the mature protein (by analogy with the
cleavage site in the human sequence) is marked by an overhead V. Nucleotide no.s
are shown as superscripts as are differences from other published ovine sequences.
Substitutions and insertions in the sequences of Young et al., (1990) and Nash et a I..
(1991) are shown in bold and normal types, respectively. Insertions are indicated by
an oblique line at the appropriate site, preceded by the additional nucleotide(s). The
bold asterisk overlying position no. 1042 represents a C residue in each of these
sequences. Arrowheads bracket the start & finish of theformer sequence and
deletions in theformer and latter sequences are indicated by double and single
overlines, respectively.
2.3.Discussion:-
Several points worthy of note arose during the course of this work.
A first concerns the initial failure of direct PCR to produce a
discrete product. Indeed, although the annealing temperatures (Tm) of
primers A and B were estimated to be 53 and 59-60°C respectively
(using the formula Tm = 3 x [C + G] + 2 x [A + T + I]"C [Bolton &
McCarthy, 1962], where C,G,A,T and I represent the number of
corresponding bases contained in the primer), no product was formed at
all unless the annealing temperature of the PCR was <45°C. Once the
final sequence of the ovine cDNA was established, it could be seen
that it contained the exact sequence of one of the mixes comprising
primer B and that primer A differed from its complementary region
(with the exception of its inositol base) by just one base. This base,
however, was at the extreme 3' end of the primer, a crucial position
for commencing polymerisation, and is likely to account for the
difficulties experienced, although the paucity of TNFa encoding
molecules suggested by Northern blotting anlysis (see below) may have
been a contributory factor.
'Nested' PCR, a procedure adopted by Ohara et al. (1989) to amplify
equivalent genes from species of wide evolutionary divergence, was
clearly successful in predominantly amplifying the desired fragment.
Whilst primer C shared 100% identity with its complementary region in
the ovine sequence, primer D contained 2 mismatches. However, these
were both contained within the 5' half of the primer.
Several problems also arose during the use of inverse PCR. The non¬
specific amplification of other molecules by primer F alone may be
related to its content of C/G residues, which, at 57%, is slightly
higher than the 50% considered ideal and may render this a generally
'sticky' primer. Nevertheless, it could be considered unfortunate that
the main product of amplification by this primer alone was of similar
size to the main product of primers E and F working together,
necessitating further work before the TNFa-specific product could be
analysed. The ability to generate significant product using a single
primer also serves to illustrate the importance of ensuring sufficient
dilution of cDNA during circularisation reactions. Since the PCR is
such a powerful amplification device, the joining of only a handful of
molecules in head-to-head, or tail-to-tail fashion, with or without
other, intervening molecules, could result in significant
contamination of inverse PCR products by undesired products. This
scenario clearly becomes more probable when attempting to amplify
abundant molecules where such ligations are more likely to occur.
Further problems in the use of inverse PCR were related to the
heterogeneous nature of the cDNA produced. In the original development
of inverse PCR, Ochman et al. (1988) and Triglia et al. (1988) had
worked with homogeneous fragments of genomic DNA. During the course of
this work, Huang et al. (1990) subsequently described the successful
use of inverse PCR on cDNA but made no mention of encountering any
problems.
The smaller-than-anticipated, major, TNFa-specific product of
inverse PCR was clearly due to the amplification of incomplete
templates. Such templates are more likely to be present when cDNA is
synthesised from RNA which has been extracted from a source rich in
RNAses (e.g. macrophages) or from lengthy RNA molecules, particularly
when they contain regions of strong secondary structure, resulting in
polymerase 'pause' sites, and the incomplete extension of first strand
cDNA to the 5' terminus. Within a mixed population, shorter templates,
with fewer 'pause' sites, are then likely to be preferentially
amplified during PCR. On this note, using the methods of Freier et al.
(1986) and the sequence determined above, one can demonstrate the
potential for complex secondary structure in ovine TNFa mRNA molecules
just 5' to the region where primer E would anneal (fig.2.9). Whilst
the physiological significance of such a structure is unknown, its
presence would account for the fact that the major product of inverse
PCR derived from amplification of molecules whose sequence (prior to
circularisation) terminated before this region, as demonstrated by the
sequencing of povTNF4,5 and povTNF6,7. Although not analysed, it would
also seem likely that the c.lOOObp major product of fully-nested
inverse PCR, using primers G and H, derived from amplification of
templates whose sequence terminated (again prior to circularisation)
just 5' to the complementary region for primer H. It may have been
fortunate that in this instance, having 'by-passed' a few hundred bp




Figure 2.9:-potential secondary: structure within the ovine TNFa transcript, as
predicted using the method ofFreier et al. (1986). Numbering ofnucleotides is as in
fig.2.8.
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An initial response to the problem of trying to amplify fuller
length molecules, by carefully separating and further amplifying the
lesser amounts of larger molecules produced by inverse PCR, was
clearly unsuccessful (fig. 2.6c). Here, a c.lOOObp major product again
resulted when a c.2000bp band was used as the template. Whilst this
could have resulted from preferential amplification of a small number
of contaminating c.lOOObp molecules, great care was taken to minimise
such contamination, by using a small amount of PCR product in slow,
preparative electrophoresis, extended to allow wide band separation.
The likely implication of this finding is that the c.2000bp product is
a concatemer of the c.lOOObp product, produced as a result of Tag
polymerase working in a 'rolling-circle' fashion (Gilbert & Dressier,
1968) on the original circular template. Whilst there is a shortage of
reports concerning the ability of Tag polymerase to cause the strand
displacement necessary for rolling-circle replication per se , such
displacement would have been favoured by the high temperature of
polymerisation. The presence of other positively-hybridising molecules
far larger than the maximum anticipated size of an inverse PCR
product, including a faint concentration of c.3000bp molecules (as
revealed by careful scrutiny of fig.2.5b), lend support to the notion
that rolling-circle replication had occurred, though its definitive
demonstration clearly requires sequencing of one of these larger
products.
The above findings suggest that there are limitations to the
usefullness of the inverse PCR in cloning cDNA molecules when a
proportion of these templates are likely to be incomplete. Separation
of fuller length products on the basis of their size alone may not
always be possible, in contrast to the situation one might expect when
using anchored PCR. Clearly, the use of a primer complementary to a
region as near the 5' extremity of known sequence as possible is to be
highly recommended.
Difficulties were also experienced when attempting to clone the
three PCR products selected for cloning. In each case only one or two
desired clones were obtained from several ligations and
transformations. Controls suggested that transformation efficiencies
were adequate, the ligase was functional and there was nothing present
in the PCR product inhibiting transformation. Furthermore, use of the
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same reagents in 'cohesive-ended' ligations when transferring the
inserts of povTNF2 and povTNF3 to pTZ18R produced a more than
satisfactory result. Others have also experienced poor results
following attempts to blunt-end ligate PCR product into cloning
vectors (Shuldiner et al.. 1990; C.Fiskerstrand, C.Cousens & I.Bennett
- personal communications). Approaches to overcome this problem have
been described. These include the incorporation of restriction
endonuclease sites at the 5' ends of PCR primers, with PCR products
being submitted to digestion and 'sticky-ended' ligation, or the
incorporation into primers of several bases of sequence complementary
to vector sequence, allowing subsequent 'ligase-free' cloning
(Shuldiner et al., 1990). Neither is perfectly satisfactory, since the
first requires that no similar endonuclease sites exist within the
unknown sequence (in order to clone it in entirety in one procedure)
and cleavage at the termini of PCR product may not be very efficient
(Kaufman & Evans, 1990) whilst the second requires the use of
imperfect primers whose bulky nature makes them expensive and less
than ideal for use in PCR. There is clearly a place for a more
satisfactory alternative. The large number of non-hybridising
recombinants present after two cloning attempts was likely to be due
to inadvertant contamination of communal reagents.
Given the poor success rate in cloning PCR product it was somewhat
fortuitous that much of this was able to be sequenced directly, since
double-stranded sequencing may not always give consistently clear
results. The protocol adopted, however, was similar to that described
as optimal for the sequencing of double-stranded products by Casanova
et al. (1990). Failure to obtain readable sequence by direct
sequencing of the c.lOOObp product of semi-nested PCR using primer E
was likely to be due to the heterogeneous nature of this product in
respect of the 5' extent of its TNFa sequence and length of poly-A
tract, as demonstrated by the sequencing of povTNF4-7. Other failures
could have been due to poor specificity of primer annealing, or
incomplete extension of complementary strands, leading to the presence
of only part of the annealing site and thus poor annealing efficiency.
The final nucleotide sequence presented in fig.2.8 is a composite
of direct sequencing of PCR product and the consensus sequence of a
handful of clones. In the light of the difficulties encountered in
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amplifying the 5' terminus and obtaining sufficient clones, two
immediate questions to consider about this sequence are:- 1) is it
complete? and 2) is it accurate?
1658 bases of ovine TNFa cDNA sequence were ascertained (excluding
the poly-A tail). This compares favourably with the overall lengths of
TNFa cDNA sequences from other species (1643b in humans, Pennica et
al. , 1984; 1644b in mice, Fransen et_al., 1985; and 1671b in rabbits,
Ito et al., 1986). Furthermore, this ovine sequence can be broken down
into an open reading frame, from the first coded methionine residue,
of 234 codons, preceded by a 5' untranslated region (5'UTR) of 156
bases. Such a breakdown is similar to that obtained in other species
(233 codons, 152b of 5' UTR in humans; 235 codons, 156b of 5' UTR in
mice; and 235 codons, 173b of 5' UTR in rabbits). Such homology
clearly suggests that most, if not all, of the ovine sequence had been
obtained. Northern blotting analysis, however, does cast a little
doubt on this conclusion. Several studies in humans and mice have
shown that their TNFa transcripts have a similar, or slightly greater,
mobility through agarose gels than their respective 18S RNA's (e.g.
Pennica et al., 1985; Beutler et al.. 1986a; Remick et al., 1989;
Sugama et al., 1990). Careful measurement of the gel and blot shown in
fig.2.4 clearly demonstrated that ovine TNFa transcripts show slower
mobility than ovine 18S RNA. This result was confirmed by a second
Northern blotting experiment (see chapter 4, fig.4.2). Whilst this
discrepancy could be due to species' differences in the sizes of 18S
RNA, the lengths of polyadenosine tailing, secondary RNA structure
surviving formamide/formaldehyde denaturation, or any combination of
these, a further contributing possibility could clearly be a larger
ovine TNFa transcript. A further interesting observation is that the
5' 'UTR' of this ovine sequence is actually an open reading frame, in
frame with the 234 codons described above, although it contains no
triplets encoding a methionine residue. Questions regarding the
possible existence and sequence of more ovine 5' UTR are likely to be
answered only by genomic cloning with definitive identification of the
transcription initiation site by SI mapping. The answers would clearly
help to ascertain whether the above 'open reading frame' observation
75
is merely a chance one, or whether an extremely unusual situation
exists in the sheep, whereby it could produce a much larger TNFa
preprotein than in other species.
Other observations worthy of note were also made from Northern
blotting experiments. As in other species, TNFa transcripts in a sheep
proved to be rapidly and greatly inducible from a cell population rich
in macrophages, reaching a maximum concentration between 90 and 180
minutes with a subsequent rapid decline, when cells were stimulated
immediately after preparation. However, similar induction was noted in
the absence of added LPS, hence no conclusion can be drawn regarding
the induction of ovine TNFa mRNA by LPS (see also fig. 4.2). Nor can
any firm conclusions be drawn regarding the earlier failure to detect
ovine TNFa transcripts when cells were stimulated 24 hours after
plating out, since the intended positive control, which had also been
prepared following stimulation 24 hours after plating out, did not
show detectable hybridisation. However, it can be said that similar
amounts of RNA were electrophoresed (as judged by OD measurements
prior to electrophoresis and the intensities of fluorescence following
electrophoresis and transillumination) and the same reagents
(including probe) and techniques were subsequently used as in the
successful Northern blotting experiment. In the absence of any
inadvertant error(s) in protocol, this would suggest that these
samples contained levels of TNFa transcripts below the detection limit
of Northern blotting. In the light of the above observation that ovine
TNFa transcripts can be greatly induced during cell preparation and
the demonstration that macrophages can become tolerant to LPS, with
respect to TNFa production, by pre-exposure to only very low levels of
LPS (Takasuka et al., 1991), it is possible that the ovine cells were
refractory to LPS stimulation 24 hours after plating out. If this
interpretation is correct, it could be considered fortunate that PCR
proved to be sufficiently powerful at amplifying a small number of
'constitutive' or 'surviving' transcripts for the direct PCR to
succeed. Other possible alternative explanations for the original
Northern blotting failure would clearly include:- death of cells
within 24 hours; insensitivity of ovine cells to the dose or type of
LPS used; and/or the original non-adherent fraction of the lung cell
population were the source of TNFa transcripts. Each of these
possibilities would appear to be remote. Premature cell death seems
unlikely as intact RNA was extracted and several subsequent
experiments (see chapter 5) demonstrate the survival of similarly-
prepared lung cells for several weeks, whilst the same dose and type
of LPS was successfully used in the induction of ovine IL-1J3 mRNA from
the adherent fraction of a lung-cell preparation (Fiskerstrand et al..
1992). (The above findings will be discussed further in chapter 4.)
On the question of sequence accuracy, it can be seen from fig.2.7
that the sequence from base no.11 to base no.738, as presented in
fig.2.8, was derived by directly sequencing PCR products, with further
confirmation by the single-stranded sequencing (in the opposite
direction) of two overlapping clones. As such there can be few doubts
regarding the accuracy of this sequence. Bases 1 to 10 of the
presented sequence were arrived at by the sequencing of a single clone
and as such could clearly contain a PCR-derived error. Counting
povTNF2,4 & 5 and povTNF3,6 & 7 as single clones, sequences from bases
739 to 758, 759 to 1081, 1082 to 1642 and 1643 to 1658 were derived as
consensus sequences from only 4,3,2 and 3 clones respectively. No
differences were seen between the sequences of any clones from base
739 to 861 (the end of the coding region). Furthermore, this sequence
was confirmed by the consensus sequence of five clones obtained for
expression purposes and sequenced in both directions (see chapter 3).
There can therefore be few doubts regarding the accuracy of this
section.
Differences were noticed between the sequences of the three clones
in the section from b.862 to b.1081 at four positions. These comprised
a T instead of a G residue at position 958 in povTNF2 and, in povTNF3,
a C instead of a T residue at positions 910 and 1042, and a 3 base
deletion at positions 992-994. The change at position 1042 was
confirmed in the sequences of povTNF6 and 7. PovTNF8 contained the
consensus sequence. No differences between clone sequences were noted
in the remaining sections. Under these circumstances, whilst the
majority of the 3' UTR sequence presented is likely to be correct,
there exists the possibility that a few of the bases shown may be PCR-
derived artefacts. In one survey, Saiki et al. (1988) estimated an
error rate of 0.25% for any given base following 30 cycles of
amplification of a particular fragment. Whilst error rates may be
dependent on the sequence of DNA amplified, the possibility of
sequences here containing errors would have been increased by the fact
that as many as 70 rounds of amplification were needed before cloning.
Clearly, the differences that were noted between clone sequences could
have been due to such PCR errors or, alternatively, allelic
polymorphism in an heterozygous individual (see below).
During the course of this work two other groups cloned and
sequenced ovine TNFa cDNA and published their data, which was derived
following the identification of a single (Young et al., 1990) or two,
identical (Nash et al., 1991) cDNA clones. A few differences exist
between the three sequences (see fig.2.8). The sequence of Young et
al. appears to be incomplete in that it contains only 3 bases of 5'
UTR. These 3 bases differ totally to those in the corresponding
positions of the other two sequences and, in contrast to these, show
no homology to the equivalent positions in the human sequence. Since
these bases are at the extreme end of a cloned insert, they may
represent a cloning artefact.
With the exception of position 1, the entire 5' UTR sequence
presented here is in total agreement with that in the sequence of Nash
et al.(which does, however, contain four additional bases at the 5'
terminus), as is the sequence of the coding region. 2 differences from
the sequence of Young et al. were noted in this region though. These
included a conservative 3rd base substitution and a 3 base deletion in
the latter sequence, leading to one fewer amino acid in its predicted
preprotein structure. As well as being present in the sequence of Nash
et al., this additional triplet was present in cDNA amplified by both
direct and indirect PCR, and hence in cDNA derived from both of the
two sheep used in this work. Furthermore, whilst this extra amino acid
has no counterpart in the human sequence, the same residue is present
in the same position in a bovine TNFa amino acid sequence (Goeddel et
al. , 1986; see chapter 4, fig.4.11).
A handful of differences between the 3 sequences are present in the
3' UTR, where most doubt exists concerning my own sequence. However,
the other two sequences were in agreement against my sequence in only
one of these positions (a C for T substitution at b.1042), so that,
with this exception, my sequence, from base 2 onwards, was the same as
the consensus of all 3 sequences. It is notable, however, that one of
my three clones covering b.1042 contained the same residue at this
position as the two alternative sequences. Also of note was the fact
that the sequence of Nash et al. lacked the same 3 bases as povTNF3.
Since their sequence derived from cDNA clones, and a survey of
multiple PCR-derived errors identified only single base substitions
(Saiki et al., 1988), it seems likely that this short deletion
represents an allelic polymorphism. Other sequence differences could
clearly also be due to other polymorphisms or, alternatively, errors,
be they human or polymerase-induced. Whilst further studies would
clearly be required to resolve this issue, polymorphism in TNFa genes
is not without precedent. Jacob and McDevitt (1988) noted an RFLP in
the TNFa genes of different strains of mice (see 1.8.6) which could be
linked to differential abilities to produce TNFa, whilst Jongeneel et
al. (1990) identified at least eight different alleles, involving a
polymorphic microsatellite, in the murine TNFa gene promoter. More
recently, Freund et al. (1992) discovered several differences between
the TNFa genes of toxoplasmic encephalitis -resistant and -susceptible
mice, which could be localised to the promoter, first intron and 3'
end of the TNFa gene. Furthermore, polymorphism could perhaps be
expected in an immune system gene in a species such as the sheep,
which has been line-bred for several centuries, often on the basis of
disease resistance. In this regard it can be noted that at least two
widely-differing breeds of sheep (Scottish Blackface and Merino, [the
breed used by Young et al. was not stated]) from three different
continents were used in these studies. Differences also exist in the
published sequences of cDNA's encoding other ovine cytokines, such as
IL-1B (Fiskerstrand & Sargan, 1990; Andrews et al., 1991) and IFN
gamma (Mclnnes et al., 1990; Radford et al., 1991).
An overall alignment of the ovine and human nucleotide sequences
can be made which suggests that the two share 78% homology overall (a
similar divergence to that found for human and rabbit or murine
sequences), though certain regions show a much higher degree of
homology. These include the coding regions, which share 84% homology
at the nucleotide level (a discussion on the predicted amino acid
sequence of ovine TNFa and its comparison with those of other species
will be presented in chapter 4). Another well-conserved region is that
immediately preceding the coding region. Here, 11/13 bases share
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identity between the two sequences, with the final 6 bases (GACACC)
being the same in both cases. These six bases show homology with the
sequence identified by Kozak (1987) as a consensus sequence for
translation initiation (GCCa/gCC), and the conservation of sequence in
this region would argue against the possible existence of a larger
ovine TNFa preprotein discussed earlier. 2 regions of high homology in
the 3' UTR are also worthy of note. These include a typical
polyadenylation signal sequence (Proudfoot & Brownlee, 1976) close to
the 3' terminus and a 34 base AT-exclusive region, which is perfectly
conserved between the two, and most of which is also conserved with
the rabbit and mouse sequences. Such AT-exclusive regions have been
identified as conferring the properties of instability (Shaw & Kamen,
1986), as well as translational inducibility by LPS (provided the
sequence is in appropriate context and in the correct cell type [Han
et al.,19901), on transcripts bearing them (see 1.3.3). With regard to
the context of this sequence, it is also apparent that 90% of 50
nucleotides flanking this region share identity between the sequences.
The ovine sequence also contains an additional, earlier 10 base AT-
exclusive region. One might therefore predict that ovine TNFa
transcripts would also display the properties of instability and
translational inducibility. The instability of ovine TNFa transcripts
is suggested by their rate of disappearance following induction (see
fig.2.4). Further studies by Nash et al. (1991), using deletion
constructs for protein expression in mammalian cells, suggested that
the presence of this region contributed to decreased yields, with
transcript instability being one potential explanation. The
translational inducibility of ovine TNFa transcripts by LPS will be
discussed in chapter 4.
CHAPTER 3:- EXPRESSION AND CHARACTERISATION OF RECOMBINANT OVINE TNFq.
3.1.Introduction: -
A further objective in the study of ovine TNFa was to express
recombinant ovine TNFa (rovTNFa), firstly, to be able to answer
questions regarding the biological properties of a protein with the
sequence of ovine TNFa and secondly, to provide an immunogen for
raising antibodies which might be capable of recognising native ovine
TNFa. Several factors were considered in the choice of a suitable
expression system for this work, including precedents in the
production of recombinant TNF'sa, the possible importance of a correct
glycosylation pattern, ease of purification and anticipated yields of
recombinant protein, and finally, the cost and availability of
reagents and equipment.
Recombinant TNF'sa from other species have previously been
recovered from a variety of bacterial, yeast and mammalian expression
systems and have proven to be highly active when derived from any of
these sources (e.g. Pennica et_al., 1984; Sreekrishna et al., 1989;
Marmenout et al., 1985). Thus a wide choice of potential systems could
have been considered. Whilst the function of glycosylation in TNF'sa
is unknown, it does not appear to be important for activity, certainly
in the murine system, since human TNFa, which is not glycosylated, and
unglycosylated recombinant murine TNFa are both highly active on
murine cells (Pennica et al., 1984, 1985), even though native murine
TNFa is glycosylated (Green et al., 1976). Hence, although the
sequence of ovine TNFa predicts one potential Asn-linked glycosylation
site (see fig.2.8), the production of a recombinant protein with an
authentic glycosylation pattern, as might be achieved using a
mammalian expression system with attendant problems of low yields,
contamination with other mammalian proteins and possible cytotoxicity
of the product, took lower priority than selection of a system for
high yield and ease of purification.
The expression system chosen was the yeast Ty-'virus-like particle'
(VLP) system originally described by Mellor et al. (1985). An
attractive feature of this system is the ease of purification of an
expressed protein. Here, proteins are expressed as fusion products
with, and downstream from, the Ty element protein PI (Dobson et al.,
1984), whose ability to self-assemble into VLP's (Adams et al., 1987b)
is generally retained in the presence of a fusion partner (Adams et
al., 1987a). The particulate nature of the fusion protein can then be
exploited in a simple purification process involving centrifugation
and/or size-exclusion procedures. By including a specific proteolytic
cleavage site between the fusion partners, the protein of interest can
subsequently be freed from PI. Reagents for this system were available
within the department and it had already proved capable of producing
adequate yields and purity of recombinant protein with the equipment
available (Reyburn et al., 1992). This system has previously been used
to express another recombinant cytokine (human IFNa2), which was found
to have biological activity (Mellor et al.. 1985) and furthermore, the
production of a recombinant TNFa as the carboxy-terminal fragment of a
larger precursor, and its subsequent release by proteolytic cleavage,
could be considered to be similar to the production and release of
mature, native TNFa (Pennica et al., 1984; Scuderi, 1989). Another
possible beneficial feature of this system, which has previously been
proposed, is that the immunogenicity of the recombinant protein, when
inoculated as a fusion protein in uncleaved form, may actually be
enhanced by its particulate nature (Adams et al., 1987a).
Several vectors have been constructed for use in producing proteins
via the Ty-VLP, including those where expression of the fusion protein
is placed under the control of either a constitutive (Adams et al.,
1987a) or an inducible promoter (Kingsman et al., 1990). Given the
possibility that the presence of a large amount of inappropriate,
intracellular TNFa might be detrimental to the host cell (Smith M. et
al., 1990), the vector chosen for this work was pOGS40. In this
vector, expression of the fusion protein is under the control of a
strong galactose-inducible, hybrid promoter (PGK-GAL, Kingsman et al.,
1990). Other features of pOGS40 include:- the ability to replicate in
both bacteria and yeast; an ampicillin resistance gene allowing
selection of bacterial transformants in ampicillin-containing media; a
leu2 gene (see below); and an engineered yeast Ty A gene, which
encodes PI and ends in a BamHI restriction endonuclease site (an
unique site in this plasmid) followed by termination codons in all
three reading frames.
The inducibility of galactose-regulated genes can be limited by the
level of GAL4 protein within a cell (Johnston & Hopper, 1982). Co-
transformation of yeast with another plasmid, pUG41S, which contains
the structural gene for GAL4 (also under the control of a galactose-
inducible promotor), can, therefore, be used to increase the yield of
fusion protein obtained when using a pOGS40-derived plasmid (Kingsman
et al. , 1990). p(JG41S also contains a ura3 gene. This gene, and the
leu2 gene of pOGS40, confer uracil- and leucine- independance
respectively, on a uracil- and leucine- dependent host strain of
yeast, allowing the selection of double transformants by growth in
minimal media. The host strain of yeast used in this work,
Saccharomyces cerevisiae, strain BJ 2168, as well as containing
incapacitating mutations in its ura3 and leu2 genes, is also protease-
deficient, reducing the risk of undesired digestion of the recombinant
product (Jones, 1991).
Bovine factor Xa, a protease which specifically cleaves a
polypeptide immediately after its recognition sequence (Ile-Glu-Gly-
Arg; Magnusson et al., 1975) has previously been used to cleave fusion
partners in order to leave a recombinant protein with an authentic
amino terminus (Nagai & Thorgersen, 1984). Fortunately, there are no
recognition sites for this enzyme, or for the restriction endonuclease
BamHI (GGATCC), in the predicted amino acid and nucleotide sequences
respectively of mature ovine TNFa (see fig.2.8). The strategy adopted
in order to construct an ovine TNFa expression cassette, therefore,
was to use 'tailored' primers in a PCR on ovine cDNA. These inward-
facing primers were designed to be capable of annealing to the first
and last few bases of the coding sequence for mature ovine TNFa but
also contained additional, flanking nucleotides, so that in an
amplified fragment of DNA the ovine TNFa sequence would be immediately
preceded by sequence encoding a factor Xa cleavage site and the whole
of this would be flanked at both ends by BamHI sites. (Without
knowledge of the actual first amino acid of mature ovine TNFa, this
was assumed, by analogy with human TNFa, to be the 78th aa of the
preprotein [see figs.2.8, 4.11 and discussion, 3.3] giving the mature
protein [without glycosylation] a predicted molecular weight of
17kDa.)
Fragments of DNA thus amplified, then digested with BamHI, would be
inserted into the BamHI site of pOGS40 (after first cloning and
sequencing via the 'phagemid pTZ18R to eliminate potential errors in
sequence introduced by PCR [see chapter 2]). Following co-
transformation (with pUG41S) and culture of yeast, then purification
of VLP's, rovTNFa would be freed from PI by digestion with factor Xa
and characterised, in order to ascertain whether it shows properties
similar to TNF'sa from other species.
3.2.Results:-
3.2■1.Production of a 'rovTNFa cDNA expression cassette'
The following primers (with positions of complementary sequences
and recognition sites indicated overhead) were selected for use in the
production of an ovine TNFa expression cassette:-
Sense primer-
*** BamHI FactorXa ovine TNFa*
5' AAG CTT GGA TCC ATA GAA GGT AGA CTC AGG TCA TCT TCT CAA GCC 3'
Anti-sense primer-
*** BamHI (Stop) ovine TNFa**
5' AAG CTT GGA TCC TCA CAG GGC GAT GAT CCC AAA GTA GAC C 3'.
positions 388-408, ** positions 861-834 [no.s according to
fig.2.8]; *** additional nucleotides were included 5' to the BamHI
sites to help extension of the opposite strand through these regions
during PCR, hence ensuring the synthesis of complete endonuclease
recognition sites. )
When PCR's were performed using these primers on templates of lOng
of first strand or ds cDNA (see 2.2.1 and 2.2.6), at an annealing
temperature of 48°C, a product of anticipated size (c.510bp) was
produced in either case (fig.3.la).
Figure 3.1:-
Figure 3.1photographs of 1.2% agarose gels following electrophoresis &
transillumination, with the positions ofmolecular size markers (in kb) indicated.
Samples submitted to electrophoresis comprised 10% ofthe product ofPCR's,
involving the tailored primers described in the text, on templates ofdouble stranded-
orfirst strand- cDNA (3.1a, lanes 1 & 2, respectively) & plasmid preparations, after
digestion with BamHI, offour selected colonies which had been transformed with
pOGS40-derivedplasmids (3.1b, lanes 1-4). Colonies whose extracts are shown in















Table 3.1:- the OD's600 offour selected yeast colonies after 24 h growth in
glucose-containing medium (Sc-glc) (column 1) & 24 h after transfer to
galactose-containing medium (Sc-glc-gal)(column 2).
After purifying the PCR product of one of these reactions (first
strand template), digesting it with BamHI, repurifying and submitting
it to preparative electrophoresis through LGT agarose, an estimated
lpg of c.510bp product was available for 'cohesive-ended' ligation
into the BamHI site of pTZ18R. When 25 or 50ng of this were used in
ligations with 50ng of linearised 'phagemid and the products used to
transform E.coli, >100 recombinant colonies resulted from either
ligation. >90% of these hybridised to an ovine TNFa cDNA probe
(c.500bp product of direct PCR, 2.2.3). It was also noted that most
positively-hybridising colonies were pale blue rather than white in
colour.
21 positive colonies were randomly selected for further analysis
involving agarose gel electrophoresis of miniplasmid preparations
after their digestion by BamHI. Suitably-sized inserts were excised
from 15 of these preparations. Undigested miniplasmid preparations
were also analysed to help assess overall plasmid size, thereby
hopefully avoiding clones with multiple inserts. 5 clones (designated
povTNF 9-13), with similarly-sized plasmids from which a c.510bp
insert could be excised, were chosen for sequencing after preparation
of ssDNA.
Initial sequencing reactions using reverse sequencing primer, and
their analyses, showed that povTNF9 & 11 contained a similar insert in
one orientation, extending from the sense primer (above) through
sequence of ovine TNFa cDNA 3' to the complementary region for this
primer, and that povTNF10,12 & 13 contained insert in the other
orientation, starting with the sequence of the antisense primer.
Subsequent sequencing reactions using primers E or F (fig.2.2) on
preparations from povTNF10,12 & 13 or povTNF9 & 11, respectively,
confirmed these sequences in the regions of overlap and extended the
known sequences of these inserts through their full extent. In each
case plasmids contained only a single insertion of the PCR product and
the consensus sequence of all 5 clones (having converted the sequences
of povTNF10,12 & 13 to sense form) was in agreement with the
appropriate region of sequence presented in fig.2.8. However, povTNF9
contained a C instead of a T residue at position 560 and povTNFll, a C
instead of a G residue at position 424, whilst povTNF12 contained
approximately 30 bases of DNA of unknown origin inserted between the
sense primer and the multiple cloning site of pTZ. Since either of
these base alterations would have resulted in a different amino acid
from the consensus sequence, and the presence of an extra fragment of
DNA might have interfered with 'clean' insertion of DNA, only two
clones were considered suitable for providing an insert for ligation
into pOGS40.
An estimated lpg of insert, ready for use as the rovTNFa cDNA
expression cassette, was obtained from a large scale plasmid
preparation of povTNF13, after BamHI-digestion and purification by
agarose gel electrophoresis and electroelution.
3.2.2.Preparation of a rovTNFa expression vector:-
When 50, 100 or 250 ng of the above rovTNFa cDNA expression
cassette were incubated with 200ng of BamHI-cut, CIP-treated pOGS40 in
cohesive-ended ligation reactions, and the purified ligation reactions
used to transform E.coli, strain JM83, >100 colonies resulted from
each ligation. However, a similar number resulted from a control
ligation reaction involving vector with no DNA for insertion. (Strain
JM83 [Messing, 1979] was used here because of its greater
susceptibility to transformation, likely to be important when using a
relatively large plasmid such as pOGS40.)
After 200 randomly-selected colonies were screened by colony
hybridisation to an ovine TNFa cDNA probe (c.500bp product of direct
PCR, 2.2.3), 14 colonies gave a positive signal, with four giving a
much stronger signal than the rest. When plasmids from these colonies
were analysed on agarose gels alongside a preparation of uncut pOGS40,
the four strong-signal colony plasmids showed significantly faster
mobilities than pOGS40, whilst those derived from the 10 weaker signal
colonies showed slightly slower mobilities than pOGS40.
When 4 of these 10 latter preparations were randomly selected and
further analysed following digestion with BamHI, it was found that a
c.510bp insert could be excised from at least 3 of the 4 (fig.3.lb).
An estimated 150pg of plasmid DNA were then obtained from a large
scale preparation of each of these 3 plasmids. Following submission of
these preparations to double-stranded sequencing reactions, using a
pOGS40-specific primer (chosen for its complementarity to a site 50-30
bases upstream from the BamHI site) the sequences obtained comprised
some 20 bases of the TyA gene through to the BamHI site, followed by
c.100 bases of readable sequence derived from the ovine TNFa
expression cassette. It was found that 2 plasmids (pOGSTNFl & 2)
contained this expression cassette inserted in the correct orientation
and in the same reading frame as the TyA gene, whilst in the third, it
was in reverse orientation.
3.2■3.Transformation of yeast
When 5 or lOpg each of pOGSTNFl and pUG41S, with or without 20pg of
salmon sperm carrier DNA, were used to co-transform aliquots of yeast
spheroplasts, a total of 75 colonies were counted on leucine- and
uracil- deficient plates 6 days later. By contrast no colonies were
seen on similar negative control plates (spheroplasts with lOpg pUG41S
only) whilst hundreds of colonies were seen on a plate which included
leucine and uracil as a positive control for regeneration. Notably
more colonies derived when salmon sperm DNA had been used as a carrier
(50 cf 25), though similar numbers derived whether 5 or lOpg of
plasmid had been used (43 cf 32).
3.2.4.Verification of the presence of Pl-fusion protein in yeast
transformants:-
4 of the largest colonies (designated ScTNF12-15 and derived from
transformations involving 5 or lOpg of plasmid without carrier
[ScTNF12,13], or 5 or lOpg of plasmid with carrier [ScTNF14,15,
respectively]) were selected for further work. After a single fast-
growing sub-clone derived from each was used to initiate a small-scale
broth culture, yeast cells continued to grow and divide, even after
transfer to galactose-containing medium, as assessed by optical
density measurements and phase-contrast microscopy (table 3.1,
Crude extracts of each of the four cultures were then analysed by
SDS PAGE with visualisation of proteins by Coomassie blue staining and
by Western blotting using an anti-Pi polyclonal antiserum as the
primary antibody (fig.3.3). On Coomassie-stained gels, a dense band,
which could not be seen in an extract of untransformed yeast, was seen
at the anticipated position of a Pl-TNF fusion protein (c.67kDa) in 3
of the 4 extracts, whilst a dense band seen at the expected position
fig.3.2).
Figure 3.2:
Figure 3.2:- shows representative fields ofa drop ofScTNF12 culture, when
examined by phase contrast microscopy, 24 h after growth in glucose-containing
medium (above) and 24 h after transfer to galactose-containing medium (below).
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Figures 3.3a & b:-photographs ofa Coomassie blue-stained gel & Western blot,
respectively, following electrophoresis, under reducing conditions, ofextracts of
assorted yeast cultures through SDS- 10% polyacrylamide gels. The primary
detection reagent usedfor the Western blot was an and-PI polyclonal rabbit
antiserum, used at a recommended dilution of 1:1000. The positions ofmolecular
weight markers are indicated (in kDa), as are the anticipated positions ofPI & a
Pl-TNFfusion protein. Samples submitted to electrophoresis comprised:- 7pis of
extracts from ScTNF12,13,14 & 15, untransformed yeast & yeast transformed with
pMA5260 (fig.3.3a, lanes 1-6, respectively) & 2pis ofextractsfrom the latter colony,
yeast expressing a c.75kDfusion protein (P1-P25, Reyburn et al., 1992) & ScTNF 15,
14, 13 & 12 (fig.3.3b, lanes 1-6, respectively).
of PI (c.50kDa) in an extract of yeast transformed with pMA5620 (which
constitutively expresses PI [Adams et al. , 1987a]), could not be seen
in extracts of ScTNF12-15 (fig.3.3a). Western blotting confirmed that
in the three extracts with an extra, dense band there was an apparent
decrease in electrophoretic mobility of PI consistent with the
formation of a Pl-TNF fusion protein, whilst the fourth (ScTNF14) was
not apparently expressing PI at all (fig.3.3b).
3.2.5.Large-scale preparation of hybrid VLP's:-
48 hours after a glycerol stock of ScTNF12 was used for its
initiation, a larger scale yeast culture had reached an OD600 of 1.4
and, following a 5-fold dilution, it had regained an OD600 of 1.2, 24
hours later. Having ascertained that a shift into galactose-containing
media did not appear to prevent yeast growth (see above), further
culture then involved simple dilution into this medium. 24 hours after
such a 9-fold dilution, the culture had regained an OD600 of 1.0.
Electron microscopy demonstrated the presence of large numbers of
VLP's within these cells at this stage (fig.3.4).
4 rounds of vortexing with glass beads were required to achieve
>85% cell destruction. After low speed spins to remove gross debris
from the crude extracts of these cells, a large amount of material was
collected on and within a 60% sucrose cushion following a subsequent
higher speed spin. When a dialysate of this material was separated by
centrifugation through a sucrose density gradient, large amounts of
protein(s) of appropriate size for a Pl-TNF fusion protein collected
in the bottom half of this gradient, whilst some other yeast proteins
remained in the top half (fig.3.5). This pattern was consistently seen
on each gradient. When fractions 9-18 (fig.3.5) were pooled and
dialysed into a recommended buffer for factor Xa, a flocculent
precipitate was formed. Analysis of dialysate and supernatant
suggested that further purification could be achieved by precipitate
removal (fig.3.6a) and, having done so, the putative fusion protein
was left at an estimated purity of c.80%, in a preparation containing
700pg protein/ml. Electron microscopy of this final preparation
revealed the presence of large numbers of VLP's with the typical
morphology described by Adams et al. (1987a,b) (fig.3.6b,c).
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Figure 3.4:-
Figure 3.4:- an electron micrograph ofa yeast cell taken from a culture ofScTNF12,
after growth in galactose-containing medium (magnification x 60.000). Note the
presence oflarge numbers ofvirus-like particles within the cytoplasm.
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Figure 3.5:-
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Figure 3.5:- photographs of2 Coomassie blue-stained. SDS-10% polyacrylamide
gels, following electrophoresis under reducing conditions. The positions ofmolecular
size markers are indicated (in kDa). Samples subjected to analysis comprised:- 7pis
ofcrude extract ofScTNF12 at the end ofculture (lane Cr);5pl aliquots of2ml
fractions (numberedfrom top to bottom) removedfrom a sucrose density gradient
following centrifugation (see text) (lanes 1 -18: lane no.s correspond to fraction no.s);
an estimated 3pg ofa preparation ofPI (lane PI); & an estimated 10pg of a




Figure 3.6a:- an SDS-10% polyacrylamide gelfollowing electrophoresis, under
reducing conditions, of20pi samples removedfrom pooled & dialysed sucrose
density gradientfractions (9-18, Jig.3.5), before (lane I) & after (lane 2) removal of
precipitates formed during dialysis. The positions ofmolecular size markers are
indicated (in kDa). Figures 3.6b & c:- electron micrographs (magnifications
x 165,000 &xl00.000. respectively) of the final PI-TNF hybrid VLP preparation.
3.2■6■Cleavage of fusion protein:-
It has previously been found necessary to add chaotropic agents to
VLP suspensions to enable the cleavage of some Pl-fusion proteins by
factor Xa (Braddock et al. , 1989; Gilmour et_al., 1989) and indeed no
cleavage of fusion protein in aliquots of the above Pl-TNF suspension
occurred when no other additions were made, even using a high
concentration of factor Xa and an extended incubation time. Nor was
any cleavage achieved when urea or the detergents CHAPS or
deoxycholate (DOC) were added on their own (to 1M, 0.05% or 0.05%
respectively) (fig.3.7a). Partial cleavage was achieved using 0.5%
Triton-X-100. However, full cleavage could be obtained when 0.05% DOC
was added in addition to Triton-X-100 or CHAPS (fig.3.7b). Since they
can both be removed by dialysis, the 0.05% CHAPS/ 0.05% DOC
combination was then used for subsequent cleavages. A further
experiment was conducted to ascertain the minimum concentration of
factor Xa that would effect c.100% cleavage in an overnight
incubation. The results (fig.3.8a) showed that the appearance of
c.50kDa (PI) and c.l7kDa (rovTNFa) proteins required the presence of
both the Pl-TNF preparation and factor Xa, and suggested that 1 part
Xa to 50 parts fusion protein would be the most cost-effective
concentration for cleavage. This concentration was therefore
subsequently used to cleave the rest of the VLP suspension.
c.27kDa and lesser amounts of c.24kDa proteins were also visible in
some of these experiments [see fig.3.7a and especially b] but only
where high concentrations of factor Xa had been added (see discussion,
3.3).
3.2,7.Final purification of the recombinant protein:-
After cleaved suspensions were submitted to high speed
centrifugation and the supernatants dialysed into PBS, the c.l7kDa
putative rovTNFa protein was the only protein clearly visible when
lOpl of supernatant were analysed by SDS PAGE and Coomassie blue
staining (fig.3.8b, lane 2). Most of the PI protein appeared to be
contained in the pellet formed after high speed spinning (fig.3.8b,
lane 3).
Figure 3.7:- 3.7a
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Figures 3.7a & b:- Coomassie blue-stained, SDS-12% polyacrylarnide gels run under
reducing conditions. Positions ofmolecular weight markers (in kDa) are indicated for
each. Samples analysed comprised:- a PI preparation (3.7a, lane 1; 3.7b, lane 9);
10pi ofPl-TNFpreparation with no additions or incubation (3.7b, lane 8) or
following incubation for 18 h with I partfactor Xa to 10 parts PJ-TNF, w/w, (3.7a,
lanes 2-5; 3.7b, lanes 2-7); & a PI-P25 preparation (Reyburn et al„ 1992) following
similar incubation to serve as a positive control (3.7b. lane I). Other additions, prior
to incubation,were as follows:- urea to IM (3.7a, lane 3); CHAPS, to 0.05% (3.7a,
lane 4; 3.7b, lanes I & 5), 0.5% (3.7b, lane 4) or 0.01% (3.7b. lane 6); DOC, to
0.05% (3.7a, lane 5; 3.7b, lanes 3,5 & 7). 0.5%, (3.7b. lane 4) or 0.01% (3.7b, lane










Figures 3.8a & b:-Coomassie blue-stained. SDS- 12%- & 5-20% gradient- poly-
acrylamide gels, run under reducing- & non-reducing- conditions, respectively.
Positions ofsize markers are shown (in kDa) for each. Samples analysed in 3.8a
comprised:- 10pi oJ'Pl-TNFpreparation, without (lane I), orfollowing (lanes 2 &
5-9), 18 h incubation & a similarly-incubated PI preparation (lane 4) or buffer (lane
3). Prior to incubation, all samples had CHAPS & DOC added (each to 0.05%) and
factor Xa was added to the samples analysed in lanes 5-9 (to I part per 12.5, 25, 50,
100 & 200parts [w/w] ofPl-TNF, respectively) as well as to the samples of lanes 3
& 4 (to the same final concentration [w/vj as the sample in lane 5). Samples analysed
in 3.8b comprised:- 10pi ofcleaved Pl-TNF preparation (lane I) & the precipitate
(lane 3) & dialysed supernatant (lane 2) formed by centrifligation ofthe same.
3.2.8.A second, large-scale preparation of rovTNFa:-
Because of the necessarily protracted nature of its preparation,
this initial batch of rovTNFa was only used in immunisations. In order
to study the biological activity of rovTNFa, a second batch was
prepared following the same methods, but with no delays in its
preparation, whilst fewer aliquots were removed for analysis.
The rates of growth of this second large-scale culture were
virtually identical to the first and similar levels of fusion protein
were present in the same fractions of sucrose density gradients
following centrifugation of the yeast extracts. Once again a 17kDa
protein was the only protein clearly visible following separation of
the final preparation by SDS PAGE and staining by Coomassie blue
(fig.3.16a, lane 1), though faint concentrations of higher molecular
weight proteins could also be seen.
The final protein concentration in this second preparation was
125pg/ml in a total of 80mls of preparation. Because of the presence
of other faint concentrations of protein, the 17kDa protein was
estimated to comprise 80% of the total content, giving a final yield
of 2mg rovTNFa/1 of yeast culture. All subsequently quoted rovTNFa
concentrations are therefore based on this estimate. Multiple aliquots
of the second preparation were stored at -70°C, immediately after the
final preparative step, either with the addition of 0.1% BSA as a
stabilising agent for subsequent use in bioassays, or without for use
in analysis and immunisations.
3.2.9.A preparation of yeast extract for use as a negative control
Advantage was taken of departmental stocks of yeast transformed
with plasmid pMA5620, which constitutively produce PI (Adams et al.,
1987a), to make a negative control preparation of yeast extract with
factor Xa. Somewhat fortuitously, these yeast grew at exactly the same
rate as ScTNF12 in a parallel incubation with the second large-scale
culture.
When extracts of these yeast were submitted to identical
purification procedures as used in rovTNFa preparation, it was found
that most of the PI VLP's collected in fractions 9-12 of the sucrose
density gradients and were therefore included when fractions 9-18 were
Figure 3.9:- 3.9a














Figure 3.9:- Coomassie blue-stained. SDS-10%- (3.9a,b) & 15%- (3.9c) poly-
acrylamide gels, mn under reducing- & non-reducing- conditions, respectively,
showing stages in the preparation ofa yeast extract/factor Xa negative control
preparation. The positions ofsize markers are indicated (in kDa) for each gel.
Samples submitted to electrophoresis comprised:- 5pi aliquots of2mlfractions
removedfrom a sucrose density gradient (3.9a) (fractions [& corresponding lanes]
were numberedfrom top to bottom ofthe gradient; 5-1 represents a pooling ofthe top
5 fractions); I Dpi offractions 9-13 after they were pooled, dialysed & centrifuged
(3.9b); & 10pi ofthefinal negative control preparation after the addition of factor







pooled (fig.3.9a). Once these pooled fractions had been dialysed and
microfuged, however, the final concentration and purity of PI was poor
in comparison to that achieved for Pl-TNF (fig.3.9b).
After mock cleavage (having added the same concentration [w/v] of
factor Xa as used for Pl-TNF cleavage), centrifugation and dialysis of
this preparation into PBS, faint concentrations of proteins were
visible when lOpl were separated by SDS PAGE and stained by Coomassie
blue (fig.3.9c). The total protein content of this preparation, which
was immediately stored in identical ways to the rovTNFa preparation,
was 25pg/ml, a similar concentration to that estimated for
contaminants in the rovTNFa preparation, and it was subsequently used
in assorted procedures at equivalent dilutions as the rovTNFa
preparation.
3,2.10.The cytotoxic activity of rovTNFa:-
Initial assessments of the activity of the rovTNFa preparation were
made using 'classical' cytotoxicity assays on TNF-sensitive murine
cells (Meager et al.. 1989). In a preliminary experiment, the activity
of one aliquot of rovTNFa, which had not been frozen but simply stored
at 4°C (for 3 days after preparation prior to assay), was found to be
similar to that of an aliquot which had been stored frozen
(fig.3.10a). Since this implied that one cycle of freeze/thawing had
not been particularly detrimental to activity, only aliquots which had
been stored frozen, and thawed once, were used in all subsequent
bioassays involving rovTNFa.
However, whilst it did induce cell death when used at high
concentrations, in each of 4 such experiments the rovTNFa preparation
consistently showed much less of this activity on a weight-for-weight
basis than a preparation of rhTNFa (fig.3.10a-d). Typically,
approximately 1000-fold more rovTNFa was required to achieve the same
effect as rhTNFa, either in 18 hour incubations with L929 cells in the
presence of actinomycin D, or in a 3 day incubation with WEHI
164:clone 13 cells without actinomycin D. For example, in one
experiment (see fig.3.10c) the levels of rovTNFa and rhTNFa required




Figures 3.10 a & (see over) b(i), c &d:- the results ofcytotoxicity assays (expressed
as mean percentage cell death, +/- standard de\'iations, ofquadruplicate wells)
performed on L929- (3.10a-c) & WEH1164:clone 13- (3.10d) cells. Concentrations
of TNFa refer to those in added samples (see symbol legends for individualfigures),
which comprised 25 %(3.10a-c) or 50% (3.10d) of thefinal volume. Results for a
yeast extract/factor Xa negative control preparation are plotted at equivalent
dilutions to rovTNFa. Figure 3.10b(ii) (see over):- a photograph of the tissue culture
platefrom which the results shown in 3.10b(i) were derived. Here, added samples
contained PBS + 0.1%BSA only (columns 1, 2, 11 & 12) or rovTNFa (rows A-D in
columns 3-10), the negative control preparation (rows E-H in columns 3-5) &
rhTNFa (rows E-H in columns 6-10). Recombinant proteins were diluted in PBS +
0.1% BSA to l(f, 10s, l(f, 10, 1, IP', IP2 or IP3 ng TNFaJml (or equivalent
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No cytotoxicity was seen when either recombinant protein was used
on the TNF-resistant cell line L929L/R (Matthews & Watkins, 1978) at
concentrations sufficient to induce 100% cytotoxicity on L929 cells
(table 3.2), nor was any cytotoxicity seen when the negative control
preparation was used on any of the above cell lines at any
concentration tested (fig.3.10a,b,d).
In attempts to ascertain whether the preparation might show
significantly increased activity, relative to the human preparation,
when used on ovine cells, the cytotoxic actions of rovTNFa on
transformed ovine cells were also assessed. 2 such cell lines were
available for this study.
No detectable cytotoxicity was caused by either recombinant TNFa at
any concentration when used on ST6 cells, an adherent cell line
derived from a sheep adenocarcinoma, in a 3 day incubation without
actinomycin D (table 3.3). (Low concentrations of actinomycin D can
kill these cells per se, Dr.G.Entrican, personal communication.)
Since the other cell line tested, line 5, was a non-adherent line
of ovine peripheral blood mononuclear cells transformed by sporozoites
of Theileria annulata (Entrican et al. 1991), a 3H-thymidine
incorporation assay was conducted to determine whether TNF might
induce either cytotoxicity/cytostasis or cell proliferation. No
significant effect was seen using any of the recombinant proteins at
any concentration, under the conditions employed (fig.3.11).
3.2■11.Induction of ovine thymocyte proliferation by rovTNFa acting as
a comitogen: -
Since the above results implied that the two ovine cell lines
tested were insensitive to the cytotoxic actions of TNFa (see
discussion, 3.3) the ability of the rovTNFa preparation to act in
other ways on ovine cells was also tested.
TNFa can act as a comitogen for thymocytes in the presence of
phytohaemagglutinin (Ranges et al, 1988). When tested in such assays
on material derived from 3 different lambs, rovTNFa consistently
caused more enhancement of ovine thymocyte proliferation (as assessed
by 3H-thymidine uptake during the final 18 hours of a 3 day
Table 3.2:-
Added sample Mean Standard deviation
PBS + 0.1% BSA _0.206 _0.024
rovTNFa, lOpg/ml _0.201 _0.011
rhTNFa. lOng/ml _0.209 _0.014
Table 3.2:- the results ofcytotoxicity assays performed on L929L/R cells, expressed
as the mean OD's540 (& standard deviations ofmean OD's) ofquadruplicate wells,
after incubation with the quoted samples (which comprised 25% of thefinal volume),
washing & staining with crystal violet. Monolayers of intact cells were visible in all
wells when examined by light microscopy at the end of the experiment.
Table 3.3:-
Added sample Mean 00^ Standard deviation
PBS + 0.1% BSA _0.415 _0.032
rovTNFa, 50pg/ml _0.393 _0.036
, lOpg/ml _0.438 _0.048
, lpg/ml _0.409 J).021
, 1 OOng/ml _0.362 _0.055
"
, lOng/ml _0.390 _0.041
rhTNFa, 1 pg/ml _0.417 _0.052
"
, 1 OOng/ml _0.433 _0.039
"
, lOng/ml _0.398 _0.026
neg. cntrl, 50pg/ml eq. _0.381 _0.043
, lpg/ml eq. _0.412 _0.040
"
, 1 Ong/ml eq. _0.378 _0.049
Table 3.3:- the results ofcytotoxicity assays performed on ST6 cells, expressed as the
mean OD's540 (& standard deviations ofmean OD's) ofquadruplicate wells, after
incubation with the quoted samples (which comprised 50% of the final volume),
washing & staining with crystal violet. Results for a yeast extract/factor Xa negative
control preparation are quoted at equivalent dilutions to rovTNFa. All wells
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Figure 3.11:- shows the (lack of) activity of recombinant TNF's-a on ovine PBL's,
transformed by T.annulata (line 5 cells). Results are expressed as mean incorporated
counts per minute per well (+/- standard dex'iations) ofquadruplicate wells, after
incubation with samples ofrecombinant proteins (see symbol legends). The
concentrations quoted are those ofthe added samples, which comprised 50% of the
total incubation volume, prior to the addition of 3H-thymidinefor thefinal 18 hours.
The results for a yeast extract/factor Xa negative control preparation are plotted at
equivalent dilutions ofrovTNFa.
(O G
incubation), than equivalent concentrations of rhTNFa (fig.3.12). The
negative control preparation showed no activity over the use of medium
alone at any concentration tested.
3.2.12,Cartilage-degrading activity of rovTNFa:-
To further confirm the activity of the rovTNFa preparation on
material of ovine origin, cartilage degradation assays (Saklatvala,
1986) were performed on discs of ovine, xiphoid cartilage. In each of
three assays to assess the release of glycosaminoglycans from the
cartilage of different individuals the rovTNFa performed very
similarly to rhTNFa (fig.3.13). Again the negative control preparation
showed no activity at any concentration tested.
3.2.13.Influence of contaminants in the rovTNFa preparation:-
To test the possibility that contaminants likely to be present in
the rovTNFa preparation (such as factor Xa) might be affecting its
activity, the negative control preparation was mixed with rhTNFa (25pg
yeast/Xa proteins / lOOpg rhTNFa, a similar level to that estimated to
contaminate rovTNFa) and the adulterated rhTNFa preparation was then
compared to pure rhTNFa. Contamination of rhTNFa did not significantly
affect its activity in any of the above assays (fig.3.14).
3.2.14.Induction of fibroblast proliferation by rovTNFa:-
The ability of rovTNFa to enhance the proliferation of fibroblasts
(Vilcek et al., 1986) of ovine origin was also assessed. RovTNFa was
indeed able to increase the uptake of 3H-thymidine by Weybridge Sheep
Choroid Plexus cells (WSCP's) (a fibroblast-like cell type [Harter &
Choppin, 1967]) over control levels (fig.3.15). No such activity was
seen from the negative control preparation at any concentration
tested. (The ability of rovTNFa to enhance WSCP cell density was later
confirmed in a subsequent experiment [see chapter 5].) RovTNFa was not
compared with rhTNFa in this assay owing to a shortage of the latter.
3,2.15,1s rovTNFa present in multimeric form?:-
Since the active form of TNFa is believed to be a non-covalently
bound, self-associating homotrimer (Smith & Baglioni, 1987), it was of






-nj 1 1 i i i i i i [ I i 1—i—i i i i | 1 1 i—i rr
10 100 1000 10000
cone TNF (ng/ml)
Figures 3.12 a & (see over) b & c:- the results of3 separate co-mitogen proliferation
assays, performed on ovine thymocytes, expressed as the mean incorporated counts
per minute per well (+/- standard deviations) ofquintuplicate wells, after incubation
with samples of recombinant proteins (see symbol legends). The concentrations
quoted are those in added samples, which comprised 50% ofthe incubation volume
prior to the inclusion of3H-thymidinefor the final 18 hours of incubation. Results for
a yeast extract/factor Xa negative control preparation are plotted at equivalent
dilutions to rovTNFa. Mean incorporated c.p.m. x 10~3, associated with the addition
ofsamples comprising PBS + 0.1% BSA only, were:- 2.5 (SD 0.5), 11.0 (SD 1.8) &
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Figures 3.13 a & (see over) b & c:- the results of3 separate degradation assays,
performed on discs ofovine xiphoid cartilage. Results are expressed as the mean
OD'sU0 (+/- SD's) when the supernatants of discs which had been incubated, in
quintuplicate, with samples ofrecombinant proteins (see symbol legends) were
analysedfollowing the addition ofdimethyl-methylene blue. Results for a yeast
extract/factor Xa negative control preparation are plotted at equivalent dilutions to
rovTNFa. The concentrations quoted are those in the added samples which
comprised 25% of the incubation volume. The ODU0 associated with similar analysis
of a mix of 75% medium and 25% PBS/0.1%BSA has been subtractedfrom each
mean figure. No difference in this 'baseline' OD was caused by the addition of
lpg/ml of rovTNFa, or rhTNFa, to the PBS/BSA, nor was any difference noted in
thefinal ODU0 of a supernatantfrom a disc incubated with medium alone, whether a
sample added to itprior to similar analysis (to 25% offinal volume) contained 0 or
1/jg/ml of these proteins. The increases in ODU0 over baseline associated with the
incubation ofdiscs with samples containing PBS/BSA alone were 0.057 (SD 0.007),



















Figures 3.14 a & (see over) b & c:- the results ofa cytotoxicity assay (on L929 cells),
a co-mitogen proliferation assay (on ovine thymocytes) & a cartilage degradation
assay (on ovine cartilage), respectively, demonstrating thefailure ofadulteration of
rhTNFa with the yeast extract/factor Xa negative control preparation to influence the
activity of the former (see symbol legends). Assays were conducted, & results are
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Figure 3.15:- the results ofa fibroblast proliferation assay, performed on WSCP
cells, expressed as the mean incorporated counts per minute (+/- standard
deviations) ofqiuntuplicate wells. The concentrations of rovTNFa quoted are those
in the added samples, which comprised 33.3% of the incubation volume, prior to the
inclusion of 3H-thymidine for thefinal 18 hours of incubation. Resultsfor a yeast
extract/factor Xa negative control preparation are plotted at equivalent dilutions of
rovTNFa. The mean incorporated c.p.m. x IP3 associated with a sample containing
PBS + 0.1% BSA only was 7.79 (SD 0.32).
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multimer. The homobifunctional cross-linking agent BSOCOES has
previously been used to cross-link rhTNFa in order to identify
trimers, which then typically show eqivalent mobility to a 42kDa
protein during SDS PAGE (Van Ostade et al., 1991). When rovTNFa was
cross-linked by this reagent and similarly analysed, the 17kDa protein
virtually disappeared and an increased density of 30-50kDa proteins
was observed, although distinct bands could not be clearly seen
(fig.3.16a). (No such increased density was noted when the negative
control sample was submitted to cross-linking.) However, when a
similar gel was analysed by Western blotting, using a rovTNFa-specific
monoclonal antibody, cytl (see chapter 4), as the primary detection
agent, distinct bands with the anticipated mobilities of dimers and
trimers could be observed in cross-linked samples (fig.3.16b). As well
as the distinct monomeric band, faint bands with the anticipated
mobilities of dimers and residual, uncleaved, Pl-TNF fusion protein
were also present in non cross-linked samples. A small amount of very
high molecular weight material, which may correspond to cross-linked
residual fusion protein, or aggregates of rovTNFa (see discussion,
3.3), was also detected in the cross-linked sample. No bands were seen
either when negative control samples (whether cross-linked or not)
were submitted to the same procedure or when a duplicate blot was
incubated with an irrelevant monoclonal antibody preparation (VPM53,
see chapter 4) as the primary antibody, when used at the same dilution
as the cytl preparation.
3.3.Discussion:-
Having obtained a final preparation with appropriate activity
(cytotoxicity to TNF-sensitive but not TNF-resistant cells) and a
major component of appropriate size (17kDa - suggesting that no
glycosylation had occurred, see chapter 4), one can conclude that a
recombinant TNF with some biological activity was successfully
produced. Knowledge of the sequence of cDNA employed defines this rTNF
as rovTNFa. However, some observations made during its production are
worthy of discussion.
The sequencing of several clones of the initial PGR product
confirmed its slightly heterogeneous nature and underlined the



















Figures 3.16 a & b:- a Coomassie blue-stained. SDS-15% polyacrylamide gel
(3.16a) & a Western blot (using a 1:30 dilution ofcytl saturated supernatant [see
chapter 4] as the primary, ovTNFa-detecting- antibody) ofan SDS- 5-20% gradient
polyacrylamide gel (3.16b) showing the effect ofcross-linking rovTNFa. Both gels
were run under non-reducing conditions & the positions ofmolecular size markers
are indicated (in kDa) for each, as are the positions ofputative mono-, di- and tri-
mers in 3.16b. Samples submitted to electrophoresis comprised 10pi aliquots of
rovTNFa, incubated without (3.16a, lane 1; 3.16b, lane 2), or with (3.16a, lane 2;
3.16b, lane 1) the cross-linking reagent BSOCOES.
a protein with 100% authentic primary structure. Whilst an error rate
of 2 residues in some 2,130 bases of cloned material, following 35
cycles of amplification, compares favourably with the rate of 0.25%
quoted by Saiki et al. (1988) following 30 cycles, inadvertant
selection of 2 out of 5 clones could have had a significant effect on
the sequence of the recombinant protein.
The pale blue appearance of these clones, in the presence of X-Gal
and IPTG, also demonstrated that the blue/white colour selection
method, which is frequently used to identify recombinant plasmids, may
not always be a clear-cut process. If the inserted DNA contains a
perfect number of codons, with no termination codons in the lac Z
reading frame, then it can still be possible for a partially
functional LAC Z protein to result.
In spite of careful preparation of the rovTNFa cDNA expression
cassette for ligation into pOGS40, some smaller plasmids (probably
povTNF13 'carry-over' from a consideration of their size and positive
hybridisation) appeared to contaminate the ligation reactions. Given
the likely higher transforming efficiency of these plasmids in
comparison to the larger pOGS40, the effects of such contamination can
be out of proportion to its degree and could have posed problems in
the selection of desired colonies. Others have also encountered
similar 'carry-over' problems (Dr.N.Carey, C.Cousens, C.Fiskerstrand &
Dr.H.Reyburn, personal communications). Fortunately, their stronger
hybridisation signal (possibly a reflection of plasmid copy number)
and obviously smaller plasmid size did help to distinguish colonies
transformed by these contaminants. The fact that similar numbers of
colonies were seen on plates derived from control ligations involving
plasmid without added DNA may reflect the presence of other
contaminants or simply poor efficiency of CIP treatment.
Although a carrier DNA was employed to help in case of difficulty,
yeast transformation was not found to be a problem, with several
transformants becoming available for characterisation and control
plates giving predicted results. It was surprising, therefore, to find
that one of four transformants selected for analysis did not appear to
be expressing PI at all. Whilst this could have been a wild-type
contaminant or leu2 revertant, the facts that no colonies were seen on
a control plate derived from transformations without pOGSTNFl and that
BJ2168 contains a double mutation in its leu2 gene (Jones, 1991)
reduce the likelihoods of these possibilities. Examination of a crude
extract of a culture of this yeast did reveal that it contained a
c.28kDa protein, which was neither expressed by the others (fig.3.3a)
nor recognised by a polyclonal anti-Pi antiserum (fig.3.3b). A third
possibility, therefore, is that this was a transformant containing a
frame-shifting mutation early in the TyA gene, which led to the
production of a truncated, irrelevant protein.
The prominence of a putative Pl-TNF fusion protein in crude
extracts of the other three chosen transformants suggested a
potentially high yield of recombinant product. Indeed the estimated
final yield of rovTNFa (2mg/l) compares favourably with those of other
proteins expressed via this system under similar conditions (e.g.
O.lmg/1 for rovIL-113, <0.05mg/l for Maedi-Visna virus rev and gp41
proteins [C.Fiskerstrand, M.Fotheringham, C.Cousens, personal
communications] and 15mg/l for Maedi-Visna virus core protein P25
[Reyburn et al, 1992]). Given that much of the success of this system
lies in the ability of a fusion protein to self-assemble into VLP's
(usually mediated solely by the PI component), one can speculate that
the known structural homology of TNFa to a viral coat protein (Eck &
Sprang, 1989) and its ability, as well as that of Maedi-Visna virus
P25, to aggregate into multimers may actually help to stabilise the
structure of the VLP and corttribute to the relatively high yields of
these proteins in this system.
Several possibilities existed for the purification of fusion
protein and final product, with the initial choice being a simple
method previously employed to produce a satisfactory result (Reyburn
et al., 1992). A considerable degree of purification was clearly
achieved since only putative PI and rovTNFa proteins were distinct on
analysis of final cleavage suspensions. Although c.27kDa and c.24kDa
proteins were visible following a few experimental cleavages, these
were only seen when high concentrations of factor Xa were added. Given
that factor Xa comprises covalently-bound 27kDa and 17kDa subunits
(Fujikawa et al., 1972) it seems likely that the c.27kDa protein seen
in these gels was the larger component of Xa, with the c.24kDa protein
being either a breakdown product or contaminant of the Xa preparation.
Although no putative Xa proteins were seen following the analysis of
11%
other preparations which utilised lesser amounts of this protein, all
subsequent gels were run under non-reducing conditions to avoid
possible confusion of rovTNFa with the smaller subunit of Xa.
Even though the final preparation contained a 17kDa entity as the
only band clearly visible in Coomassie-stained gels, the purification
methods used could undoubtedly have been improved upon. The wide
spread of fusion protein throughout the sucrose density gradient meant
that it became more dilute and less pure than might have been achieved
with a tighter banding pattern and, with the further addition of
factor Xa (and no specific method for removing it), it is probable
that there was still significant contamination of the final rovTNFa
preparation (for further consideration of the purity of this
preparation see below and chapter 4). Nevertheless, whilst greater
purification might have been achieved by adjustments to protocol and/
or additional chromatographic or affinity procedures, the level of
purity attained was considered adequate for the initial
characterisation of rovTNFa (and proved sufficient for the raising of
antibodies [see chapter 4]). Since the activity of TNFa declines with
time, particularly when stored at temperatures above freezing (Aderka
et_al., 1992) the main aim during the production of a second batch of
rovTNFa, therefore, was to reach the same level of purity as quickly
as possible, in order to test the activity of the preparation.
Several possibilities were considered when initial experiments
demonstrated that the rovTNFa preparation showed poor cytotoxic
activity, when compared with rhTNFa, towards TNF-sensitive murine
cells. These included:- 1) there was a potential contribution from
innaccuracy in the estimation of rovTNFa concentration; 2) the choice
of starting amino acid for mature rovTNFa might have been
inappropriate; 3) inhibitors of ovine, but not human TNFa might be
present in the media used; 4) contaminants in the rovTNFa preparation
might be conferring a protective effect on the cells; 5) the methods
employed had created a preparation with generally poor activity and 6)
a species 'barrier' might exist, reducing the activity of ovine TNFa
on murine cells.
1) Purity:- Since the estimated purity and hence concentration of
rovTNFa was based on the visual assessment of a gel, these could
clearly have been subject to errors of perhaps +/- 25%. However, a 25%
overestimate of rovTNFa concentration could make only a very limited
contribution towards the 1000-fold discrepancy in activity between the
two rTNF'sa noted. (Improvement to the estimate of purity by, for
example, densitometric scanning, was complicated by the continued
presence of dimers as well as monomers on gels [fig.3.16b] a
phenomenon seen previously in other TNFa analyses [e.g. Arbustini et
al. , 1991].)
2) Starting amino acid:- Some thought had been given to the authentic
start site of mature TNFa and the amino acid selected was chosen
because of its homologous position to the start site of mature human
TNFa. Although all factors involved in the cleavage of human TNFa
preprotein to release the mature form are not understood, Scuderi
(1989) demonstrated that one or more serine proteases, which cleave
the second bond prior to an arginine-serine link, are involved. The
ovine sequence also contains such a pairing in the same position as
the human sequence (see chapter 4, fig.4.11). Furthermore, 3
dimensional analyses of human TNFa have revealed that all but the
first 4-5 amino acids of the mature protein are folded and held in a
compact structure (Jones et al., 1989, Eck & Sprang, 1989). Given the
homology between the ovine and human sequences (again see fig.4.11),
and the demonstration by cross-linking analysis that rovTNFa can, like
human TNFa, also self-associate into trimers, it seems likely that
ovine TNFa has a similar secondary structure. Whilst the presence of
10 extra amino acids at this terminus can significantly reduce the
activity of the molecule (Cseh & Beutler, 1989), those present in the
small 'loose end' referred to above can be removed without in-
activation (Creasey et al., 1987) and there may, therefore, be a
little leeway either side of the true starting position for the
production of a molecule with genuine activity.
3) Inhibitors:- The third possibility was considered feasible since
soluble TNF receptors can bind to TNFa and inhibit its actions
(Engelmann et al.. 1990b), are present at significant levels in serum
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(Aderka et_al. , 1991) and any present in the bovine serum used in
these experiments would presumably have greater affinity for TNF'sa
from more closely-related species. However, the fact that dose-
response curves, in the presence of a fixed concentration of FCS, were
parallel on logarithmic not linear scales (fig.3.10) tended to argue
against significant effects caused by such a specific inhibitor.
4) Contaminants:- Although failure to kill TNF-resistant cells
confirmed that the rovTNFa preparation's cytotoxic activity was due to
a TNF, the possible influence of contaminants could not initially be
ruled out. For example, though much of the factor Xa activity was
likely to have been exhausted by an overnight incubation, it was
possible that any residual proteolytic activity could be damaging TNF-
R's, hence conferring a protective effect on the cells. Whilst several
different methods of producing a negative control preparation were
considered, it is unlikely that any method could produce a perfect
combination of the contaminants present. Likely contaminants included
factor Xa, residual PI not removed by centrifugation and other,
unknown, yeast constituents. Although use of a pOGS40/pUG41S double-
transformant would have been preferred, expediency dictated that the
negative control preparation was prepared from a pMA5620-transformed
yeast, a constitutive producer of PI (Adams et_al., 1987a).
Nevertheless, the final negative control preparation was likely to
contain similar levels of Xa, as well as some PI protein and many
other yeast components as found in the rovTNFa preparation. (This was
subsequently confirmed, to an extent, by immunoblotting, see chapter
4.) Since this preparation neither showed activity of its own at any
concentration in each of the assays described here, nor affected the
activity of rhTNFa when mixed with it, it seems unlikely that
contaminants could have contributed greatly to the effects described
in this chapter.
5) General activity:- Because the activity of TNFa does decline with
time, particularly at higher temperatures (Aderka et al., 1992), it is
possible that a more active (though more costly and contaminated)
preparation could have been produced by using higher concentrations of
factor Xa and shorter incubation times for cleavage. However, such
decline in activity is generally associated with the breakdown of
trimers into monomers and the subsequent formation of high molecular
weight aggregates (Petersen et_al., 1989; Aderka et al., 1992). The
relative densities of the bands seen in the cross-linking studies
described here, and the purity of the rovTNFa preparation, tend to
rule out an association of TNF monomers with contaminants and
therefore suggest that rovTNFa, in common with TNF'sa from other
species, is capable of self-association into multimeric forms.
Furthermore, although a proportion of rovTNFa may have been present as
monomers and high molecular weight aggregates, more than half was
present in trimeric or possibly dimeric forms (assuming an equal
affinity of cytl for each). (The extents to which dimeric forms
represent incompletely cross-linked trimers, or trimeric forms
possibly represent 'over' cross-linked dimers are unclear [Petersen et
al, 1989].) Such results, as well as those of experiments performed on
ovine cells (see below), tend to rule out suspicions that a highly
degraded and inactive form of rTNFa had been produced (see below).
6) Species barrier:- Although murine cells have been used to detect
and assay TNF's from a wide range of species (see chapter 4), with
only minor degrees of species specificity noted for the induction of
cytotoxicity and interaction with the murine TNF-RI (Smith et al.,
1986, Lewis et al., 1991), the possible contribution of a species
barrier was further examined by looking at the activity of rovTNFa on
ovine cells.
Little significance was attached to the failure to detect any
cytotoxicity towards the two transformed, ovine cell lines, since, in
one survey, Sugarman et al. (1985) found that only 30% of transformed,
human cell lines were susceptible to the cytostatic/toxic effect of
TNFa. De Martini & Baldwin (1991) have since demonstrated that rhTNFa
also shows no toxicity towards Theileria-infected bovine cells.
RovTNFa clearly showed a much increased activity relative to rhTNFa
in two other types of assay on ovine tissues, however, including
consistently superior activity in thymocyte proliferation assays.
Although rhTNFa has previously been shown to have very significant
effects on ovine tissue at doses as low as lOpg/kg in vivo (Johnson et
al., 1989; Redl et al., 1990) a possibly reduced affinity of ovine
cells for human TNFa could clearly contribute to the improvement in
relative activity seen on these cells, particularly in an assay such
as the thymocyte proliferation assay, known to involve a high degree
of species specificity in murine systems (Ranges et_al., 1988; Ehrke
et al. , 1988). However, the concentrations of rovTNFa displaying
activity in these assays, as well as in the fibroblast proliferation
assay, are similar to those of other TNF'sa described as displaying
activity in similar systems using similar methods. For example, in
thymocyte co-mitogen proliferation assays performed on a murine
thymocyte cell line, Ranges et al. (1988) and Ehrke et al. (1988) each
found that recombinant murine TNFa began to have an effect at
approximately 3ng/ml and the latter workers also found that activity
peaked at a concentration between 30 and 300 ng/ml: converting the
concentrations shown in fig.3.12 to final concentrations reveals that,
in these assays, rovTNFa began to have an effect at <5ng/ml and showed
peak activity in 2 out of 3 experiments between 50 and 500 ng/ml.
Furthermore, Vilcek et al. (1986) found that rhTNFa's proliferating
activity towards human fibroblasts reached a plateau between 1 and
lOng/ml, which also compares favourably with the final concentration
of c.3.33ng/ml at which the fibroblast proliferating activity of
rovTNFa appears to plateau (fig.3.15). These results suggest that an
appropriately-active rTNFa preparation had indeed been produced
(unless ovine cells are both exquisitely sensitive to rovTNFa in
comparison to other syngeneic systems and greatly insensitive to
rhTNFa). Consequently, these findings help to strengthen the argument
that murine cells may be relatively insensitive to the cytotoxic
actions of ovine TNFa.
One other group have expressed rovTNFa, using a mammalian
expression system (Nash et al., 1991), and, although they did not
examine their preparation for activity on ovine cells, they too found
that rovTNFa showed very poor cytotoxic activity on TNF-sensitive,
murine cells.
Some other observations were also made from these experiments.
Whereas murine thymocyte co-mitogen proliferation assays demonstrate
complete insensitivity to human TNFa (Ranges et al., 1988; Ehrke et
al., 1988), caused by total failure of human TNFa to interact with the
murine TNF-RII which is responsible for mediating this action (Lewis
et al., 1991; Tartaglia et_al., 1991), ovine thymocytes clearly show
some response to rhTNFa. Furthermore, whilst the dose-response curves
and sensitivities of these assays were all slightly different
(possibly reflecting individual variation of genetically-unrelated
sheep and/or differences in pre-existing in vivo stimulation of these
cells), the peak level of enhanced proliferation caused by rhTNFa
never reached that caused by rovTNFa and tended to occur at similar
concentrations of the two (see fig.s 3.12a,c). Assuming that ovine
thymocyte proliferation is also mediated via type II receptors, this
would suggest that the species specificity demonstrated here is not
simply a reflection of a reduced affinity of ovine type II TNF
receptors for rhTNFa, which one might expect to be overcome by
increasing the rhTNFa concentration, but may involve a more complex
ligand-receptor interaction.
RovTNFa and rhTNFa clearly showed virtually identical activities in
degradation assays on ovine cartilage. In the light of the above
observation of some ovine TNF-RII species specificity, one would
expect that this activity is likely to be predominantly mediated via
the generally less species-specific type I receptor (see 1.6). This
fits with the demonstration by Keffer et al. (1991) that in transgenic
mice, uncontrolled in vivo production of human TNFa (able to act only
via type I receptors) leads to multifocal cartilage destruction and
polyarthritis (though here possible effects of induced murine TNFa,
contributing via type II receptors, cannot be ruled out). Such
activity, as well as activity in the induction of fibroblast
proliferation, which is known to be mediated via type I receptors
(Engelmann et al., 1990a), also argue against another considered
possibility:- that the yeast system had folded rovTNFa in such a way
as to produce a protein able to interact normally with type II
receptors but only poorly with type I receptors.
One last possibility considered was that the emphasis of TNFa
function in the sheep might be different, so that it is generally less
cytotoxic. Slightly different activities of a cytokine in different
species would not be without precedent. For example, murine, but not
human, IL-3 has the ability to stimulate mast cells (Arai et al.,
1990). However, when assayed for cytotoxic effect on PK15-1512 cells
(cloned from a TNF-sensitive, porcine cell line) rovTNFa showed
cytotoxic activity which was more comparable to that of rhTNFa (Dr.E.
Peterhans, personal communication).
Since, in sensitive murine cells at least, TNF-R'sI only need to be
cross-linked for the induction of cell-death (Engelmann et al., 1990a,
see 1.6) and rovTNFa, with its multimeric make-up, can apparently
react 'normally' with ovine type 1 receptors, the conclusion drawn
from these results is that the murine TNF-RI seems likely to have a
generally poor affinity for ovine TNFa. Although binding studies were
not performed to support this conclusion, further evidence of the poor
cytotoxic activity of ovine TNFa on TNF-sensitive murine cells, and
the possible reasons for this, will be presented and discussed in the
following chapter.
CHAPTER 4:- THE DETECTION AND PRELIMINARY CHARACTERISATION OF OVINE
TNFa.
4.1.Introduction:-
Whilst useful information can be gleaned by the use of a probe to
detect TNFa transcripts, their presence does not necessarily imply
their translation (Beutler et al., 1986a), hence an ability to also
detect ovine TNFa protein was clearly essential to studies of its
induction. TNF'sa from other species have previously been detected by
both biological and immunological assays (Meager et al.. 1989).
However, the large number of different, currently-employed assays in
itself suggests that no method is likely to be ideal (see below).
Two of the most commonly-used forms of biological assay for TNFa
derive from early in vitro studies, which demonstrated its ability to
kill susceptible transformed cells (Carswell et al., 1975) or to
suppress LPL activity in adipocytes (Kawakami et al.. 1982).
Significant improvements in the sensitivity and duration of
cytotoxicity assays were soon made by including metabolic inhibitors
such as actinomycin D (Ostrove & Gifford, 1979) and protocols have
since been improved in order to provide optimum assay conditions (e.g.
Flick & Gifford, 1984). These highly-sensitive assays, employing
widely-available cells, such as murine L929 cells, have thus become
the most popular form of bio-assay (Meager et al.. 1989).
An additional feature which has contributed to their widespread use
is that such assays have displayed only a limited degree of species
specificity (Smith et al.. 1986). Thus murine cells have proven
capable of detecting TNF-like activity not just from the mouse itself
(Carswell et al., 1975) and other rodents or lagomorphs such as the
guinea pig (Zuckerman & Bendele, 1989) and rabbit (Matthews & Watkins,
1978), but also from primates, such as the human (Matthews, 1981a)
and, more recently, from ungulates such as the ox (Adams & Czuprynski,
1990), horse (MacKay et al., 1991a) and pig (Baarsch et al., 1991).
Other murine transformed cell lines, such as WEHI 164: clone 13 have
also been selected for use in cytotoxicity assays with the aim of
further increases in sensitivity, reportedly achieved even in the
absence of metabolic inhibitors (Espevik & Nissen-Meyer, 1986).
There are problems associated with such assays, however. These
include concerns about the specificity and relevance of results. Apart
from TNF's, other factors, such as high concentrations of IL-1
(Onozaki et al.. 1985) and ligand(s) for Fas antigen (Yonehara et al.,
1989), are also known to kill several types of transformed cell, as
may some yet-to-be-discovered factors. An assessment of the
specificity of action can be made using TNF-resistant sub-clones of
these lines, such as L929L/R cells (Matthews & Watkins, 1978), though
failure to kill these cells cannot establish whether cytotoxicity to
the parent cell line is due to TNF-a or 13. Blocking studies, using
specific antibodies, have been used to attribute such cytotoxicity to
either TNF (e.g. Nedwin et al., 1985b). However, quantitatively this
method too is not without problems. Synergy with other cytokines is a
common feature of TNF activity (see 1.7) and has been demonstrated
with IFN gamma in cytotoxicity assays without actinomycin D (Sugarman
et al., 1985), possibly working via an induced upregulation of TNF-Rs
(Aggarwal et al., 1985a). Clearly, any such synergistic action could
mean that the concentration of TNFa in a given sample is significantly
less than comparisons with TNFa standards and the degree of protection
afforded by anti-TNFa antibodies in blocking studies might initially
suggest.
Furthermore, given that soluble TNF-R's may be present in variable
concentrations in body fluids (Aderka et al., 1991), can be released
from certain cells by some pathophysiological stimuli (Porteu &
Nathan, 1990) and can inhibit TNF activity (Engelmann et al., 1990b)
or in some prolonged assays actually stabilise it (Aderka et al.,
1992), it is also apparent that these assays provide only a crude
assessment of the overall, accumulated, TNF-like activity of a
biological fluid, which depends on the net balance of several factors.
Thus, the results of such assays may bear little relevance to the
potential activity of TNFa at particular times during its production
and in certain micro-environments, especially when one considers the
added complication that biologically-active TNFa may be present in
membrane-bound (Kriegler et al., 1988) as well as soluble forms.
A variety of immunologically-based methods have also been applied
to the detection of TNFa, including RIA, sandwich or other forms of
ELISA (Meager et al., 1989) and Western blotting (e.g. Beutler et al.,
1986a). Fortunately, in spite of the fact that TNF's-a and 13 share
approximately 30% amino acid homology (Pennica et al., 1984), cross
reactivity with the latter rarely seems to have been a problem.
However, these assays too are not without their drawbacks, since they
may detect biologically-inactive and therefore, possibly 'irrelevant'
forms of TNF. Furthermore, some of these assays, such as RIA or ELISA,
which detect TNFa in its native form may also be influenced by the
presence of other proteins. Several TNF-binding proteins have now been
described, including the soluble forms of the two receptors (Engelmann
et al., 1990b), a2-macroglobulin (Wollenberg et al., 1991), heparin
(Lantz et al., 1991), uromodulin (Hession et al., 1987) and auto¬
antibodies to TNFa (Fomsgaard et al., 1989). Clearly, unless the anti-
TNFa antibodies employed only recognise epitopes which are not
potentially masked by these proteins, such assays could seriously, and
variably, underestimate sample concentrations of TNFa. By comparison,
the use of a technique requiring denaturation of a protein prior to
its detection, Western blotting, for example, though less sensitive
and more difficult to quantify, circumvents the problem of inter¬
ference by other proteins and can also define the molecular size(s) of
TNFa detected.
In spite of their associated problems, however, bio- and immuno¬
assays for TNFa have undoubtedly yielded a great deal of invaluable
information about its production and, in the absence of superior
alternatives, can still provide meaningful results, provided they are
interpreted carefully and preferably in conjunction with one another.
Although the induction of TNFa has now been documented in many cell
types using a variety of stimuli (see 1.2), it is generally agreed
that the LPS-stimulated macrophage remains one of the most potent
known producers of TNFa (Jaattela, 1991, Vassalli, 1992). Therefore,
early attempts to detect ovine TNF-like activity concentrated on
examining supernatants (SN's), collected after adding LPS to cultures
rich in ovine alveolar macrophages, for cytotoxic activity towards
L929 or WEHI 164: clone 13 cells. Later, advantage would be taken of
the availability of rovTNFa (see chapter 3) to raise both poly- and
mono- clonal antibodies for use in the immunological detection of
ovine TNFa, primarily by Western blotting.
4.2.Results:-
4■2.1.Preliminary cytotoxicity assays:-
An estimated 3 x 108 cells were obtained by lavage from the lungs
of a freshly-slaughtered Scottish Blackface ewe. Approximately 70% of
cells used remained adherent to the bottom of 24-well, tissue culture
plates 4 days after plating out at 3 x 105 cells/well, when the medium
in each well was completely replaced with 1ml of fresh medium
containing 0, 0.1 or lpg LPS/ml. Separate SN's were collected from
three wells of each LPS concentration 0,2,4,8,16 and 24 hours later
and analysed for their cytotoxic activity on L929 cells. No detectable
cytotoxicity was induced by any of these SN's, whatever the time point
or concentration of LPS added (table 4.1a). A positive control for the
assay comprised rhTNFa at lOng/ml in the same medium. In contrast to
test sample wells, no intact cells were visible by light microscopy in
positive control wells at the end of the assay.
This experiment was repeated, using cells from a different sheep,
although this time they were stimulated 3 days after plating out. Once
again no detectable cytotoxicity was induced by any SN and 100% cell
death/detachment was induced by the positive control (table 4.1b).
Since WEHI 164: clone 13 cells are reported to be more sensitive to
TNFa than L929 cells (Espevik & Nissen-Meyer, 1986) both assays were
repeated using the former cell line. Again no cytotoxicity was noted
in any wells where SN's had been added (table 4.1c,d). A few intact
cells were visible in some of the positive control wells, suggesting
that these cells might in my hands be less TNF-sensitive than the L929
cells. The results of a separate experiment (fig.4.1) using a range of
rhTNFa concentrations confirmed that this was the case and, since they
also proved to grow faster and were more strongly adherent, only L929
cells were used in subsequent cytotoxicity assays.
4.2.2.Further cytotoxicity assays, in cases of proven TNFa transcript
induction:-
Whilst several different factors could have contributed to the
failures to detect cytotoxic activity in the above SN's, it was
unclear whether any ovine TNFa had even been induced. Adams and
Czuprynski (1990) suggested that the ability of bovine monocytes to
Table 4.1
Sample 4,1a 4.1b 4.1c 4.td
UM _0.247(0.023) .0.213(0.011) .0.176(0.021) .0.184(0.013)
UM+Uig LPS/ml .0.236(0.029) _0.221(0.020) .0.162(0.013) .0.182(0.019)
lOng rhTNFa/ml _0.019(0.004) _0.015(0.003) .0.032(0.004) .0.034(0.006)
" + 1 |agLPS/ml _0.023(0.007) .0.015(0.002) .0.037(0.006) .0.033(0.005)
SN, no LPS, Oh _0.243(0.010) _0.231(0.014) .0.177(0.011) .0.178(0.014)
, 2h _0.239(0.021) _0.219(0.011) .0.169(0.015) .0.180(0.017)
, 4h .0.252(0.024) _0.226(0.017) .0.181(0.013) .0.169(0.010)
, 8h _0.221(0.017) .0.218(0.012) .0.179(0.019) .0.184(0.011)
, 16h .0.246(0.015) .0.220(0.010) .0.171(0.010) .0.173(0.022)
, 24h _0.246(0.020) .0.215(0.009) .0.180(0.009) .0.179(0.013)
lOOngLPS/ml, Oh .0.254(0.018) .0.233(0.016) .0.176(0.014) .0.166(0.015)
, 2h _0.263(0.023) .0.226(0.015) .0.165(0.012) .0.168(0.009)
, 4h _0.239(0.011) .0.229(0.015) .0.168(0.011) .0.173(0.016)
, 8h _0.243(0.015) .0.217(0.021) .0.170(0.013) .0.177(0.013)
, 16h _0.254(0.019) .0.222(0.011) .0.168(0.013) .0.184(0.017)
,24h _0.247(0.012) .0.232(0.012) .0.164(0.012) .0.185(0.016)
IpgLPS/ml, Oh .0.238(0.023) .0.216(0.018) .0.173(0.018) .0.191(0.018)
, 2h _0.241(0.016) .0.227(0.007) .0.168(0.011) .0.190(0.014)
, 4h .0.246(0.014) .0.225(0.015) .0.179(0.017) .0.181(0.012)
, 8h .0.235(0.019) .0.214(0.022) .0.185(0.014) .0.176(0.010)
, 16h _0.252(0.012) .0.223(0.013) .0.178(0.010) .0.174(0.011)
, 24h _0.240(0.017) .0.217(0.010) .0.182(0.011) .0.174(0.008)
Table 4. la-d:- results of4 separate assays to determine the cytotoxic potential of
ovine lung-cell supernatants (SN's), collected at indicated times after the addition of
stated concentrations ofLPS to 2 different cell preparations. Samples used in 4. la &
b correspond to those of4.1c & d respectively. Results are expressed as the mean
OD'si40 (with standard deviations in brackets) ofquadmplicate wells, after L929 cells
(4.1a,b) or WEHI164 clone 13 cells (4.1c,d) were incubated with samples, &
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Figure 4.J:- a comparison ofthe sensitivity of two different eel! lines (see symbol
legends) to rhTNFa. Results are expressed as the mean percentage cell death (+/-
standard deviations) induced in quadruplicate wells by the quoted concentrations of
rhTNFa in added samples.
ill .
secrete TNFa decreased markedly with time spent in culture. After
Northern blotting studies also suggested that ovine lung cells might
be refractory to stimulation for a while after plating out (see
2.2.5), subsequent studies concentrated on the use of freshly-isolated
cells, where TNFa mRNA at least was known to have been induced.
When all the lung-cell SN's generated during the Northern blotting
experiment shown in fig.2.4 were retained and analysed in cyto¬
toxicity assays, once again no detectable cell death was induced. In
this experiment, a range of concentrations of rhTNFa were also added
and the lower limit of detection was c.30pg rhTNFa/ml (table 4.2).
A further Northern blotting experiment was conducted to confirm
some of the results of fig.2.4. Once again the cell source, which
yielded 1.6 x 108 cells, was a pair of lungs from a Scottish Blackface
ewe. These cells were divided between 8 x 75cm2 flasks filled with
25mls of medium containing 0 or lOOng LPS/ml and RNA was collected
from 1 flask of each type 0,1,2 and 3 hours later. 10pg of RNA from
each time-point were then submitted to Northern blotting using an
ovine TNFa cDNA probe (povTNFl insert, conditions as before [see
2.2.5]). The result (fig.4.2) verified that the size of an inducible
RNA detected by this probe was slightly larger than 18S. Furthermore,
it again demonstrated induction of this transcript in the absence or
presence of added LPS and here the concentration of ovine TNFa mRNA
peaked between 0 and 2 hours.
When the SN's of these cells were tested for the presence of cyto¬
toxicity towards L929 cells, once again none could be found. The lower
limit of detection for rhTNFa was similar to the previous assay,
c.30pg/ml (table 4.3).
In spite of proven induction of TNFa mRNA, it was still conceivable
that these failures of ovine SN's to display detectable cytotoxicity
towards L929 cells, was due to an absence of secreted ovine TNFa
protein. (For example, any pre-slaughter stress could have subjected
these macrophages to the influence of corticosteroids, a situation
known to allow the accumulation of TNFa transcripts but prevent TNFa
secretion [Beutler et_al., 1986a]). With the production of rovTNFa,
however, came the opportunity to raise specific antibodies which might
be of use in detecting native ovine TNFa.
Table 4.2:-
Sample Cone" or lime Mean (SD) % eytotoxleky(SD)













/ml). 1 OOpg/ml _0.160 (0.009) _42 (3.5)
30pg/ml _0.232 (0.010) _14 (3.9)
1 Opg/ml _0.265 (0.017) _1 (6.6)
Opg/ml _0.268 (0.013) _0













3 h _0.265 (0.009) _1 (3.5)
24 h _0.260 (0.011) _3 (4.3)
SN (no LPS) 2.25 h _0.278) (0.018) _-4 (7.0)
Table 4.3:-
Sample Cone" or time Mean ODst& <SD) % cytotoxicity (S D)
lOng/ml _0.008 (0.001) _100









1 OOpg/ml _0.170 (0.009) _31 (3.5)
3 Opg/ml _0.219 (0.012) _10 (4.7)
1 Opg/ml _0.245 (0.018) _-l (7.1)
Opg/ml _0.243 (0.012) _0


























Tables 4.2 & 4.3:- results ofassays to analyse the cytotoxic potential to L929 cells of
supernatants generated in the Northern blotting experiments depicted in fig.s 2.4 &
4.2, respectively (means [&, in brackets, SD'sJ are ofquadruplicate wells).
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Figure 4.2:-
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Figure 4.2:- a Northern blot (above) following hybridisation to an ovine TNFa cDNA
probe (povTNFl insert)& the transilluminated gel (below) from which the blot was
taken (hence with corresponding lane numbers), after the electrophoresis ofan
estimated lOpg RNA per lane. The positions ofputative 28S & 18S RNA are indicated
for each. RNA was extractedfrom ovine lung-cells which had been cultured in the
absence (lanes 1-4) or presence (lanes 5-8) of lOOng LPS/mlfor 0 (lanes I & 5), 1
(lanes 2 & 6), 2 (lanes 3 & 7) or 3 (lanes 4 & 8) h.
ISLf
4.2.3.Raising polyclonal antisera to rovTNFa:-
Since the particulate nature of the VLP may enhance the
immunogenicity of a recombinant protein (Adams et al., 1987a) an
initial attempt to raise a rabbit antiserum to rovTNFa was made by
giving a primary inoculation of uncleaved, purified Pl-TNF fusion
protein in complete Freund's adjuvant (CFA) followed by a second
inoculation of purified rovTNFa in incomplete Freund's adjuvant (IFA)
three weeks later. However, whilst this rabbit developed a strong
response to higher molecular weight contaminants in rovTNFa, serum
taken two weeks after the second immunisation failed to react with any
proteins of c.l7kDa when utilised at a dilution of 1:50 in a Western
blot against lOOng of rovTNFa.
Following this attempt, two other rabbits (R198 and R199) were
immunised solely with purified rovTNFa. 2 weeks after second
inoculations (given in IFA, 3 weeks after primary inoculations given
in CFA), sera from each of these rabbits, when used at a dilution of
1:50 as primary antibodies in Western blots, demonstrated significant
affinity for a c.l7kDa protein in lOOng of the rovTNFa preparation,
but not in an equivalent volume of the yeast extract/ Xa negative
control preparation (fig.4.3a). A larger proportion of the antibodies
in each serum, however, reacted with the smaller amounts of higher
molecular weight contaminants in rovTNFa, some of which shared
immunological identity with proteins in the negative control
preparation. No activity against any of these proteins was seen when
preimmune sera were tested at the same concentration. These rabbits
were further 'boosted' by one more inoculation of rovTNFa, before
larger amounts of sera were harvested and, following heat inactivation
of complement, aliquoted and stored for subsequent characterisation
(see below).
4■2.4.Preparing monoclonal antibodies to rovTNFa: i) immune response
of mice:-
3 mice were also immunised, with the aim of producing monoclonal
antibodies (Kohler & Milstein, 1975) specific for rovTNFa. When sera
from each was collected after 4 rovTNFa inoculations and tested for
immunoreactivity with lOOng rovTNFa by Western blot, all 3 were
capable of reacting with the component of interest when used at a
Figure 4.3:-
4.3a
1 2 3 4 5
4.3b
12 3 4
Figures 4.3a & b:- blots ofSDS- 15% polyacrylamide gels, run under non-reducing
conditions, with the positions ofmolecular size markers indicated (in kDa). Samples
submitted to electrophoresis comprised:- Ipg rovTNFa (4.3a, lane I; 4.3b. lane I),
lOOng rovTNFa (4.3a. lanes 2 & 4; 4.3b, lanes 2,3 & 4) & Ipi ofa yeast
extract/factor Xa negative control preparation (4.3a, lanes 3 & 5). Strips shown in
lane I ofeach figure were stained with amido black. Other strips were submitted to
immunodetection using a 1:50 dilution ofserum (post 2nd inoculation) from rabbits
198 (4.3a, lanes 2 & 3) or 199 (4.3a, lanes 4 & 5), or a 1:1000 dilution ofserum
from mice no.s 3, 2 or 1 (4.3b, lanes 2,3 & 4, respectively), as the primary antibodies.
.
dilution of 1:1000. (This can be considered an acceptable response
before attempting a cell fusion [Fuller et al., 1988]). They all,
however, also showed significant response to the higher molecular
weight contaminants in this preparation (fig.4.3b).
4.2.5.Preparing monoclonal antibodies: ii) an ELISA for screening
hybridoma supernatants:-
Given the strong response of these mice to the contaminants in
rovTNFa, it seemed probable that anti-rovTNFa antibody-producing
colonies would comprise only a small proportion of the hybridomas
which might be obtained following fusion of splenocytes with myeloma
cells. Therefore a suitable, sensitive screening method, preferably
capable of analysing many samples simultaneously, was likely to be
required for their preferential selection. An experiment was
conducted to determine an appropriate protocol for screening potential
hybridoma SN's by ELISA (Engvall & Perlmann, 1972).
Proteins show differing abilities to adhere to plastic under
different conditions. When murine anti-rovTNFa antiserum was used at a
dilution of 1:1000 as the primary detecting antibody in an ELISA
against immobilised rovTNFa, it was found that similar responses were
obtained whether rovTNFa was diluted in PBS, pH 7.2, or in carbonate
coating-buffer, pH 9.6 prior to coating (table 4.4). By comparison,
although significant responses were obtained in ELISA's against the
yeast extract/Xa negative control preparation when it had been
immobilised following dilution in PBS, the responses seen when the
same preparation had been diluted to the same concentration in
carbonate coating-buffer were considerably less. Thus, under these
conditions a large proportion of the control preparation (and
therefore probably rovTNFa contaminants) coated relatively poorly.
Negligible responses were noted, whatever the coating conditions, when
irrelevent antibodies (normal spleen-cell SN's) were used as the
primary detecting agent against rovTNFa.
Consequently, the assay adopted for initial screening of SN's was
an ELISA performed against rovTNFa, immobilised following dilution to
300ng/ml in carbonate coating-buffer - conditions which might reduce
the number of 'false' positive results, caused by antibodies




1 2 3 4 5 6
3.000
_ 1.112 J.188 _0.726 _0.767 _0.056 _0.057
1,000 _ 1.207 _ 1.454 _0.607 _0.868 _0.097 _0.065
300 J.104 _ 1.280 _0.354 J). 826 _0.078 _0.078
100 J). 871 _0.923 _0.190 _0.498 _0.052 _0.092
30 _0.557 _0.552 _0.160 _0.276 _0.083 _0.087
Table 4.4:- results ofan ELISA to determine suitable coating conditions for
rovTNFa. Results are expressed as mean OD'sm ofduplicate wells. Primary
detecting antibodies were antiserum from mouse no.3. diluted 1:1000 (columns 1-4),
or supernatant from normal murine splenocytes (columns 5,6). Protein coating
conditions were:- rovTNFa, diluted to the stated concentration in carbonate coating
buffer (columns 1 & 5) or PBS (columns 2 & 6); or a yeast extract/factor Xa negative
control preparation (plotted at equivalent dilutions to rovTNFa), diluted in carbonate
coating buffer (column 3) or PBS (column 4).
Table 4.5:-
Test batch no. » HI 2 3 4 5 6
Day post-fusion of test 13 16 22 23 27 29
No. wells tested 22 11 27 10 23 11
Test results (controls)
+ve control 1.91 1.76 1.6 1.72 1.64 1.8
Medium 0.1 0.09 0.07 0.09 0.07 0.1
Monoclonal no. 1 0.13 0.06 0.04 0.08 0.03 0.09
" no.2 0.15 0.08 0.08 0.04 0.04 0.1
no. 3 0.11 0.08 0.08 0.04 0.06 0.09





































Table 4.5:- a summary of the results ofa fusion. Results are expressed as the mean
OD's492 ofduplicate wells following ELISA's testing hybridoma supernatantsfor
immunoreactivity against rovTNFa. The positive control was antiserum from mouse
no.3, diluted 1:1000 in medium. Prrelevent' monoclonals no.s 1 (anti-CDS), 2 (anti-
CD4) & 3 (anti-ovine MHC) were ofIgM, IgGl & IgG2a isotypes, respectively.
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reacting with rovTNFa. Secondary screening would then include an assay
against the negative control preparation, coated following a lesser
dilution in PBS.
4.2.6.Preparing monoclonal antibodies: iii) results of a fusion:-
Mouse no.3 was selected for use in a fusion, since this appeared to
show the strongest response to rovTNFa (fig.4.3b). It provided a total
of 1.8 x 108 splenocytes. Following fusion to NSO myeloma cells
(Galfre & Milstein, 1981), hybridomas appeared in 120/350 wells. 104
of these continued to grow to the point of confluency, when their SN's
were analysed. These tests were performed in 6 batches conducted over
the course of 16 days (summarised in table 4.5). Whilst 64 SN's gave
results which might be considered positive (> 3x the background
reading obtained using medium only), 2 (from wells 1G10 and 6E7) in
the first batch tested, and 1 (from well 1E2) in the second, gave
strongly-positive results ( > the result obtained using the SN of
splenocytes only). Cells from these 3 wells were submitted to
immediate cloning procedures.
4.2.7.Preparing monoclonal antibodies: iv) cloning of hybridomas
Cells from wells 1G10 and 6E7 were initially cloned by limiting
dilution whilst cells from well 1E2 were cloned by simple dilution
(see 6.4.13). Whilst all tested SN's of cells derived from 6E7 gave
positive results in an ELISA against rovTNFa, they also gave positive
results in an ELISA against the yeast extract/Xa negative control
preparation. In contrast, no SN's of clones derived from wells 1E2 or
1G10 gave positive results when analysed against the negative control,
although 10/10 of the former and 3/6 of the latter gave positive
results against rovTNFa.
Cells from a well which had demonstrated healthy cell growth and
given one of the strongest results for each clone source were then
subjected to a further cloning procedure, by simple dilution. All
wells with single colonies derived from the '1E2' clone gave positive
results in ELISA's against rovTNFa, in contrast to only 5/7 single-
colony wells derived from the '1G10' clone.
When cells from a single similarly-selected well from each original
source were subjected to a third cloning procedure, by limiting
dilution, all wells developing single colonies gave positive results
in ELISAs against rovTNFa, though the SN's from all lE2-derived clones
gave consistently greater ELISA results than those from IGlO-derived
clones. Large numbers of cells from a clone from each original source
were grown and stored in frozen aliquots before some were retrieved
for the production of monoclonal antibodies (designated cytl [1E2-
derived] and cyt2 [lGlO-derived]) in the form of saturated tissue-
culture SN's.
Whilst both of these saturated SN's (SSN's) gave positive results
in the ELISA against rovTNFa, a stronger response, greater than that
of the positive control (1:1000 dilution of antiserum from mouse
no.3), was noted for cytl. (OD's492 were 1.86, 1.34, 1.76 and 0.04 for
cytl, cyt2, positive control and medium only, respectively.)
4.2.8.Characterisation of antibodies raised to rovTNFa: i) isotype of
monoclonals:-
Use of a commercial kit determined that the monoclonal antibodies
cytl and cyt2 were of immunoglobulin isotypes G2a and G1 respectively
(fig.4.4a).
4.2.9.Characterisation of antibodies: ii) use in Western blotting:-
The polyclonal antisera and monoclonal antibodies cytl and cyt2
were tested over a range of dilutions for their ability to detect
rovTNFa on Western blots (fig.4.4b). Both antisera could react with a
c.l7kDa protein at dilutions as great as 1:4000.
Both monoclonals also recognised the same size protein. However,
whilst cytl retained detectable affinity for rovTNFa at dilutions of
SSN as low as 1:100, the ability of cyt2 to react with rovTNFa on
Western blot was lost at a dilution between 1:2 and 1:10. Cytl also
reacted with a c.32kDa protein (figs.4.4b and, more noticeably, 4.4c),
putatively rovTNFa dimer (see chapter 3).
Because it gave a stronger response and could be used at greater
dilutions, cytl was considered the more suitable antibody for use in
further Western blotting studies. Whilst, when used at a dilution of
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Figure 4.4a:- the result using
a commercial kit (Sigma) to
determine the isotypes of
monoclonal antibodies cyt 1









Figures 4.4b & c:- Western blots ofSDS-
15% polyaery lam ide gels, run under non-
reducing conditions. The positions of
molecular size markers are indicated (in
kDa). Each strip contained c.lOngof
rovTNFa (assuming 100% transferfrom
the gel) with the exception ofstrip 15
(4.4b), which contained I jug ofrovTNFa
& was stained with atnido black. All other
strips were submitted to immuno-detection
with primary antibodies asfollows:-
saturated supernatant (SSN)ofcyt 1
diluted 1:2, 1:10, 1:30, 1:100 & 1:30
(4.4b, strips 1,2,3,4 & 4.4c, strip 1,
espectively): SSN ofcyt 2 diluted 1:2 &
1:10 (4.4b, strips 5 & 6, respectively);
serum (post 3rd inoculation) from rabbits
193 & 199, diluted 1:500, 1:1,000,
1:2,000 & 1:4,000 (4.4b, strips 7-10 [193]
& 11-14 [199], respectively); & SSNfrom
VPM53 (an irrelevent control monoclonal
antibody) diluted 1:30 (4.4b, strip 2). In
\4.4c. colour development was
continuedfor a prolonged period.
rovTNFa, it failed to detect any proteins in lOOx the equivalent
volume of yeast extract/Xa negative control preparation (fig.4.7a,
lanes 3 & 4). Furthermore, an 'irrelevant' monoclonal antibody of the
same G2a isotype, VPM53 (whose specific ligand is a component of a
Campylobacter-like organism [Dr.S.McOrist, personal communication]),
failed to detect any proteins in rovTNFa, when used in SSN form (of
proven activity [E.Mills, personal communication]) at the same
dilution (fig.4.4c), suggesting that the recognition of these proteins
by cytl was a specific phenomenon.
It was also noted that whilst the polyclonal antisera displayed
affinity for high molecular weight contaminants in rovTNFa, they too
showed a strong response to a c.32kDa protein (fig.4.4b).
4.2.10.Characterisation of antibodies: iii) neutralising abilities;-
The abilities of both polyclonal antisera and the monoclonal
antibodies cytl and cyt2 to neutralise the activity of rovTNFa were
initially assessed in cytotoxicity assays on L929 cells. Whilst a 1:50
dilution of antisera from rabbits 198 and 199 were able to completely
neutralise the activity of 1 and 3pg rovTNFa /ml respectively (fig.
4.5a,b) (a protective effect which could be overcome by the addition
of surplus rovTNFa), neither of the monoclonal antibodies caused the
slightest reduction in activity of any concentration of rovTNFa
tested, when used at a 1:2 dilution of SSN (fig.4.5c).
Since it is conceivable that an anti-TNFa antibody might be capable
of interfering with TNFa binding to one, but not the other, type of
receptor, the abilities of these antibodies to neutralise rovTNFa
activity in thymocyte co-mitogen proliferation assays were also
assessed. Both rabbit antisera also proved capable of neutralising
rovTNFa activity in this assay (fig.4.6a,b). Neither monoclonal
antibody displayed any neutralising ability whatsoever (fig.4.6c). It
was also surmised that, since there was no significant difference in
the levels of proliferation induced by medium alone, whether immune or
pre-immune sera were added to the assay, endogenous TNFa seems not to
play a role in 'background' proliferation.
As in the cytotoxicity assay, the serum from rabbit 199 displayed
slightly greater neutralising potential than that from rabbit 198. The
specificity of this action was confirmed following incubation of pre-
Figure 4.5:- 4.5a
cone rovTNF (ng/ml)
Figures 4.5a & (see over) b,cresults ofcytotoxicity assays performed on L929 cells
exposed to samples ofrovTNFa which, had been pre-incubated with 2% pre- or post-
immune serum from rabbits 198 (4.5a) or 199 (4.5b), or 50% RPMI (with 15% FCS)
or 50% saturated supernatants ofcyt lor cyt 2 (4.5c) (see symbol legends). Results
are expressed as mean percentage cell death induced in quadruplicate wells.
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and post- immune sera from rabbit 199 with rovIL-15, which had been
produced by the same expression system and which also has significant
activity in this assay (Fiskerstrand et al. , 1992) (1U of IL-1B is
defined as that amount of protein causing half maximal incorporation
of label in this assay). Preincubation with immune serum did not cause
the slightest reduction in the activity of this latter cytokine
(fig.4.6d).
4.2.11■Initial use of cytl to detect ovine TNFa:-
5 x 107 lung cells, freshly-isolated from a Scottish Blackface ewe,
were cultured for 18 hours in a 125cm2 tissue culture flask at 106
cells and lpg of LPS /ml, before the SN was collected, clarified and
stored frozen in aliquots. When the proteins in 1ml of SN were
concentrated and analysed by Western blotting, using a 1:30 dilution
of SSN of cytl as the primary antibody, a c.25kDa protein was detected
(fig.4.7a). This band stained more intensely than lng of rovTNFa
detected on the same blot. No bands were seen when 1ml of the starting
culture medium was similarly analysed, nor were any bands detected
when a duplicate blot was incubated with a 1:30 dilution of VPM53 SSN.
4.2.12.Ovine TNFa is glycosylated:-
The factor detected in the above SN was clearly of greater
molecular weight than rovTNFa. Since there is one potential Asn-linked
glycosylation site predicted in the sequence of mature ovine TNFa
(figs.2.8, 4.11), these two proteins were examined for differences in
their glycosylation pattern. Incubation of rovTNFa with peptide-N-
glycosidase-F (Plummer et al., 1984) made no detectable difference to
its molecular weight, in contrast to the protein detected in ovine
lung-cell SN, whose size was reduced following deglycosylation to more
closely approximate that of rovTNFa (fig.4.7b).
4.2.13.Ovine lung-cell culture supernatant does contain biologically
active TNFa:-
The SN described above (4.2.11) showed no detectable cytotoxicity
to L929 cells in an assay capable of detecting 30pg/ml of rhTNFa
(table 4.6). It did, however, show activity in a thymocyte co-mitogen
















-43— rovTNF + pre-tmmune
-•— rovTNF + immune
M
10



















-o— rovTNF + pre-immune





Figures 4.6a, b & (see over) c &d:- results ofco-mitogen proliferation assays,
expressed as mean counts per minute per well (ofquintuplicate wells: error bars
indicate standard deviations) incorporated by ovine thymocytes, following incubation
with samples of recombinant ovine cytokines which had been pre-incubated with 1%
pre- or post- immune secum from rabbits 198 (4.6a) or 199 (4.6b,d), or 50% RPM1
(with 15%FCS) or 50% saturated supernatantsfrom cyt 1 or cyt 2 (4.6c) (see symbol
legends). Concentrations ofcytokines quoted are those in samples, which comprised

















Figures 4.7a & b:- Western blots ofSDS- 5-20% gradient polyacrylamide gels, run
under non-reducing conditions. Positions ofmolecular size markers are indicated (in
kDa) for each. The primary detecting antibody was cyt 1, used as the saturated
supernatant diluted 1:30 in each case. Final detection in 4.7b was by enhanced
chemiluminescence (see 6.3.14). Samples submitted to electrophoresis in 4.7a
comprised:- lng rovTNFa (lane 3), 1pi ofyeast extract/factor Xa negative control
preparation (lane 4) & acetone precipitates derivedfrom lml aliquots oflscove's
medium with 1pg LPS/ml (lane 1) or the supernatant ofovine lung-cells, culturedfor
18 h in the same medium (lane 2). In 4.7b. samples comprised :- resuspended acetone
precipitates, derivedfrom 0. lml aliquots of the latter supernatant, after incubation
with (lane 3) or without (lane 4) peptide-N-glvcosidase F, & 2ng rovTNFa incubated
with (lane 2) or without (lane 1) the same enzyme.
Table 4.6:-
Sample Cone6 or time Mean OD^ <SD) ^cytotoxicity (SD)
10ng/ml _0.020 (0.005) JOO









with 1 pg LPS/ml). 1 OOpg/ml _0.207 (0.013) _29 (4.9)
30pg/ml _0.246 (0.012) _14 (4.6)
1 Opg/ml _0.286 (0.019) _-l (7.2)
Opg/ml _0.283 (0.024) _0













18 h _0.280 (0.008) _1 (3.0)
25 h _0.281 (0.010) _1 (3.8)
48 h _0.278 (0.012) _2 (4.6)
" (as in fig.4.7) 18 h _0.285 (0.011) _-l (4.2)
Table 4.6:- results ofan assay to assess the cytotoxic potential of the ovine lung-cell
supernatants which have previouslyfeatured in figures 4.7 & 4.9. Results are
expressed as mean percentage cytotoxicities, calculatedfrom the displayed mean
OD's540 ofquadruplicate wells, after residual cells, following the incubation of L929
cells with the stated samples, were stained with crystal violet. Standard deviations of
the means are in brackets.
preincubation with antiserum from rabbit 199 (fig.4.8). (Relatively
high 'background' counts were seen in this assay. However, because
thymocytes for such assays were obtained from different breeds and
ages of lambs at slaughter, a lot of variation normally exists in
these assays [see fig.3.12].)
4.2.14.A time course of ovine TNFa production:-
The accumulation of the protein detected by cytl in culture SN's
was examined with respect to time. Lung cells were collected from a
Scottish Blackface tup and plated at 1.5 x 107 cells/ flask in 7 x
25cm2 tissue culture flasks, each with 7mls of medium containing LPS
at lpg/ml, before a flask SN was harvested at one of several time-
points over the following 2 days. When the proteins in 1ml of each SN
were analysed by Western blotting using cytl, a c.25kDa protein was
detected in all but the initial time-point (fig.4.9). The blot shows
an early accumulation of this protein, whose concentration appears to
'plateau' from 6 to 25 hours before a subsequent decline. The
intensity of staining of this protein in SN's collected between 2 and
48 hours after plating out was greater than that seen for lng of
rovTNFa detected on the same blot. No proteins were detected when a
duplicate blot was incubated with a similar dilution of VPM53 SSN as
the primary antibody. None of these SN's showed detectable cyto¬
toxicity to L929 cells in an assay where 30pg/ml rhTNFa was readily
detectable (table 4.6)
4.2.15.The response of ovine lung cells to increasing doses of LPS:-
The accumulation of cytl-binding protein in response to a range of
LPS concentrations was also analysed. Freshly collected lung-cells
from each of 2 Scottish Blackface ewes were plated out in identical
conditions to those used for time course analysis (4.2.14), with the
exception that flasks contained 0,1,10,100 or 1000 ng LPS/ ml of
medium. In each case, analysis of SN's collected 20 hours later,
revealed that higher concentrations of protein detected by cytl
accumulated when cells had been exposed to higher doses of LPS,



















Figure 4.8:- the results ofa co-mitogen proliferation assay, expressed as the mean
counts per minute per well, incorporated by ovine thymocytes incubated in the
presence ofassorted samples in quintuplicate wells. Samples comprised Iscove's
medium with 1pg LPS/ml (columns I & 2) and the supernatant ofovine lung-cells
which had been incubatedfor 18 h in the same medium (columns 3 & 4). These
samples had been preincubated with 0.5% pre-immune (columns 1 & 3) or immune
(columns 2 & 4) serum from rabbit 199, immediately prior to incubation with the
thymocytes. Error bars indicate standard deviations of the mean.
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Figure 4.9:-









Figure 4.9:- a Western blot ofan SDS- 5-20% gradient polyacrylamide gel, run
under non-reducing conditions, using cyt 1 (as a 1:30 dilution ofsaturated
supernatant) as the primary detecting antibody. The positions ofmolecular size
markers are indicated (in kDa). Samples submitted to electrophoresis comprised Ing
ofrovTNFa (lane 8) & the acetone precipitates derivedfrom lml ofsupernatants
collected 0, 2, 4, 6, 18, 25 & 48 h after ovine lung-cells were plated out in Iscove's
medium with 1 jug LPS/ml (lanes 1-7 respectively).
Figure 4.10:- 4.10a
1 2 3 4 5 6
4.10b
1 2 3 4 5 6
Figures 4.10a & b:- Western blots ofSDS- 5-20% gradient polyaeryIamide gels, run
under non-reducing conditions. The positions ofmolecular size markers are indicated
(in kTb)for each. The primary detecting antibody was cyt 1, used at a dilution of 1:30
of the saturated supernatant. Each blot is the result ofan experiment performed on
lung cells derivedfrom a different sheep. Samples submitted to electrophoresis
comprised 5ng rovTNFa (lanes 6) & acetone precipitates derivedfrom lml of
supernatant collected 20 h after cells were plated out in Iscove's medium containing 0
(lanes 1), 1 (lanes 2), 10 (lanes 3), 100 (lanes 4) or 1000 (lanes 5) ng ofLPS/ml.
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4.3.Discussion:-
Several possibilities were originally considered for early failures
to detect cytotoxic activity in the SN's of LPS-stimulated ovine lung
cells using TNF-sensitive murine cells. These included considerations
of whether (sufficient) TNFa was being induced, whether ovine TNFa
would be active on murine cells and whether inhibitors of action might
be present. A full appreciation of the reason(s) involved clearly
required further analysis.
It was slightly surprising to find that the sensitivity of the WEHI
164: clone 13 cells used here was somewhat lower than that of the L929
cells (as confirmed in chapter 3, see fig.3.10), in contrast to the
original description of these cells by Espevik and Nissen-Meyer
(1986), although different protocols to these authors were used.
Others have also found that these cells may be no more sensitive than
L929 cells (e.g. Meager et al.. 1989), blaming changes in phenotype of
either cell line occurring with serial passage in culture.
Unfortunately, little history was available for the cells used here.
The Northern blotting experiment described here (fig. 4.2) confirmed
some of the results of that presented in chapter 2 (see fig.2.4). In
particular, the size of transcript detected and its induction in the
absence of added LPS were as previously described. Western blotting
(fig.4.10) later corroborated this latter finding, to an extent, by
confirming that some ovine TNFa protein was also produced in the
absence of added LPS. In the light of these results, no conclusion can
be drawn regarding the induction of ovine TNFa mRNA by LPS. To what
extent the induction seen was due to pre-existing LPS contamination of
the media used, its possible presence in the sheep's trachea prior to
lavage, or to some other procedure(s) adopted during lung-cell
preparation, is unclear. Standiford et al. (1991) have noted the
induction of TNFa in a human patient following broncho-alveolar
lavage, whilst Schindler et al. (1990) have demonstrated the induction
of IL-1 mRNA by the adherence of macrophages to plastic.
The kinetics of TNFa transcript accumulation, however, did appear
to differ slightly from the first experiment. Whilst the time of
achieving maximum transcript concentration in this experiment (between
0 and 120 minutes) overlaps with that seen previously (between 90 and
180 minutes), there was a noticeably slower subsequent decay, hinting
at a degree of individual variation. However, both experiments
demonstrated undetectable levels in freshly-isolated cells, and an
early accumulation of transcripts. These findings are in general
agreement with another, subsequently-published, study of TNFa
transcript accumulation in LPS-stimulated ovine alveolar macrophages
(Nash et al.. 1992). These authors demonstrated TNFa mRNA rising from
undetectable levels in 'resting' macrophages, to a peak concentration
within five hours following LPS stimulation and becoming undetectable
by 24 hours. In their studies, however, the zero hour time-point, when
LPS was added, was actually 1 hour after plating out (to allow for the
selection of adherent cells), by which time very significant amounts
of mRNA had been induced in my own study. Nor did they observe any
subsequent mRNA induction in the absence of added LPS. Clearly, this
may have been because they used different media and/or techniques in
cell preparation. Alternatively, since they used a 100-fold higher
concentration of LPS and an human TNFa cDNA probe, higher
concentrations of transcripts may have been induced by LPS and the
sensitivity of their Northern blot could have been less than my own.
Although the rovTNFa preparation contained many highly immunogenic
impurities, it proved sufficiently pure for raising antibodies of use
in the immunological detection of ovine TNFa. The initial failure of
one rabbit to produce anti-rovTNFa antibodies, in response to a
primary immunisation with hybrid VLP's, could simply reflect the poor
response of an individual. Alternatively, the theory of improved
antigenicity of a protein as a fusion partner with PI because of its
particulate nature (Adams et al., 1987a) may not hold true,
particularly when significant homology with one of the host's own
proteins exists. Under these circumstances, responses to the more
foreign yeast element may dominate.
By comparison, the use of rovTNFa in cleaved and partially purified
form always succeeded in producing a response to the appropriate
component, in mice as well as rabbits, where two polyclonal antisera
with significant avidity for rovTNFa were produced. Calculations based
on the neutralisation assays of both type I and type II receptor-
mediated TNFa activity (figs.4.5 & 4.6) suggest that approximately 6-
7% of antibody binding sites in R199 serum could be directed against
neutralising epitopes of rovTNFa (assuming Mr 1 antibody binding site
= 75,000 and lOmg Ig/ml of serum). However, Western blotting
(figs.4.3a, 4.4b) clearly demonstrated that these antisera also
recognise higher molecular weight contaminants in rovTNFa, some of
which share immunological cross-reactivity with components of the
yeast extract/Xa negative control preparation. Blotting also revealed
quantitative and qualitative differences between the two sets of
proteins, however, casting some doubt on the validity of the yeast
extract/Xa preparation as a negative control for TNFa. It should be
re-emphasised though that this preparation never displayed any
activity in the assays described in chapter 3, at any concentration,
and some of the qualitative differences noted on blots could be due to
antibodies directed against TNFa dimers and/or residual, uncleaved Pl-
TNF fusion protein.
It was considered that the response of these antisera to
contaminants in rovTNFa, including a possible response to bovine
factor Xa and probably, therefore, ovine factor Xa, might limit their
use in the detection of ovine TNFa. However, at least one very useful
anti-rovTNFa monoclonal antibody, cytl, was also produced.
Although it did not appear to neutralise rovTNFa activity (see
below), the evidence that this monoclonal antibody recognises rovTNFa
is considerable. Firstly, it specifically reacts with an
appropriately-sized protein, not recognised by an irrelevant antibody
of the same sub-class, in very small amounts of rovTNFa on Western
blots. Secondly, it does not recognise any proteins in the yeast
extract/Xa preparation either in a Western blot or (pre-second
cloning) in an ELISA. Thirdly, it also reacts with proteins of
appropriate size to be TNFa homo-dimers and trimers in cross-linked
samples of rovTNFa (fig.3.16b), oligomerisation being a known
phenomenon of TNF'sa (see 1.3.4 & chapter 3). Finally, it recognises,
in ovine cell culture SN's, a glycoprotein of appropriate size and
inducibility to be ovine TNFa (see below).
Cytl SSN, at a dilution of 1:2, failed to neutralise any rovTNFa
activity in cytotoxicity or thymocyte co-mitogen proliferation assays,
successful neutralisation by parallel pre-incubation of rovTNFa with
R198 or R199 antisera serving as a positive control. Were cytl a
neutralising antibody and present at an average antibody concentration
of lOpg/ml in saturated supernatant (Yokoyama, 1992) a 1:2 dilution
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should have been capable of totally neutralising approximately l.lpg
rovTNFa/ml. No reduction of activity was noted, however, even though
concentrations of rovTNFa as low as 30ng/ml were active in these
assays. Given that cytl SSN is active on Western blots at relatively
high dilutions, it seems unlikely that its antibody concentration
could be several-fold lower than the average quoted concentration.
Thus one can conclude that cytl is almost certainly a non-neutralising
antibody.
Cytl consistently and specifically recognised a c.25KDa protein in
the SN's of ovine lung-cell cultures, but not in starting media.
Several lines of evidence suggest that this protein was mature ovine
TNFa. Firstly, it was specifically recognised by cytl. Secondly,
deglycosylation studies confirmed that this is a glycoprotein, there
being one potential Asn-linked glycosylation site in the predicted aa
sequence of mature ovine TNFa (figs.2.8, 4.11). Thirdly, the size of
f
the deglycosylated component was approximately the same as rovTNFa,
rovTNFa being unglycosylated (fig.4.7b). Fourthly, this protein
accumulated in stimulated-lung-cell SN's with kinetics in keeping with
my own observations of the kinetics of ovine TNFa mRNA induction and
with studies of TNFa accumulation in alveolar macrophage SN's in other
species (e.g. Becker et al., 1989; MacKay et al■, 1991a) (although
comparing the results obtained using different types of assay may not
be strictly valid [see 4.1]). Finally, as for TNF'sa from other
species, the accumulation of this protein was LPS-responsive.
In spite of the fact that peptide-N-glycosidase-F removes all
traces of the carbohydrate group (Tarentino et al.. 1985), de¬
glycosylated ovine TNFa still showed slightly slower mobility through
a gel than rovTNFa. Whilst some retardation could have been caused by
interference from the relatively large amounts of other SN proteins,
it is also possible that, in spite of theoretical considerations (see
chapter 3, 3.3) mature, native ovine TNFa may include a few more amino
acids than rovTNFa. Knowledge of the true start site of mature ovine
TNFa, however, awaits its purification and amino-terminal sequence
analysis. 'Failure' of the Ty-VLP system to glycosylate rovTNFa was
not surprising in the light of the experience of others expressing
potential glycoproteins with this system (C.Cousens, Dr.N.Carey,
personal communications). ^ ^
Two other observations worthy of note were also made from Western
blotting. Firstly, in a time-course experiment, cytl also detected
proteins of Mr c.70,000 and very high molecular weight (fig.4.9).
These might be undissociated TNFa trimers or multimers, TNFa complexed
with TNF-R's or other proteins, or simply other antigens with a shared
epitope. However, it is noticeable that, in contrast to c.25kDa ovine
TNFa, these proteins were also present at the zero time-point.
Secondly, in each of two dose-response blots (fig.4.10), more TNFa
accumulated when lOOng LPS/ml were added than when none was added.
Given that two Northern blotting experiments on cells from other
individuals suggest similar levels of transcripts might be present in
each case, this result hints that, as in other species (see 1.3.3 and
2.3), the translation of ovine TNFa transcripts is inducible by LPS.
In spite of proven ovine TNFa content, the underlying theme of
total failure to detect cytotoxic activity in the SN's of ovine lung-
cells, using murine cells, continued. Assuming complete protein
transfer during blotting and equal affinity of cytl for native and
recombinant ovTNFa, the former protein was present at concentrations
in excess of lng/ml in an 18 hour SN (see fig.4.7a) and in all but the
initial SN of a time course series (fig.4.9), yet none of these
samples were active in L929 cytotoxicity assays capable of detecting
as little as 30pg of rhTNFa/ml.
The question of whether any of this TNFa was biologically active
was answered using the 18 hour SN as a sample in a thymocyte co-
mitogen proliferation assay. Some activity, completely neutralisable
by R199 serum was clearly seen (fig.4.8). Complete neutralisation was
surprising as this sample was likely to contain IL-1, another LPS-
inducible monokine with activity in this assay (Gery et al. . 1972).
However, the activity of both a & B forms of ovine IL-1 is severely
reduced by a single freeze-thaw cycle (C.Fiskerstrand, personal
communication). Since R199 serum has no activity against rovIL-l/I, and
other proteins it may react with, such as PI or factor Xa, have no
activity in this assay, whether as part of the control yeast
extract/Xa preparation (see chapter 3) or in purified form
(C.Fiskerstrand, personal communication) one can conclude that the
activity seen in this sample was almost certainly due to ovine TNFa.
.
Furthermore, although individual assays show a degree of variation,
studies with rovTNFa (fig.3.12) suggest that the c.20% degree of
proliferation enhancement seen in this experiment would have required
a concentration of ovine TNFa in the range of 3-10ng/ml (assuming no
influences from synergists or antagonists: synergy with IL—1 and IL-2
in this assay being known phenomena, [Ranges et al.. 1988; Hurme,
1988]). Such a concentration would seem to be compatible with the
intensity of ovine TNFa staining seen in a Western blot of this sample
(fig.4.7a).
Unless inhibitors capable of blocking type I- but not type II-
receptor- mediated activity were present in this sample, one can
finally conclude that the L929 cells used are poorly sensitive to
ovine TNFa in comparison to rhTNFa. Others have also failed to detect
cytotoxic activity in the SN's of LPS-stimulated ovine macrophages
using murine cells (Nash et al., 1992; Francey et al., 1992; Dr.G.
Entrican, personal communication). These findings then are suggestive
of a poor affinity of ovine TNFa for the murine TNF-RI, in agreement
with the data presented in chapter 3. Why should this be, when murine
cells have proved so amenable for the study of TNF'sa from many other
species? Notwithstanding potential additional influences of
glycosylation and/or a possibly-extended amino terminus in native
ovine TNFa (see earlier), some potential answers can be gleaned from a
comparison of the predicted aa sequences of several TNF'sa (fig.4.11),
and knowledge gained from structure/function studies on human TNFa.
Ovine TNFa shares approximately 79 % homology with human TNFa over
the entire pre-protein, (81 % homology for the mature protein) and 91%
homology with a bovine TNFa sequence (presented in a review as un¬
published work, Goeddel et al., 1986). Some particular features are
well conserved across all the species, including the sheep, helping to
identify the ovine protein as a 'typical' TNFa. These include:- two
cysteine residues in the mature part of the molecule, believed to form
an intra-chain disulphide bridge (Davis et al.. 1987); an arginine-
serine doublet, of importance for the recognition by serine proteases
of the cleavage site for generation of mature TNFa (Scuderi, 1989); 13
amino acids at the extreme carboxyl terminus; and a stretch of 20
hydrophobic residues in the pre-protein leader sequence (positions -27
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Figure 4.11:- a comparison of the predicted amino acid sequences for TNF's afrom
assorted species (OV = ovine, BO = bovine, HU = human, MU= murine, RA =
rabbit, PO = porcine). Sequences are taken from figure 2.8, Goeddel et al. (1986),
Shirai et al.(1985), Pennica et al. (1985), Ito et al. (1986) & Pauli et al. (1989). The
presumedfirst amno acid ofthe mature ovine molecule is marked by an overhead 1;
its potential glvcosylation site (NlS)is in bold print. Amino acids which are conserv ed
in all other species illustrated, but differ in the sheep, are highlighted by an overhead
■. The amino acid which does not appear in the ovine sequence of Young et al.
(1991) is marked by an overhead *.
lbo
anchoring of full-length TNFa (Kriegler et al.. 1988). Unlike human
TNFa, one potential Asn-linked glycosylation site is present in the
ovine sequence, at a site 12 aa from the glycosylation site of murine
Human TNFa has been the subject of a number of studies to attempt
to define functional regions of the molecule. These have identified
amino acids near the amino terminus (Socher et al.. 1987), at the
extreme carboxyl terminus (Gase et al., 1990) and a cluster of
residues on either side of a groove formed between two sub-units of
the trimer (Van Ostade et al., 1991) as being particularly important
to function.
Comparison of the predicted TNFa sequences of 6 species reveal 3
positions (9, 67 & 106) in the mature TNFa molecule where amino acid
residues differ solely in the sheep. Of these, position no.9 has
previously been implicated as potentially having an important role in
cytotoxic activity. In this study, Creasey et al. (1987) showed that
deletion of the first 8 amino acids of human TNFa did not affect its
activity on murine cells, whereas deletion of the first 10 led to a
significant (c.3-fold) decline in cytotoxicity. Presumably, non-
conservative substitution rather than deletion of amino acid no.9
could lead to an equal or even greater decline in activity. Amino acid
no.10 also differs from the human sequence in the sheep (and the ox,
see below). Interestingly, in three-dimensional models of TNFa (Eck &
Sprang, 1989; Jones et al., 1989), amino acid no.9 lies immediately
adjacent to the carboxy-terminal leucine, which has also been
implicated as serving an important role in activity (Gase et al.,
Although positions 67 and 106 have not been implicated as being
important for function and appear to be somewhat remote from the
putative receptor binding site(s), it is conceivable that a change in
residue seen at any position could affect overall activity via a
subtle conformational change. A change from the human, rabbit and
murine sequences at position no.32 is also worthy of note, although
the same tyrosine for arginine substitution is seen in the bovine and
porcine sequences. This amino acid has also been implicated as
important to function and forms part of the putative receptor binding
site described by Van Ostade et al. (1991). Interestingly, although
TNFa.
1990).
Adams and Czuprynski (1990) described the use of WEHI 164: clone 13
cells to detect TNF-like activity in LPS-stimulated bovine alveolar
macrophage SN's, these authors could not detect this activity using a
somewhat less sensitive L929 assay. Furthermore, in assays on L929
cells, rboTNFa showed an activity which was intermediate, on a weight
for weight basis, between rhTNFa and my own rovTNFa (Dr.G.Entrican,
personal communication). Murine cells may also show relatively poor
sensitivity to porcine TNFa (Dr.E.Peterhans, personal communication).
Whatever the molecular basis for the poor activity of ovine TNFa on
murine cells, and whilst slight improvements to sensitivity could have
been made by adjustments to protocol (e.g. sample volumes comprised
only 25% of final volume) the inevitable consequence is that assays
involving murine cells appear to be of no use for the routine
detection of ovine TNFa, although it is conceivable that recent
further improvements to the sensitivity of such assays by a log factor
or more (Branch et al., 1991) may alter this situation.
In the light of all the above observations it was surprising to
find 2 papers suggesting that L929 cells can be used to detect ovine
TNFa. Unfortunately, in one paper (Wheeler et al., 1990) the authors
merely claim to have detected cytotoxic activity, neutralisable by a
monoclonal antibody to human TNFa, in the serum of LPS-treated sheep,
without presenting any data. In the second, the authors demonstrate
some cytotoxic activity in the SN's of some ovine alveolar macrophages
(Ellis et al., 1991). However, in these experiments cell death never
reaches 100%, in spite of using minimally-diluted samples and doses of
LPS as high as lOpg/ml for TNFa induction. Furthermore, this activity
was only partially neutralisable by a polyclonal antiserum raised to
rboTNFa and the authors describe the effect as displaying considerable
variability.
Such results are not incompatible with my own. If, as suggested by
results in chapter 3, murine cells are 1000-fold less sensitive to
ovine TNFa than human TNFa, it is conceivable that concentrations of
ovine TNFa in excess of 30ng/ml might be detected in assays displaying
an achievable sensitivity to rhTNFa of 30pg/ml. Given individual
variability in production of TNFa (compare figs.4.10a & b) and the
achievement here of concentrations in excess of lng/ml, as judged by
Western blotting, it is likely that levels higher than 30ng/ml could
be achieved in some SN's, by using even higher concentrations of LPS
in the presence of serum (known to enhance TNFa production [Matthews,
1981a]), particularly if using cells from a diseased individual, which
may already be under the influence of a known enhancer of TNFa
production such as IFN gamma (Beutler et al. , 1986b). Unfortunately,
judgement of the sensitivity of the assays used by Ellis et al. is
impossible, since they used rboTNFa as a standard and the
concentrations quoted in text and figure legends are contradictory.
Furthermore, on some occasions, cytotoxic activity in similarly
obtained ovine SN's can be demonstrated on TNF-resistant L929L/R cells
(Dr.G.Entrican, personal communication), whilst 'Tumour Necrosis
Serum' is known to be more potent at inducing cytotoxicity than
supernatant (Matthews, 1978), presumably because of synergistic
effects.
One final possible contributory factor which might occasionally
allow detectable activity of ovine TNFa on murine cells could be
polymorphic variation between individual sheep. Although different
alleles would seem to be present in the 3' UTR of the ovine TNFa gene
(see 2.3), it is entirely possible that they may also occur within the
translated region. Given that the change of a single residue of TNFa
can drastically alter its activity (Van Ostade et al.. 1991) and/or
presumably its immunoreactivity, such polymorphism in any species
could play havoc with more than one form of assay - another potential
problem in the detection and quantification of TNFa to add to those
described earlier (4.1).
CHAPTER 5, part i:- A PRELIMINARY APPRECIATION OF THE POTENTIAL ROLE
OF TNFa IN MAEDI-VISNA DISEASE.
5.1.Introduction:-
Maedi (dyspnoea) and Visna (paralysis/wasting) are descriptive
terms for two of the commonest clinical syndromes (now known to be
caused by the same virus) seen in slowly-progressive diseases with
lengthy incubation periods, which occurred as epidemics in Iceland
earlier this century (Sigurdsson, 1954; Sigurdsson et al.. 1957).
Similar syndromes have now been described in many other countries
(Marsh, 1923; Ressang et al., 1968; de Boer, 1975), including the UK
(Jones et al. , 1982). The aetiological agent, Maedi-Visna (MV) virus
(MVV) has been characterised (see below) and is the prototype of a
sub-family of retroviruses, the lentivirinae, which includes the Human
Immunodeficiency Viruses (Gonda et al., 1986).
MV virions display typical lentiviral structure comprising a
positive-stranded c.lOkb RNA genome and reverse transcriptase (RT)
enzyme in an electron-dense, bar-shaped core of non-glycosylated
proteins, surrounded by a lipid envelope from which glycoprotein
spikes project (Thormar, 1961; Pautrat et al., 1971; Brahic et al.,
1973; Haase & Baringer, 1974; Clements & Narayan, 1981; Gonda et al.,
1985). Several isolates of this virus from different countries have
now been cloned and sequenced (Sonigo et al., 1985; Braun et al.,
1987; Querat et al., 1990; Sargan et al., 1991a; Staskus et al.,
1991). These studies reveal that, as in other lentiviruses, the genome
comprises three large ORF's, gag, pol, and env, which encode the
structural core, replicative and envelope proteins respectively, as
well as several small ORF's, which may be used to produce regulatory
proteins, following multiple splicing events (see below). The genome
is flanked at each end by a 'long terminal repeat' (LTR). Sequence
variation between strains, particularly in parts of the env gene, is a
prominent feature (Braun et al., 1987) and, during the course of
infection, antigenic variants may appear in an individual animal
(Lutley et al., 1983; Thormar et al., 1983). Under conditions of
intensive housing, MVV is spread laterally via respiratory and/or
possibly oral routes (Sigurdsson et al., 1953), although in other
farming systems lateral transmission occurs very slowly and lactogenic
passage from ewe to lamb may be the main method of viral dissemination
(de Boer et al. , 1979).
The clinico-pathological features of MV disease (MVD), as they
occur in one British flock, have recently been described (Watt et al.,
1992). Sick sheep frequently become cachectic. Other clinical signs
result from chronic, active inflammatory lesions in one or more of the
following organs:- lung, central nervous system (CNS), joints, mammary
gland, spleen and lymph nodes. In the lung, the commonest organ to be
affected, massive infiltration of predominantly mononuclear cells,
proliferation of lymphocytes to form germinal centre-like structures
in the interstitium, and smooth muscle hyperplasia, all combine to
cause the progressive respiratory embarassment seen in many cases. In
a smaller number of animals, the CNS is affected. Here, lesions
comprise a mononuclear cell infiltration of the choroid plexus, and
perivascular cuffing, gliosis, astrocytic hypertrophy and
demyelination in multiple focal sites within the brain and spinal
cord. Such lesions seem to be responsible for the progressive paresis
and ataxia seen in some sheep. In a few cases, lameness also results
from joint pathology. Thickened synovial membranes, due to
proliferation of the lining layer and inflammatory cell infiltration
with occasional formation of germinal centres, may be seen,
particularly in the carpal and/or tarsal joints, sometimes in
association with erosions of the articular cartilage. Induration of
the mammary glands can also occur as a result of similar infiltration,
combined with fibrosis and loss of acinar tissue. Lympho-proliferation
may also be seen in the spleen and assorted lymph nodes. Consequently,
MVD shares many clinical features with HIV infection and has been
proposed as an experimental model for some aspects of AIDS (Perk,
1988; Petursson et al., 1989).
In contrast to the latter disease, however, secondary infections do
not appear to be a major feature of MVD, possibly because MVV, unlike
HIV, does not seem to infect CD4 + lymphocytes (Gorrell et al., 1992).
Like HIV, however, MVV is macrophage-trophic (Narayan et al. , 1982).
Macrophages, at sites of pathology, are the predominant cell type in
which viral replication can be readily detected in vivo (Kennedy et
al., 1985; Gendelman et al., 1985), though viral antigens and/or
nucleic acids can be found in association with other cell types such
as oligodendrocytes and astrocytes, as well as epithelial cells of the
choroid plexus after direct experimental infection of the CNS (Brahic
et al. . 1981; Stowring et al., 1985). Infected, multinucleate giant
cells (possibly a consequence of virally-induced cell fusion [see
below]) may also be seen (Peluso et al., 1985). Following infection by
the respiratory route, some bone marrow monocyte/macrophage precursors
harbour virus, forming a reservoir of infection (Gendelman et al.,
1985), and virus may be spread to other tissues within monocytes or
possibly dendritic cells (Peluso et al., 1985; Gorrell et al., 1992).
What governs the cell and tissue tropism of MVV is unclear, though
factors in the viral LTR may be involved (Small et al.. 1989).
Maturation of monocytic 'Trojan horses' to tissue macrophages can then
be associated with increased viral replication (Gendelman et al.,
1986). However, infected cells are present in only very small numbers
in lesions of MVD and only a small percentage of these may actually be
expressing viral protein at any one time (Haase et al., 1977).
Different workers have concluded that this restriction involves
transcriptional (Brahic et al., 1981; Geballe et al., 1985) or post-
transcriptional blocks (Gendelman et al., 1985). Whatever the
mechanism, sheltering of viral nucleic acid within cells which do not
express viral antigen would seem to be one mechanism by which MVV
persists in sheep in the face of both cellular and humoral immune
responses (Petursson et al., 1976; Larsen et al., 1982).
The development of the dramatic pathology of MVD in the presence of
such a small amount of antigen has been a puzzle. Since immuno¬
suppression greatly diminishes the severity of lesions seen in
experimentally-induced Visna (Nathanson et al., 1976) and hyper-
immunisation can exacerbate this disease (Nathanson et al., 1981),
lesions may have an immuno-pathological basis. One conceivable
pathogenetic mechanism for a macrophage-trophic virus could be via
dysregulating the activity of one or more monokines, including TNFa. A
chronic increase in TNFa activity could clearly contribute to the
cachexia, inflammatory cell accumulation, lymphocyte proliferation,
demyelination, astrocytosis, fibrosis and cartilage destruction seen
in MVD (see 1.4,5).
Little is known about the involvement of cytokines in this disease,
though a unique form of IFN may be produced by ovine lymphocytes
following specific interaction with MVV-infected macrophages (Narayan
et al. , 1985). This 'lentiferon' can markedly restrict the replication
of MVV in macrophages in vitro (Kennedy et al., 1985), though it may
have a less marked effect on other infected cell types (Lairmore et
al., 1988). In spite of restricting viral replication, lentiferon
would seem to be one potential amplifier of the inflammatory lesions
of MVD, working in part via enhancing the expression of MHC class II
proteins by local macrophages (Kennedy et al., 1985). Alveolar
macrophages lavaged from Maedi lungs also appear to be 'activated' by
other criteria and spontaneously secrete 'neutrophil chemotactic
activity,' though the factors involved have not been characterised
(Cordier et al., 1990).
Having established that ovine TNFa exists and has many of the same
properties as TNF'sa in other species, it was of interest to examine
its potential role in MVD, beginning with some preliminary experiments
to determine whether MVV could induce ovine TNFa and/or rovTNFa could
influence the life-cycle of MVV in vitro.
In contrast to the in vivo situation, MVV replicates productively
in ovine or caprine macrophages and fibroblast-like cells in vitro
(Sigurdsson et al., 1960; Thormar, 1963; Narayan et al., 1982),
following binding to a cell surface receptor (Crane et al., 1991a;
Dalziel et al., 1991). Exposure of cells to a high moi of MVV can
cause cell-fusion 'from without' (Harter & Choppin, 1967), an effect
which may be mediated via the transmembrane component of its envelope
glycoproteins (Crane et al., 1991b). Once the viral core has entered
the cell, RT activity produces proviral dsDNA (Haase et al., 1982),
most of which, though nuclear in location, does not appear to
integrate into host cell DNA, in contrast to the oncogenic retro¬
viruses (Harris et al., 1984).
Expression of viral mRNA then proceeds and can be divisible into an
early phase, when small, multiply-spliced, viral transcripts appear,
and a later phase when larger transcripts, including full length
genomic RNA's, accumulate (Vigne et al., 1987). Hess et al. (1985)
showed that enhancement of MVV gene expression by viral products
occurs. This effect can be accounted for by the accumulation of
regulatory proteins, such as tat and rev, largely translated from the
small ORF's located within the early transcripts (Mazarin et al.,
1988; Gordou et al., 1989; Sargan & Bennet, 1989). These proteins have
similar functions to their homologs in HIV. Tat transactivates viral
expression via interaction with an element in the LTR (Davis &
Clements, 1989), whilst sufficient rev must accumulate before larger
transcripts, needed for the translation of structural proteins, appear
in the cytoplasm (Tiley et al., 1990).
Viral core proteins are produced from these unspliced transcripts
as a polyprotein precursor joined to replicative enzymes, which
include RT and, by sequence analogy to other retroviruses, viral
proteases responsible for processing this large protein (Vigne et al.,
1982; McClure et al., 1987). MVV envelope proteins may be produced
from singly-spliced or unspliced transcripts. These structural
components, including unspliced transcripts which form new genomes,
are assembled at cell membranes (Coward et al., 1970), where they may
then induce fusion from within or be secreted. Eventually viral
replication may lead to cell lysis, especially in fibroblasts. This
entire cycle can be completed within a few days. However, infection of
macrophages, which seem to be more resistant to fusion from without,
may involve fewer cytopathic effects (CPE). Furthermore, many virions
appear to bud from the internal membranes of these cells and
accumulate in cytoplasmic vacuoles rather than cell supernatants,
resulting in lower final titres of virus (Narayan et al., 1982).
Different strains of MVV appear to have varying abilities to
replicate productively in culture (Narayan et al., 1982; Querat et
al., 1984). Those strains which replicate most productively and cause
the most CPE in macrophages in vitro tend to be the most pathogenic in
vivo (Lairmore et al., 1987). The strain of MVV used in the following
experiments was EV-1, a British isolate, which has been cloned and
sequenced, and which can replicate productively to induce syncitial
formation in fibroblasts (Sargan et al. , 1991a).
5.2.Results:~
5.2.1.RovTNFa has an antiviral effect on MVV-infected ovine
fibroblasts:-
When WSCP cells were infected with MVV at a low moi (0.17
TCIDso/cell) the level of viral proteins (as assayed by the level of
RT activity) had risen by the end of 9 days of incubation. However, a
dose-dependent reduction in the total (SN and cell-associated) viral
yield was caused by continuous incubation with rovTNFa, from 2 days
post-infection (PI) onwards (fig.5.1). The yeast extract/Xa negative
control preparation had no effect. Since some ovine cultures may
harbour latent retrovirus which can be induced by various stimuli
(Barban et al., 1984), uninfected cells were also analysed. No
spontaneous RT activity appeared in these cells nor was any induced by
rovTNFa. When a duplicate plate was stained and analysed, it was
apparent that rovTNFa had increased the overall density of uninfected
wells, in agreement with findings in chapter 3, and viral infection
had reduced the numbers of remaining cells at the end of the
experiment, though no clear, dose-dependent effect was discernible for
rovTNFa-treated infected wells (table 5.1).
Since the antiviral effect of TNFa, as mediated via 2'-5'
oligoadenylate synthetase and/or IFN induction, may be even greater
following pretreatment of aged fibroblasts (Van Damme et al.. 1987;
Mestan et al., 1988), the above experiment was repeated on WSCP's
which had been maintained as a monolayer for several days and treated
with rovTNFa, or controls, for 24 hours prior to infection, when
incubation with the same sample concentration continued. Whilst the
same amount of virus was inoculated into each well as in the previous
experiment, the moi here was impossible to assess owing to cell
replication post-plating. Once again rovTNFa caused a reduction in
total viral yield in duplicate plates at both 7 and 10 days PI, though
the maximum effect seen (c.50% reduction in RT activity) was similar
to that in the previous experiment (fig.5.2). On the 10th day,
refractile, necrotic-looking cells were seen detaching from infected
wells treated with concentrations of rovTNFa in excess of lOng/ml, but
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Figure 5.1:- results ofan assay to analyse the effect of incubating EV-J- exposed
WSCP cells with different concentrations ofrovTNFa, or yeast extract/factor Xa
negative controlpreparation (plotted at equivalent dilutions;see symbol legends), on
the accumulation of total (supernatant & cell-associated) reverse transcriptase (RT)
activity, 9 days post-infection. Results are expressed as the mean RT activities of
sextuplicate wells (error bars indicate standard dexiations). The RT activities
associated with similarly-incubated uninfected wells, whether or not 1pg
rovTNFa/ml was added, and with the initial viral inoculum (diluted to the final





EV-1 Cone" rovTNFa (ng/ml) SD
- 0 _0.664 _0.041
- 1,000 1.117 0.033
+ 0 0.497 _0.029
+ 1 0.503 _0.043
+ 10 _0.538 _0.045
+ 100 _0.425 _0.021
+ 1,000 _0.447 0.046
Table 5.1:- the effects of incubation with rovTNFa and/or EV-1 infection on the
eventual density ofWSCP cells in an experiment which duplicated, and was run in
parallel with, that described in fig. 5.1. Results are expressed as the mean OD 540 °f
sextuplicate wells (with standard deviations [SD's]) after residual cells at the end ofa




Cone" rovTNFa (ng/ml) Mean RT activity (c.p.m,: SB 'sin brackets)
Exp'l Exp' 2 Exp13
- 0 625 (198) 811 ( 171) _ 532 ( 95)
- 500 716 (233) 754 ( 154) _ 498 (127)
+ 0 _10,822 (1240) _ 8,892 ( 981) _1,987 (482)
+ 5
_ 9,830 (1117) _ 8,079 (1173) _2,676 (604)
+ 50 _11,406 (1349) _ 8,205 ( 892) _3,278 (852)
+ 500 _13,054 (1205) _11,120 ( 903) _3,287 (495)
+
Cone* aeg. entrl (eq.dij*).
_11,074 (1221) _ 9,088 (1073) _2,270 (488)500
Table 5.2:- results ofassays to determine the total accumulated RT activity in
cultures of3 different preparations ofadherent, ovine lung-cells 13, 12 and 9 d post¬
infection with EV-1 (experiments 1,2 & 3, respectively), following incubation with
rovTNFa or a yeast extract/factor Xa negative control (whose concentration is
expressed as an equivalent dilution to rovTNFa [ng/ml]). Results are expressed as
mean c's.p.m. (& standard deviations) ofsextuplicate wells. The RT activity
associated with the initial viral inoculum (diluted to the final concentration assayed)
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Figures 5.2a & b:- the effects on total, accumulated (at 7 & lOdpost-infection,
respectively) RT activity in cultures ofEV-1-infected WSCP cells, following
pre-infection treatment (& continuedpost-infection exposure) to rovTNFa or a yeast
extract/factor Xa negative control preparation (plotted at equivalent dilutions; see
symbol legends). Results are expressed as the mean c's.p.m. (with error bars
indicating standard deviations) ofsextuplicate wells.
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Figure 5.3:-
Figiire 5.3:- representative fields ofunstained. EV-1-infected. WSCP cells from the
experiment represented in fig. 5.2b, when examined by light microscopy prior to the
measurement ofRTactivity. Cells had been incubated with 0 (above) or 1,000
(below) ngrov TNFa/ml.
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5.2.2.RovTNFa does not have an antiviral effect on MVV-infected ovine
lung-cells:-
3 similar experiments, using;an/ moi of 0.1 TCIDso/cell, with
rovTNFa or control samples being added at (experiments 1 & 2) or 24
hours after (experiment 3) the time of infection, were repeated on the
adherent fraction of an ovine lung-cell preparation, which had been
allowed to settle for several days after preparation. Wells were
incubated with the same sample concentration throughout and remained
free from bacterial, yeast or fungal infection (as judged by light
microscopy). No statistically-significant difference in the eventual
total viral yield (9-13 days later) was caused by incubation with
rovTNFa, though a slight increase in yield was consistently caused by
the highest concentration of rovTNFa (table 5.2). RovTNFa caused no
increase in the low level of spontaneous RT activity seen in
uninfected wells.
It was apparent, however, that within 24 hours of treatment,
rovTNFa consistently caused both infected and uninfected cells to
aggregate into large clusters which persisted for several days
(fig.5.4). It was also noted that when giant cells, presumably
syncitia, began to form in infected wells from 6 days PI, these were,
on each occasion, larger and more numerous in wells treated with
rovTNFa than in those subjected to control preparations (fig.5.5). No
giant cells were noted in un-infected wells at any stage of culture.
5.2.3.MVV induces ovine TNFa:-
When SN's from wells treated with PBS/BSA only in experiment 3
(table 5.2) were analysed by acetone precipitation and Western
blotting, using cytl as the primary antibody, ovine TNFa was found to
have accumulated in the infected but not the uninfected wells
(fig.5.6).
Similar cell preparations were infected with MVV at a higher moi
(1 TCID5o/cell) for 2 hours, before the inoculum was removed and the
cells refed. This treatment seemed to induce a change in morphology
(mainly elongation) of a large percentage of the cells over the
following 24 hours (fig.5.7). When the SN's, which were collected at
assorted timepoints after refeeding were analysed as above, ovine TNFa
could be seen to have accumulated in those wells which had been
Figure 5.4:- 5.4a
Figure 5.4a.b & (see over) c,d:- representative, light microscope fields at low (5.4a &
b) and high (5.4c & d) powers ofuninfected ovine lung-cells, 4 d after adding
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Figure 5.5:- representative, light-microscopefields ofovine litng-cells, 7 d post¬
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Figure 5.6:- a Western blot ofan SDS- 5-20% gradient- polyacrylamide gel. run
under non-reducing conditions. The primary detecting antibody was cytl. used at a
1:30 dilution ofthe saturated supernatant. Samples submitted to electrophoresis
comprised 3ng rovTNFa (lanes I & 7) and acetone precipitates collectedfrom 0.33
ml ofmedium (lane 2) orfrom 0.33ml of contents pooledfrom 6 uninfected (lanes 3
& 4) or 6 EV-l-infected (lanes 5 & 6) wells ofcultured ovine lung-cells. Duplicate
plates of the lung-cell preparation represented in table 5.2, experiment 3, were frozen
5 (lanes 3 & 5) or 9 (lanes 4 & 6) d post-infection, prior to collection ofsamples.
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Figure 5.7:- representative light microscope fields ofunstained, ovine lung-cells 24h
after the addition ofconditioned medium (above) or El'-1-containing medium
(below).
Ill
infected with MVV, reaching a peak concentration between 2 and 24
hours. No ovine TNFa was detected in wells treated with conditioned
medium (fig.5.8). When tested by a limulus amoebocyte lysate assay,
the viral inoculum contained <50pg/ml of LPS (the detection limit of
this assay). No ovine TNFa was detected when conditioned medium which
had been deliberately doctored with 500pg/ml of LPS (derived from
Salmonella abortus equi, a pathogenic source) was similarly used on
these cells (fig.5.8).
5.3.Discussion:-
RovTNFa clearly had a negative net effect on the accumulation of RT
activity in cultures of infected fibroblasts (figs.5.1,2), in spite of
enhancing the density of potential host cells (table 5.1). Although
different protocols and cell-types were involved, the concentrations
of rovTNFa displaying anti-lentiviral activity in these assays are
similar to the range of concentrations (c.10-1000ng/ml) previously
described as having activity against HIV-l-infected cells (Wong et
al., 1988, Matsuyama et al., 1989a). How the downregulation of viral
expression was achieved in this case is unclear, however. Whilst more
than one mechanism has been described for TNFa's antiviral actions
(see 1.4.4,6), the appearance of apparently dead cells in rovTNFa-
treated wells (fig.5.3) suggests that a proportion of the activity
seen here might be mediated via the killing of infected cells.
Alternatively, rovTNFa may have protected the majority of cells from
infection, but enhanced viral replication in a small subpopulation,
leading to their earlier death. Cytotoxicity, cellular protection and
enhancement of viral replication by TNFa have all been observed in HIV
infections of lymphocytes (see 1.8.5) and therefore one or more
actions could operate here, though further work is clearly required to
determine which mechanisms are actually involved. Subsequent studies
have failed to detect any IFN in rovTNFa-treated, MVV-infected WSCP
cell extracts or SN's, using a Vesicular Stomatitis virus growth
retardation assay (Dr.G.Entrican, personal communication), nor do
these cells seem to die by apoptosis, as judged by microscopic
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Figure 5.8:- A Western blot ofan SDS- 5-20% gradient-polyacrylamide gel run under
non-reducing conditions. The primary detecting antibody was cytl, used as a 1:30
dilution ofthe saturated supernatant. Samples submitted to electrophoresis comprised
3ng rovTNFa (lanes 1 & 15) or the acetone precipitates collectedfrom 0.33ml ofpooled
supernatant removedfrom triplicate wells exposed to conditioned medium (lanes 2-6),
EV-1 -containing medium (lanes 7-10) or conditioned medium contaminated with 500pg
LPS/ml (lanes 11-14). These supernatants had been removed 0 (lane 2), 2 (lanes 3, 7 &
11), 5 (lanes 4, 8 & 12), 24 (lanes 5, 9 & 13) or 48 (lanes 6, 10 & 14) h after a 2h
exposure to the above media.
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Analysis of the net effect of rovTNFa on a population of infected
lung cells, rich in macrophages, was complicated by several factors,
including the induction of endogenous ovine TNFa (fig.5.6). This might
account for the fact that any changes noticed were slight and only
seen at the highest concentration of rovTNFa added. Though not
statistically-significant in individual experiments, an enhancement of
the final accumulation of RT activity was consistently seen at this
concentration in each of three preparations. Notwithstanding the fact
that blocking studies are required to ascertain the part played by
endogenous TNFa, one might conclude, therefore, that the net effect of
rovTNFa on this population was not antiviral but possibly even the
opposite. Cell-type restriction of TNFa's antiviral activity is
certainly a feature in other species and infections (Schijns et al.,
1991) and, furthermore, Ohmann et al. (1989a) found that rboTNFa was
unable to induce 2'-5' oligoadenylate synthetase in bovine alveolar
macrophages and leukocytes, in contrast to its effects in non-lymphoid
cells.
TNFa is known to enhance the replication of HIV via the induction
of NF-kappaB proteins binding to sites in the viral LTR (see 1.8.5).
Strains of MVV so far sequenced, including EV-1, do not contain any
NF-kappaB sites in their LTR's (Sonigo et al., 1985; Braun et al.,
1987; Querat et al., 1990; Sargan et al., 1991a; Staskus et al..
1991). However, they do contain more than one site for another TNFa-
inducible transcriptional factor, AP-1, and these sites appear to be
important in controlling basal MVV transcriptional activity (Hess et
al., 1989). Furthermore, transcriptional activation of another retro¬
virus, Human Foamy Virus, also appears to be modulated via AP-1 sites
in its LTR (Maurer et al., 1991) and the binding of AP-1 to an
intragenic enhancer in the HIV provirus has been linked to
upregulation of lentiviral transcription (van Lint et al., 1991).
'Activation' of ovine macrophages by phorbol esters can certainly
increase transcription directed by the MVV LTR (Small et al., 1989)
and an AP-1 site appears to be essential for such inducibility
(Gabuzda et al.. 1989). Therefore enhancement of MVV replication in
macrophages by ovine TNFa remains a possibility. In agreement with
this, Ellis et al. (1991) claim to have increased the replication of
another strain of MVV in ovine alveolar macrophages, using rboTNFa,
though they give no details.
RovTNFa may have influenced viral replication by other mechanisms,
however. Although TNFa can upregulate the expression of several cell
adhesion molecules (see 1.4.1), the induction of macrophage
aggregation by rovTNFa was an unexpected finding, as this does not
appear to be a generally-recognised phenomenon in other species. It
has been observed for one human promonocytic cell line however
(Kharbanda et al., 1990), whilst macrophage aggregation in response to
lymphocyte-derived factors has been well documented (Lolekha et al.,
1970; Garcia-Moreno & Myrvik, 1977). Whether the aggregation seen here
represents a species-specific response to TNFa by ovine cells, was
influenced by contaminating cell-types, or was perhaps due to some
combined activity of rovTNFa and impurities such as factor Xa, remains
to be seen. However, such aggregation could certainly have helped
increase viral replication by aiding the inter-cellular spread of
virus.
Several workers have observed that rhTNFa can enhance the CPE (in
cultures (Matsuyama et al., 1989b; Vyakarnam et al., 1990). Though
this might be attributable to the upregulation of viral replication,
others have found that viral replication and CPE do not always
correlate, suggesting the involvement of other factors (Pantaleo et
al., 1991). Whilst similar enhancement of CPE was seen here (fig. 5.5),
and enhanced viral replication at the highest concentration of TNFa
might have contributed, pre-existing cellular intimacy, as a result of
aggregation, would seem to be a more likely cause of the phenomenon in
this model. Furthermore, the resulting changes in cell numbers and
sizes clearly add to the factors complicating the net effect of
rovTNFa on viral replication.
Addition of viral samples to these cells appeared to activate them,
as judged by their change in morphology (fig.5.7), and was associated
with the production of ovine TNFa, following either the acute
administration of large quantities of virus (fig.5.8) or infection
with a smaller inoculum given time for further replication (fig.5.6).
There did not appear to be any 'spontaneous' ovine TNFa production
frequency) seen in HIV-infected cell X
from these alveolar macrophages, which had been cultured for several
days, in contrast to the situation with freshly-isolated cells (see
chapter 4). Considerable controversy over the ability of other
lentiviruses to induce TNFa has clearly existed (see 1.8.5). Some have
blamed observed inductions on LPS, or possibly components of the cells
on which the virus was grown, contaminating viral inocula (Molina et
al. , 1990a), though Merrill et al. (1989) and Clouse et al. (1991)
have been able to prevent induction using a soluble form of CD4, the
HIV receptor. Since the addition to conditioned medium of more than
ten times the amount of LPS known to contaminate the preparation of
EV-1 failed to induce detectable ovine TNFa, it seems unlikely that a
higher level of LPS in the viral sample than the conditioned medium
negative control was to blame per se. In addition, the virus isolate
used here was free of mycoplasmal contamination (D.Sargan, personal
communication) and was grown on normal, not transformed, cells,
further suggesting that the accumulation of ovine TNFa was a direct
consequence of the presence of MVV. Ellis et al. (1991) have also
looked for induction of TNFa by MVV. Though they failed to detect
accumulation of TNFa in the SN's of MVV-infected ovine alveolar
macrophages, their assay involved L929 cells and, almost certainly,
therefore, a poor level of sensitivity (see chapter 4).
Given that the presence of MVV can lead to TNFa accumulation, the
mechanism of induction becomes an important consideration in trying to
ascertain whether sufficient TNFa might be produced in vivo to account
for some of the pathology of MVD, since acute exposure to a large
number of viral particles in vitro may bear little similarity to the
situation in vivo where few virions are to be found (see 5.1). Merrill
et al. (1989) proposed that the binding of gpl20 to CD4 was
responsible for the induction of TNFa by HIV. Though CD4 is not a
receptor for MVV, this virus interacts with members of the same
immunoglobulin superfamily to which CD4 belongs, MHC class II
molecules (Dalziel et al., 1991), as well as other cell surface
proteins (Crane et al., 1991a). The production of ovine TNFa within a
few hours of exposure to MVV (fig.5.8) is certainly consistent with a
receptor-mediated mechanism of induction. Since the structure of the
envelope glycoprotein includes highly-variable sites in both HIV
(Starcich et al., 1986) and MVV (Braun et al., 1987), one might also
speculate that differences in this molecule between viral strains
could mediate differential abilities to induce TNFa, particularly
since more than one epitope appears to be involved in contact with
cell surface antigens (Crane et al., 1988). This might also help to
account for the failure of some workers using different strains to
observe the induction of TNFa by lentiviridae (see 1.8.5 and above).
Alternative and/or additional mechanisms leading to the induction
of TNFa by MVV also exist, however. Infection with HIV seems to be
associated with a TNFa-independent increased availability of some
forms of NF-kappaB (Bachelerie et al., 1991; Neuvert et al.. 1991;
Roulston et al., 1992) and this may be related in part to an ability
of viral protease to process a precursor of one of the subunits
(Riviere et al., 1991). HIV can also upregulate the intracellular
levels of cyclic nucleotides (Nokta & Pollard, 1991). Clearly, such
effects could enhance TNFa gene transcription (see 1.3.2). More direct
viral transactivation of the ovine TNFa gene might also occur. Tax,
the viral transactivator of another retro-virus, HTLV-1, can
transactivate the TNFi3 gene, possibly via its single NF-kappaB site
(Paul et al■, 1990; Lindholm et al.. 1992) and HIV-tat has also been
shown to transactivate this gene in one cell line (Sastry et al.,
1990). Furthermore, HIV-tat can also be secreted and influence cell
functions in a paracrine fashion (Ensoli et al., 1990; Viscidi et al.,
1989). MVV-tat displays some similarities to HIV-tat (Davis &
Clements, 1989; Gourdou et al., 1989) though whether it can
transactivate any cellular genes remains to be demonstrated. Extremely
heightened sensitivity to low levels of contaminating LPS, as has been
postulated for HIV (see 1.8.5), and/or induction by factors produced
by MVV-infected fibroblasts when preparing the EV-1 stocks, remain two
other possible causes of the accumulation of ovine TNFa seen in these
studies. One must also be aware that macrophages may not be the only
source of TNFa in MVD. Proliferating lymphocytes, which abound in this
disease (see 5.1), can also produce TNFa (see 1.2). Once again,
further studies, to elucidate the mechanisms involved and to ascertain
whether ovine TNFa is actually chronically overproduced during MVD in
vivo, are in order.
Given that ovine TNFa might be produced during MVD and the well-
documented synergy (and/or occasionally antagonism) between TNFa and
IFN's (see 1.7), interesting possible interactions with 'lentiferon'
exist. Not only might the latter further enhance the production of
TNFa in response to assorted stimuli, but the two could synergise in
causing the observed upregulation of class II MHC expression in MVD
lesions (Kennedy et al., 1985), as well as in their antiviral
activity, including cytotoxicity, on some cell types.
Two intriguing aspects of infection with MVV have been the
restricted nature of its replication in macrophages and an apparent
failure to infect most fibroblasts in vivo, in spite of its ability to
replicate productively in both cell types in vitro (see earlier).
Whilst increasing cellular maturation may be one mechanism allowing
productive replication in macrophages (Gendelman et al., 1986) and
cell-culture adaptation could also be involved (Narayan et al■, 1982),
it seems likely that antiviral activities exerted by factors derived
from other cell types could contribute to the in vivo restriction. A
powerful antiviral combination of lentiferon and TNFa might therefore
be one mechanism of removing infected fibroblasts and/or preventing
the infection of this cell type in vivo. Ligand for Fas antigen has
also been shown to kill HIV-infected cells (Kobayashi et al., 1990b)
and clearly other factors could therefore also contribute. In this
regard, TNFa is but one of several monokines whose activity is
potentially dysregulated by MVV.
In contrast to the situation in fibroblasts, lentiferon and TNFa
would seem to have antagonistic effects on viral replication in
macrophages. Consequently, one might speculate that viral latency or
progression could be influenced, at least in part, by the balance
between lentiferon and TNFa or other activating factors. Removal from
the restriction of lymphocyte-derived lentiferon and possibly some
autocrine stimulation of viral transcription by ovine TNFa might then
assist the conversion to productive viral replication in purified
macrophages in vitro.
Notwithstanding the fact that further work is clearly required to
more fully assess the part that ovine TNFa plays in the pathogenesis
of MVD, these preliminary findings suggest that the role TNFa plays in
this disease is, not surprisingly, likely to be complex, as in many
other diseases (see 1.8). Furthermore, given the induction of ovine
TNFa by MVV and its anti- and probable pro-lentiviral activities, the
role that this cytokine plays in MVD would seem to share similarities
with the role that human TNFa plays in AIDS. Since TNFa has been
considered one of the most influential factors in the pathogenesis of
the latter disease (Matsuyama et al., 1991), this adds to the case for
considering MVD as a model for some aspects of HIV infection.
CHAPTER 5, part ii:- CONCLUSIONS.
Whereas little was previously known about ovine TNFa, it is now
possible to make several conclusions about this cytokine and the work
described in this thesis.
In summary:-
1) Cloning and sequencing of amplified ovine cDNA demonstrates the
existence in sheep of a mRNA with a high degree of sequence homology
to the mRNA's encoding TNFa in other species.
2) As in other species this mRNA is rapidly and greatly inducible
from a cell population rich in macrophages.
3) Comparison of this sequence with those of of other published
TNFa cDNA sequences confirms the conservation of several structurally
and functionally important regions and suggests the probability of
allelic polymorphisms in other regions of the ovine molecule.
4) Amplification of cDNA molecules using inverse PCR may not be as
'straightforward' as using this technique on uniform length genomic
segments of DNA.
5) An unglycosylated, recombinant TNFa has been translated from
ovine cDNA, starting at a presumed (by analogy with mature human TNFa)
first codon of the mature protein, via a yeast Ty VLP expression
system.
6) This expression system works well for the production and simple
partial purification of rovTNFa.
7) RovTNFa shows a wide range of biological activities similar to
TNF'sa from other species. These include cytotoxicity, enhancement of
thymocyte and fibroblast proliferation and cartilage-degrading and
anti-viral activities.
8) RovTNFa also shows similar multimeric structure to other TNF'sa,
with an ability to self-associate into trimers and/or dimers.
9) RovTNFa shows activity in assays on ovine cells at
concentrations comparable to those described for other TNF'sa in
similar syngeneic systems.
10) However, it is 1000-fold less active than rhTNFa in
cytotoxicity assays on TNF-sensitive murine cells on a weight-for-
weight basis.
11) 2 monoclonal antibodies have been raised which specifically
recognise rovTNFa.
12) At least one of these, cytl, specifically recognises a
glycoprotein of appropriate size to be mature ovine TNFa in the
supernatants of stimulated ovine cell cultures.
13) Since all such ovine supernatants failed to induce detectable
cytotoxicity when tested in assays on L929 cells (sensitive to 30pg
rhTNFa/ml) in spite of the fact that many contained >lng ovine TNFa/ml
and at least one of these contained biological activity attributable
to ovine TNFa through its neutralisation by a polyclonal antiserum to
rovTNFa, TNF-sensitive murine cells are insufficiently sensitive to
ovine TNFa to be of use in its routine detection.
14) Such results suggest that there may be a higher degree of
species specificity in the interaction of murine TNF-RI's with TNF'sa
from some species than had previously been recognised.
15) As in other species ovine TNFa is inducible and its induction
is enhanced by LPS.
16) TNFa can be induced from a population of adherent ovine lung
cells (predominantly alveolar macrophages) in vitro by media
containing MVV but not conditioned media.
17) RovTNFa has an antiviral activity on MVV-infected ovine
fibroblasts but not on adherent lung cells. Indeed its effect on these
cells may even be pro-viral.
18) Consequently, ovine TNFa may play a complex role in the
pathology of MVD.
CHAPTER 6:- MATERIALS AND METHODS.
6.1. Materials and methods - general:-
6.1.1. General considerations:-
During the course of this work different methods or conditions have
been used for similar procedures. If methods are incompletely defined
in this chapter, or alternatives are described, precise conditions
pertaining to individual experiments will be found in the appropriate
results sections.
Some other, general features are worthy of note. Aseptic techniques
are implied throughout for handling bacterial, yeast and established
mammalian cell cultures, hence all media used for culture were
autoclaved prior to use, as were, where possible, concentrated stock
solutions of pure chemicals from which buffers or other complex
solutions were generally derived. Where autoclaving was inappropriate,
solutions were filter-sterilised. In deriving primary tissue cell
cultures, 'clean' rather than aseptic techniques were used. Disposable
sterile plasticware or baked/autoclaved containers were used through¬
out to limit contamination of samples.
Unless otherwise stated, all incubations of bacteria and yeast were
carried out in air at 37°C and 30°C respectively, with those cultures
involving liquid media being placed in shaking incubators. Mammalian
cells were incubated at 37°C in air with 5% added CO2. All other
procedures where no temperature (T°) is given were performed at room
T°. Manipulations involving virions were performed in class II safety
cabinets. All other tissue culture manipulations and preparations for
PCR's were performed in laminar flow hoods. L-glutamine was added, to
2mM, to all media used for mammalian cell culture and, when used,
penicillin, streptomycin and fungizone were added to 100U, lOOpg and
2.5pg/ml respectively.
In this chapter, water means distilled water and 'microfuging' of
samples means spinning them at 13,000 rpm in an MSE 'microcentaur'
centrifuge for the stated period. Unless details to the contrary, or G
forces, are given, 'centrifugation' means spinning at the stated speed
in a bench centrifuge (Beckman TJ6, MSE centaur 2 or Wifug 500E).
All dialyses were performed at 4°C over a minimum of 16h with at
least 3 changes of the stated buffer. Each change of buffer was >100 x
the sample volume. All dialysis tubing was prepared by boiling for
5min in each of two changes of 5% NaHC03, 0.1% NaEDTA.
Finally, all animal inoculations and blood sampling were actually
performed by suitably-licensed colleagues.
6.1,2. Materials:-
Unless otherwise stated, the materials used in this work were from
the following sources:- all radionucleotides and hybridisation
membranes were supplied by Amersham (UK) Ltd. and all enzymes by
Northumbria Biologicals Ltd. (NBL), whilst tissue culture media were
by Gibco/BRL; all other 'general' consumables were purchased from
Sigma. Reagents were of analytical or tissue culture grade as
appropriate. RovIL-1^ and P1-P25 fusion proteins were kind gifts from
C.Fiskerstrand and Dr.H.Reyburn, respectively. A polyclonal anti-Pi
antiserum was supplied by Dr.S.Adams (British Biotechnology Ltd.). All
'control' monoclonal antibodies and normal murine splenocyte SN's as
well as plasmids, 'phages, bacteria, yeast and a PI preparation were
from departmental stocks. Sources of primers, a human TNFa cDNA probe,
rhTNFa and cell lines are described elsewhere (6.2.3,12, 6.3.9 &
6.4.4).
6.1.3. Formulae:-
The formulae of all buffers, media and other complex solutions
referred to in the rest of this chapter are listed in alphabetical
order below.
BamHI buffer:- lOmM Tris/HCl pH8.0, lOOmM NaCl, 5mM MgCl2, ImM 2-ME.
Carbonate coating-buffer:- 7.63g/l Na2C03, 4.6g/l NaHC03, pH9.6.
Circularisation buffer:- 50mM Tris/HClpH 7.4, lOmM MgCl2, lOmM DTT,
ImM ATP, lOpg/ml gelatin.
DNA denaturing solution:- 1.5M NaCl, 0.5M NaOH.
DNA loading buffer:- 0.25% bromophenol blue, 0.25% xylene cyanol, 15%
ficoll (w/v), 5xTAE (see below).
DNA pre-hybridisation mix:- 20mM NaP04 pH7.0 (see below), 3xSSC (see
below), 0.5% milk powder (w/v), 0.1% SDS (w/v), ImM EDTA, lOOpg/ml
yeast RNA.
Formate buffer:- 2.1ml formic acid, 2g Na formate, 5ml ethanol/1.
Freezing mix:- 90% v/v FCS, 10% v/v DMSO.
GTC:- 5M Guanidine thiocyanate, 25mM Na citrate, 0.5% Na
laurylsarcosinate (w/v), lOOmM 2-ME, ImM EDTA.
GTE:- 50mM glucose, 25mM Tris/HCl pH8.0, lOmM EDTA.
High-salt digestion buffer:- lOmM Tris/HCl pH7.5, lOOmM NaCl, 7mM
MgCl2, 7mM 2-ME.
High-salt elution buffer:- 580g NH40Ac/l, 0.01% bromophenol blue
(w/v).
Kinase buffer:- lOmM Tris/HCl pH7.5, 7mM MgCl2, O.lmM EDTA, 5mM DTT,
lOpM ATP.
5M KOAc pH4.8:- 60mls 5M KOAc, 11.5mls glacial acetic acid /100ml.
LB:- 50mM Tris/HCl pH7.5, lOmM MgCl2, 5% PEG 6000 (w/v), ImM ATP, ImM
DTT.
Ligase buffer:- 50mM Tris/HCl pH7.5, lOmM MgCl2, ImM ATP, ImM DTT,
lOOpg/ml BSA.
Low-salt digestion buffer:- lOmM Tris/HCl pH7.5, 60mM NaCl, 7mM
MgCl2, 7mM 2-ME.
Low-salt running buffer:- 200mM Tris/HCl pH8.0, 2mM EDTA, 50mM NaCl.
20mM NaP04 pH7.0:-1.7g Na2HP04, 1.24g NaH2P04.2H2O/I.
Neutralising solution:- 2M NaCl, 1M Tris/HCl pH7.0.
Ohara buffer:-lOmM Tris/HCl pH8.8, 1.5mM MgCl2, 3mM DTT, 50mM KC1.
OLB:- a 100:250:150 mix of solutions A,B & C, where:- solution A =
1000 parts 1.25M Tris/HCl pH8.0, 0.125M MgCl2 to 18 parts 14.33M 2-ME,
5 parts 0.1M dATP, 5 parts 0.1M dTTP, and 5 parts 0.1M dGTP (each dNTP
being dissolved in 3mM Tris/HCl pH7.0, 0.2mM EDTA); solution B = 2M
Hepes pH6.6, 4M NaOH; and solution C = random hexadeoxyribo-
nucleotides at 90 OD260 U/ml in lOmM Tris/HCl pH7.5, ImM EDTA.
PBS:- 170mM NaCl, 3.4mM KC1, ImM Na2HP04, 2mM KH2PO4 pH7.2.
Peroxide substrate solution:- 0.04% w/v OPD, 0.008% v/v H2O2 in a
buffer made by adding 0.1M citric acid to 0.2M Na2HP04 until pH=5.0.
Pretreatment buffer:-0.1M 2-ME, 20mM EDTA, 200mM Tris/HCl pH8.0.
m
Protein loading buffer:- lOOmM Tris/HCl pH6.8, 30% glycerol v/v, 1%
SDS w/v, 2.9M 2-ME and 0.01% w/v bromophenol blue. For non-reducing
conditions, the 2-ME was omitted.
Protein running buffer:- 25mM Tris base, 50mM EDTA, 0.1% w/v SDS, 0.1%
w/v glycine.
Regeneration agar:- 3% w/v bacto-agar, 0.67% w/v yeast nitrogen base
without amino acids (Difco), 1% w/v glucose, in 1M sorbitol.
RNA denaturing buffer:- 60% deionised formamide (v/v), 7.2%
formaldehyde (w/v), 20mM NaP04 pH7.0 (see above), O.lmM EDTA.
RNA loading buffer:- 30% ficoll, 0.5% bromophenol blue (w/v), 250pg/ml
EtBr, 20mM NaP04 pH7.0 (see above).
RNA prehybridisation mix:- 5xSSC (see below), 50% formamide (v/v),
0.5% dried milk powder (w/v), 0.5% SDS (w/v), lOOpg/ml yeast RNA.
RNA resuspension buffer:- 0.3 M NaOAc pH5.2, lOmM EDTA, 0.1% SDS(w/v).
RPMIioME:- RPMI with 10% v/v FCS, 10"5M 2-ME, penicillin and
streptomycin.
RPMIis:- RPMI with 15% v/v FCS, ImM Na pyruvate.
RPMIisHAT:- RPMI with 15% v/v FCS, O.lmM hypoxanthine, 0.4pM
aminopterin, 16pM thymidine, ImM Na pyruvate.
RPMI15HT:- RPMI with 15% v/v FCS, O.lmM hypoxanthine, 16pM thymidine,
ImM Na pyruvate.
RPMI20:- RPMI with 20% v/v FCS.
RPMI20HAT:- RPMI with 20% v/v FCS, O.lmM hypoxanthine, 0.4pM
aminopterin, 16pM thymidine, ImM Na pyruvate.
2.5x RT reaction mix:- 375mM KC1, 25mM MgCl2, 25mM Tris HC1 pH8.0, 5mM
DTT, 1.25mM EGTA, 0.25% w/v Triton X-100, 62.5pg/ml BSA, 75 pg/ml poly
(rA).oligo(dT 12-18), 5% v/v deionised ethane diol and lOOpCi/ml 3H-
TTP (20 Ci/mMol).
Sc-glc agar:- a filtered, 1% w/v solution of L-tryptophan added, to
2ml/l, to an autoclaved preparation of 2% w/v bacto-agar, 0.67% w/v
yeast nitrogen base without amino acids (Difco), 1% w/v glucose.
Sc-glc medium:- as Sc-glc agar (above) but without agar.
Sc-glc/gal medium:- 0.67% w/v yeast nitrogen base without amino acids
(Difco), 0.3% w/v glucose, 1% w/v galactose with L-tryptophan added as
for Sc-glc above.
SSC:- 0.15M NaCl, 0.015M Na Citrate, pH7.0.
STC:- 1M sorbitol, 10 mM Tris/HCl pH7.5, lOmM CaCl2.
TAE:- 40mM Tris/OAc pH7.8, ImM EDTA.
TBE:- 89mM Tris/HCl pH8.0, 8.9mM boric acid, 2mM EDTA.
TC buffer:- lOOmM Tris/HCl pH7.4, lOmM CaCl2.
TCM buffer:- lOmM Tris/HCl pH7.5, lOmM MgCl2, 10mMCaCl2.
TE 10:1:- lOmM Tris/HCl pH8.0, ImM EDTA.
TEN buffer:- lOmM Tris/HCl pH7.4, 2mM EDTA, 140 mM NaCl.
TE RNAse A:- lOmM Tris/HCl pH7.5, ImM EDTA , 50yg/ml RNAse A.
TNE 20:20:1:- 20mM Tris/HCl pH7.5, 20mM NaCl, ImM EDTA.
TNE 10:100:1:- lOmM Tris/HCl pH8.0, lOOmM NaCl, ImM EDTA.
2xYT broth:- lOg NaCl, lOg yeast extract and 16g bactotryptone/1.
6.2. Manipulation and analysis of nucleic acids; culture of bacteria:-
6.2.1. Purification of nucleic acids by phenol/chloroform extraction
and ethanol precipitation:-
Nucleic acids (NA) in complex solutions were purified by phenol/
chloroform extraction and ethanol precipitation. Phenol/chloroform
extraction involved successive additions to an aqueous, NA-containing
solution of an equal volume of:- phenol; a phenol/ chloroform/ iso-
amyl alcohol mix (25:24:1 v/v/v); and finally, a chloroform/ iso-amyl
alcohol mix (24:1 v/v). (Here, phenol means phenol with 0.1% hydroxy-
quinoline and equilibrated with an appropriate buffer:- 0.3M NaOAc
pH5.2 for purification of RNA or 0.1M Tris/HCl pH8.0 for DNA.) After
each addition, samples were vortexed to form an emulsion before
separation of the aqueous and organic phases by briefly microfuging.
The aqueous phase was then removed and transferred to a fresh tube
ready for the next addition. When purifying DNA, NaOAc was added to
the aqueous phase (to 0.3M) after the final separation. NA's were then
precipitated by adding 2.5 volumes of absolute ethanol and storing the
tubes in dry ice for a minimum of 30min. Precipitates were collected
by microfuging for 15min at 4°C then washed in 70% v/v ethanol and
recentrifuged as above. SN's were discarded and the final pellet
desiccated before resuspension in water or an appropriate buffer.
6.2.2. Collection and purification of RNA from cell cultures:-
Total RNA was prepared by the method of Sargan et al. (1986). Cell
culture SN's were decanted and clarified by centrifuging for lOmin at
2500 rpm and 4°C, whilst the adherent cells were dissolved in 5ml/
flask of GTC buffer (6.1.3). The cell pellet formed from any non¬
adherent cells was dissolved in the GTC buffer used to dissolve cells
from the corresponding flask. Thus, RNA was always collected from the
total starting cell population.
These 'GTC' solutions were then diluted with GTC buffer (to an
appropriate volume for the polyallomer ultracentrifuge tubes
subsequently used) and layered over 1.6ml of a solution containing
5.7M CsCl (previously baked at 180°C for 2h), 25mM NaOAc pH5.2, 2mM
EDTA before being centrifuged for 16h at 76,000 x g and 20°C.
Resulting pellets were resuspended in 300pl of ice-cold RNA re-
suspension buffer (6.1.3). The RNA in these solutions was then further
purified (6.2.1) with particular attention being paid to keeping them
ice-cold throughout. RNA pellets were finally resuspended in 30pl of
water.
The concentrations of RNA obtained were estimated by measuring the
OD260 of aliquots diluted 1:500 with water and applying the
equation:- cone" of RNA = OD x 500 x 40 pg/ml. OD's280 were also
measured. Any solutions with a ratio of OD260 : OD280 of <1.8 were
considered insufficiently pure and submitted to a further round of
purification (6.2.1), resuspension and OD measurement.
6.2.3. Oligonucleotide primers:-
All oligodeoxyribonucleotide primers, with the exception of poly-dT
primer (Amersham) and reverse sequencing primer (Pharmacia), were
synthesised by the Oswel DNA service, University of Edinburgh.
6.2.4. Synthesis of cDNA:-
Ss and ds cDNA's were synthesised by the method of Gubler and
Hoffman (1983), from total RNA (6.2.2), using a commercial kit (cDNA
Synthesis System Plus, Amersham). Oligo dT-primed 1st strand cDNA
synthesis was generally performed by incubating 12pg of RNA with 48U
of reverse transcriptase and 500pM each dNTP for 1.5h at 42°C, in a
total volume of 70pl with other reagents as recommended by the
manufacturer. To monitor the efficiency of 1st strand synthesis, lOpCi
of 35S dCTP (>600Ci/mmol, lOpCi/pl) were incubated with a separate
20pl aliquot of the above mix. In the synthesis of ss cDNA, the above
reactions were stopped by adding EDTA to lOmM.
To synthesise ds cDNA, 1st strand reactions were diluted 5-fold, as
recommended, with the addition of 0.8U of E.coli ribonuclease H and
23U of E.coli DNA polymerase I / lOOpl of diluted mix. To monitor the
efficiency of 2nd strand synthesis, lOpCi 35S dCTP (as above) were
added to a separate 20% aliquot of previously unlabelled 1st strand
reaction, before successive incubations of the tubes at 12°C for
60min, then 22°C for 60min and lastly 70°C for lOmin. After cooling,
1U of T4 DNA polymerase was added to each 50pl of reaction mix and
incubation was continued at 37°C for a further lOmin. Reactions were
finally stopped by the addition of EDTA to lOmM.
To analyse the efficiency of synthesis of either strand, paired
aliquots of a labelled reaction mix, after completion of the
appropriate incubation, were spotted onto each of 2 Whatman glass
microfibre filter discs. 1 disc from a pair was then flushed through
thoroughly with 5% TCA (w/v) before both were dried and counted in a
proprietary scintillant (Optisafe, LKB) using a 'rack' ^-scintillation
counter. The mass of cDNA synthesised was estimated from the
percentage of dCTP incorporated into acid-precipitable DNA as
determined above, assuming equal usage of the four nucleotides.
cDNA from stopped reactions was then purified (6.2.1). The sizes of
cDNA synthesised were analysed by agarose gel electrophoresis (6.2.7)
of an aliquot of purified DNA from a labelled reaction followed by
autoradiography of the gel (6.2.14).
6.2.5. Circularisation of cDNA:-
Ds cDNA was circularised by the method of Ochman et al. (1988).
cDNA was diluted to O.lpg/ml in circularisation buffer (6.1.3). T4 DNA
ligase was added to 1 Weiss unit /60pl and reaction mixes incubated
for 16h at 12°C. After stopping reactions by a lOmin incubation at
70°C, the DNA was repurified (6.2.1).
6.2.6. Polymerase chain reactions
PCR's were performed on an automated thermocycler, in reaction mix
volumes of lOOpl, overlaid with paraffin oil. Buffer conditions were
those used by Ohara et al. (1989) (6.1.3). 170pg/ml BSA, 1U Taq
polymerase and lOOpM of each dNTP were also included in every
reaction. Unless otherwise stated, indicated primers were used at
O.lpM on the DNA templates described.
Typically, PCR's involved 35 cycles of denaturation at 95°C for
0.5min, 0.5min at an indicated, lower, annealing T°, and 1.5min at an
extension T° of 70°C with a final 7min extension at 70°C. DNA produced
by a PCR was examined by analysing (6.2.7,9) 10% of the mix.
6.2.7. Agarose gel electrophoresis of DNA:-
DNA samples were analysed by electrophoresis through 1-2% (w/v)
agarose gels containing lxTAE (6.1.3) and 0.5pg/ml EtBr, followed by
UV transillumination (6.2.9). Samples were mixed with 0.25 volumes of
DNA loading buffer (6.1.3) before loading in individual wells cast in
horizontal slab gels. Running buffer was lxTAE and an electrophoretic
gradient of 5 V/cm was generally used. Some gels used low gel T° (LGT)
agarose and in these cases electrophoresis was performed at reduced
voltage (3 V/cm) at 4°C. Samples undergoing 'preparative' electro¬
phoresis were also submitted to the same reduced voltage. Electro¬
phoresis was allowed to proceed until the leading dye front had
migrated a suitable distance (3-10cm).
6.2.8. Agarose gel electrophoresis of RNA :-
RNA samples were analysed by electrophoresis on 25cm-long,
horizontal, slab, 1.2% (w/v) agarose gels containing 7.2% formaldehyde
and 20mM NaPCU pH7.0 (6.1.3), using a circulating running buffer of
20mM NaP04 pH7.0, followed by UV transillumination (6.2.9). Before
electrophoresis, 1 volume of RNA sample was incubated at 52°C for
15min with 3 volumes of RNA denaturing buffer (6.1.3), then mixed with
1 volume of RNA loading buffer (6.1.3) before samples were submitted
to electrophoresis at 2 V/cm for 16h.
6.2.9. Visualisation of nucleic acids in gels. Estimating size and
mass:-
NA bands in agarose gels were identified by their fluorescence on
transillumination at 302nm. Estimates of molecular size and mass of
DNA bands were made by comparing their mobility, and intensity of
fluorescence, with those of known standards (lpg EcoRI, Hindlll-cut
lambda phage DNA [NBL]) run in parallel. All transilluminated gels
were photographed alongside rulers in order to identify band positions
on blots and autoradiographs.
6.2.10. Transfer of nucleic acids from gels to nitrocellulose
membranes:-
NA's contained within agarose gels were transferred to, and
immobilised on, nitrocellulose membranes (Hybond-C) using techniques
based on the methods of Southern (1975) for DNA ('Southern blots') and
Thomas (1980) for RNA ('Northern blots').
After electrophoresis and visualisation of NA's, agarose gels were
suitably trimmed. Before transfer of NA's to membranes, DNA-
containing gels were bathed in DNA denaturing solution (6.1.3) for
15min then soaked in 3 changes of neutralising solution (6.1.3) over
Ih, whilst RNA gels were simply soaked in lOxSSC (6.1.3) for lOmin to
wash out formalin.
Treated gels were laid on a wick of Whatmann 3mm filter paper
(connected to a reservoir of lOxSSC) and overlaid with a nitro¬
cellulose membrane, prewetted in lOxSSC. Transfer of NA's to the
membrane was effected by a continual upward migration of buffer for
16h, induced by overlaying the membrane with 2 sheets of 3mm paper and
a weighted wad of paper towels. After then air-drying the membranes,
NA's were cross-linked to them by baking for 2h at 80°C under vacuum.
6.2.11. Radio-labelling of DNA:-
The technique of random prime labelling (Feinberg & Vogelstein,
1983, 1984) was used to label DNA to a high specific activity for use
as probes. 50ng of appropriate DNA was added to 6pl of OLB (6.1.3) and
diluted with water to a total volume of 25pl, then boiled for 3min and
allowed to cool. After adding 45pCi of 32P dCTP (>400Ci/mmol,
lOpCi/pl) and 2U Klenow fragment of DNA polymerase, reaction mixes
were incubated for 3h at 37°C. Reactions were stopped by adding 170pl
of 1M Tris/HCl pH7.4, lOmM EDTA. The percentage of radioactivity
incorporated into acid precipitable DNA was measured using paired
aliquots of stopped reaction mixes and glass microfibre filter discs
in an identical manner to the assessment of the efficiency of cDNA
synthesis (6.2.4). This allowed calculation of the degree to which the
probe had been labelled. All probes used were labelled to > 4 x 107
counts/minute/pg.
Labelled DNA was stored at -20°C until use, which was always within
two weeks of its preparation.
6.2.12. A cDNA Probe for Human TNFa
A cloned fragment of the cDNA for human TNFa, corresponding to
positions 402-854 (numbering according to Pennica et al.. 1984) was a
gift from Dr.K. Murray.
6.2.13. Hybridisation of labelled probes to immobilised nucleic
acids:-
After transfer and cross-linking of NA's from gels to nitro¬
cellulose (6.2.10) or from bacterial colonies to nylon (6.2.19),
membranes were prewetted in 5xSSC (6.1.3) before being incubated, with
shaking, in a DNA or RNA pre-hybridisation mix (6.1.3) as appropriate
(typically 40ml/membrane). Incubations were performed at 52°C for
hybridisation of DNA probes to RNA, or at 65°C for DNA-DNA
hybridisations.
After 4-20h, prehybridisation mixes were removed and replaced with
similar fresh mixes (typically lOml/membrane) to which a freshly-
boiled (for 2min) and quickly-cooled DNA probe had been added (at
2xl06 incorporated counts/membrane). Incubations were continued for a
further 4-16h.
Membranes were then washed. 3 successive initial washes in 2xSSC,
0.1% SDS (w/v), each for 15min, were followed by 2 further 15min
washes, also containing 0.1%SDS (w/v) with other conditions defined by
'final stringency' parameters in the appropriate results section.
After the final wash, blots were air dried before being submitted to
autoradiography (6.2.14).
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6.2.14. Autoradiography of blots and sequencing gels:-
Hvbridised membranes (6.2.13) were autoradiographed by exposure to
X ray film (XAR or Xomat S, Kodak) at -70°C within light-proof
cassettes fitted with intensifying screens. Dried sequencing gels
(6.2.23) or cling film-wrapped agarose gels were similarly
radiographed, though here no intensifying screens and room
temperatures were used.
Initial exposure times varied from lh to 1 week. For sequencing
gels, initial exposures were generally made overnight. Lengths of
subsequent exposures, where required, were based on the appearance of
the initial radiograph.
6.2.15. Preparation of PGR product for:- ligation; labelling as a
probe; or direct sequencing:-
After verifying the synthesis by a PCR of an appropriate product
([6.2.7,9] +/- [6.2.10,13,14]), DNA contained within the remainder of
a PCR mix was purified (6.2.1).
PCR product destined for 'blunt-ended' ligation was diluted to ClnM
in kinase buffer (6.1.3). After incubation with 600U/ml of T4 poly¬
nucleotide kinase for 30min at 37°C to phosphorylate the 5' ends of
the DNA molecules, 0.2 volumes of the above buffer with 0.6mM of each
dNTP were added. This was followed by a further 30min incubation at
room T" with 2.5 U of Klenow fragment of DNA polymerase/60pl to 'end-
fill' DNA termini. Reactions were stopped by the addition of EDTA to
20mM and the DNA was repurified (6.2.1).
PCR product destined for 'cohesive-ended' ligation was resuspended
in 20pl of BamHI buffer (6.1.3) with 20U BamHI and incubated at 37°C
for 6h. Reactions were stopped by a lOmin incubation at 70°C, before
the DNA was repurified (6.2.1).
For PCR product destined for use as a probe, or in direct
sequencing, no such preliminary procedures were required.
Specific DNA bands of interest were then separated from
contaminating bands and identified by preparative agarose gel electro¬
phoresis (6.2.7,9) and slices of gel containing appropriate bands of
DNA were excised.
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During the course of this work, 3 different techniques were applied
to make use of DNA within gel slices. For some separations LGT agarose
had been used and subsequent procedures took place in its presence. In
other cases purification was achieved using a commercial kit (Gene
clean II, Bio 101), to the manufacturer's instructions. In later
experiments, use was made of an electro-elution apparatus (Uni¬
directional electroelutor analytical, International Biotechnologies
inc.). Elution of DNA from a gel slice into 80pl of a trapped high-
salt elution buffer (6.1.3) was effected by electrophoresis at 100V
for 30min in a low-salt running buffer (6.1.3). DNA recovered by
electroelution was repurified by protocol 6.2.1 with a slight
modification. Due to the presence of a high concentration of salt, no
NaOAc needed to be added and DNA was precipitated with 2 volumes of
isopropanol instead of ethanol. The final DNA precipitate was
resuspended in lOpl or less of water. Yield and purity of DNA
recovered by 'gene-cleaning' or electroelution was checked by analysis
(6.2.7,9) of an aliquot of the final preparation.
6.2.16. Preparation of plasmids for ligation:-
Phagemids pTZ18R and pTZ19R (Mead et al.. 1986) were originally
obtained by the department from Pharmacia and the plasmid pOGS40
(Kingsman et al., 1990) from Dr.S.Adams, British Biotechnology Ltd.
Smal-digested, calf intestinal phosphatase (ClP)-treated, gel-
purified and gene-cleaned pTZ19R (at 50ng/pl in water), used for blunt
ended ligations with PGR products, and EcoRI-, Hindlll-digested, CIP-
treated, gel-purified pTZ18R (at 50ng/pl in LGT agar), used to accept
inserts excised from pTZ19R, were obtained from departmental stocks.
3pg of pTZ18R or pOGS40 were linearised by incubation with 30U of
BamHI in total volumes of 30pl of BamHI buffer (6.1.3) for 6h at 37°C.
The termini of these digested plasmids were dephosphorylated by
including 20U of CIP for the final 30min of incubation and a further
20U for the final 5min. Reactions were then stopped by a lOmin
incubation at 70°C. Plasmid DNA was then purified (6.2.1), after
checking for complete digestion of circular forms by analysis
(6.2.7,9) of an aliquot.
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6.2.17. Ligation of DNA into plasmids:-
2 different methods were employed for inserting DNA into plasmids.
The choice of method was dependent on whether the DNA fragment
contained 'blunt' or 'protruding' termini.
Blunt-end ligations were performed in LB (6.1.3), in total reaction
volumes of 20pl containing 2 Weiss U of T4 DNA ligase. 50ng of Smal-
digested, CIP-treated pTZ19R (6.2.16) were included per reaction as
well as PCR product (see below) suitably prepared for insertion
(6.2.15). These reaction mixes were incubated at 15°C for 16h.
Ligations between the cohesive ends of digested PCR product
(6.2.15), or purified DNA fragments excised from plasmids (6.2.21),
and appropriately digested plasmids (6.2.16) took place in total
volumes of 20pl of ligase buffer (6.1.3) with 2 Weiss U of T4 DNA
ligase. As well as DNA for insertion (see below) each reaction mix
contained 50ng of BamHI-digested, CIP-treated pTZ18R, 50ng' of EcoRI-,
HindiII-digested, CIP-treated pTZ18R, or 200ng of BamHI-digested, CIP-
treated pOGS40. These mixes were incubated at 25°C for 16h.
For most DNA fragments to be inserted several reaction mixes,
containing a range of concentrations of that fragment, were incubated.
Control mixes, with either no ligase or no DNA for insertion, were
also included in each set of ligation reactions. Ligations involving
DNA contained in LGT agarose were set up at 37°C, with a maximum LGT
agarose concentration of 0.3% (having first melted the agarose by a
brief spell at 60°C), before cooling to the incubation T°. Estimates
of the DNA concentration in LGT agarose were based on analysis of the
DNA (6.2.9) and the weight of the gel slice.
After incubation, all ligation reactions were stopped by a lOmin
incubation at 70°C before the DNA was repurified (6.2.1).
6.2.18. Transformation and growth of E.coli:-
Transformation-competent E,coli, strains JM83 or JM101 (Messing,
1979), prepared according to the 'CaCl2' method of Maniatis et al.
(1982), were obtained from departmental stocks, which were stored at
-70°C in 200pl aliquots, at an estimated concentration of 5x10s
bacteria/ml. Strain JM83 was used for transformation by pOGS40-derived
plasmids. All other transformations involved strain JM101.
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Purified DNA from a ligation reaction (6.2.17) was resuspended in
200pl of TCM buffer (6.1.3), added to a thawed aliquot of E,coli and
left on ice for 45min. After a 42°C "heat shock' for 1.5min followed
by cooling on ice, 1ml of L-broth was added and suspensions were
incubated for lh at 37°C. The bacteria were then pelleted by a brief
microfugation, before being resuspended in 200pl of L-broth. 20, 50 or
130 pi portions of this suspension were then spread over 3 previously
prepared agar plates.
Each plate contained L-broth, with ampicillin at 150pg/ml, set in
1.5% w/v bacterial agar. For growth of bacteria transformed by pTZ-
derived plasmids these plates also contained a thinner, 'top (0.8%)
agar' layer which included X-gal at 400pg/ml and IPTG at 170pg/ml.
Control plates, included with each set of transformations, were
coated with a 50pl portion of an E.coli aliquot, transformed with lng
of undigested plasmid vector, or left untransformed.
After allowing the added fluid to be absorbed, plates were inverted
and incubated for 16h before being inspected for the growth of
ampicillin-resistant (i.e. transformed) bacteria.
6.2.19. Screening of transformed bacteria. Glycerol stocks:-
After growth of transformed E.coli (6.2.18), bacteria transformed
by 'phagemids pTZ18R or pTZ19R containing inserted DNA were identified
by their colony colour (white/pale blue = recombinant; dark blue =
non-recombinant). No such colour selection exists to distinguish
recombinant and non-recombinant pOGS40 plasmids.
Colonies with recombinant, pTZ-derived plasmids and all colonies of
bacteria transformed by pOGS40-derived plasmids were screened for the
presence of a desired insert by hybridisation (6.2.13,14) of an
appropriate probe to bacterial NA's immobilised by the following
method. Selected colonies, as well as a negative- (non-recombinant
plasmid containing) and, where possible, a positive- control colony
were individually transferred to identifiable positions on each of two
duplicate bacterial agar plates (6.2.18). These plates were incubated
for a further 20h. One plate from each pair was then stored at 4°C,
whilst colonies from the second were transferred to a nylon membrane
(Hybond-N), which was laid on the plate in a marked orientation for
30s. Membranes were then laid colony side up on Whatman 3MM filter
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paper soaked in 2xSSC (6.1.3), 5% w/v SDS for 2min, before being
incubated in a microwave oven at 650W for 2min. After hybridisation
(6.2.13) these membranes were washed to a final stringency of 0.2xSSC,
60°C, regardless of the probe used. Autoradiography (6.2.14) then
allowed identification of positively-hybridising colonies.
Corresponding colonies on the duplicate plate were used to inoculate
5ml aliquots of L-broth with ampicillin (150yg/ml), which were then
incubated for 16h.
Following transformations with pTZ-derived plasmids where <12
colonies containing recombinant plasmids were obtained, this screening
procedure was bypassed and all such colonies were used for these
inoculations.
A portion of each of these 5ml cultures was then used to make a
'mini' preparation of plasmid DNA as follows. 1.5ml of each culture
was centrifuged for 3min at 2,500 rpm (the remainder of the culture
was meanwhile stored at 4°C) and cell pellets were resuspended in 50yl
of TNE 10:100:1 (6.1.3). Suspensions were vortexed with 50pl of phenol
pH8.0/chloroform/isoamyl alcohol (25:24:1 v/v/v), then microfuged for
5min to separate aqueous and organic phases. After recovery, the
aqueous phases were incubated at 70°C for lOmin to inactivate any
endogenous nucleases, before plasmid DNA was further purified by a
modification of procedure 6.2.1. (NH4OAC being added, instead of
NaOAc, to 2M, immediately prior to ethanol precipitation). NA pellets
were then resuspended in 8yl of TE RNAse A (6.1.3). These preparations
of plasmid DNA were analysed (6.2.7,9) either directly after a 0.5h
incubation at room T° to digest contaminating RNA and/or after being
digested with appropriate restriction endonucleases (6.2.21).
The remains of selected 5ml cultures were then used to inoculate
further cultures (6.2.20,22) and to make glycerol stocks in case of
future requirement. These were prepared by adding glycerol to 20%
(v/v) and stored at -70°C.
6.2.20. Large-scale preparations of plasmid DNA:-
These were used for ds sequencing of plasmids, transforming yeast
and producing larger amounts of insert DNA for use, following excision
(6.2.21), as probes.
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lml of an appropriate culture (6.2.19) was used to inoculate 500ml
of L-broth, with ampicillin (150pg/ml). After 16h incubation, bacteria
were collected by centrifugation (2,500 x g, lOmin) and resuspended in
10ml of GTE (6.1.3) with 5mg/ml lysozyme in a 50ml tube. After 5min,
20ml of 0.2M NaOH with 1% w/v SDS were added and the tube left on ice
for lOmin. Next, 15ml of 5M KOAc pH4.8 (6.1.3) were mixed in before a
further lOmin incubation on ice. This suspension was then centrifuged
for 20min at 2,500 rpm, 4°C, after which the SN was collected and
mixed with 0.6 volumes of isopropanol. The precipitate formed after
15min at room T° was collected by centrifugation for 30min at 2,500
rpm, washed in 10ml of 70% ethanol, repelleted by a lOmin spin at
2,500 rpm and desiccated. Next, it was dissolved in 30ml of TE 10:1
(6.1.3), to which 30g baked (6.2.2) CsCl and 2.4ml of EtBr (at
lOmg/ml) were then added. This solution was centrifuged in a sealed
tube in a Beckman L8-60M ultracentrifuge at 40,000 rpm, for 18h in a
vertical rotor (VTi 50). The plasmid band, separated in the density
gradient so formed, was visualised by transillumination at 302nm and
withdrawn by side puncture of the tube. This sample was shaken with
several changes of an equal volume of isoamyl alcohol, with the 2
phases being separated by 5min of centrifugation at 1,500 rpm on each
occasion. The aqueous phase was retrieved and dialysed against TNE
10:100:1 (6.1.3), before the DNA was precipitated by adding 2 volumes
of ethanol and leaving for 30min on dry ice, then collected by
centrifugation at 2,500 rpm for 30min. It was washed in 70% v/v
ethanol, repelleted by a lOmin spin at 2,500 rpm and dried. This
plasmid DNA was finally resuspended in 40pl of water and an aliquot
analysed (6.2.7,9) for purity and yield.
6.2.21. Excising inserts from plasmids:-
Inserts were excised, both from small- (6.2.19) and large- (6.2.20)
scale preparations of plasmid, for analysis, transfer to another
plasmid or separation of DNA suitable for labelling and use as a
probe. Similar protocols were followed in each case.
Recombinant plasmids derived by ligating DNA to BamHI-digested
plasmids were digested with BamHI. All other recombinant plasmids were
sequentially digested by Hindi 11 then ECoRI.
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BamHI digestion of plasmid preparations (whether purified pellets,
or dissolved in TE RNAse A) was performed by diluting DNA to <3pg/pl,
in reaction mixes, which finally contained lpl of lOx BamHI buffer
(6.1.3) and 10U BamHI /10pl, then incubating for 16h at 37°C.
Sequential digestions were commenced by making similar dilutions,
but with the final inclusion of lpl of lOx low-salt digestion buffer
(6.1.3) and 10U of HindiII/ lOpl (instead of BamHI enzyme and buffer),
followed by a 2h incubation at 37°C. Samples were then diluted 2-fold
by adding a solution containing lpl of lOx high-salt digestion buffer
(6.1.3) and 10U ECoRI/ lOpl and incubated for a further lh. All
digestions were stopped by a lOmin exposure to 70°C.
Samples were then analysed (6.2.7,9) to identify excised inserts,
which were recovered, when required, by previously described methods
(6.2.15).
6,2.22, Preparing single-stranded DNA in E.coli strain JM101:-
500pl of a culture of a selected transformant (6.2.19) were used to
inoculate 10ml of 2xYT broth (6.1.3) and the bacteria grown to an
OD600 of 0.6. (approximately 2h incubation). 400pl were then
transferred to a 50ml tube with 30pl M13K07 phage (Pharmacia) at
7xl010/ml in 2xYT (departmental stocks) and incubated for lh. 10ml of
2xYT and 29pl kanamycin at 25mg/ml were then added before continuing
incubation.
After 16h, this culture was centrifuged at 2,000 rpm for lOmin.
2.5ml of 20% w/v PEG 6000 in 3M NaCl were added to the clarified SN,
which was then left on ice for 30min. The resulting precipitate was
collected by centrifugation at 40,000 rpm in a Beckman L8-60M
ultracentrifuge, Ti 70.1 rotor, for 40min at 4°C and dissolved in
400pl of TNE 20:20:1 (6.1.3). This DNA was then purified (6.2.1 -
modified by an additional phenol /chloroform /isoamyl alcohol
extraction immediately after the first), resuspended in 20pl of water
and heated to 70°C for lOmin before a 5% aliquot was analysed
(6.2.7,9) to check the yield.
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6.2.23. Sequencing:-
All sequencing was performed with the aid of a commercial kit
(Sequenase version 2.0, USB) based on the chain termination method of
Sanger et al. (1977). Sequencing reactions for ssDNA preparations were
performed exactly to the manufacturer's protocol, using lpg of ssDNA
(6.2.21) annealed to an equimolar concentration of an indicated primer
with polymerisation by T7 DNA polymerase, chain termination by one of
a set of 4 dideoxynucleotides and the inclusion of 0.5pl [a-35S]dATP
(lOmCi/ml, 400Ci/mmol) for labelling.
Alterations to the recommended protocol were made for ds
sequencing. For the direct sequencing of PGR product, only 300ng of
DNA template (6.2.15) were used/ reaction, whilst for the ds
sequencing of inserts in pOGS40, 3pg of plasmid DNA (6.2.20) were
used. These templates were boiled for 2min with equimolar
concentrations of primer in the manufacturer's buffer with DMSO added
to 30% v/v, then snap-cooled on ice for the annealing step. Additions
for the labelling reactions were as recommended but the latter were
performed by a 5min incubation on ice. Termination reactions were at
50°C for 2min.
All sequencing reactions were repeated with the substitution of
dITP for dGTP in the labelling step to clarify sequence in GC-rich
regions (Mizusawa et al., 1986).
All sequencing reactions were analysed by electrophoresis through
45cm-long x lmm-thick, vertical, slab gels containing 6% w/v
(degassed) acrylamide, 0.3% w/v bis-acrylamide, 7.67M urea and 0.5xTBE
(6.1.3), set by the addition of APS to 0.025% and TEMED to 0.1% (w/v).
3.5pl aliquots of each of the 4 terminated reactions from a set were
heated to 70°C for 2min before being submitted to electrophoresis, at
2500V and 50°C in a running buffer of 0.5xTBE, for periods of 1.5, 4
and 7 h. Afterwards, gels were dried at 80°C for 2h under vacuum
before being autoradiographed (6.2.14) then 'read.' When bands
appeared in more than one lane at a given position on the radiograph
(as happened on occasion, particularly when directly sequencing PGR
product) the densest band was interpreted as the 'true' result.
6.3.Yeast cell culture: manipulation arid analysis of protein samples:-
6.3.1, Transformation of yeast:-
The host strain of yeast (sp. Saccharomyces cerevisiae) used in
this work, BJ 2168 (Jones, 1991), was transformed with plasmid DNA by
the method of Hinnen et al. (1978).
A freshly-grown (from departmental stock), 1.51 culture of
untransformed yeast, at 1.5 x 107 cells /ml, was centrifuged at 3,500
x g for 15min. Harvested cells were washed in 20ml of 1M sorbitol,
recentrifuged as above, then suspended in 10ml of 1M sorbitol. After
adding 200pl of glusulase (DuPont [>10,000U sulphatase, >90,000U
glucuronidase/ml]) the cells were incubated, with continual rotation,
at 30°C for 2h. Having verified that this procedure had produced a
suitably high percentage (>90%) of spheroplasts competent for
transformation (see below), the cells were washed twice with 10ml of
1M sorbitol and once with 10ml of STC solution (6.1.3) with
intervening centrifugation steps as above. Verification of the
formation of spheroplasts was by light microscopy of an aliquot of
cell suspension diluted in 10 volumes of water (lysed cells =
spheroplasts). The cells were finally resuspended in 1ml of STC.
Various amounts of DNA (5 or lOpg pOGS40-derived plasmid [6.2.20]
and 5 or lOpg pUG41S plasmid [originally supplied by BBL], +/- 20pg of
carrier:- boiled, salmon sperm DNA), in total volumes <15pl, were
mixed with lOOpl aliquots of the spheroplast suspension and left for
15min. Then, 1ml of sterile 44% w/v PEG 4000 was added to each of the
aliquots, which were left for a further lOmin. A 45s microfugation was
then used to pellet the cells, which were gently resuspended in 1ml of
1M sorbitol. A quarter of this suspension was added, along with 40pl
of a filtered, 1% w/v solution of L-tryptophan, to each of 4 tubes
containing 20ml of warm (but <48°C), molten, regeneration agar
(6.1.3). 40pl of 1% w/v solutions of uracil and leucine were also
added to one tube of agar, which was mixed with an aliquot of
untransformed cells and used as a positive control for yeast
regeneration. Each spheroplast/agar mix was poured into a petri dish
and allowed to set. These plates were then inverted and incubated for
several days, with a daily inspection for colony growth.
Once identified, a few transformed colonies, selected on the basis
of faster growth, were sub-cloned by streaking onto Sc-glc agar plates
(6.1.3) and incubating for a further 3d.
6.3.2. Small-scale culture of transformed yeast. Preparation and
storage of glycerol stocks:-
One fast-growing sub-clone derived from each of four original
transformants (6.3.1) was selected for further culture. Each sub-clone
was used to inoculate 5ml of Sc-glc medium (6.1.3). This was incubated
for 24h, before a 1ml aliquot was used to initiate a culture in 100ml
of Sc-glc which was incubated for Id. An aliquot was then checked by
light microscopy for healthy yeast (presence of multiple budding
forms) and freedom from bacterial contamination. A further 12ml of
culture were also removed at this point and mixed with an equal volume
of 40% v/v glycerol. 2ml aliquots of this mix were then stored at -70°
C forming parent stocks used for subsequent initiation of larger scale
cultures. The remainder of the culture was pelleted by centrifugation
at 3,500 x g for lOmin and resuspended in 100ml of Sc-glc/gal medium
(6.1.3). The yeast were then incubated for a further 24h.
6.3.3. Verifying the presence of fusion protein in initial yeast
cultures:-
After growth in Sc-glc/gal (6.3.2), yeast cells were pelleted by
centrifugation at 3,500 x g for 5min and resuspended in 1ml of TEN
buffer (6.1.3). They were then broken by vortexing with an equal
volume of acid-washed (0.2M HC1 for 16h), water-rinsed, glass beads
for 3 x lmin spells with lmin on ice between. Aliquots of each crude
extract were electrophoresed through SDS-polyacrylamide gels (6.3.12),
alongside similar extracts (taken from departmental stocks) of other
yeasts. Gels were then stained with Coomassie blue (6.3.13) or
analysed by Western blotting (6.3.14).
6.3.4. Large-scale yeast culture:-
A glycerol stock (6.3.2) of yeast was thawed and used to inoculate
100ml of Sc-glc medium (6.1.3), then incubated for 48h. Next, this
culture was equally divided between 4 flasks, each of which contained
a further 100ml of Sc-glc medium, before another 24h of incubation.
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Each of these cultures was then added to 11 of Sc-glc/gal (6.1.3) and
incubated for a final 24h. Aliquots of cultures were removed and
assessed for cell density (by measuring ODeoo), cell viability and
freedom from bacterial contamination (by light microscopy) after each
incubation step. On occasion, a 10ml aliquot was also removed at the
end for analysis by electron microscopy (6.3.6), before cells were
harvested by centrifugation at 3,500 x g for 15min and subjected to 3
washes, each in 40ml of water, with repelleting by 5min
centrifugations at 3,500 x g in between. Finally, cells were
resuspended in TEN (6.1.3), repelleted as above and, after removing
the SN, frozen at -20°C until required.
6.3.5. Purification of hybrid TNF-Ty, virus-like particles:'-
Hybrid VLP's were purified by a modification of the method of Adams
et al. (1987b). Frozen cells (6.3.4) were thawed and resuspended in
20ml of TEN (6.1.3). All subsequent procedures in the purification of
VLP's were then performed at 4°C. Cells were broken by vortexing with
20ml of acid-washed glass beads (6.3.3) for 10 x lmin spells, with
lmin on ice between. The suspension was then clarified by
centrifugation at 2000 x g for 5min and the VLP-containing SN
retained. A further 8ml of TEN were added to the cell pellet. Rounds
of vortexing, centrifugation and resuspension were repeated as above
until the integrity of >85% of cells was destroyed, as assessed by
phase contrast microscopy of an aliquot.
SN's from each round were pooled and centrifuged at 13,000 x g for
20min. The clarified SN obtained was then centrifuged at 100,000 x g
for lh in tubes containing a 2ml cushion of 60% w/v sucrose in TEN at
the bottom. These cushions, together with cushion interfaces, were
then collected and dialysed against TEN. The dialysate was microfuged
for 20min before being divided and loaded on the top of four, 15-45%
sucrose gradients. These gradients had been prepared by layering 8ml
aliquots of solutions of 45, 35, 25 and 15 % w/v sucrose in TEN, in
Beckman SW28 tubes, 20h earlier. A bottom 2ml cushion of 60% w/v
sucrose in TEN was added immediately prior to use. These tubes were
then centrifuged at 53,000 x g for 3h, before the gradients were
separated into 2ml fractions. These fractions were analysed
(6.3.12,13) and those containing high concentrations of protein of
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appropriate size for a Pl-TNF fusion protein were pooled and dialysed
against TC buffer (6.1.3). Removal of precipitates formed during
dialysis was by microfuging for lOmin. Aliquots of this VLP
preparation were removed for analysis (6.3.6,10,12,13) whilst the
remainder was stored at 4°C prior to cleavage of the fusion protein
(6.3.7).
6.3.6. Electron microscopy of yeast cells and purified virus-like
particles:-
An aliquot of yeast cell culture (6.3.4) was prepared for electron
microscopy by the method of Byers and Goetsch, (1975). Cells were
pelleted by centrifugation at 2,500 rpm for 5min and suspended in 10ml
of 3% w/v glutaraldehyde (in 0.1M cacodylate pH6.8, 5mM CaCl2). After
a 30min incubation, with rotation, at room T°, cells were pelleted as
before, then resuspended in 10ml of glutaraldehyde as above, prior to
a further 16h incubation at 4°C.
Cells were then harvested as before and washed 3 times in 10ml of
pretreatment buffer (6.1.3) before resuspension in 5ml of 0.2M citrate
/P04 pH5.8. After adding 200pl of glusulase (6.3.1) the cells were
incubated for Ih at 30°C, with rotation, then repelleted. Finally, the
cells were washed twice in 10ml of 0.2M citrate/P04 pH5.8 and
resuspended in 5ml of the same.'Post-fixing,' mounting and sectioning
of the cells was performed by staff in the 'EM suite' by standard
methods.
Purified VLP's (6.3.5) were prepared for electron microscopy by
allowing a drop of VLP suspension to dry on an EM grid, which was then
washed by successively adding and removing 3 drops of water. VLP's
were negatively stained by adding 1 drop of 2% w/v uranyl OAc. Surplus
stain was removed with filter paper and the grid allowed to dry.
Stained VLP's and fixed, sectioned yeasts were examined by
transmission electron microscopy.
6.3.7. Cleavage of Pl-TNF fusion protein. Final purification and
storage of recombinant ovine TNFa:-
Cleavage of Pl-TNF fusion protein was achieved by the addition of
chaotropic agents and bovine factor Xa (BCL) to purified VLP's (6.3.5)
followed by an 18h incubation, with occasional agitation, at 25°C.
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After assessing (6.3.12,13) the cleavage obtained in aliquots of the
VLP suspension using different chaotropic agents and concentrations of
factor Xa, subsequent large-scale cleavage of VLP preparations was
performed by adding the detergents CHAPS and NaDOC, each to 0.05%
(w/v), and using bovine factor Xa at 2% (w/w) of the total protein
content of the suspension.
Having checked for 100% cleavage by analysing (6.3.12,13) an
aliquot, cleavage mixes were clarified by centrifugation at 100,000 x
g for lh and resulting SN's dialysed against PBS (6.1.3). This
dialysate, the final rovTNFa preparation, was aliquoted, either with
the addition of BSA to 0.1% (w/v), for subsequent use in bioassays, or
without, for use in analysis (6.3.10,12,13,14,15,16) and immunisations
and stored, until needed, at -70°C.
6.3.8. A control preparation of yeast extract with factor Xa:-
A preparation of yeast extract with added bovine factor Xa was made
for use as a control as follows:- a glycerol stock of yeast strain
BJ2168 transformed with pMA 5620 (which constitutively produces yeast
protein PI [Adams et_al., 1987a]), was used to initiate cultures grown
in identical conditions (except for the extra addition of 2ml/l of 1%
w/v uracil) as yeast transformed with recombinant-p0GS40 + pUG41S
(6.3.4). These yeast were harvested and submitted to further
procedures identical to those used for preparing, and storing, rovTNFa
(6.3.5,7). This included collecting gradient fractions from the same
positions as those taken to collect hybrid VLP's and using factor Xa
at the same final concentration (w/v) used to cleave Pl-TNF.
6.3.9 Recombinant human TNFa:-
E.coli-derived, rhTNFa was purchased from BBL in lyophilised form,
reconstituted (in PBS with 0.1% w/v BSA) to lpg/ml and stored in
aliquots at -70°C till needed.
6.3.10. Measurement of protein concentration:-
The concentration of protein in a sample was measured by the method
of Bradford (1976). A linear range of concentrations (from 5 to
30pg/ml) of BSA in PBS (6.1.3) and assorted dilutions (in PBS) of
sample were prepared. 0.4ml of diluted sample or BSA standard was
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mixed with 0.1ml of Bradford dye (Biorad). After 15min the OD595 of
each was measured. Protein concentrations of suitably diluted samples
were estimated by fitting their OD results to a standard curve
constructed from the results of known concentrations of BSA.
6.3.11. Acetone precipitation of protein:-
Dilute proteins were concentrated, for analysis (6.3.12,14,16), by
acetone precipitation. After the addition of 4 volumes of cold
acetone, samples were left at -20°C for at least lh. Precipitates were
then collected by centrifugation at 2,500 rpm for lOmin and
resuspended as described.
6.3.12. SDS-Polyacrylamide gel electrophoresis of protein samples:-
Proteins were separated according to size, by electrophoresis using
the method of Laemmli (1970). Samples were generally run through 1mm
thick, vertical slab gels using the Biorad mini protean II system
apparatus. The larger amounts of protein in acetone precipitates of
conditioned RPMI20 (6.4.2,3), however, were separated in 1.5mm-thick
gels using the Biorad protean II slab cell system.
Separating gels contained either a single percentage, or
concentration gradient (from 5-20% w/v), of polyacrylamide, as stated
(bis-acrylamide was included at 1 part to 37.5 parts acrylamide w/w).
Separating gels also included 250mM Tris HC1 pH 8.7, 1.3mM EDTA and
0.1% w/v SDS, with APS and TEMED being added (each to 0.05%) to set
the gel.
Separating gels were overlaid by 3-4mm of stacking gel, comprising
3.5% w/v acrylamide with bis-acrylamide as above, 145 mM Tris/HCl pH
6.8, 0.1% w/v SDS, set using APS and TEMED at 0.05% and 0.1% w/v
respectively.
Samples for analysis were mixed with an equal volume of protein
loading buffer (6.1.3) and boiled for 2min before being loaded into
wells set in the stacking gel. (Precipitates were resuspended in
suitably small volumes of 0.5 x loading buffer before boiling.) A set
of proteins of known molecular weight (Sigma) were used as size
markers.
Electrophoresis conditions were 100-200V for mini gels, or 50V for
larger gels in protein running buffer (6.1.3) until the dye front
reached the bottom of the gel.
6.3.13. Staining of SDS Polyacrylamide gels:-
Protein gels (6.3.12) were stained by Coomassie blue. This involved
immersion in 0.25% w/v Coomassie brilliant blue G, 20% v/v methanol,
5% v/v glacial acetic acid for 30min. Gel backgrounds were then
destained in several changes of 20% v/v methanol, 5% v/v glacial
acetic acid over 24h. After staining, gels were dried at 80°C under
vacuum.
6.3.14. Western blotting:-
As an alternative to staining (6,3,13), separated proteins were
also analysed by transfer to membranes and immunodetection (Western
blotting).
After electrophoresis (6.3.12), transfer was effected as follows:-
gels, laid in marked orientation on nitrocellulose membranes (Hybond-
C), were sandwiched between 6 sheets of 3mm paper (Whatman) (membranes
and paper had been prewetted in 25mM Tris/HCl pH9.5, 20% v/v methanol)
in a semi-dry electroblotting apparatus (Ancos, Denmark), through
which 120 mA were passed for lh.
After protein transfer, membrane portions corresponding to size
marker tracks were cut off and stained in 0.5% w/v amido black, 50%
v/v methanol, 5% v/v glacial acetic acid, for 30min, then destained in
several changes of 50% v/v methanol, 5% v/v glacial acetic acid over
2h. Such portions were later realigned with the rest of the membrane
to determine the size of detected proteins.
The rest of the membrane was incubated in PBS (6.1.3) with 5% w/v
milk powder for 1.5h at room T° to block remaining binding sites and
then incubated, for 16h at 4°C, with an indicated, primary antibody,
diluted, as described, in PBS with 1% w/v milk powder.
After washing for 30min in at least 5 changes of 1% w/v milk powder
in PBS, blots were next incubated for lh at room T° with a secondary
antibody, also diluted in 1% w/v milk powder in PBS. All secondary
antibodies were:- polyclonal; affinity-purified; commercially
prepared; and used at recommended dilutions. They comprised:- an
alkaline phosphatase-conjugated goat anti-[rabbit immunoglobulin G]
preparation, used, at a dilution of 1:8000, when the primary antibody
was derived from rabbits; and an alkaline phosphatase-conjugated
rabbit anti-[mouse immunoglobulin G] preparation, used, at 1:1000,
when the primary antibody was murine, unless the detection system used
was enhanced chemiluminescence (ECL- see below), when a horseradish
peroxidase-conjugated rabbit anti-[mouse immunoglobulin G] preparation
was used at 1:2000.
After incubation with secondary antibody, blots were again washed
in PBS/milk powder as above. Then, for alkaline phosphatase-based
detection, there were two further washes, over lOmin, in 0.1M Tris/HCl
pH9.5. These blots were developed in 10ml of 0.1M Tris/HCl pH9.5,
0.2mg/ml NBT, O.lmg/ml BCIP, 20mM MgCl2. Colour development was
stopped by rinsing in water.
Detection by ECL, which was used once only (see fig.4.7b, 6.3.16),
was performed using a commercial kit (Amersham). A washed blot was
covered, in the dark, with 2ml of a 50:50 mix of supplied reagents A &
B. After lmin, the fluid was drained off, the blots were wrapped in
cling film and then autoradiographed using hyperfilm ECL (Amersham) in
a cassette with intensifying screens and an exposure time of 4h.
6.3.15. Cross-linking of recombinant ovine TNFa:-
RovTNFa was cross-linked by the method used by Van Ostade et al.
(1991) on rhTNFa. 6pl of BSOCOES (Pierce) at 30mg/ml in DMSO (or, for
control, 6pl DMSO) were added to 40pl of sample in PBS (6.3.7) and
left for 30min before proteins were analysed (6.3.12,13,14).
6.3.16. Deglycosylation of ovine TNFa:-
Ovine TNFa was submitted to procedures recommended by Haselbeck &
Hosel (1988), to test for the presence of glycosylation. Proteins in
lml aliquots of SN from ovine lung cells stimulated with lpg/ml LPS
for 18h (6.4.3), or 20ng aliquots of rovTNFa (6.3.7), were
precipitated (6.3.11), resuspended in 20pl 1% w/v SDS, boiled for
2min, and diluted by the addition of 180pl of lOOmM NaP04, pH7.0
(6.1.3), 25mM EDTA, 1% w/v octyl glucoside. An aliquot of each type
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was then incubated with 0 or 2 U peptide-N-glycosidase F (BCL) for
18h at 37°C. Afterwards, 10% of each mix was analysed by Western
blotting (6.3.12,14).
6.4. Mammalian cell culture: bioassays; antibody production:-
6.4.1. Cell Counting:-
The concentration of viable cells in any suspension was estimated
by counting the number of unstained cells in 4 x 10"4mis on an
haemocytometer slide after applying an aliquot of recently-mixed
suspension, diluted 100 fold with 1% w/v trypan blue.
6.4.2. Ovine lung-cell cultures:-
Populations of ovine lung cells were derived by broncho-alveolar
lavage performed on lungs dissected from a freshly-slaughtered sheep.
21 of cold Hank's balanced saline solution (HBSS) were poured into a
pair of lungs via the trachea. Lavage fluid was retrieved by the same
route and spun at 1500 rpm, in an MSE coolspin 2, for 15min at 4°C.
Resulting cell pellets were washed in 50ml HBSS and centrifuged at
1500 rpm for a further 15min at 4°C before resuspension in 9ml HBSS.
Erythrocytes were lysed by the addition of 13.5ml of water to induce a
hypotonic shock. Normal osmolarity was returned by adding 1.5ml of
lOxPBS (6.1.3) 5s later. After adding 25ml of the medium to be used in
incubation (see below), the cells were repelleted by a 15min
centrifugation at 1500 rpm and 4°C. Finally, the cells were re-
suspended in incubation medium, counted (6,4.1) and diluted as
required, before plating out as described. Incubation media used
depended on the duration of the experiment. Short term incubations
(<3d) were conducted in Iscove's medium with penicillin and
streptomycin. For incubations lasting >3d, cells were cultured
throughout in RPMI20 (6.1.3) with penicillin, streptomycin and
fungizone. In experiments not involving immediate stimulation of the
cells, only cells which were adherent after 24h were selected, by
discarding SN's, washing with PBS and refeeding with fresh medium.
Cells cultured for >5d were totally refed with fresh medium twice
weekly or as described (6.5.4).
6.4.3. Lipopolysaccharide stimulation of lung cells;-
Preparations of ovine lung cells (6.4.2) were stimulated by the
addition of LPS derived from Salmonella abortus equi, at the final
concentrations, and times after plating out, described. Unless cells
were stimulated immediately after cell preparation, LPS addition also
involved complete replacement of the old incubation medium with an
equal volume of fresh medium. SN's were later harvested, clarified by
centrifugation for lOmin at 2,500 rpm and 4°C, then aliquoted and
stored at -70°C until analysed.
6.4.4. Sources and maintenance of established cell lines:-
L929 and L929L/R cells (Matthews & Watkins, 1978) in culture were
donated by Dr.G.Entrican. Frozen stocks of these cells were made as
follows:- cells were harvested by trypsinisation and centrifugation
(see below) and resuspended in freezing mix (6.1.3); aliquots were
then frozen slowly to -70°C and transferred to liquid nitrogen for
storage until required. WEHI 164: clone 13 (Espevik & Nissen-Meyer,
1986) and ST6 cells (derived from an ovine intestinal adenocarcinoma)
were obtained from aliquots of departmental stocks stored in liquid
nitrogen. When used to initiate a culture, a frozen aliquot of cells
was rapidly thawed, in a 37°C water bath, before being added to
culture medium and transferred to an appropriate flask.
Weybridge sheep choroid plexus cells (WSCP's, a fibroblastoid cell
line) were obtained, in culture, from departmental stocks. A line of
sheep cells derived by infecting peripheral blood mononuclear cells
with sporozoites of Theileria annulata (line 5, Entrican et al., 1991)
was obtained, in culture, from Dr G.Entrican.
WEHI 164: clone 13, ST6 and WSCP cells were cultured in DME medium
with 5% v/v FCS. L929 and L929L/R cells were cultured in Iscove's
medium with 5% v/v FCS, and line 5 cells in RPMI with 10% v/v FCS
(media these cells were supplied in). All media also included
penicillin and streptomycin.
Passage and maintenance of cells in culture was as follows:-
suspensions of line 5 cells, which are non-adherent, were divided
twice weekly, by a simple 4-fold dilution in fresh medium; cultures of
the remaining, adherent cell lines were divided, when cells approached
confluency, by trypsinisation (see below) and dilution; typically,
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L929 and L929L/R cell cultures were divided 7-fold, twice weekly, WEHI
164: clone 13 cultures 4-fold, twice weekly and ST6 and WSCP cultures
3-fold every 5-7 days; WSCP cells were cultured in 75cm2 flasks
containing 25ml of medium; all other cells were grown in 25cm2 flasks
with 8ml of medium. L929, L929L/R and WEHI 164: clone 13 cells were
passaged no more than 6 times before use in bioassays.
Trypsinisation of a cell monolayer involved rinsing the cells,
first in PBS (6.1.3) then in 0.02% w/v versene (in PBS), before they
were just covered in 0.05% w/v trypsin, 0.02% w/v versene (in PBS) and
incubated until the majority had detached. Digestion was then stopped
by adding an equal volume of culture medium. Detached cells were
harvested by centrifugation at 1500 rpm for lOmin. Cells were then
resuspended in freezing mix (when destined for freezing, see above) or
culture medium. Cells destined for immediate use in bioassays were
counted (6.4.1) before being plated out as described for each assay,
whilst those used for maintaining a culture were diluted and returned
to tissue flasks as above.
6.4.5. Cytotoxicity assays:-
Cytotoxicity assays were performed on L929, L929L/R, WEHI 164:
clone 13 and ST6 cells using methods based on those described by Flick
& Gifford (1984). Harvested cells (6.4.4) were diluted to 5 x 104
cells/ml in their respective media and plated out, at lOOpl/well, in
96-well, flat-bottomed plates. After 20h incubation, additions were
made as follows:- in assays involving L929 and L929L/R cells, 50pl of
medium with 4pg/ml of actinomycin D and 50pl of sample were added; in
all other assays lOOpl of sample only were added. A set of samples in
any assay included:- a range of concentrations of recombinant proteins
(6.3.7,8,9) in PBS with 0.1% BSA; or undiluted, conditioned media
(6.4.3) and rhTNFa (6.3.9) at various dilutions in unconditioned
medium (+/- LPS at the concentration used for lung-cell stimulation);
or, for neutralisation assays, rovTNFa (6.3.7), which had been diluted
to 2x sample concentration in PBS, 0.1% w/v BSA, then incubated for
1.5h with an equal volume of indicated antibodies similarly at 2 x
sample concentration. All samples were assayed in quadruplicate.
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After these additions, L929 and L929L/R cells were incubated for
18h, whilst all other cells were incubated for 3d. After incubation,
wells were examined by light microscopy, then the SN's were decanted
and remaining cells rinsed once in PBS before being fixed and stained
using 0.25% w/v crystal violet, 20% v/v methanol, at 40pl/well, for
2min. Afterwards, cells were gently, but thoroughly, rinsed in water
and dried. The absorbance of each well at 540nm was then measured
using an ELISA plate reader (Titertek). Figures for cytotoxicity are
derived as follows:-
%age cytotoxicity = mean abs. neg. control* - mean abs. sample x 100
mean abs. neg. control* - mean abs. pos.control**
* = PBS/0.1% BSA, or unconditioned culture medium + LPS.
** = lOng/ml rhTNFa (or, where appropriate, lOOng/ml rhTNFa or lOpg/ml
rovTNFa) giving 100% cytotoxicity as detected by light microscopy.
An assay on non-adherent T.annulata transformed cells was performed
slightly differently and was designed to be able to detect induction
of cytotoxicity /cytostasis or increased cytoproliferation. Line 5
cells (6.4.4) were plated out and initially incubated as described for
the other cell lines above. After the addition of lOOpl samples
(recombinant proteins in PBS, 0.1% w/v BSA) in quadruplicate, cells
were incubated for 3 more days with the inclusion of lpCi of 3H
thymidine/well for the final 18h. After light microscopy, cells from a
well were transferred onto individual discs in glass fibre mats
(Skatron) and rinsed, using a semi-automatic cell harvester
(Titertek), before incorporated radioactivity was measured by placing
dried discs in vials with 1ml of scintillation fluid (Optisafe, LKB)
and counting with a rack /i-scintillation counter.
6.4.6. Thymocyte proliferation assays:-
Assessment of the proliferation of sheep thymocytes in the presence
of samples, using phytohaemagglutinin (PHA) as a co-mitogen, was based
on the method of Harkiss et al. (1989). A normal thymus was obtained
from a freshly-slaughtered lamb for each assay. Thymocytes were teased
from small pieces of tissue into RPMI with 10% v/v FCS, pelleted by
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centrifugation at 1500 rpm for 15min at 4°C and resuspended in 50ml of
RPMI10ME (6.1.3). After waiting 5min to allow large pieces of tissue
to settle, the top 40ml was transferred to a fresh tube and spun as
above, before resuspending the pellet in 10ml of RPMIioME. These cells
were then counted (6.4.1) and diluted, in the same medium, to 4 x 106/
ml, before being plated out into the central 60 wells of round-
bottomed, 96-well plates at 50pl/well (the outer wells were filled
with PBS). 50pl of RPMIioME with PHA at 36pg/ml and lOOpl of sample
were also added to each well. All samples were assayed in
quintuplicate. For assessing the activity of recombinant proteins,
samples comprised recombinant proteins (6.3.7,8,9) diluted in PBS,
0.1% w/v BSA. For assessing the neutralising capability of antibodies,
samples comprised rovTNFa (6.3.7) (or rovIL-1/1) diluted and
preincubated with antibodies as for cytotoxicity assays (6.4.5); for
assessing thymocyte proliferating potential of conditioned media
(6.4.3), samples comprised 99.5pl of conditioned or unconditioned
(with LPS at the concentration used for stimulation) media,
preincubated for 1.5h with 0.5pl of pre-immune, or post-final
immunisation, rabbit serum (6.4.9).
After 2d incubation, wells were pulsed with lpCi of 3H-thymidine
each and incubated for a further 18h. All wells were checked by light
microscopy to confirm freedom from bacterial contamination before the
radioactivity incorporated into cells in a given well was measured as
in the cytostasis assay on line 5 cells (6.4.5).
6.4.7. Cartilage degradation assays:-
Cartilage degradation assays were performed by modifications of the
method of Harkiss et al. (1989). A xiphoid cartilage was obtained from
a freshly-slaughtered sheep for each assay and stripped of adherent
adipose and fibrous tissue. >60 2mm diameter discs of cartilage were
punched from the flattest region of the cartilage and cultured in
petri dishes containing DME medium with 5% v/v FCS, penicillin,
streptomycin and fungizone. After 2d, discs were transferred to the
central 60 wells of flat-bottomed, 96-well tissue culture plates (1
disc/well) with 150pl of fresh medium as above and 50pl sample/well
(outer wells were filled with PBS). Samples were recombinant proteins
(6.3.7,8,9) diluted in PBS with 0.1% w/v BSA. All samples were assayed
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in quintuplicate. Some wells were filled with medium and sample but no
disc. After a further 2d incubation, all discs were removed and plates
were frozen at -20°C. Analysis of the relative concentrations of
chondroitin sulphate in the SN's was performed as follows:- lOpl of
thawed SN from each well were transferred to individual wells of an
ELISA plate in duplicate; 250pl of a 0.0018% w/v solution of
dimethylmethylene blue (Pierce) in a formate buffer (6.1.3) were added
to each well and the absorbance of each well at 540nm was then
measured using an ELISA plate reader (Titertek).
6.4.8 Fibroblast proliferation assay:-
A fibroblast proliferation assay was perfomed, based on the method
of Vilcek et al. (1986). WSCP cells (6.4.4) were plated out at 6 x 103
cells/well into the central 60 wells of a flat-bottomed, 96-well plate
in lOOpl of DME medium with 5% v/v FCS, penicillin and streptomycin
(the outer wells were filled with PBS), then incubated for 18h before
the addition of 50pl sample to each well. Samples were recombinant
proteins (6.3.7,8) in PBS with 0.1% w/v BSA. All samples were assayed
in quintuplicate. Plates were then incubated for a further 3d, with
lpCi of 3H-thymidine/well being included for the final 18h. Wells were
checked by light microscopy before cells were detached from the plate
by trypsinisation (6.4.4). Cellular incorporation of radioisotope was
then measured for each well as before (6.4.5).
6.4.9. Immunisation of rabbits. Collection and treatment of sera:-
3 rabbits were immunised during the course of this work. 15ml of
blood were withdrawn from each rabbit, to act as a control,
immediately prior to its first immunisation. The first rabbit (R175)
was immunised with 250pg of hybrid VLP's in 0.5ml of TC (6.3.5)
emulsified in 0.5ml CFA. This was injected SC via several sites. 3
weeks later it was boosted, SC, with 50pg of rovTNFa in 0.5ml PBS
(6.3.7), emulsified with an equal volume of IFA. 10ml of blood were
withdrawn 2 weeks after the 2nd injection.
Two subsequently immunised rabbits (R198 & R199), were immunised
only with purified rovTNFa (6.3.7). Their first immunisations
consisted of 150pg of protein/ rabbit in 1.5ml of PBS emulsified with
1.5ml of CFA, injected SC via several sites. These were followed by
2nd immunisations 3 weeks later of 50pg in 0.5ml PBS, emulsified with
0.5ml IFA. 5ml of blood were withdrawn from each 2 weeks later, and a
third immunisation performed 1 week after that by injecting 20pg in
0.2ml PBS IV. 20ml of blood were removed from each rabbit 2 weeks
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after the final injection.
After collection, blood was allowed to clot overnight, before the
serum was removed and clarified by centrifugation at 2500 rpm for
lOmin. All sera were then 'heat-inactivated' by incubation at 56°C for
30min before being aliquoted and stored at -20°C until use.
6.4.10. Immunisation of mice:-
3 Balb/c mice were immunised with rovTNFa (6.3.7) at a
concentration of lOOpg/ml. Each mouse was initially immunised SC with
20pg protein in PBS emulsified with an equal volume of CFA. They were
sequentially boosted with lOpg (emulsified with lOOpl IFA) SC, 13pg IP
and lOpg IP, 3, 7 and 10 weeks later respectively. One mouse, selected
for use in a fusion (6.4.11), was immunised 3 weeks after the final
boost with 18pg IP and 2pg IV.
Blood samples (lOpl) were taken from the tail veins 2 weeks after
the 3rd and 4th injections. Serum, collected from these samples after
overnight clotting, was used fresh, as a primary antibody in Western
blots (6.3.14) or after aliquoting, storage at -20°C and thawing, as a
positive control in ELISA's (6.4.12).
6.4.11. Fusion of mouse splenocvtes to myeloma cells. Early hybridoma
culture:-
3d after a mouse's final IV/IP boost (6.4.10), a frozen aliquot
(departmental stock) of mixed thymocyte medium (MTM), previously
prepared according to Reading (1982), was thawed, plated out at
lOOpl/well in the central 60 wells of each of 6, 96-well, flat-
bottomed tissue culture plates and pre-incubated (mammalian cell
culture conditions).
Fusion of murine splenocytes to NSO myeloma cells was then
performed by the method of Galfre & Milstein (1981). 4d after its
final boost, the mouse was killed by cervical dislocation and its
spleen was removed and homogenised in 10ml of RPMI medium. The freed
splenocytes were then pelleted. This and all subsequent
centrifugations in this procedure were performed at 1000 rpm for 5min.
Cells were then resuspended in 10ml of RPMI. After allowing 2min for
large pieces of tissue to settle, the suspension was transferred to a
fresh tube and the number of cells counted (6.4.1). These were diluted
to 9 x 106/ml. A 1ml aliquot was removed and added at lOOpl/well to 10
of the wells containing MTM for control purposes (see below).
NSO myeloma cells were cultured (in RPMI medium with 10% v/v FCS,
ImM Na pyruvate), harvested by centrifugation, resuspended in RPMI,
counted (6.4.1) and diluted to 3 x 106 cells /ml. 20ml of splenocyte
suspension were then mixed with 20ml of NSO suspension and
centrifuged. The cell pellet and a 50% w/v solution of PEG 1500
(Boehringer) in 75mM Hepes were simultaneously warmed at 37°C for
2min. 1ml of PEG solution was then slowly added to the cell pellet,
with gentle rotation, over the course of lmin, then left at 37°C for a
further 4min. 25ml of RPMI were next added, dropwise, over the course
of 6min, again with gentle rotation of the suspension. The cells were
then repelleted before suspension in 35ml of RPMI20HAT (6.1.3), and
plated out at lOOpl/well in the 350 wells containing MTM only. All 6
plates were then incubated for several weeks. Cells were refed by
adding 50pl of fresh medium to each well twice weekly. After the first
week, subsequent refeeds required prior removal of an equivalent
volume of old medium. After 7d, each well was examined daily, under
the light microscope, for growth of a colony of hybridoma cells. Any
such colonies growing in a tightly clustered formation were dispersed
by gentle agitation of the medium.
Once the hybridoma colony/colonies in any given well had grown to
nearly cover the floor of that well, 200pl of its SN were removed for
analysis by ELISA (6.4.12). Refeeding of wells with colonies nearing
this state was postponed to prevent dilution of the SN. SN's were
either tested immediately (6.4.12), or stored at -20°C for later
testing, after accumulation of a suitable number of samples. At any
testing, 200pl of supernatant were also removed from a control
splenocyte-only well.
After removal of a SN sample, cells from that well were resuspended
in remaining SN and transferred to a well of a 24-well plate with 1ml
of RPMI15HAT (6.1.3).
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6.4.12. Analysis of hybridoma supernatants:-
Neat SN's of initial (6.4.11) and cloned (6.4.13) hybridomas were
analysed by ELISA. After a preliminary ELISA to optimise coating
conditions, all subsequent ELISA's were performed against rovTNFa
immobilised as follows:- rovTNFa (6.3.7) was diluted to 300ng/ml in
carbonate coating-buffer (6.1.3) and plated out, at lOOpl/well in an
ELISA plate (Dynatech Immulon no.4) then incubated at 4°C for at least
All subsequent incubations were performed at 37°C, in a sealed
container, with the exception of the final colour development step
which occurred at room T° in open plates. After emptying the coated
plates, unused binding sites were blocked by adding 200pl of 2% w/v
BSA in PBS (6.1.3)/well and incubating for lh. Plates were then washed
3 times with PBS before adding lOOpl of sample to a well. After a
further lh incubation plates were washed 4 times in PBS. lOOpl of an
horseradish peroxidase-conjugated, rabbit anti-[mouse immunoglobulin
G, whole molecule] preparation, which had been diluted 1:1000 in PBS
with 0.25% w/v BSA, were then added to each well before a further
30min incubation. Plates were next washed 6 times in PBS. lOOpl of
peroxide substrate solution (6.1.3) were then added and the plates
left for up to 30min whilst watching for appropriate colour
development. Further reaction was stopped by adding lOOpl of 12.5% v/v
sulphuric acid and the OD492 of each well was measured on an ELISA
plate reader (Titertek).
SN's of initial colonies, as well as those derived after 2 or 3
cloning procedures were assayed in duplicate. After a first cloning,
however, whilst lOOpl of SN was assessed exactly as above, the second
lOOpl of sample was assessed in an ELISA on wells coated, by overnight
incubation at 4°C, with lOOpl of yeast extract/factor Xa control
preparation (6.3.8), diluted in PBS, by the same degree required to
dilute rovTNFa stock (6.3.7) to lpg/ml. All subsequent steps in this
ELISA were as above.
Wells whose SN ELISA OD readings were >3x the OD obtained using
medium alone were scored as positive. Where these readings were also >
the OD obtained using splenocyte SN, wells were considered strongly
positive.
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6.4.13. Cloning and storage of hybridomas:-
The fate of hybridoma cells initially transferred to 24-well tissue
culture plates was dependent on the ELISA scores obtained from their
SN's. Cells from all positive wells (6.4.12) were used to produce
frozen stocks whilst cells from strongly-positive wells were also used
in a first cloning procedure (see below).
Cells were transferred to wells, containing 1ml of fresh medium, of
24-well tissue culture plates after initial growth (6.4.11) and after
cloning procedures (see below). Hybridoma cells of interest thus
transferred were refed twice weekly with 0.5mls of fresh medium (after
1 week this required removal of an equivalent volume of SN) and
examined daily. When transferred from initial cultures the medium used
was RPMI15HAT (6.1.3). Cells transferred after first and subsequent
cloning procedures were grown in RPMI15HT and RPMI15 (6.1.3),
respectively.
Cells selected for cloning were submitted to the cloning procedure
described below within 3 days of transfer to a 24-well plate. A mouse
was killed by cervical dislocation and its spleen removed aseptically,
then homogenised into 10ml of RPMI. Freed splenocytes were pelleted by
centrifugation at 1000 rpm for lOmin, then resuspended in 7ml of
medium (first cloning-RPMIisHAT, second cloning-RPMIi5HT, third
cloning-RPMIis). After waiting 2min for large aggregates to settle
out, the cell suspension was transferred to a fresh tube, counted
(6.4.1), then irradiated (2.5krad, 137Cs). The cell suspension was
diluted, in the same medium, to 5 x 106 cells/ml, plated out at
lOOpl/well in the central 60 wells of 96-well, flat-bottomed tissue
culture plates and incubated to provide 'feeder' cells. 24h later,
cells selected for cloning were suspended, harvested by centrifugation
at 1000 rpm for 5min, resuspended in 6ml of the same medium used for
the splenocytes and counted (6.4.1). (Remaining cells in the emptied
well of the 24 well plate were refed with 1ml of the same medium and
cultured, to later form a frozen stock [see below].) One of two
protocols was then adopted. When sufficient cells were obtained, they
were successively diluted to each of three concentrations:- 50,10 and
5 cells /ml. lOOpl of each dilution was added to 20 wells with feeder
cells. When insufficient cells were obtained, they were simply diluted
to an estimated 8 live cells /ml and plated at lOOpl /well in each of
60 wells with feeder cells. All plates were then incubated for a
further 2-4 weeks. After 7d, wells were examined by light microscopy
for the presence of individual hybridoma colonies. Only those wells
with a single colony were retained. These were now refed twice weekly
with 50pl of fresh medium as above (with removal of an equivalent
volume of SN when required) and 'clustered' colonies were dispersed by
agitation. Once hybridoma cells in any well reached confluency, 200pl
of SN was removed and analysed (6.4.12) whilst the cells were
suspended in remaining SN and transferred to a well of a 24-well
plate.
After a first cloning, any clones whose SN's gave a positive result
in an ELISA against the immobilised negative control preparation
(6.4.12) were discarded. Other clones, selected on the basis of rate
of growth and magnitude of ELISA results, were submitted to second and
third clonings. Some third clones were then similarly chosen to
provide cells for larger numbers of frozen stocks. After 48h in one
well of a 24-well plate, these were divided 1:3 and 24h later further
divided 1:2 (1ml of fresh medium/well at each division), before
incubation was continued as below.
Cells destined to form frozen stocks were incubated until they
neared 50% confluency, when they were suspended, centrifuged at 1000
rpm for 5min, resuspended in 1ml of freezing mix (6.1.3) and slowly
frozen to -70°C before being transferred to liquid nitrogen for
storage. Cells remaining in the well were refed with lm.1 of fresh
medium and regrown as above to allow storage of a second vial.
6.4,14. Production of saturated supernatant:-
1 frozen vial of a selected hybridoma third clone (6.4.13) was
quickly thawed and transferred to 20ml of RPMIis (6.1.3) in a 75cm2
flask. After 7d growth, this was divided between 2 similar flasks
which were then 7/8 filled with fresh medium and incubated for a
further 2 weeks. The SN's were clarified by centrifugation at 2,500
rpm for lOmin, aliquoted and stored at -20°C until needed.
6.4.15. Isotvning of monoclonal antibodies:-
The isotype of monoclonal antibodies was determined using a
commercial kit (Isotype plus, Sigma) according to the manufacturer's
instructions.
6.5. Maedi-Visna virus: stocks, analysis and experimental protocols:-
6.5.1. Maedi-Visna virus stocks:-
Aliquots of MVV, strain EV-1 (Sargan et al., 1991a), were obtained
from departmental stocks. These comprised the clarified (by
centrifugation) SN from a culture of normal, ovine fibroblasts, which
had been infected with MVV and incubated, in DME with 5% v/v FCS,
penicillin and streptomycin, to 100% cytolysis, then stored at -70°C.
This stock contained 105 TCIDso/ ml as had been previously judged by
limiting dilution analysis using the same cell line (C.Cousens,
personal communication). A conditioned medium was prepared for use as
a negative control by similarly clarifying the SN from an uninfected
culture of the same fibroblast line grown in the same medium for the
same period, then aliquoting it and similarly storing at -70°C.
The level of contamination of these stocks by LPS was estimated
using a commercial kit (E-toxate, Sigma) to the manufacturer's
instructions.
6.5.2. MVV reverse transcriptase assays
RT assays were performed according to Sargan et al. (1991b). 15pl
samples for assay were placed, in duplicate, in wells of 96-well,
round-bottomed plates. lOpl of 2.5x RT reaction mix (7.1.3) were added
and the plate incubated at 37°C for 90min. Reactions were stopped by
adding lOOpl of 10% w/v TCA, 50pg/ml yeast RNA to each well. Plates
were left on ice for 15min before reaction mixes were harvested onto
glass fibre mats using a titertek cell harvester. Filters were washed
for 40s with 5% w/v TCA, 3% w/v NaPPi and for a further 40s with 70%
v/v ethanol, then dried. Radioactivity incorporated into acid-
precipitable DNA was then measured by immersing the glass fibre discs
in scintillant (Optisafe, LKB) and counting emissions in a rack 13-
scintillation counter.
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6.5.3. Infecting ovine fibroblasts with virus. Addition of recombinant
proteins:-
2 experiments were performed to assess the impact of rovTNFa on
MVV-infected WSCP cells using slightly different protocols. In the
first experiment, WSCP cells (6.4.4) were plated into the wells of 2
duplicate, 96-well, flat-bottomed, tissue culture plates at 10,000
cells /well in lOOpl of DME medium with 5% v/v FCS, penicillin and
streptomycin. After 2d incubation, 50pl of virus stock or conditioned
medium (6.5.1), each diluted 1:3 with the above medium, were added to
each well, as were 50pl of sample, 2d later. All samples were assayed
in sextuplicate and comprised recombinant proteins (6.3.7,8), at 4x
final concentration, in PBS with 0.1% w/v BSA. Some wells contained
the above additions but no cells. Plates were then returned to the
incubator and assessed daily by light microscopy. 9d PI, 1 plate was
frozen at -20°C, thawed, refrozen, and thawed again before well
contents were mixed and analysed (6.5.2). SN's were removed from the
second plate. The cells on this plate were rinsed with PBS (6.1.3),
stained with 0.25% w/v crystal violet in 20% v/v methanol (40pl/well)
for 2min, rinsed gently, but thoroughly, in water, and the OD540 of
each well was measured on an ELISA plate reader.
In a second experiment, WSCP cells were plated at 8,000/well in
lOOpl of the above medium, again in wells of 2 duplicate 96-well
plates. 1 week later, SN's were removed and cells refed with DME + 2%
FCS, penicillin and streptomycin (lOOpl/well). After 6d, 50pl samples
(as above but with recombinant proteins at 3x final concentration),
all in sextuplicate, were added and plates returned for incubation.
24h later, 50pl of virus stock or uninfected conditioned medium (each
diluted as above, but including samples with recombinant proteins at
final concentration) were added. Plates were then incubated, frozen
(at indicated time-points PI) and thawed twice, and analysed as above.
6.5.4. Infecting ovine lung cells with virus. Addition of recombinant
proteins:-
In each experiment involving MVV infection of ovine lung cells,
cells from a pair of lungs (6.4.2) were plated into wells of several
24-well tissue culture plates at (initially) 2 x 105 cells/ml,
lml/well and incubated, with refeeding (6.4.2), for 7-9d before
UZ°}
infection. On infection, all old medium was removed and replaced, in
all but one experiment, with 0.75ml of fresh medium and 0.2ml of neat
virus stock or conditioned medium (6.5.1).
In the exception (fig.5.8), 2ml of virus stock or conditioned
medium (+/- added LPS) were added to a well for 2h, then removed
before the wells were washed once with PBS and filled with 0.5ml of
fresh medium. These SN's were removed at assorted time points
thereafter before the proteins they contained were concentrated
(6.3.11) and analysed (6.3.12,14).
In all other cases, 50pl of sample (PBS with 0.1% w/v BSA +/-
recombinant proteins [6.3.7,8] at 20x final concentration) were added
at the time of infection or 24h later as indicated. Cells were refed
4, 7 and (where applicable) 10 d PI, by adding 250pl of medium
containing the same final concentration of sample /well. In these
experiments, plates were frozen at -20°C at indicated times after
infection, then thawed, refrozen and rethawed before well contents
were mixed for analysis (6.5.2). To assess the production of ovine
TNFa in one of these experiments (table 5.2, experiment 3), proteins
in the remaining contents from cells which had been exposed to samples
of PBS with BSA only, were concentrated (6.3.11) and analysed
(6.3.12,14).
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APPENDIX 1:- ABBREVIATIONS.
The following list (in alphabetical order) defines all abbreviations
used in this thesis, with the exception of standard abbreviations for
amino acids, and those abbreviations which have been used to describe














BSA:- bovine serum albumin.
BSOCOES:- bis [2-(succinimido-oxy-carbonyloxy) ethyl] sulphone.
c.:- circa.
C:- cytosine
cAMP:- cyclic adenosine monophosphate.
cDNA:- DNA complementary to mRNA.
CFA:- complete Freund's adjuvant.
cGMP:- cyclic guanidine monophosphate.
CHAPS:- 3-[(3-cholamidopropyl)-dimethylammonio]-l-propane-sulphonate.
CIP:- calf intestinal phosphatase.
CNS:- central nervous system.
cone'"':- concentration.
CPE:- cytopathic effect(s).










DOC:- deoxy-cholate (or deoxy-cholic acid),
ds.:- double-stranded.
DTT:- dithiothreitol.
EAE:- experimental allergic encephalomyelitis.
EDTA:- ethylene diamine tetra-acetic acid.
EGF:- epidermal growth factor.
EGTA:- ethylene glycol tetra-acetic acid.
ELAM:- endothelial-leukocyte adhesion molecule.
ELISA:- enzyme-linked immunoabsorbent assay.
EM:- electron microscopy.
eq. dil":- equivalent dilution.
EtBr:- ethidium bromide.
Expt:- experiment
FCS:- foetal calf serum.
FSH:- follicle stimulating hormone.
G:- guanidine.
GM-CSF:- granulocyte/macrophage colony stimulating factor,
gp:- glycoprotein,
h:- hour(s).
HBSS:- Hanks' balanced salt solution.
HCG:- human chorionic gonadotrophin.
HIV:- human immunodeficiency virus.
HTLV:- human T-lymphotrophic virus.
I:- inositol.
ICAM:- intercellular adhesion molecule.















LTR:- long terminal repeat.
M-CSF:- macrophage colony stimulating factor.
ME:- mercaptoethanol.
MHC:- major histocompatability complex,
min:- minute(s).
MnSOD:- manganous superoxide dismutase.
moi:- moiety of infection.
mRNA:- messenger RNA.
MS:- multiple sclerosis.





NBL:- Northumbria Biologicals Limited.
NBT:- nitro-blue tetrazolium.
neg cntrl:- negative control.
NF:- nuclear factor.




ODx:- optical density at x nm.
OPD:- orthophenylenediamine.
ORF:- open reading frame.
PAF:- platelet activating factor.
PAGE:- polyacrylamide gel electrophoresis.
PBM:- peripheral blood mononuclear (cells).
y
PBS:- phosphate-buffered saline.
PCR:- polymerase chain reaction.









rboTNFa:- recombinant bovine TNFa.
RFLP:- restriction fragment length polymorphism.
rhTNFa:- recombinant human TNFa.
RIA:- radioimmunoassay.
RNA:- ribonucleic acid.
rovIL-1^:- recombinant ovine interleukin-1 beta.
rovTNFa:- recombinant ovine TNFa.
RP:- reverse sequencing primer.




SCID:- severe combined immunodeficiency.
SD:- standard deviation.
SDS:- sodium dodecyl sulphate.








TCIDso:- 50% tissue culture infectious dose (i.e. that dose of
infectious agent capable of successfully infecting 50% of susceptible
cultures to which it is applied).
TCR:- T-cell receptor.
TEMED:- Tetramethyl ethylene diamine.
TGF:- transforming growth factor.
T«:~ annealing temperature.







VCAM:- vascular cell adhesion molecule.
VLP:- virus-like particle,
w:- weight.
WSCP:- Weybridge sheep choroid plexus (cells).
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APPENDIX 2:- PAPERS PUBLISHED.
The papers included in the following pages have been published as a
result of the work described in this thesis. Publisher's permission
has been granted to include a photocopy of the second paper.
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SUMMARY
We have cloned and sequenced the ovine tumor necrosis factor-a (TNF-a)-encoding cDNA, using gene amplification by
polymerase chain reaction (PCR) technology, to aid studies of assorted diseases in this species. We used primers selected
from published TnfA sequences of other species on a cDNA template prepared from lipopolysaccharide-stimulated ovine
alveolar macrophages, to generate a product representing the central region of the molecule. We then used a novel method
based on 'inverse PCR' to generate a product containing the 5' and 3' ends of the molecule. Here, we present the complete
sequence of the ovine TNF-a cDNA and compare it with other published TNF sequences. The cloned cDNA has a leader
sequence of 156 bp followed by a protein-coding sequence of 702 bp and a 3'-untranslated region of 800 bp. The protein
product of the gene is a protein of Mr = 25 586, 79% homologous to human TNF-a. An mRNA produced by alveolar
macrophages, which hybridises to the cloned gene, is induced greatly, with a peak induction time of approx. 135 min, in
response to stimulation by lipopolysaccharide and to plating on plastic. We also discuss the resolution of some artefacts of
the inverse PCR technique.
INTRODUCTION
Tumor necrosis factor-a (TNF-a, also known as cachec¬
tin) is an inflammatory cytokine produced by activated
macrophages, Langerhans cells and astrocytes, and in
smaller quantities by NK cells and other lymphocytes or
lymphocytic cell lines, and by mast cells. TNF-a's cytocidal
Correspondence to: Dr. D. Sargan, Department of Veterinary Pathology,
University of Edinburgh, Summerhall, Edinburgh EH9 1QH (U.K.)
Tel. ( + 44-31 )-650-6167; Fax ( + 44-31 )-662-0373.
Abbreviations: aa, amino acid(s); bp. base pair(s); BSA, bovine serum
albumin; cDNA, DNA complementary to mRNA; ds, double strand(ed);
DTT, dithiothreitol; EtdBr, ethidium bromide; kb, kilobase(s) or
1000 bp; TPS, lipopolysaccharide; NK. natural killer; nt, nucleotide(s);
PCR. polymerase chain reaction; Pollk, Klenow (large) fragment of
E.coli DNA polymerase; ss, single strand(ed); SSC, 0.15 M
NaCl/0.015 M Na, • citrate pH 7.6; TNF, tumor necrosis factor; TnfA and
TnfB, genes encoding TNF-a and TNF-/?; u, unit(s).
and lymphocyte activating roles have been extensively
reviewed (Maennel, 1986; Beutler and Cerami, 1989), and
a very large number of effects on many other cell types have
been catalogued. It is present at elevated levels in a variety
of disease states including septic shock (reviewed in Cerami
and Bcutler, 1988), arthritis, and several autoimmune states
(see for example Teppo and Murray, 1987), and cachexia
associated with various cancers (Balkwill et al., 1987), as
well as in a variety of viral, parasitic and other diseases.
Sequences of TnfA genes from a number of species includ¬
ing human, rabbit, and mouse, as well as partial sequences
from pig and cat have been published (Pennica et al., 1984;
1985; Shirai et al., 1985; Ito et al., 1986; McGraw et al.,
1990; Pauli et al., 1989; Drews et al., 1990). These
sequences code for preproteins of 233-235 aa in length
which are cleaved to give 156 or 157 aa mature proteins.
These proteins are approx. 80% homologous at the aa level,
somewhat better conserved than many other cytokine
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sequences. TNF-/? or lymphotoxin has a similar spectrum
of biological activity to TNF-a, but is only 30% homol¬
ogous at the aa sequence level.
In cloning highly conserved genes from particular species
PCR has been used a number of times when a homologous
gene from a different species has already been sequenced
(e.g., Lee et al., 1988). The approach has been successfully
transferred to ovine cytokine genes by this laboratory
(Fiskcrstrand and Sargan, 1990), and others (Seow et al.,
1990; Mclnnes et al., 1990). A problem with the use of PCR
in cloning has been the difficulty of obtaining complete gene
sequences including both 5' and 3' ends of the transcript.
Several approaches to this problem have been described
including the use of'anchored' PCR in which the molecule
to be cloned is attached to a vector or terminal oligo of
known sequence, and the PCR run off this sequence (Ohara
et al., 1989), and 'inverse' PCR in which the molecule to be
cloned is circularised and amplified using outward facing
primers (Ochman et al., 1988; Triglia et al., 1988).
The aim of this study was to clone the complete cDNA
encoding ovine TNF-a by using direct and inverse PCR.
The derived protein sequence from this molecule is com¬
pared with other published TNF-a sequences. Northern-
blot analysis is used to study its expression in isolated
alveolar macrophages. Problems encountered in cloning
using inverse PCR are discussed.
RESULTS AND DISCUSSION
(a) Generation of a TnfA gene fragment and analysis of
TnfA gene expression in macrophages
Published sequences of TnfA genes of rabbit, mouse and
human were compared to identify areas of the molecules
which were highly conserved between these species, and
PCR primers were constructed from these areas (primers a,
b, c, and d, Fig. 1). Ovine alveolar macrophages were stimu¬
lated in vitro with 100 ng LPS/ml for 2 h and used as a
source of RNA containing TnfA transcripts (Kawakami
and Cerami, 1981). An ss cDNA was prepared from this
RNA and used as a template for gene amplification using
these primers. After two successive rounds of 35 cycles of
PCR using nested primers, a band of 493 bp was identified
by gel electrophoresis (Fig. 2a), cut out from the gel, and
sequenced directly. Some of the DNA was cloned into a
phagemid vector. A clone was picked and sequenced to
ensure that it was representative of the whole PCR-
generated band. The DNA was approx. 80% homologous
to the equivalent region of the human TnfA gene.
This clone was used as a probe in Northern-blot analysis
of RNA collected from ovine alveolar macrophages at var¬
ious time points after plating out and simultaneously adding
LPS (Fig. 2b). A single species of RNA of size approx.











1 ATG ^ L_ <—
h e TGA(stop)
a) CTC AGC CTC TTC TCI TTC CTG (sense, 249-269)
b) CCA AAG TAG ACC TGC CCR GAC TC (antisense, 816-838)
c) CAC CAC GCT CTT CTG CC (sense, 284-300)
d) GGT CAC CCT TCT CCA ICT GG (antisense, 752-771)
e) GCA GAG AGG ATG TTG ACC (antisense, 657-674)
f) ATC AAG AGC CCT TCC CAC AGG (sense, 676-696)
g) AAG CCC TGG TAC GAA CCC (sense, 721-738)
h) ACC AGA GGC CTG TTG AAG G (antisense, 362-380)
Fig. 1. Cloning strategy and positions of primers used in this paper. The structure of a human TnfA cDNA molecule and a circularised ovine TnfA cDNA
molecule are shown, together with the initial methionine and stop codons of the structural sequences. The positions of primers referred to elsewhere
in this paper are shown by numbering relative to the human sequence of Pennica et al. (1984) (primers a,b,c,d) or to the cloned ovine sequence given
in Fig. 4 (primers e,f,g,h). The sequences of primers a-d were derived after comparison of the human, murine and rabbit TnfA sequences. At positions
where these sequences differed in primers a and c inosine residues (I) were incorporated in the primer. In primer b, R represents a 50:50 mixture of
A and G residues at this position. The bold line represents the segment of the ovine cDNA cloned using the human derived primers, and sequenced
prior to cloning the remainder of the gene using inverse PCR (referred to elsewhere as the ovine TnfA central region clone).
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Fig. 2. Production of a clone of the central region of the ovine TnfA cDNA and its use to analyse TnfA gene expression in alveolar macrophages. (Panel
A) A TnfA cDNA fragment generated by nested PCR on total RNA from stimulated alveolar macrophages. Lanes 1, 2, and 3 show products of nested
PCR using TnfA specific primers on three different cDNA populations. Methods. Cell populations rich in alveolar macrophages (typically about 85 %
pure) were obtained by bronchio-alveolar lavage of Scottish blackface sheep at post mortem. Erythrocytes were removed by hypotonic shock, and the
cells washed in Hanks buffered saline solution and transferred into serum-free Iscove's medium, before plating out into 75 cm2 tissue-culture bottles at
a density of 2 x 107 cells/bottle. Macrophages (which are partially stimulated by adherence to plastic; data not shown), were further stimulated by the
addition of lipopolysaccharide (from Salmonella abortus equi) to 100 ng/ml. RNA was prepared by a slight modification of the method of Chirgwin et al.,
1981 (see Sargan et ah, 1986). cDNA was synthesised using a dT,2_,8 primer from total RNA. Nested PCR's were performed using primers a and b
followed by c and d (see Fig. 1). PCR's were carried out in 100 fil samples in 10 mM Tris ■ HC1 pH 8.8/1.5 mM MgCl2/3 mM DTT/50 mM KC1/170 fig/ml
BSA/100 /tM dNTPs/1 u Taq DNA polymerase, using 0.1 /iM of each primer and 5-25 ng of cDNA (or 1 fil of a previous PCR). 35 cycles of 0.5 min
at 95°C, 0.3 min at 48°C (or 40°C for primers a and b) and 1.5 min at 70°C were used. The 10-/rl samples from these reactions were analysed by
electrophoresis on 1% agarose gels containing 40 mM Tris • acetate pH 7.8/1 mM EDTA and staining with 0.5 /rg/ml EtdBr. (Panel B) Northern-blot
analysis of TnfA RNA in alveolar macrophages stimulated by LPS and adherence. Alveolar macrophages were prepared and stimulated with LPS as
before. At the times after stimulation shown, 10 /jg of total RNA were analysed by electrophoresis on 1.2% agarose/7.2% formaldehyde gels containing
20 mM Na • phosphate pH 7.0, blotted onto nitrocellulose, and probed using the ovine TnfA central region clone by standard methods (Thomas, 1980).
The positions of28S rRNA (4.7 kb) and 18S rRNA (1.85 kb) are shown.
reaching a maximum concentration at about 135 min after
stimulation.
(b) Generation of a clone of the remainder of the TnfA gene
RNA from the 135-min time point was used to prepare
ds cDNA which was self-ligated. The product was used to
drive an inverse PCR (as described by Triglia et al., 1988,
and Ochman et al., 1988) with primers e and f. Circularised
TnfA encoding cDNA molecules can act as templates in
PCR to generate the 5' and 3' ends of the TnfA molecule,
whilst retaining the ability to hybridise to probes derived
from the cloned central portion of TnfA. The main product
of this PCR hybridised to the central region probe (Fig. 3,
lanes 1, 2, 5 and 6), but was only 1000 bp long instead of
the anticipated size of about 1800 bp.
This result might occur in three ways. (/') During the self
ligation step, bimolecular events causing the joining of
cDNA molecules head-to-head or tail-to-tail predominate
over intramolecular circularisation or intermolecular head-
to-tail joining (these forms would not be of the expected
length); («) the cDNA was incompletely but uniformly
extended towards the 5' end, so that a shortened product
was formed; (Hi) during cDNA synthesis, oligo(dT) mis-
priming was occurring off A-rich sequences within TnfA
cDNA molecules, causing a ds cDNA shortened at the 3'



















Fig. 3. Products of inverse PCR with different primers. Products of PCR on cDNA from stimulated alveolar macrophages with different sets of primers
are shown, both on EtdBr-stained agarose gels (as before), and on Southern blots of these gels. PCR used: lanes 1, 2, 5 and 6, primers e and f (duplicate
reactions); lanes 3 and 7, primer e alone; lanes 4 and 8, primer f alone; lane 9, primers e and g; lanes 10-13, primers g and h (duplicate reactions). Southern
blots were carried out using standard methods (Sambrook et al., 1989). Stringencies for hybridisations were 4 x SSC at 65°C for 16 h, and filters were
washed to a final stringency of0.3 x SSC at 65°C. Lanes 5-9 were probed with the ovine TnfA central region clone. A clone containing the 1-kb product
from PCR with primers e and g was used to probe lanes 5 and 6.
the frequency of bimolecular collisions involving two TnfA
cDNA molecules rather than a TnfA cDNA molecule and
a cDNA molecule from a different gene should be very low
(from the intensity of Northern-blot signals we estimate that
TnfA RNA represents about 0.1% of the mRNA from
which the cDNA was made). Only the former would allow
the possibility of head-to-head or tail-to-tail amplification
by primers e or f. Nonetheless the hypothesis was tested by
performing a second PCR on 1 /rl of the ligated product
from the first PCR using either one or other of the two
primers e and f, by itself. Neither primer alone was capable
of generating a band which could hybridise to our TNF
central region clone (though primer f alone did generate a
band of about 1000 bp, incapable of so hybridising, and
therefore distinct in sequence from at least part of the
1000 bp band generated by primers e and f used together)
(Fig. 3, lanes 4 and 8).
A PCR was therefore performed on 1 fi\ of the product
of the e + f-primed inverted PCR using primers e and g
(Fig. 3, lane 9). Again this generated a band of 1000 bp
which hybridised to the TnfA central region probe. Cloning
and sequencing of this product showed that it was produced
from cDNA molecules incompletely extended to the 5' end
of the TnfA gene: sequence just 5' to primer e was joined
to sequence derived from the poly(A) tail. Repeated prepa¬
rations of cDNA, circularised and subject to repeat PCRs
were never successful in producing a larger main product
(data not shown). A smear of larger DNA molecules within
this PCR product hybridised to the TnfA central region
probe, including many far larger than the maximum
expected size. These might represent molecules produced
by polymerase travelling round the original circular tem¬
plate more than once, in a 'rolling circle' fashion. We know
of no reports of whether Taq DNA polymerase is capable
of strand displacement, but such a reaction would be
favoured by the high temperature during polymerisation.
The DNA in the smear was purified by agarose gel electro¬
phoresis and used as a template in a further round of PCR.
The main product was again a band of 1000 bp, consistent
with the larger bands containing a concatemer of the
1000 bp molecule (data not shown).
Another test PCR on the 'smear' product, using primers
c and e, where primer c is 5' to the end of the 1000 bp band,
produced a product of 390 bp (data not shown), the size
anticipated from our known sequence - revealing that
amongst these large molecules, there were also molecules
which originated from more completely made cDNA mole¬
cules. A final PCR was therefore performed using primers
h and g where h was selected from as near to the 5' end of
the known central region as possible. (Any product from
these two primers would now have little overlap with the
original clone, but share 3' sequence with the 1000 bp
clones.) The main product of the PCR was once again a
band of approx. 1000 bp. However, another band was pres¬
ent of about 1300 bp. Both hands hybridised to the 1000-bp
clones (Fig. 3, lanes 10-13). A cloned copy of the larger
band was sequenced to generate all the sequence data 5' to
the central clone. This sequence was checked by direct
sequencing of the PCR product. The full sequence is pres¬
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tatgttttttaaaaaatatttatgtgatcaagttgtctaaatgatgctgatttggtgactgatttgtcgctacatcactgaacctccgctccccagggga
• ccg< • 1669
gtcatgcctgtaaccgccctactggtcagtggcgagaaataaagtgtcctgagaaaagaaaaaaaaaaa
Fig. 4. The complete sequence of ovine TnfA cDNA and TNF-a. The nt and derived aa sequences are shown. The positions of a potential glycosylation
site (NIS) and of the conserved A + T-rich destabilising signals are underlined, as is the polyadenylation signal (AATAAA). The presumed cleavage site
between pre-protein and mature protein (between aa 77 and 78) is shown by an arrowhead at aa 78. Differences from a previously published ovine TNF
sequence (Young et al., 1990) are shown as superscripts, with overlines representing deletions of the overlined nt [the start and finish positions of the
Young et al. (1990) sequence are bracketed by arrowheads at nt positions 153 and 1654], The asterisk after aa 234 represents a stop codon. Methods.
For cloning, PCR products were made blunt-ended by filling-in with Pollk and phosphorylated using T4 polynucleotide kinase. After PCR, nucleic acids
were recovered from the reaction by extraction with phenol/chloroform and ethanol precipitation, and resuspended in 50 ^tl of 10 mM Tris ■ HC1 pFl
7.5/7 mM MgCl2/0.1 mM EDTA/5 mM DTT/10 mM ATP/30 u ofT4 polynucleotide kinase. After 30 min at 37°C, 0.6 mM each of dATP, dCTP, dGTP,
TTP and 2.5 u of Pollk were added. Reactions were allowed to proceed for a further 30 min at room temperature. Amplified fragments were purified
by preparative electrophoresis on a 1.2% agarose gel and recovered by electroelution (McDonell et al., 1977), phenol/chloroform extraction and ethanol
precipitation. They were resuspended in 50 mM Tris ■ HC1 pH 7.4/10 mM MgCl2/2 mM DTT/1 mM spermidine/1 mM ATP and ligated into the SmaI
site of the phagemid pTZ 19R (Pharmacia). Recombinant clones containing an insert of appropriate size were selected by hybridisation to the PCR product.
Single-stranded phagemid DNAs were prepared as recommended by Pharmacia and sequenced by the chain-termination method of Sanger et al. (1977),
using a commercial kit (U.S. Biochemical Corp., Cleveland, OH). For direct sequencing, ds PCR products were purified by electrophoresis in
low-gelling-temperature agarose (1.2%) prior to sequencing by the method of Casanova et al. (1990). Sequences were assembled and analysed using
version 6.2 of the University of Wisconsin Genetics Computer Group package (Devereux et al., 1984) and submitted under EMBL database sequence
accession No. X55152.
(c) Sequence features of ovine TNF-a
The sequence determined here for the ovine TnfA gene
product would encode a protein of 234 aa, with an Mr of
25 586. There is one potential Asn-linked glycosylation site.
The ovine gene shows 85% homology to human TNF-a in
the coding sequence, 80% homology in the RNA leader
sequence and 11% in the 3'-untranslated region. The
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Fig. 5. Comparison of ovine TNF-a with other published TNF sequences. Dots in the human, murine and rabbit sequences represent residues conserved
relative to the ovine sequence. Dashes represent gaps introduced to maximise the alignment. The first aa of the mature protein is shown by an open
arrowhead. A single aa insertion (Gin) compared with the sequence of Young et al. (1990), is shown by an asterisk above the residue. The potential
glycosylation site (NIS) is shown in bold type. The other sequences shown are taken from Shirai et al. (1985; human); Pennica et al. (1985; mouse) and
Ito et al. (1986; rabbit).
previously published mammalian TNF-a sequences
(Fig. 5). In contrast to previous studies from other species,
the ovine propeptide sequence has diverged more rapidly
from the equivalent human, murine or rabbit sequences
than has the mature protein, largely because of wide diver¬
gence in the 20 or so aa residues upstream from the cleavage
site for protein maturation. Two Cys residues believed to
form a disulfide bridge in the mature protein are conserved,
and there is conservation of the final 13 aa residues, dele¬
tion of which is known to abrogate protein function. In a
5'-TTATTTATTTA motif in the 3'-untranslated region
34 nt are completely conserved when compared with the
human sequence. This motif probably acts to destabilise the
RNA (Shaw and Kamen, 1986; Caput et al., 1986; Beutler
et al., 1988).
During the preparation of this manuscript, another labo¬
ratory has published an ovine TnfA cDNA sequence
(Young et al., 1990). That sequence is 99% similar to the
one published here, but appears to be incomplete. It lacks
153 nt of 5'-untranslated sequence when compared with
the sequence presented here, the other 3 nt of the leader
being different from our sequence. Our sequence also dis¬
plays the following polymorphisms relative to that of Young
et al. (1990): an additional 3 nt in the signal peptide region
leading to an extra aa; one conservative third nt substitution
at position 567 in the coding sequence and six single nt
substitutions, as well as three single nt insertions and two
deletions in the untranslated tail. The length of the sequence
presented here is in reasonable agreement with that meas¬
ured by Northern blotting, allowing for polyadenylation.
From alignment of the sequence with those of human and
murine TnfA genes, for which the 5' end of the transcript
is well established (Pennica et al., 1984; 1985) it would
appear that the sequence is nearly complete, though it may
be missing 10-20 nt at the 5' end (data not shown).
(d) Conclusions
(/) We have cloned the ovine TnfA cDNA encoding
TNF-a using an oligo(dT) primer to generate an ss cDNA
followed by the PCR or by inverse PCR. This method
allowed the production of a molecule with an intact 3' end,
despite the presence of A + T-rich RNA-destabilising ele¬
ments.
(2) We have demonstrated some potential problems of
inverse PCR. A non-TNF-specific major product was gen¬
erated by one outward-facing primer alone, illustrating that
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significant product can come from any abundant cDNA
which is cross-reactive with either primer alone, which can
form a significant number of head-to-head or tail-to-tail
homodimeric molecules after ligation, or which can prime
internally from two sites.
(5) Examination of our sequence for secondary structure
shows the presence of an extremely stable hairpin structure
in the RNA in nt positions 436-648 (Fig. 6). This hairpin
was probably responsible for the difficulties encountered in
extending to the 5' end of the gene.
(4) In the inverse PCR problems will arise if a high
proportion of the original cDNA is incomplete because the
PCR works more efficiently on shorter amplification pro¬
ducts. After PCR it is not sufficient to separate larger
molecules for cloning, as many of these may have been
generated by concatenation from smaller templates.
Fig. 6. Potential secondary structure in the RNA transcript of ovine TnfA. Secondary structure predictions were derived using the values of Freier et al.
(19S6), for the ovine TnfA transcript. A stable hairpin between nt positions 430 and 660 of the RNA sequence is shown (numbering as in Fig. 4). The
stability of the structure is -64.4 kcal/mol.
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EXPRESSION AND CHARACTERIZATION OF
BIOACTIVE RECOMBINANT OVINE TNF-a: SOME
SPECIES SPECIFICITY IN CYTOTOXIC RESPONSE
TO TNF
I.R.Green.1 C. Fiskerstrand.1 G. Bertoni.2 D.J.Roy,1 E. Peterhans.2
D.R. Sargan1
We have expressed and partially purified recombinant ovine tumour necrosis factor a
irovTNF-a) using a yeast Ty, virus like particle, expression system. RovTNF-a is at least
as active as recombinant human TNF-a (rhTNF-ai in two different bio-assays performed on
ovine material, whilst approximately 1000-fold more rovrT\F-a than rhTNF-a is required
to induce the same level of cytotoxicity in TNF-sensitive murine cell lines L929 and WEHI
164 clone 13. When cytotoxic assays are performed on the porcine TNF sensitive cell line
PKil5 t-1512 rot TNF-a shows about 2 logs greater activity than on murine cells, w hilst
rhTNF-a is about 1 log more active. A monoclonal antibody, raised against rovTNF-a,
has been used to demonstrate the presence of nanogram amounts of an appropriately sized
glycoprotein to be native ovine T\F-a in supernatants of LPS stimulated ovine alveolar
macrophages. These samples show no detectable cytotoxicity to L929 cells, although they
show activity attributable to TNF-a s through neutralization by a polyclonal antiserum raised
to rovTNF-a) in an assay on ovine material. The relative lack of activity on murine cells helps
to explain previous reports of inability to assay native ovine TNF-a using these cells, in spite
of their routine use to assay TNF-a from several other species. The sequence features in ovine
TNF-a which might reduce its affinity for the murine TNF type 1 receptor are discussed,
Tumour necrosis factor a (TNF-a), a pleiotropic
cytokine produced by lipolysaccharide (LPS) stimu¬
lated macrophages and other cell types.1 is thought
to play a central role in the pathogenesis of diseases
involving endotoxinaemia2 and cachexia associated
with chronic diseases of assorted aetiologies.3-5 Its
multiple antitumour and proinflammatory properties
have been extensively reviewed.1-6-7 Human TNF-a is
secreted as a 17 kDa protein cleaved from a larger
precursor" and is capable of self associating9 into
its biologically active trimeric10 or possibly dimeric11
form.
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TNF-a exerts its effects by interacting with cellular
receptors12 of which two human types (1 and 2)
have been identified and cloned13-15 as have their
murine homologs.16 Whilst type 2 TNF receptor
mediated activities, such as thymocyte proliferation
in the presence of a comitogen.1" are highly species
specific18 (possibly reflecting the lower degree of cross
species homology of the extracellular domain of this
receptor), only minor degrees of species specificity
have been noted for activities such as cytotoxicity19
which are believed to be mediated via the type 1
receptor.1" Hence TNFs-a from species as diverse as
mouse, rabbit, human, ox and horse are all active in
cytotoxicity assays using highly sensitive murine cell
lines such as L929 or WEHI 164 clone 13. allowing
these lines to form the basis of bioassavs for TNF in
each of these species.20-25
Several recent reports have suggested that
cytotoxicity to murine TNF sensitive cells is not
present even in supernatants from ovine cells
which might be expected to contain TNF. We
ourselves have consistently obtained disappointing
results when attempting to use murine TNF sensitive
cells to detect TNF-a in the supernatants of LPS
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stimulated, ovine, alveolar macrophages (unpublished
observations). To aid in studies of ovine TNF-a. we
have therefore expressed recombinant ovine TNF-a
1 rovTNF-a) using a yeast Tv-VLP expression system.
In this system a recombinant protein is expressed as
a fusion product with the yeast Ty element protein.
PI. whose ability to self assemble into virus like
particles (VLPs) is exploited in a simple purification
procedure involving successive centnfugations. An
ovine TN'F-a cDNA expression cassette was produced
by a polymerase chain reaction (PCR) and included
a specific proteolytic cleavage site between the two
fusion partners to allow rovTNF-a to be freed from
PI. After cleavage, the latter remains particulate and
can therefore be removed by further centrtfugation.
Recombinant human TN'F-a (rhTNF-a) has previously
been expressed in yeast and shown to have biological
activity" whilst the Tv-VLP system has previously-
been used to express a biologically active cytokine
(human a2-lFN).-s This laboratory has used this
system to express other ovine cytokines such as
interieukin (IL)-la and 3 which are biologically-
active.20
We have assessed the biological activity of the
rovTNT-a in a variety of systems, and have used it
to raise both polyclonal and monoclonal antibodies
capable of identifying production of native ovine
TNF-a by stimulated ovine alveolar macrophages.
The rox TNF-a protein displays activities characteristic
of other TNT proteins and has comparable activity
to rhTNF-a in two assays on ovine tissues, but has
relatively reduced activity in cytotoxic assays on TNF
sensitive murine cell lines. However it is cytotoxic to a
porcine kidney cell line.
RESULTS
Expression ofRecombinant Ovine TNF-a
Primers were chosen to anneal to the first 21 and
final 2S bases of the coding sequence for mature ovine
TNF-a.30 Flanking nucleotides were added to these
primers so that in the PCR product coding sequence
was preceded by 4 codons encoding a factor Xa recog¬
nition sequence31 and flanked by BamW I restriction
endonuclease sites (see Materials and Methods). (No
internal factor Xa or BamH I sites exist in the mature
ovine TNF-a sequence.) After amplification by PCR
of cDNA from ovine alveolar macrophages stimulated
with LPS. a product of anticipated size was produced
and cloned into pTZ18R. Inserts from 5 clones were
completely sequenced. A BamH I excised insert with
internal sequence perfectly matching the ovine TNF-a
sequence30 was selected and ligated into the unique
BamH I site of the expression plasmid pOGS40.3:
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which places fusion protein production under the con¬
trol of a galactose inducible promoter. Recombinant
clones in E. coli were sequenced through the insertion
site to select a clone with the correct orientation
and maintenance of reading frame of insert. Suitable
plasmids were chosen for transformation of yeasts.
Crude extracts were prepared from four yeast
transformants, after culture and galactose induction,
and analysed on Coomassie Blue stained 10% SDS
PAGE gels. In a typical extract an extra, heavily
stained, protein band was observed at the predicted
size of a P,-TNF fusion protein (Fig. 1A).
One of these transformants was selected for fur¬
ther work. After purification of VLPs from galactose
induced cultures of this yeast, a preparation of —90%
pure fusion protein was obtained (Fig. IB) in which
electron microscopy demonstrated typical VLPs (not
shown). Cleavage of the fusion protein with factor Xa
produced 2 proteins corresponding in weight to P,
(50 kDa) and TNF (17 kDa) (Fig. 1C). Centnfugation
of cleavage solutions and dialysis of the supernatants
into PBS left a solution containing the 17 kDa pro¬
tein at estimated purity 80% (Fig. 1C) as judged
by Coomassie Blue staining. However, this protein
appears to stain relatively poorly with silver stain (data
not shown). (These gels were run under nonreducing
conditions to avoid any confusion with the 17 kDa
subunit of factor Xa.33) Final yields were of the order
of 2 mg rovTNF-a per litre of yeast culture. A negative
control preparation of yeast transformed with plasmid
without insert contained similar lex-els of other proteins
(data not shown). Cross-linking studies suggest that a
large proportion of the rovTNF-a is present as a trimer
(Fig. ID).
Cytotoxicity Assays on Murine and Porcine Cell
Lines
When used in cytotoxicity assays on L929 cells this,
and other. rovTNF-a preparations repeatedly had only
limited cytotoxic activity when compared with rhTNF-
a (see Fig. 2A) requiring approximately 1000 fold more
roxTNF-a to achiex e the same cytotoxic effect (CD50
= 8 pg-weli for rhTNF-a: 8 ng/well for roxTNF-a). A
similar discrepancy in activity was observed for killing
of WEHI 164: clone 13 cells (data not shown) as well
as for MTT dye reduction assays on the latter cell
type (Dr P. Preston, personal communication). No
cytotoxicity was observed from the negative control
preparation assayed on either cell line at any dilution.
Neither was any cytotoxicity observed by the use of
ro\TNF-a on L929L'R cells (a TNF-resistant L929
derivative34) even at concentrations able to induce
100%- cytotoxicity on L929 cells (data not shown). To
test whether contaminants such as factor Xa might be
exerting a protective effect on the cells, the negative
-K-111 / S





Figure I. Purification of rovTNF-a.
A-C are photographs of Coomassie Blue stained gels, and D a Western blot, with detection of rovTNF-a bv
the monoclonal antibody cvti as described in the text. Fig. 1A shows a 10°7c poivacryiamide gel. All other
gels were 5-20T gradient gets Geis in Figs 1A and B were run under reducing conditions and those in !C
and D non-reducing conditions. Lanes are as follows: 1. 2 and 3 - crude extracts of typical pOT40.1. an-, anc
pMA 5260 transformed yeasts respectively (pOT40.1 encodes an ovine TN'F-a-Pl fusion protein. pMA 5260
encodes PI with no fusion partner): 4 - a pOT40.i derived VLP preparation: 5 and 6 - partially and fulls
cleaved (with factor Xa) pOT40.i derived VXP preparations: 7 - final rovTNF-a preparation after removing
PI by centrifugation: 8 and 9 - rovTNF-a preparation after and before cross-linking: positions of molecular
size markers for gels la. b. c and d are shown, as are anticipated mobilities of PI and PI-TNF fusion protein
ana of putative TNF mono-, ai- and tn-mers.
control preparation was mixed with rhTNF-a ana
compared to the action of pure rhTNF-a. No difference
was observed (data not shown).
Very recently a porcine TNT sensitive cell line has
been reported.35 When rovTNF-a was assayed in this
cell line a more than 100 fold increase in cytotoxicity
was observed (CD50 = 60 pg well). Tne cytotoxicity
of rhTNF-a is also increased in this cell type in
comparison to that observed on L929 cells but the
increase is about 10 fold (CD50 = 0.9 pg-well) (Fie.
-B).
Assays for TNF Activity of the Recombinant
Protein on Ovine Material
We assessed the activity of our material as a
comitogen for ovine thymocytes. In each of 3 assays
with thvmocvtes from different animals it showed
pg TNF
pg TNF
Figure 2. Cytotoxicity of ovine TNF-a to murine and porcine
cells.
(A) TNF cytotoxicity towards L929 cells. Error bars show standard
deviations in cytotoxicity measurements (in this experiment, n = 4).
(B) TNF cytotoxicity towards PK(15)- 1512 cells. Error bars show
standard deviations in cytotoxicity measurements (in this experi¬
ment n = 2). Cytotoxicity of the preparations was measured as
described. • rovTNF-a. C rhTNF-a. The veast control preparation
had no measurable cytotoxicity in these assays.
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activity surpassing that of rhTNF-a. A representative
experiment is shown in Fig. 3. In no experiment did
a negative control preparation show any activity over
the use of media alone. Neither did mixing the negative
control preparation with rhTNF-a change the latter's
activity.
Another of TNF-a's multiple activities is its ability
to promote resorption of cartilage.36 To further con¬
firm activity on ovine cells we performed 3 cartilage
degradation assays on ovine Xiphoid cartilage. A rep¬
resentative experiment is shown in Fig. 4. In all three
experiments the rovTNF-a preparation performed
similarly to rhTNF-a. Again the negative control
preparation showed no activity on its own. nor did
it alter the activity of rhTNF-a when they were mixed.
To date, we have not identified any ovine cell lines
susceptible to the cytotoxic action of TNF-a.
Antibodies Against the Recombinant Protein
Detect Native Ovine T.XF-a
A monoclonal antibody, cyt 1. raised against the
purified rovTNF-a. recognizes a protein of M,. =
I7 000 in the recombinant material but not in negative
control preparations. This monoclonal recognizes a
YL = 25 000 protein in 18 h condition medium from
LPS-stimulated alveolar macrophages, but not from
non-conditioned medium (Fig. 5A). The size of this
protein is reduced to more closely approximate
that of the recombinant protein by digestion with
peptide-.V-glycosidase F. The recombinant material
is unaffected by this treatment (Fig. 5B). The pre¬
dicted ammo acid sequence of mature ovine TNF-a
contains one potential Asn-linked glvcosvlation site.30
TNF conc. (ng/mll
Figure 3. Ovine TNF-a induces proliferation of ovine thymocytes.
The figure shows the result of a representative co-mitogen
stimulation assay performed on ovine thymocytes as described.
Error bars show standard deviations of incorporated counts (n = 5).
The concentrations of TNF shown are those of the added samples
(i.e. twice the final concentrations in the assay). ■ rovTNF-a, G
rhTNF-a, A veast control preparation.
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Figure 4. Cartilage degrading activity of ovine TNF-a.
The figure shows the results of a typical cartilage degradation assay-
performed on ovine xiphoid cartilage disc as described. Error bars
show standard deviations of the OD changes measured in = 5).
The concentrations of TNF quoted are those of the added samples
(i.e. 4 times the final concentration in the assay) ■ rovTNF-a. G
rhTNF-a. A veast control preparation.
Whilst this supernatant, estimated by Western blot to
contain more than 1 ng/ml TNF. shows no detect¬
able cytotoxicity to L929 cells in an assay capable
of detecting 30 pg ml human TNF diluted in the
same medium (not shown), it did indeed contain
bioactive TNF-a. as judged by its ability to induce
proliferation in an ovine thymocyte comitogen assay
over and above that caused by medium, alone. This
proliferation could be completely neutralized by a
polyclonal antiserum raised against rovTNF-a (Fig,
6). Complete neutralization is somewhat unexpected
as the supernatant may contain IL-1 as well as TNT.
However, ovine IL-1 is very susceptible to freeze-thaw
cycles (unpublished observations). The polvconal anti¬
serum shows no activity against recombinant ovine
IL-1 3 (not shown).
A time course of TNF-a accumulation in media
from LPS stimulated ovine alveolar macrophages is
shown in Fig. 7. None of the supernatants were
active in L929 cytotoxicity assays. In these extracts,
in addition to the predominant 25 kDa protein, the
monoclonal cytl also detects proteins of YL = 70 000
(undissociated TNF tnmers or TNF-receptor com¬
plexes?) and of very high molecular weight (muitimeric
aggregates?).
DISCUSSION
We have expressed and purified ovine TNF-a
protein from a TN'F-Pl encoding plasmid in yeast. A
significant proportion of the M,. = 17 000 recombinant
material appears to be present as dimers and trimers
and is therefore potentially active.10-11
«A'i I l/i>
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Figure 5. A monoclonal antibody against ovine TNF-a.
Western biots of rovTNF-a and native ovine TNF-a were performed using 5-20T gradient SDS-PAGE gels
run under non-reducing conditions. Ovine TNF-a was detected by cvtl. Final visualization was achieved
bv standard methods in A and by enhanced chemiluminescene (Amersham) in B Lanes are as follows: 1
and 2 - acetone precipitates of 1 ml of Iscove's/LPS medium and 18 h supernatant from LPS conditioned
ovine alveolar lavage cells; 3 - lng rovTNF-a: 4 - lng equivalent of negative control preparation; 5 and 6 -
rovTNF-a without and with peptide-,V-givcosidase F treatment: 7 and 8 - native ovine TNF-a preparation with
and without peptide-,V-glvcosidase F treatment. Positions of molecular size markers for each gel are shown.
Both monoclonal antibodies and a polyclonal anti¬
serum (data not shown) raised to this protein recognize
a protein secreted by a population of alveolar lavage
ceils rich in macrophages when induced by LPS. with
a time course in keeping with our own observation of
induction of ovine TNF-a mRNA.30
Comparison of the mobilities on SDS gels of the
recombinant and native proteins, before and after
treatment with peptide-iY-glvcosidase F. suggests that
the recombinant protein is not glycosylated, but
that native TNF-a secreted by ovine macrophages
is glycosylated. A potential A'-linked glvcosvlation
site exists at position 19 of the mature protein.30
Whilst the function of glvcosvlation in TNFs-a is
unknown, unglycosviated recombinant murine TNF is
fully active.37 (Native murine TNF-a is glycosylated.38
whilst native human TNF-a is not.39)
Although rovTNF-a performs as well as. or better
than. rhTNF-a in two assays of activity on ovine
material, it has very poor cytotoxic activity on two
TNF sensitive murine cell lines. On the other hand it
is cytotoxic to a porcine TNF sensitive cell line. The
concentrations of rovTNF-a required to produce ovine
thymocyte proliferation and cartilage degradation are
of similar magnitude to those required in other species
using homologous rTNF's18-36-40 suggesting that the
ovine rTNF-a is fully functional, but half maximal
thymocyte proliferation is seen at a concentration less
than a quarter of that required to give half maximal
cytotoxicity on murine cells in what is normally a much
more sensitive TNF assav.
There are several possible explanations for the
relatively poor activity of rovTNF-a in cytotoxicity
assays on munne cell lines. It is unlikely that
inhibitor(s) exist in the rovTNF-a preparations, or
Figure 6. A supernatant from LPS stimulated macrophages
enhances the uptake of -'H-thymidine by ovine thymocytes and is
neutralized by a polyclonal antiserum raised to rovTNF-a.
Thymocyte comitogen proliferation assays, and TNF neutralization
were performed as stated in Materials and methods. Error bars
show standard deviations of the incorporated counts (n = 5).
Column 1: thymocytes stimulated with fresh Iscove's medium con¬
taining 1 (ig'ml LPS treated with preimmune rabbit serum; column
2: thymocytes stimulated with fresh Iscove's medium containing
1 ug'ml LPS treated with polyclonal rabbit anti-rovTNF-a serum;
column 3: thvmocvtes treated with 18 h supernatant from alveolar
macrophages plated into Iscove's medium containing 1 ug'ml LPS
and treated with preimmune rabbit serum: column 4: thymocytes
treated with 18 h alveolar macrophage supernatant as before, but
treated with polyclonal rabbit anti-rovTNF-a serum.
<rif-7 I l/b
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Figure 7. Time course of TNF-a production by
ovine lung cells.
Western blot of a 5-20A gradient SDS-PAGE
gel run under non-reducing conditions, showing
TNF-a production in vitro by ovine lung cells
after lavage and stimulation with 1 pgrnl LPS.
Ovine TNF-a was detected by the monoclonal
antibody cvtl. Lanes 1-7: acetone precipitates of
1 ml supernatants from 0. 2. 4. 6. IS. 25 and 48 h
(after stimulation) time points respectively; lane 8:
1 ng rovTNF-a. The position of molecular weight
markers is shown.
media used, capable of inhibiting one activity of
ovine TNF-a without inhibiting other activities, or
the activates of human TNF-a. It is possible that during
production of ovine TNF-a by the VLP system the
protein becomes folded in such a way as to affect
one function (cytotoxicity on murine cells) without
affecting others. But this seems unlikely in view of
the cytotoxicity of the preparation to porcine cells.
It is known that cytotoxic and thymocvie proliferat¬
ing functions of TNF-a are mediated via different
receptors in the mouse17 and this is likely to be true for
other species. Species specificity of the type 2 recep¬
tor which mediates thymocyte proliferation has been
previously demonstrated (and rovTNF does not act as
a comitogen for murine thymocytes, data not shown),
but species specificity of the type 1 receptor has not
been noted previously.16 Nonetheless, the most likely
explanation for the results presented here is a much
reduced affinity of ovine TNF-a for the murine type 1
TNF receptor.
This latter possibility is in keeping with consist¬
ently negative attempts to assay ovine TNF-a in the
supernatants of stimulated alveolar macrophages in
spite of the production of abundant TNF-a mRNA
(unpublished observations30) and the presence of
ovine TNF-a protein detectable by Western blot in
concentrations exceeding 1 ng/ml (Figs 5 and 7) in
an assay where 300 pg/ml human TNF-a could induce
lOOFb cytotoxicity and 30 pg/ml was readily detectable
(not shown). Others have also failed to detect ovine
TNF-a using these cells.41-42 One study43 does describe
some cytotoxicity in ovine macrophage supernatants,
but the effect is described as displaying 'considerable
variability." A recent report of expression of a cDNA
for ovine TNF-a in cos cells suggests that material
cvtotoxic to WEHI 164 clone 13 cells is found in
concentrates derived from the supernatants of these
cells. But no indication of the purity of TNF-a in this
material or its likely concentration is given, and the
effect cannot be observed prior to 15 x concentration
of the supernatants.44
Fluman TNF-a has been the subject of several
studies by antibody and mutational or deletion analysis
to attempt to define functional sites of the molecule
(e.g. refs 45—49). These have implicated several amino
acids which form a cluster on either side of a groove
formed between two subunits of a trimer45 as well as
amino acids at the carboxyl,47 and near to the amino45
terminals of the molecule. Three amino acid residues
(nos. 9.67.106) are conserved in the TNF-a sequences
of 5 other species (including pig) whose TNFs-a can
be successfully detected by bioassavs for cytotoxicity
using murine cells, but differ in sheep TNF-a (Fig.
8). Of these residues, that at position 9 has previously
been implicated as being important for cytotoxic
function on L929 cells in one study49 in which deletions
of the first 8 amino acids of human TNF-a did not affect
its cytotoxic activity but deletion of the first 10 amino
acids led to a significant decline in this activity. To our
knowledge the two other positions have not so far been
implicated as being particularly important to function
and in the predicted three dimensional structure of
human TNF-a50-51 appear to be somewhat remote
from the proposed receptor binding sites though they
may be important for the overall conformation of the
molecule. Whilst most of the amino acids in the cluster
identified by Van Ostade et al.45 are conserved in the
ovine sequence, one at position 32 differs. The amino
acid at this position also differs in the ox and pig. It
is interesting to note that in one study23 TNF-a could
only be detected in the supernatants of LPS-stimulated
bovine alveolar macrophages using WEHI 164 clone
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Figure 8. A comparison of pre¬
dicted amino acid sequences of
TNF-a from several species.
(sequences taken from refs
30.36.60.61.62.63). The presumed
first ammo acid of the mature
protein is shown by the number 1.
The potential glvcosvlation site for
ovine TN'F-a is shown in bold print.
Ammo acids which are conserved
in all other species but differ in
the sheep are marked by an over¬
head =.
13 cells not the less sensitive L929 cells. RovTNF-a
is more active in cytotoxic assays on porcine than on
murine cells, and displays greater sequence similarity
to porcine TNF-a than to human or murine TNF-a. but
is still less active than rhuTNF-a on either cell type.
From these data, it is clear that TNF-a-sensitive
murine cell lines are insufficiently sensitive to ovine
TNF-a for them to be used in cytotoxicity assays for
routine detection of ovine TNF-a.
Although strict species specificity has been pre¬
viously demonstrated for type 2 TNF receptors, the
present work demonstrates that there may be a higher
degree of specificity in the interaction of TNFs-a from
some species with the type 1 receptor than has previ-
ouslv been recounized.
MATERIALS .AND .METHODS
Generation ofcDNA Expression Cassettefor the
Ovine TNF-a Gene
A DNA fragment encoding the structural sequence of
mature ovine TNF-a was generated by gene amplification
from ovine cDNA. prepared as described previously.30
A PCR was performed on this cDNA in the buffer
conditions of Ohara et al.52 using 35 cycles of 95°C. 0.5
mm: 48°C. 0.5 mm: 71°C. 1.5 min: and a final extension
at 7FC for 7.5 min. 1 U Taa polymerase. 5 ng of cDNA
and 0.1 pm each of the following primers (see below) were
used. PCR products were purified by phenol-chloroform
extraction and ethanol precipitation prior to digestion with
BamH I. After an intermediate cloning and sequencing step
5' primer BamH I Factor Xa Ovine TNF-a
AAG CTT GGA TCC ATA GAA GGT AGA CTC AGG TCA TCT TCT CAA GCC
3' primer BamH 1 TNF-a
AAG CTT GGA TCC TCA CAG GGC GAT GAT CCC AAA GTA GAC C
Stop
4-(|117A
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via the 'phagemid pTZlSR, (Pharmacia) to eliminate insert
fragments containing errors introduced by PCR. the BamH
1 digested ovine TNF-a expression cassette was ligated into
the unique Bam H I site in the TvA gene of the yeastiE.
coh shuttle vector pOGS-4032 to form a Pl-TNF fusion
protein gene. In pOGS40 the TyA gene encoding protein
PI has been placed under the control of a strong galactose
inducible hybrid promoter PGK-GAL (PAL). The TyA gene
ends with an unique BamH I site, followed by determination
codons in ail three reading frames.
After growth in E. coli JM83, recombinant clones
selected by colony hybridization to an ovine TNF-a probe,30
were used to prepare plasmid DNA for ds.DNA sequencing
through the insertion site using a pOGS40 specific pnmer.
Plasmids with correctly inserted expression cassettes were
used in cotransfections of yeast strain BJ2168 (a, leu2=,
trpl~, ura3-52, prbl-1122, pep4-3. perl—407, gal2)53 with
plasmid pUG41S. which aids galactose inducibility by
virtue of its gal4 gene,54 by standard methods.55 Double
transformants were selected by their ability to grow on
minimal media. After initial characterization, one of these
(containing the TNF-a expression plasmid pOT40.1) was
used for further work.
Production ofRecombinant Ovine TNF-a
Selected yeast transformants were incubated at 37°C
in minimal medium (6.7 g/1 yeast nitrogen base (Difco),
20 mgfi tryptophan) supplemented with glucose (10 g/1) as
a sugar source for 72 h before being moved into minimal
medium + galactose (10 g/1) for a further 18 h. Yeast cells
were harvested by centrifugation and rovTNF-a containing
VLPs were prepared by a modification of the method
of Adams et al.26 Crude veast extracts were made by
homogenization with glass beads into TEN buffer at 4°C
(TEN is 10 mM Tris pH 7.4, 2 mM EDTA, 140 mM NaCl)
(5 ml TEN per 11 culture). These lvsates were clarified
by centrifugation at 13 000 x g for 15 min before being
centrifuged at 100 000 x g onto a cushion of 60% sucrose
in TEN for 1 h. VLPs at. and below, the cushion interface
were collected and dialvsed against TEN before being loaded
onto 15—45% linear sucrose gradients, with a 60% cushion,
in TEN and spun at 53 000 x g for 3 h.
VLP containing fractions were identified by Coomassie
Blue staining of SDS PAGE gels.56 They were pooled and
dialysed into a buffer containing 100 mM Tris-HCl pH 7.4.
10 mM CaCL. Precipitates formed after dialysis steps were
removed by microfuge centrifugation Total protein concen¬
trations were measured by dye staining57 and comparing with
protein standards. Estimates of protein purity were made by
densitometry scanning of stained SDS PAGE gels.
Cleavage of fusion protein was achieved by addition of
Bovine Factor Xa (BCL) to the dialvsate to which 0.05%
CHAPS (Sigma) and 0.05% Na deoxycholate were added,
(Factor Xa was used at a ratio of 1 part to 50 parts Pl-
TNF), and incubated at 25°C for 18 h. After incubation the
suspension was clarified by centrifugation at 100 000 x g for
1 h. then dialysed against several changes of PBS over 18 h.
The final dialvsate was stored in aliquots at —70°C either
with the addition of 0.1% BSA for later use in bioassays, or
without BSA. for use in estimating protein concentration, gel
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analysis and immunizations. rhTNF-a was purchased from
British Biotechnology Ltd. Oxford. UK, reconstituted at
1 pg/'ml in PBS with 0.1% BSA. aliquoted and frozen at
-70°C until use.
Negative control preparations were prepared in an
identical manner to the rovTNF-a preparations, from yeast
transformed with pMA5260 (a constitutive expressor of PI
protein)26 with addition of the same concentration of Factor
Xa. and were stored and used in assays in the same manner.
Polyclonal Antibodies
Rabbits were immunized with 150 pg of rovTNF-a in
CFA by SC injection at several sites, followed by a second
immunization of 50 pg of rovTNF-a in IFA SC 3 weeks
later with a third injection of 20 pg of rovTNF-a IV after a
further 3 weeks. Serum was collected 2 weeks after the third
injection.
Monoclonal A ntibodies
Balb C mice were immunized SC with 20 pg rovTNF-a
in CFA. They were boosted at 3 weeks with 10 pg rovTNF-a
in IFA s.c., at 7 weeks with 13 pg i.p.. at 10 weeks with
10 pg i.p.. and at 13 weeks with 8 pg i.p. and 2 pg i.v.
Fusion of splenocvtes to NSO myeloma cells was performed
4 days after the last boost using the method of Galfre et
al.58 Positive hybridomas were identified by ELISA against
immobilized rovTNF-a preparations. A positive hybridoma
designated cytl was cloned three times before use of the
saturated supernatant as the primary antibody in further
assays.
Cytotoxicity Assays
Murine fibrosarcoma lines L929 and L929L.R34 for
cytotoxicity assays were diluted to 5 x lOVml in Iscove's
medium containing 5% FBS. L-Glutamine, penicillin and
streptomycin, and plated at 100 pl/well into 96 well flat
bottomed, tissue culture plates. After 20 h incubation 50 pi
of Iscove's medium with 4 pg/rni actinomycin D. and 50 pi
of sample in PBS. 0.1 % BSA (or 50 pi of conditioned media
from macrophages) was added. After a further 18 h incuba¬
tion. cells were washed once with PBS. fixed and stained for
2 mm with 0.25% crystal violet in 20% methanol, rinsed,
dried and the optical density of each well was measured at
540 nm.
Figures for cytotoxicity are derived as follows: % cytotoxicity =
Mean absorbance (-ve control*-) — Mean absorbance (sample) x 100
Mean absorbance (— ve control*) — Mean absorbance (-rve control**)
•(PBS/BSA only in well)
**(10 ng ml rhTNF giving lOO^c cytotoxicity).
Each sample was assayed in quadruplicate.
Cyiotoxicity assays using WEHI 164 clone 13 murine
fibroblasts25 were performed as for L929 assays with the
following modifications - after plating out and overnight
incubation 100 pi sample only were added, plates were
incubated a further three days before staining and the
medium used was DME 5% FBS.
44*11 ( / "
Cytotoxicity assays on porcine kidney cells PK(15)-15l2
were performed as described.3-' Briefly. 2.5 x 104 PK(15)
cells were seeded in wells of a 96-well flat-bottomed tissue
culture plate in UK) pi EMEM. 7% FBS. After 24 h at
37°C the medium was removed and replaced with 50 pi of
basal Iscove's medium supplemented with 7.5% FBS. 0.5%
bactopeptone (Difco. Detroit. USA) and containing 3 pg/ml
Actinomvcin D. After 2 h at 37°C, 50 pi of sample was added
to each well, and after an additional 18 h at 37°C the plates
were pulsed with 50 pi per well of a 3 mg/ml solution of 3-
(4.5-dimethylthiazol-2-yl)-2.5-diphenyltetrazolium bromide
(MTT) (Sigma. St. Louis. MO, USA) in dH;0 for 3 h at
37°C. The test was terminated by aspirating off the medium,
and solubilizing the contents of the well in dissolving solution
(0.5% SDS, 36 mM HC1 in isopropanol). Optical density at
590 nm was determined spectrophotometncallv. In this case
3 wells per plate were washed with dFTO to lvse the cells to
act as -i-ve controls for cytotoxicity, since it was not known
how much rhTNF would be needed to engender 100%
cytotoxicity. Other assays were performed in duplicate.
Negative controls and calculation of % age cytotoxicity were
as before.
Thymocyte Proliferation Assays
Thvmii were obtained from freshly slaughtered sheep.
Thymocytes were teased out from small pieces of tissue
into RPMI 10% FBS. penicillin and streptomycin, washed,
counted and plated out at 2 x 105 viable cells/well of 96 well
tissue culture plates in 50 pi medium. To each well was added
50 pi RPMI 10% FBS + phytohaemagglutmin at 36 pg/ml
and 100 pi sample. Samples w=ere diluted in PBS + 0.1%
BSA and assayed in quintuplicate. After 2 days incubation
at 37°C wells were pulsed with 0.25 pCi 3H-thymidine,
incubated for a further 18 h. harvested and incorporated
radioactivity counted. To measure neutralization of TNF-a
by antibodies. TNF-a containing samples, or media, were
preincubated with a 1/200 dilution of heat inactivated pre-
immune or immune serum for 90 min at room temperature
prior to assay.
Cartilage Degradation Assays
Release of glycosaminoglycans from ovine xiphoid car¬
tilage discs was measured in the presence of recombinant
TNF-a according to Harkiss et al.59 Relative concentrations
of chondroitin sulphate were assessed by colorimetric change
of a 0.0018% solution of dimethylmethylene blue (Pierce)
in a formate buffer (2.1 ml formic acid. 2 g Na formate.
5 ml ethanol /I) at 540 nm measured on an ELISA plate
reader. Results are expressed as mean absorbance of




Alveolar marcrophages were harvested into Hank's bal¬
anced saline solution (HBSS) by bronchoalveolar lavage
from ovine lungs, washed with HBSS and resuspended in
Iscove's medium containing 1 pg/ml LPS 2 x 107 cells in
5 ml media (c. 90% macrophages by morphology) were
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seeded into 25 cm2 tissue culture flasks and clarified
supernatants harvested at the times shown. Supernatants
were aliquoted and stored at —70°C till used. For
Western blots. 1 ml of supernatant for each time point
was precipitated with 4 ml cold acetone, resuspended in
20 pi loading buffer and loaded onto an SDS PAGE gel.
Western blotting using monoclonal antibody cvtl was by
standard methods.
Deglycosylation of Ovine TNF-a
Acetone precipitates from 1 ml of supernatant from 18 h
LPS stimulated alveolar macrophage cultures, or 20 ng of
rovTNFa were bolied for 2 min in 20 pi 1% w/v SDS. then
diluted to 200 pi with 100 m.M sodium phosphate pH 7.2.
25 mM EDTA. 1% octyl glucoside (Sigma). 0 or 2 units
of peptide-iV-glvcosidase F (BCL) were added to duplicate
vials, and incubation continued for 18 h. A 20 pi aliquot of
each was removed for analysis as before.
Crosslinking ofRecombinant Ovine TNF-a
RovTNF-a was cross-linked using bis [2-(succinimido-
oxy-carbonvloxy) ethyl] sulfone (BSOCOES. Pierce) under
conditions previously used to cross-link human TNF-a.45
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